US20170327503A1 - Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases - Google Patents
Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases Download PDFInfo
- Publication number
- US20170327503A1 US20170327503A1 US15/501,233 US201515501233A US2017327503A1 US 20170327503 A1 US20170327503 A1 US 20170327503A1 US 201515501233 A US201515501233 A US 201515501233A US 2017327503 A1 US2017327503 A1 US 2017327503A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- unsubstituted
- group
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims description 14
- 230000002757 inflammatory effect Effects 0.000 title claims description 12
- 230000002503 metabolic effect Effects 0.000 title claims description 9
- 238000011282 treatment Methods 0.000 title description 29
- 230000000771 oncological effect Effects 0.000 title description 4
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 326
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 46
- -1 —OH Inorganic materials 0.000 claims description 432
- 229910052739 hydrogen Inorganic materials 0.000 claims description 159
- 239000001257 hydrogen Substances 0.000 claims description 159
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 109
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 104
- 125000003118 aryl group Chemical group 0.000 claims description 101
- 125000004122 cyclic group Chemical group 0.000 claims description 96
- 229910052736 halogen Inorganic materials 0.000 claims description 89
- 150000002367 halogens Chemical class 0.000 claims description 89
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 87
- 125000001072 heteroaryl group Chemical group 0.000 claims description 81
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 79
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 claims description 63
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 63
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 51
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 47
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 46
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 42
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 41
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 39
- 125000003342 alkenyl group Chemical group 0.000 claims description 37
- 125000004043 oxo group Chemical group O=* 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 27
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 25
- 125000004076 pyridyl group Chemical group 0.000 claims description 25
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 18
- 229910052731 fluorine Inorganic materials 0.000 claims description 18
- 239000011737 fluorine Substances 0.000 claims description 17
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 15
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 15
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 15
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 14
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 13
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 13
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000002541 furyl group Chemical group 0.000 claims description 13
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 12
- 125000002619 bicyclic group Chemical group 0.000 claims description 12
- 150000001721 carbon Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 125000004429 atom Chemical group 0.000 claims description 11
- 239000000460 chlorine Chemical group 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- 125000003566 oxetanyl group Chemical group 0.000 claims description 11
- 125000001425 triazolyl group Chemical group 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 9
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 8
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 8
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 7
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 125000005458 thianyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000000532 dioxanyl group Chemical group 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 5
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 102000016978 Orphan receptors Human genes 0.000 claims description 5
- 108070000031 Orphan receptors Proteins 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 5
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 5
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 4
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims description 4
- PANGDCFLXUDHDI-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NCCC2=C1 PANGDCFLXUDHDI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 4
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000004306 triazinyl group Chemical group 0.000 claims description 4
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 3
- 206010016946 Food allergy Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 206010019375 Helicobacter infections Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000022873 Ocular disease Diseases 0.000 claims description 3
- 208000003435 Optic Neuritis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 206010039705 Scleritis Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical compound C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 3
- 125000005883 dithianyl group Chemical group 0.000 claims description 3
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 claims description 3
- 235000020932 food allergy Nutrition 0.000 claims description 3
- 125000003838 furazanyl group Chemical group 0.000 claims description 3
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 3
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- 230000007863 steatosis Effects 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 3
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 3
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 3
- 125000002053 thietanyl group Chemical group 0.000 claims description 3
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 claims description 2
- HRCMXYXVAWHBTH-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazole Chemical compound C1=CC=C2OCNC2=C1 HRCMXYXVAWHBTH-UHFFFAOYSA-N 0.000 claims description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 claims description 2
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 claims description 2
- YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 claims description 2
- QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 29
- 108020005497 Nuclear hormone receptor Proteins 0.000 abstract description 18
- 108020004017 nuclear receptors Proteins 0.000 abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 102000006255 nuclear receptors Human genes 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 151
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 150
- 238000005160 1H NMR spectroscopy Methods 0.000 description 141
- AQKOJKCYBNUFLU-UHFFFAOYSA-N 4,5,6-trifluoropyrimidine Chemical compound FC1=NC=NC(F)=C1F AQKOJKCYBNUFLU-UHFFFAOYSA-N 0.000 description 108
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 106
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 97
- GSOGADJIIMVREB-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]pyrrolidine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1NCCC1 GSOGADJIIMVREB-UHFFFAOYSA-N 0.000 description 86
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 74
- 239000000203 mixture Substances 0.000 description 73
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 66
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 64
- 238000003556 assay Methods 0.000 description 58
- 125000000217 alkyl group Chemical group 0.000 description 50
- 235000019439 ethyl acetate Nutrition 0.000 description 41
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 37
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 37
- 102000005962 receptors Human genes 0.000 description 34
- 108020003175 receptors Proteins 0.000 description 34
- 239000000243 solution Substances 0.000 description 34
- 125000002947 alkylene group Chemical group 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 33
- 125000004432 carbon atom Chemical group C* 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 27
- 239000003814 drug Substances 0.000 description 27
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 26
- CWCQQMOYDNXYSC-UHFFFAOYSA-N FC(F)(F)C1=CC=C(C2CCCC2)C=C1 Chemical compound FC(F)(F)C1=CC=C(C2CCCC2)C=C1 CWCQQMOYDNXYSC-UHFFFAOYSA-N 0.000 description 26
- 108010001515 Galectin 4 Proteins 0.000 description 26
- 102100039556 Galectin-4 Human genes 0.000 description 26
- 239000003480 eluent Substances 0.000 description 26
- 238000004440 column chromatography Methods 0.000 description 25
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 23
- 238000002875 fluorescence polarization Methods 0.000 description 23
- 239000002904 solvent Substances 0.000 description 22
- GSOGADJIIMVREB-SNVBAGLBSA-N (2r)-2-[4-(trifluoromethyl)phenyl]pyrrolidine Chemical compound C1=CC(C(F)(F)F)=CC=C1[C@@H]1NCCC1 GSOGADJIIMVREB-SNVBAGLBSA-N 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 229910052938 sodium sulfate Inorganic materials 0.000 description 21
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 20
- RPLVCXKSSXJFDS-LJQANCHMSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4,4-dimethylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 RPLVCXKSSXJFDS-LJQANCHMSA-N 0.000 description 19
- 0 *C.*C(*)([5*])[Y]C1=NC([1*])=NC(NCC)=C1[2*].B.C.CC.CC Chemical compound *C.*C(*)([5*])[Y]C1=NC([1*])=NC(NCC)=C1[2*].B.C.CC.CC 0.000 description 19
- 239000012267 brine Substances 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 18
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 17
- 125000000304 alkynyl group Chemical group 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- LYBDHGMSPQBSNW-UHFFFAOYSA-N 2,4,5-trifluoropyrimidine Chemical compound FC1=NC=C(F)C(F)=N1 LYBDHGMSPQBSNW-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 12
- 239000003085 diluting agent Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000007429 general method Methods 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 12
- 239000007832 Na2SO4 Substances 0.000 description 11
- 108091008731 RAR-related orphan receptors α Proteins 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 125000004414 alkyl thio group Chemical group 0.000 description 11
- 125000003710 aryl alkyl group Chemical group 0.000 description 11
- 229940113083 morpholine Drugs 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 125000005631 S-sulfonamido group Chemical group 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 125000005110 aryl thio group Chemical group 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 108091008778 RORγ2 Proteins 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 125000004475 heteroaralkyl group Chemical group 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- 125000003396 thiol group Chemical class [H]S* 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- DDKYWWMTJDDHKO-UHFFFAOYSA-N 2-[4-(chloromethyl)phenyl]acetamide Chemical compound NC(=O)CC1=CC=C(CCl)C=C1 DDKYWWMTJDDHKO-UHFFFAOYSA-N 0.000 description 8
- PQNWKBAYDBUQAL-UHFFFAOYSA-N 4-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidine Chemical compound C1C(C)CNC1C1=CC=C(C(F)(F)F)C=C1 PQNWKBAYDBUQAL-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 125000004104 aryloxy group Chemical group 0.000 description 8
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 125000005423 trihalomethanesulfonamido group Chemical group 0.000 description 8
- HBXMNLJLIGPTDU-SNVBAGLBSA-N (3S)-3-[4-(trifluoromethoxy)phenyl]morpholine Chemical compound FC(OC1=CC=C(C=C1)[C@@H]1NCCOC1)(F)F HBXMNLJLIGPTDU-SNVBAGLBSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 108091008730 RAR-related orphan receptors β Proteins 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 201000002491 encephalomyelitis Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 7
- 239000000375 suspending agent Substances 0.000 description 7
- 125000005152 trihalomethanesulfonyl group Chemical group 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NZPFQOXRHLUPRT-UHFFFAOYSA-N CC1=CC=C(CN)C=N1 Chemical compound CC1=CC=C(CN)C=N1 NZPFQOXRHLUPRT-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 6
- 239000002274 desiccant Substances 0.000 description 6
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 108020001756 ligand binding domains Proteins 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 239000011877 solvent mixture Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000010626 work up procedure Methods 0.000 description 6
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 5
- 102100033461 Interleukin-17A Human genes 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 210000000068 Th17 cell Anatomy 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000008298 dragée Substances 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Chemical group 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 229910052717 sulfur Chemical group 0.000 description 5
- 239000011593 sulfur Chemical group 0.000 description 5
- AUNZOQQYNSWKDJ-HZPDHXFCSA-N (2R)-2-[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]oxy-4-methylpentanamide Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)O[C@@H](C(=O)N)CC(C)C AUNZOQQYNSWKDJ-HZPDHXFCSA-N 0.000 description 4
- SEOQZGKOJIMEHW-HZPDHXFCSA-N (2R)-2-[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC(C)(C)C SEOQZGKOJIMEHW-HZPDHXFCSA-N 0.000 description 4
- CKCJOQMDMYPVKX-SNVBAGLBSA-N (3S)-3-[4-(trifluoromethyl)phenyl]morpholine Chemical compound FC(C1=CC=C(C=C1)[C@@H]1NCCOC1)(F)F CKCJOQMDMYPVKX-SNVBAGLBSA-N 0.000 description 4
- KVHKWAZUPPBMLL-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-[3-fluoro-4-[4-[[4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]phenyl]phenyl]propan-2-ol Chemical compound FC1=CC(C(O)(C(F)(F)F)C(F)(F)F)=CC=C1C(C=C1)=CC=C1CN1CCN(CC=2C=CN=CC=2)CC1 KVHKWAZUPPBMLL-UHFFFAOYSA-N 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- AKPSLMUFDIXDJJ-UHFFFAOYSA-N 4-(bromomethyl)-1,2-dimethoxybenzene Chemical compound COC1=CC=C(CBr)C=C1OC AKPSLMUFDIXDJJ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 108091008779 RORγ1 Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000001118 alkylidene group Chemical group 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 102000004311 liver X receptors Human genes 0.000 description 4
- 108090000865 liver X receptors Proteins 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000000825 ultraviolet detection Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- JCDOFNHYNXSIEV-UHFFFAOYSA-N 2-[2-chloro-4-(trifluoromethyl)phenyl]pyrrolidine Chemical compound ClC1=CC(C(F)(F)F)=CC=C1C1NCCC1 JCDOFNHYNXSIEV-UHFFFAOYSA-N 0.000 description 3
- LUXQAWYVSZIBGC-UHFFFAOYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]pyrrolidine Chemical compound C1=C(C(F)(F)F)C(F)=CC(C2NCCC2)=C1 LUXQAWYVSZIBGC-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- AKEUBCJGKNPKCL-MRXNPFEDSA-N 5-fluoro-N-(thiophen-3-ylmethyl)-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CSC=C1 AKEUBCJGKNPKCL-MRXNPFEDSA-N 0.000 description 3
- ATHDMVRDFVMVTG-QGZVFWFLSA-N 5-fluoro-N-[(4-fluoro-1-methylsulfonylpiperidin-4-yl)methyl]-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCN(CC1)S(=O)(=O)C)F ATHDMVRDFVMVTG-QGZVFWFLSA-N 0.000 description 3
- GHGZXAIXAQYZHZ-UHFFFAOYSA-N 7-[(3,4-dimethoxyphenyl)methyl]-4-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrrolo[2,3-d]pyrimidine Chemical compound COC=1C=C(C=CC=1OC)CN1C=CC2=C1N=CN=C2N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F GHGZXAIXAQYZHZ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- FDKXIWNDNOCAAO-UHFFFAOYSA-N CC1=CC=C(CNC2=NC=NC(N3CCCC3C3=CC=CC=C3)=C2)C=C1 Chemical compound CC1=CC=C(CNC2=NC=NC(N3CCCC3C3=CC=CC=C3)=C2)C=C1 FDKXIWNDNOCAAO-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- SLEJZQYOXXCDQU-UHFFFAOYSA-N FC1=CC=NC(F)=C1F Chemical compound FC1=CC=NC(F)=C1F SLEJZQYOXXCDQU-UHFFFAOYSA-N 0.000 description 3
- ZBZJRODRPRZIHC-UHFFFAOYSA-N FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NC(CC1CCOCC1)C Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NC(CC1CCOCC1)C ZBZJRODRPRZIHC-UHFFFAOYSA-N 0.000 description 3
- HQJBXXZIBFRPRA-UHFFFAOYSA-N FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)OCC=1C=NC(=NC=1)CC(=O)N Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)OCC=1C=NC(=NC=1)CC(=O)N HQJBXXZIBFRPRA-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- KLFGZGKEYXWRET-UHFFFAOYSA-N N-cyclopropyl-4-[[[5-fluoro-6-(3-phenylmorpholin-4-yl)pyrimidin-4-yl]amino]methyl]benzenesulfonamide Chemical compound FC1=C(N=CN=C1NCC1=CC=C(C=C1)S(=O)(=O)NC1CC1)N1CCOCC1C1=CC=CC=C1 KLFGZGKEYXWRET-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229940125425 inverse agonist Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- AUNZOQQYNSWKDJ-JKSUJKDBSA-N (2R)-2-[5-fluoro-6-[(2S)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]oxy-4-methylpentanamide Chemical compound FC=1C(=NC=NC=1N1[C@@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)O[C@@H](C(=O)N)CC(C)C AUNZOQQYNSWKDJ-JKSUJKDBSA-N 0.000 description 2
- JBNNGGCBCUKGKA-MRTLOADZSA-N (2R)-2-[[2,5-dimethyl-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound CC1=NC(=C(C(=N1)N[C@@H](C(=O)N)CC(C)(C)C)C)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F JBNNGGCBCUKGKA-MRTLOADZSA-N 0.000 description 2
- OPXLLDQUFCSHFE-QNSVNVJESA-N (2R)-2-[[3-fluoro-2-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyridin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC=CC=1N[C@@H](C(=O)N)CC(C)(C)C)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F OPXLLDQUFCSHFE-QNSVNVJESA-N 0.000 description 2
- NNVQIHRIEXCIOV-GICMACPYSA-N (2R)-2-[[5-fluoro-2-(trifluoromethyl)-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC(=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)C(F)(F)F)N[C@@H](C(=O)N)CC(C)(C)C NNVQIHRIEXCIOV-GICMACPYSA-N 0.000 description 2
- VQKGPFKWSPQCGO-AAFJCEBUSA-N (2R)-2-[[5-fluoro-6-[2-[2-methoxy-4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=C(C=C(C=C1)C(F)(F)F)OC)N[C@@H](C(=O)N)CC(C)(C)C VQKGPFKWSPQCGO-AAFJCEBUSA-N 0.000 description 2
- MVDDOBWXGGGHTJ-AAFJCEBUSA-N (2R)-2-[[5-fluoro-6-[2-[3-fluoro-4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC(=C(C=C1)C(F)(F)F)F)N[C@@H](C(=O)N)CC(C)(C)C MVDDOBWXGGGHTJ-AAFJCEBUSA-N 0.000 description 2
- ZGGOWNPJKMKCLZ-QRWMCTBCSA-N (2R)-2-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]-methylamino]-N,4,4-trimethylpentanamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)N([C@@H](C(=O)NC)CC(C)(C)C)C ZGGOWNPJKMKCLZ-QRWMCTBCSA-N 0.000 description 2
- MJXZZAPGIYWOAQ-OGVSOVDVSA-N (2R)-2-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-3-(2-oxopyrrolidin-3-yl)propanamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC1C(NCC1)=O MJXZZAPGIYWOAQ-OGVSOVDVSA-N 0.000 description 2
- NPIJVQJMZOVULD-YMBRHYMPSA-N (2R)-2-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-3-(4-methoxyphenyl)propan-1-ol Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](CO)CC1=CC=C(C=C1)OC NPIJVQJMZOVULD-YMBRHYMPSA-N 0.000 description 2
- YLRJSBPJQNPPJY-FIWHBWSRSA-N (2R)-2-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-3-(4-methoxyphenyl)propanamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC1=CC=C(C=C1)OC YLRJSBPJQNPPJY-FIWHBWSRSA-N 0.000 description 2
- NEQGGBYUZUNIHG-QNSVNVJESA-N (2R)-2-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-3-(oxan-4-yl)propanamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC1CCOCC1 NEQGGBYUZUNIHG-QNSVNVJESA-N 0.000 description 2
- GWBFPGOLLYBRQJ-PVCYVWKFSA-N (2R)-2-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-3-[(2-methylpropan-2-yl)oxy]butanamide Chemical compound C(C)(C)(C)OC([C@H](C(=O)N)NC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)C GWBFPGOLLYBRQJ-PVCYVWKFSA-N 0.000 description 2
- BQELLSAKLIZIMZ-TZHYSIJRSA-N (2R)-2-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentan-1-ol Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](CO)CC(C)(C)C BQELLSAKLIZIMZ-TZHYSIJRSA-N 0.000 description 2
- ALUUMQXKDDXVRQ-GICMACPYSA-N (2R)-2-[[5-fluoro-6-[2-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=NC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC(C)(C)C ALUUMQXKDDXVRQ-GICMACPYSA-N 0.000 description 2
- AJIAVGRXTYLRIK-AAFJCEBUSA-N (2R)-2-[[5-fluoro-6-[3-[4-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC=NC=1N1C(COCC1)C1=CC=C(C=C1)OC(F)(F)F)N[C@@H](C(=O)N)CC(C)(C)C AJIAVGRXTYLRIK-AAFJCEBUSA-N 0.000 description 2
- RNRZBGUHARVZMX-AAFJCEBUSA-N (2R)-2-[[5-fluoro-6-[3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC=NC=1N1C(COCC1)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC(C)(C)C RNRZBGUHARVZMX-AAFJCEBUSA-N 0.000 description 2
- WGMWOFFLLBCCRA-CRPOECCBSA-N (2R)-2-[[5-fluoro-6-[3-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC=NC=1N1C(C(CC1)C)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC(C)(C)C WGMWOFFLLBCCRA-CRPOECCBSA-N 0.000 description 2
- LQEADQIQXFKNET-BLDCVEFLSA-N (2R)-2-[[5-fluoro-6-[4-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC=NC=1N1C(CC(C1)C)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC(C)(C)C LQEADQIQXFKNET-BLDCVEFLSA-N 0.000 description 2
- BIEPJAAFJFWJPZ-BLDCVEFLSA-N (2R)-2-[[5-fluoro-6-[4-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4-methylpentanamide Chemical compound FC=1C(=NC=NC=1N1C(CC(C1)C)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC(C)C BIEPJAAFJFWJPZ-BLDCVEFLSA-N 0.000 description 2
- UEOWZHZISOTXLZ-BLDCVEFLSA-N (2R)-2-[[5-fluoro-6-[4-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4-methylpentanoic acid Chemical compound FC=1C(=NC=NC=1N1C(CC(C1)C)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)O)CC(C)C UEOWZHZISOTXLZ-BLDCVEFLSA-N 0.000 description 2
- ISQHUCKZAMDUCS-AAFJCEBUSA-N (2R)-2-[[6-[2-(2,4-dichlorophenyl)pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound ClC1=C(C=CC(=C1)Cl)C1N(CCC1)C1=C(C(=NC=N1)N[C@@H](C(=O)N)CC(C)(C)C)F ISQHUCKZAMDUCS-AAFJCEBUSA-N 0.000 description 2
- FDOHDMZEGVMMLQ-AAFJCEBUSA-N (2R)-2-[[6-[2-[2-chloro-4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]-4,4-dimethylpentanoic acid Chemical compound ClC1=C(C=CC(=C1)C(F)(F)F)C1N(CCC1)C1=C(C(=NC=N1)N[C@@H](C(=O)O)CC(C)(C)C)F FDOHDMZEGVMMLQ-AAFJCEBUSA-N 0.000 description 2
- QMWKXTBPTFTPHZ-TZHYSIJRSA-N (2R)-4,4-dimethyl-2-[[6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]pentanamide Chemical compound CC(C[C@H](C(=O)N)NC1=NC=NC(=C1)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)(C)C QMWKXTBPTFTPHZ-TZHYSIJRSA-N 0.000 description 2
- IXUMACXMEZBPJG-JOCHJYFZSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-fluorophenyl)propanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(F)C=C1 IXUMACXMEZBPJG-JOCHJYFZSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- IFSOBWSSXYQNIZ-SECBINFHSA-N (3S)-3-[5-(trifluoromethyl)pyridin-2-yl]morpholine Chemical compound FC(C=1C=CC(=NC=1)[C@@H]1NCCOC1)(F)F IFSOBWSSXYQNIZ-SECBINFHSA-N 0.000 description 2
- NURIHQDMLNJNTC-OAQYLSRUSA-N (3S)-4-[7-[(5-methylsulfonylpyridin-2-yl)methyl]pyrrolo[2,3-d]pyrimidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]morpholine Chemical compound CS(=O)(=O)C=1C=CC(=NC=1)CN1C=CC2=C1N=CN=C2N1[C@H](COCC1)C1=CC=C(C=C1)OC(F)(F)F NURIHQDMLNJNTC-OAQYLSRUSA-N 0.000 description 2
- NVONUARWCDBXSU-HXUWFJFHSA-N (3S)-4-[7-[(6-methylsulfonylpyridin-3-yl)methyl]pyrrolo[2,3-d]pyrimidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]morpholine Chemical compound CS(=O)(=O)C1=CC=C(C=N1)CN1C=CC2=C1N=CN=C2N1[C@H](COCC1)C1=CC=C(C=C1)OC(F)(F)F NVONUARWCDBXSU-HXUWFJFHSA-N 0.000 description 2
- DOBLSIPGLYWKPE-GOSISDBHSA-N 1,1,1-trifluoro-N-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]phenyl]methanesulfonamide Chemical compound FC1=C(N=CN=C1NCC1=CC=C(NS(=O)(=O)C(F)(F)F)C=C1)N1CCOC[C@@H]1C1=CC=C(C=C1)C(F)(F)F DOBLSIPGLYWKPE-GOSISDBHSA-N 0.000 description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 2
- PTJCOUYZLVVANE-UHFFFAOYSA-N 1-(oxan-4-yl)propan-2-amine Chemical compound CC(N)CC1CCOCC1 PTJCOUYZLVVANE-UHFFFAOYSA-N 0.000 description 2
- ZZKLBDMNUYSPOR-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-4-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrrolo[2,3-b]pyridine Chemical compound COC=1C=C(C=CC=1OC)CN1C=CC=2C1=NC=CC=2N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F ZZKLBDMNUYSPOR-UHFFFAOYSA-N 0.000 description 2
- DUFZWEVPDMUOFH-ITAUSPCMSA-N 1-[2-[(1R)-1-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-3,3-dimethylbutyl]morpholin-4-yl]ethanone Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)N[C@H](CC(C)(C)C)C1CN(CCO1)C(C)=O DUFZWEVPDMUOFH-ITAUSPCMSA-N 0.000 description 2
- PYQQIHQDQGVHEQ-GOSISDBHSA-N 1-[4-fluoro-4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]piperidin-1-yl]ethanone Chemical compound FC1(CCN(CC1)C(C)=O)CNC1=NC=NC(=C1F)N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F PYQQIHQDQGVHEQ-GOSISDBHSA-N 0.000 description 2
- PHKYTOWTXISLPV-GOSISDBHSA-N 1-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]-N,N-dimethylcyclopentane-1-carboxamide Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCCC1)C(=O)N(C)C PHKYTOWTXISLPV-GOSISDBHSA-N 0.000 description 2
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- CDMRYARHYKNFLS-UHFFFAOYSA-N 2,2-dimethylpentanamide Chemical compound CCCC(C)(C)C(N)=O CDMRYARHYKNFLS-UHFFFAOYSA-N 0.000 description 2
- LSNPFVDQLTUQCE-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrrolidine Chemical compound C1CCNC1C1=CC=C(OCCO2)C2=C1 LSNPFVDQLTUQCE-UHFFFAOYSA-N 0.000 description 2
- WCTZJESQSBXRJL-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)pyrrolidine Chemical compound ClC1=CC(Cl)=CC=C1C1NCCC1 WCTZJESQSBXRJL-UHFFFAOYSA-N 0.000 description 2
- HCBLZPKEGFYHDN-UHFFFAOYSA-N 2-(4-methoxyphenyl)pyrrolidine Chemical compound C1=CC(OC)=CC=C1C1NCCC1 HCBLZPKEGFYHDN-UHFFFAOYSA-N 0.000 description 2
- SSSRLHJWMBEUAF-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenyl]acetamide Chemical compound NC(=O)CC1=CC=C(CO)C=C1 SSSRLHJWMBEUAF-UHFFFAOYSA-N 0.000 description 2
- TYFRVGQDSKRTAV-UHFFFAOYSA-N 2-[4-[[4-(3-phenylmorpholin-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]methyl]phenyl]acetamide Chemical compound C1(=CC=CC=C1)C1N(CCOC1)C=1C2=C(N=CN=1)N(C=C2)CC1=CC=C(C=C1)CC(=O)N TYFRVGQDSKRTAV-UHFFFAOYSA-N 0.000 description 2
- NFYSFWYGGBUUBC-JOCHJYFZSA-N 2-[4-[[4-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrrolo[2,3-d]pyrimidin-7-yl]methyl]phenyl]acetamide Chemical compound FC(C1=CC=C(C=C1)[C@@H]1N(CCC1)C=1C2=C(N=CN=1)N(C=C2)CC1=CC=C(C=C1)CC(=O)N)(F)F NFYSFWYGGBUUBC-JOCHJYFZSA-N 0.000 description 2
- DYLXHPUUYWZVON-JOCHJYFZSA-N 2-[4-[[4-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrrolo[2,3-d]pyrimidin-7-yl]methyl]phenyl]acetic acid Chemical compound FC(C1=CC=C(C=C1)[C@@H]1N(CCC1)C=1C2=C(N=CN=1)N(C=C2)CC1=CC=C(C=C1)CC(=O)O)(F)F DYLXHPUUYWZVON-JOCHJYFZSA-N 0.000 description 2
- GQTGYYHTXTXCKQ-JOCHJYFZSA-N 2-[4-[[4-[(3S)-3-[4-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrrolo[2,3-d]pyrimidin-7-yl]methyl]phenyl]acetamide Chemical compound FC(OC1=CC=C(C=C1)[C@@H]1N(CCOC1)C=1C2=C(N=CN=1)N(C=C2)CC1=CC=C(C=C1)CC(=O)N)(F)F GQTGYYHTXTXCKQ-JOCHJYFZSA-N 0.000 description 2
- SLWVKQOAPGHXAB-OAQYLSRUSA-N 2-[4-[[4-[(3S)-3-[5-(trifluoromethyl)pyridin-2-yl]morpholin-4-yl]pyrrolo[2,3-d]pyrimidin-7-yl]methyl]phenyl]acetamide Chemical compound FC(C=1C=CC(=NC=1)[C@@H]1N(CCOC1)C=1C2=C(N=CN=1)N(C=C2)CC1=CC=C(C=C1)CC(=O)N)(F)F SLWVKQOAPGHXAB-OAQYLSRUSA-N 0.000 description 2
- PYSXYYNAKACDQZ-HXUWFJFHSA-N 2-[4-[[4-[(3S)-3-[6-(trifluoromethyl)pyridin-3-yl]morpholin-4-yl]pyrrolo[2,3-d]pyrimidin-7-yl]methyl]phenyl]acetamide Chemical compound FC(C1=CC=C(C=N1)[C@@H]1N(CCOC1)C=1C2=C(N=CN=1)N(C=C2)CC1=CC=C(C=C1)CC(=O)N)(F)F PYSXYYNAKACDQZ-HXUWFJFHSA-N 0.000 description 2
- DYLXHPUUYWZVON-UHFFFAOYSA-N 2-[4-[[4-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrrolo[2,3-d]pyrimidin-7-yl]methyl]phenyl]acetic acid Chemical compound FC(C1=CC=C(C=C1)C1N(CCC1)C=1C2=C(N=CN=1)N(C=C2)CC1=CC=C(C=C1)CC(=O)O)(F)F DYLXHPUUYWZVON-UHFFFAOYSA-N 0.000 description 2
- WNVAPEUVUWLXHN-UHFFFAOYSA-N 2-[4-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]oxymethyl]phenyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)OCC1=CC=C(C=C1)CC(=O)O WNVAPEUVUWLXHN-UHFFFAOYSA-N 0.000 description 2
- XWJHLQVYWLVYRN-UHFFFAOYSA-N 2-[4-[[5-fluoro-6-[2-[6-(trifluoromethyl)pyridin-3-yl]pyrrolidin-1-yl]pyrimidin-4-yl]oxymethyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C=1C=NC(=CC=1)C(F)(F)F)OCC1=CC=C(C=C1)CC(=O)N XWJHLQVYWLVYRN-UHFFFAOYSA-N 0.000 description 2
- VXHVYOHFMZQWNR-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-(2-phenylpyrrolidin-1-yl)pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=CC=C1)NCC1=CC=C(C=C1)CC(=O)N VXHVYOHFMZQWNR-UHFFFAOYSA-N 0.000 description 2
- CYHBSYRVLMHXGB-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-(3-phenylmorpholin-4-yl)pyrimidin-4-yl]amino]methyl]phenyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1C(COCC1)C1=CC=CC=C1)NCC1=CC=C(C=C1)CC(=O)O CYHBSYRVLMHXGB-UHFFFAOYSA-N 0.000 description 2
- AOQNRSVQXSHZMO-HXUWFJFHSA-N 2-[4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]-N-methylacetamide Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)NC AOQNRSVQXSHZMO-HXUWFJFHSA-N 0.000 description 2
- FGPDUHWVPMJPCC-MOPGFXCFSA-N 2-[4-[[[5-fluoro-6-[(2S,4R)-4-fluoro-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1[C@@H](C[C@H](C1)F)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)N FGPDUHWVPMJPCC-MOPGFXCFSA-N 0.000 description 2
- UCRRMKFZEAERFY-LJQANCHMSA-N 2-[4-[[[5-fluoro-6-[(3S)-3-[2-fluoro-4-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=C(C=C(C=C1)OC(F)(F)F)F)NCC1=CC=C(C=C1)CC(=O)N UCRRMKFZEAERFY-LJQANCHMSA-N 0.000 description 2
- CGHSJERIMKWVDQ-LADRWXRNSA-N 2-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]cyclohexyl]acetamide Chemical compound NC(=O)CC1CCC(CNC2=C(F)C(=NC=N2)N2CCOC[C@@H]2C2=CC=C(OC(F)(F)F)C=C2)CC1 CGHSJERIMKWVDQ-LADRWXRNSA-N 0.000 description 2
- NAFRTQQGXMMCNI-HXUWFJFHSA-N 2-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]phenyl]-N-methylacetamide Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)NC NAFRTQQGXMMCNI-HXUWFJFHSA-N 0.000 description 2
- DNKLHURFZDIRSS-LJQANCHMSA-N 2-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)N DNKLHURFZDIRSS-LJQANCHMSA-N 0.000 description 2
- CIIZCQFNUJKMOK-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-[4-(trifluoromethoxy)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)OC(F)(F)F)NCC1=CC=C(C=C1)CC(=O)O CIIZCQFNUJKMOK-UHFFFAOYSA-N 0.000 description 2
- MBSLOARNCPWLKR-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)N MBSLOARNCPWLKR-UHFFFAOYSA-N 0.000 description 2
- NGGXGCQEPCOPHW-UHFFFAOYSA-N 2-[4-[[[6-[2-(2,4-dimethoxyphenyl)pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound COC1=C(C=CC(=C1)OC)C1N(CCC1)C1=C(C(=NC=N1)NCC1=CC=C(C=C1)CC(=O)N)F NGGXGCQEPCOPHW-UHFFFAOYSA-N 0.000 description 2
- TVYYYHGFTRHEBB-UHFFFAOYSA-N 2-[5-[[[5-fluoro-6-(3-phenylmorpholin-4-yl)pyrimidin-4-yl]amino]methyl]thiophen-2-yl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(COCC1)C1=CC=CC=C1)NCC1=CC=C(S1)CC(=O)N TVYYYHGFTRHEBB-UHFFFAOYSA-N 0.000 description 2
- UXMJSULVNZILDS-UHFFFAOYSA-N 2-[5-[[[5-fluoro-6-(3-phenylmorpholin-4-yl)pyrimidin-4-yl]amino]methyl]thiophen-2-yl]acetic acid Chemical compound FC=1C(=NC=NC=1N1C(COCC1)C1=CC=CC=C1)NCC1=CC=C(S1)CC(=O)O UXMJSULVNZILDS-UHFFFAOYSA-N 0.000 description 2
- YTKAWFHOEDFUOP-UHFFFAOYSA-N 2-pyrrolidin-2-yl-1,3-benzothiazole Chemical compound C1CCNC1C1=NC2=CC=CC=C2S1 YTKAWFHOEDFUOP-UHFFFAOYSA-N 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- KDILELGCKJTGJA-UHFFFAOYSA-N 3-[[2-[4-[2-(4-phenylphenyl)pyrrolidin-1-yl]pyrrolo[2,3-d]pyrimidin-7-yl]butanoylamino]methyl]furan-2-carboxamide Chemical compound C1(=CC=CC=C1)C1=CC=C(C=C1)C1N(CCC1)C=1C2=C(N=CN=1)N(C=C2)C(C(=O)NCC1=C(OC=C1)C(=O)N)CC KDILELGCKJTGJA-UHFFFAOYSA-N 0.000 description 2
- WTXVOYBPTBDXNA-NYRJJRHWSA-N 3-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]oxolan-3-ol Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(COCC1)O WTXVOYBPTBDXNA-NYRJJRHWSA-N 0.000 description 2
- AEJHDUMDGIUZMD-NYRJJRHWSA-N 3-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]thiolan-3-ol Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CSCC1)O AEJHDUMDGIUZMD-NYRJJRHWSA-N 0.000 description 2
- JEVJGIUIOKKUNY-NYRJJRHWSA-N 3-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]oxolan-3-ol Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(COCC1)O JEVJGIUIOKKUNY-NYRJJRHWSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- MHZXKVPCJBPNKI-UHFFFAOYSA-N 3-phenylmorpholine Chemical compound N1CCOCC1C1=CC=CC=C1 MHZXKVPCJBPNKI-UHFFFAOYSA-N 0.000 description 2
- CFQRESDOVUMMOL-UHFFFAOYSA-N 4-[2-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]ethyl]benzoic acid Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCCC1=CC=C(C(=O)O)C=C1 CFQRESDOVUMMOL-UHFFFAOYSA-N 0.000 description 2
- CIMSOBZTMNZVQE-MRXNPFEDSA-N 4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]-1,1-dioxothian-4-ol Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCS(CC1)(=O)=O)O CIMSOBZTMNZVQE-MRXNPFEDSA-N 0.000 description 2
- BUPFBRXCXFEZAC-OAQYLSRUSA-N 4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]-N-(2-methoxyethyl)benzenesulfonamide Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)S(=O)(=O)NCCOC BUPFBRXCXFEZAC-OAQYLSRUSA-N 0.000 description 2
- DVHCZFLUWIWINE-MRXNPFEDSA-N 4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]-1,1-dioxothian-4-ol Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCS(CC1)(=O)=O)O DVHCZFLUWIWINE-MRXNPFEDSA-N 0.000 description 2
- HFCKHXBNZUTBLG-QGZVFWFLSA-N 4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]-N-methyloxane-4-carboxamide Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)C(=O)NC HFCKHXBNZUTBLG-QGZVFWFLSA-N 0.000 description 2
- KOSUHBYYXAQESO-MRXNPFEDSA-N 4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]oxane-4-carboxamide Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)C(=O)N KOSUHBYYXAQESO-MRXNPFEDSA-N 0.000 description 2
- FWKWALJNBKSCET-UHFFFAOYSA-N 4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]-methylamino]methyl]-1-methylpyrrolidin-2-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)N(C)CC1CC(N(C1)C)=O FWKWALJNBKSCET-UHFFFAOYSA-N 0.000 description 2
- ZSQURANBWBPLOA-UHFFFAOYSA-N 4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]oxan-4-ol Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)O ZSQURANBWBPLOA-UHFFFAOYSA-N 0.000 description 2
- JBJWRXXZRHDHPF-UHFFFAOYSA-N 4-[[[5-fluoro-6-[3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]oxane-4-carboxylic acid Chemical compound FC=1C(=NC=NC=1N1C(COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)C(=O)O JBJWRXXZRHDHPF-UHFFFAOYSA-N 0.000 description 2
- LJXVPXRXXVHTBP-UHFFFAOYSA-N 4-chloro-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1CCN2 LJXVPXRXXVHTBP-UHFFFAOYSA-N 0.000 description 2
- AFVCTLSWUKLFSP-UHFFFAOYSA-N 5-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]-1,2-oxazol-3-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC(=NO1)O AFVCTLSWUKLFSP-UHFFFAOYSA-N 0.000 description 2
- BKRGSPZZIKZUOR-UHFFFAOYSA-N 5-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]-3H-1,3,4-oxadiazol-2-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=NN=C(O1)O BKRGSPZZIKZUOR-UHFFFAOYSA-N 0.000 description 2
- XNVDQCNHABMPKR-UHFFFAOYSA-N 5-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]pyrrolidin-2-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCC(N1)=O XNVDQCNHABMPKR-UHFFFAOYSA-N 0.000 description 2
- LCBOTXJEZCKYGN-UHFFFAOYSA-N 5-fluoro-4-[(6-methylpyridin-3-yl)methoxy]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)OCC=1C=NC(=CC=1)C LCBOTXJEZCKYGN-UHFFFAOYSA-N 0.000 description 2
- KYFRIDOUKSDKEJ-UHFFFAOYSA-N 5-fluoro-4-[2-[3-fluoro-4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]-6-[(6-methylpyridin-3-yl)methoxy]pyrimidine Chemical compound FC=1C(=NC=NC=1OCC=1C=NC(=CC=1)C)N1C(CCC1)C1=CC(=C(C=C1)C(F)(F)F)F KYFRIDOUKSDKEJ-UHFFFAOYSA-N 0.000 description 2
- WLTUNDNGKNUZDU-GOSISDBHSA-N 5-fluoro-6-[(2R)-2-[2-fluoro-4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]-N-[(6-methylpyridin-3-yl)methyl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=C(C=C(C=C1)C(F)(F)F)F)NCC=1C=NC(=CC=1)C WLTUNDNGKNUZDU-GOSISDBHSA-N 0.000 description 2
- RERXMFBPOJAUAP-QGZVFWFLSA-N 5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]-N-[[1-(trifluoromethylsulfonyl)piperidin-4-yl]methyl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCN(CC1)S(=O)(=O)C(F)(F)F RERXMFBPOJAUAP-QGZVFWFLSA-N 0.000 description 2
- ZAEKPHPGZIWIAM-UHFFFAOYSA-N 5-fluoro-6-[4-methoxy-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]-N-[(6-methylpyridin-3-yl)methyl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CC(C1)OC)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=NC(=CC=1)C ZAEKPHPGZIWIAM-UHFFFAOYSA-N 0.000 description 2
- MNVHNCWWTUDZGO-UHFFFAOYSA-N 5-fluoro-N-(4-methoxy-4-methylpentan-2-yl)-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NC(CC(C)(C)OC)C MNVHNCWWTUDZGO-UHFFFAOYSA-N 0.000 description 2
- CALXUQPGWRZCEB-ZYMOGRSISA-N 5-fluoro-N-(oxan-2-ylmethyl)-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1OCCCC1 CALXUQPGWRZCEB-ZYMOGRSISA-N 0.000 description 2
- KHNQZMYJWAYSDB-FBMWCMRBSA-N 5-fluoro-N-(oxan-3-ylmethyl)-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1COCCC1 KHNQZMYJWAYSDB-FBMWCMRBSA-N 0.000 description 2
- FPYDJGDAFXEOQM-QGZVFWFLSA-N 5-fluoro-N-(oxan-4-ylmethyl)-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCOCC1 FPYDJGDAFXEOQM-QGZVFWFLSA-N 0.000 description 2
- DFPRVPWLMSMINL-QGZVFWFLSA-N 5-fluoro-N-(oxan-4-ylmethyl)-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCOCC1 DFPRVPWLMSMINL-QGZVFWFLSA-N 0.000 description 2
- YNHKBAHTHSCKSU-OEMAIJDKSA-N 5-fluoro-N-(oxolan-2-ylmethyl)-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1OCCC1 YNHKBAHTHSCKSU-OEMAIJDKSA-N 0.000 description 2
- DNXYOPUKODUMDC-UHFFFAOYSA-N 5-fluoro-N-(pyridin-3-ylmethyl)-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=NC=CC=1 DNXYOPUKODUMDC-UHFFFAOYSA-N 0.000 description 2
- VYMLQPXDSPNCHL-UHFFFAOYSA-N 5-fluoro-N-(pyridin-4-ylmethyl)-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=NC=C1 VYMLQPXDSPNCHL-UHFFFAOYSA-N 0.000 description 2
- RQMRFCHCQMISKG-QGZVFWFLSA-N 5-fluoro-N-(thian-4-ylmethyl)-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCSCC1 RQMRFCHCQMISKG-QGZVFWFLSA-N 0.000 description 2
- UNYZFCLXMOKFKD-OEMAIJDKSA-N 5-fluoro-N-(thiolan-2-ylmethyl)-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1SCCC1 UNYZFCLXMOKFKD-OEMAIJDKSA-N 0.000 description 2
- UQTKURCHPVEKAL-MRXNPFEDSA-N 5-fluoro-N-(thiophen-2-ylmethyl)-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1SC=CC=1 UQTKURCHPVEKAL-MRXNPFEDSA-N 0.000 description 2
- JPKGGPSPBZKMGB-UHFFFAOYSA-N 5-fluoro-N-[(1-methylcyclobutyl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCC1)C JPKGGPSPBZKMGB-UHFFFAOYSA-N 0.000 description 2
- MGHIBRYGAALTQC-UHFFFAOYSA-N 5-fluoro-N-[(1-methylpyrrol-3-yl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CN(C=C1)C MGHIBRYGAALTQC-UHFFFAOYSA-N 0.000 description 2
- UWQTUXITOFGZBY-UHFFFAOYSA-N 5-fluoro-N-[(1-methylsulfonylpiperidin-4-yl)methyl]-6-(3-phenylmorpholin-4-yl)pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(COCC1)C1=CC=CC=C1)NCC1CCN(CC1)S(=O)(=O)C UWQTUXITOFGZBY-UHFFFAOYSA-N 0.000 description 2
- AIPPCEVSEFTNNY-FBMWCMRBSA-N 5-fluoro-N-[(1-methylsulfonylpyrrolidin-3-yl)methyl]-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CN(CC1)S(=O)(=O)C AIPPCEVSEFTNNY-FBMWCMRBSA-N 0.000 description 2
- NHOTXJJCMYJFDZ-QRIPLOBPSA-N 5-fluoro-N-[(2-methyloxolan-2-yl)methyl]-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(OCCC1)C NHOTXJJCMYJFDZ-QRIPLOBPSA-N 0.000 description 2
- LFBWLFFDFNUMGR-OAHLLOKOSA-N 5-fluoro-N-[(3-methyloxetan-3-yl)methyl]-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(COC1)C LFBWLFFDFNUMGR-OAHLLOKOSA-N 0.000 description 2
- JWXDOVFSSFPWMP-MRXNPFEDSA-N 5-fluoro-N-[(4-fluorooxan-4-yl)methyl]-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)F JWXDOVFSSFPWMP-MRXNPFEDSA-N 0.000 description 2
- BLCWPFBTEONXQX-UHFFFAOYSA-N 5-fluoro-N-[(4-methylcyclohexyl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCC(CC1)C BLCWPFBTEONXQX-UHFFFAOYSA-N 0.000 description 2
- NLOJBWHEXFUKMJ-ZYMOGRSISA-N 5-fluoro-N-[(4-methylsulfonylmorpholin-2-yl)methyl]-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CN(CCO1)S(=O)(=O)C NLOJBWHEXFUKMJ-ZYMOGRSISA-N 0.000 description 2
- YYZYUJHEWSUXEL-UHFFFAOYSA-N 5-fluoro-N-[(5-methyl-1,3-oxazol-2-yl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1OC(=CN=1)C YYZYUJHEWSUXEL-UHFFFAOYSA-N 0.000 description 2
- BEAGFXJNVOQISJ-UHFFFAOYSA-N 5-fluoro-N-[(5-methylfuran-2-yl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1OC(=CC=1)C BEAGFXJNVOQISJ-UHFFFAOYSA-N 0.000 description 2
- HXNRPLWULJQYAD-UHFFFAOYSA-N 5-fluoro-N-[(6-methoxypyridin-3-yl)methyl]-N-methyl-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)N(C)CC=1C=NC(=CC=1)OC HXNRPLWULJQYAD-UHFFFAOYSA-N 0.000 description 2
- KUQKVGJHRVAIPK-UHFFFAOYSA-N 5-fluoro-N-[(6-methylpyridin-3-yl)methyl]-6-[2-[4-(trifluoromethoxy)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)OC(F)(F)F)NCC=1C=NC(=CC=1)C KUQKVGJHRVAIPK-UHFFFAOYSA-N 0.000 description 2
- YOOUVOXEFXINSI-UHFFFAOYSA-N 5-fluoro-N-[(6-methylpyridin-3-yl)methyl]-6-[4-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CC(C1)C)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=NC(=CC=1)C YOOUVOXEFXINSI-UHFFFAOYSA-N 0.000 description 2
- JUMBVTQCRFWIGM-QGZVFWFLSA-N 5-fluoro-N-[(6-methylsulfonylpyridin-3-yl)methyl]-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=NC(=CC=1)S(=O)(=O)C JUMBVTQCRFWIGM-QGZVFWFLSA-N 0.000 description 2
- RCXQSIQHIYFBPW-LJQANCHMSA-N 5-fluoro-N-[[4-(2H-tetrazol-5-ylmethyl)phenyl]methyl]-6-[(3S)-3-[4-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)OC(F)(F)F)NCC1=CC=C(C=C1)CC1=NN=NN1 RCXQSIQHIYFBPW-LJQANCHMSA-N 0.000 description 2
- ZANAFRIHMBEOBA-GOSISDBHSA-N 5-fluoro-N-[[4-(methylsulfonylmethyl)oxan-4-yl]methyl]-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)CS(=O)(=O)C ZANAFRIHMBEOBA-GOSISDBHSA-N 0.000 description 2
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 2
- ROJSDJCJUDMREC-UHFFFAOYSA-N 6-[4,4-difluoro-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]-5-fluoro-N-(oxan-4-ylmethyl)pyrimidin-4-amine Chemical compound FC1(CC(N(C1)C1=C(C(=NC=N1)NCC1CCOCC1)F)C1=CC=C(C=C1)C(F)(F)F)F ROJSDJCJUDMREC-UHFFFAOYSA-N 0.000 description 2
- MJAKNNQGSIULMX-UHFFFAOYSA-N 6-[4,4-difluoro-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]-5-fluoro-N-[[4-(methylsulfonylmethyl)oxan-4-yl]methyl]pyrimidin-4-amine Chemical compound FC1(CC(N(C1)C1=C(C(=NC=N1)NCC1(CCOCC1)CS(=O)(=O)C)F)C1=CC=C(C=C1)C(F)(F)F)F MJAKNNQGSIULMX-UHFFFAOYSA-N 0.000 description 2
- PWLCLVRTIZKKMH-UHFFFAOYSA-N 7-[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]-2,7-diazaspiro[4.5]decan-3-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)N1CCCC2(CNC(C2)=O)C1 PWLCLVRTIZKKMH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- ZQSBWQASCRLOTJ-NFJWQWPMSA-N CC(=O)N1CCOC([C@H](N)CC(C)(C)C)C1 Chemical compound CC(=O)N1CCOC([C@H](N)CC(C)(C)C)C1 ZQSBWQASCRLOTJ-NFJWQWPMSA-N 0.000 description 2
- FBQWUQZSZGEFOF-OAHLLOKOSA-N CC(C)(C)C[C@@H](CC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)O Chemical compound CC(C)(C)C[C@@H](CC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)O FBQWUQZSZGEFOF-OAHLLOKOSA-N 0.000 description 2
- LVRFTAZAXQPQHI-RXMQYKEDSA-N CC(C)C[C@@H](O)C(=O)O Chemical compound CC(C)C[C@@H](O)C(=O)O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 description 2
- DJCJOWDAAZEMCI-UHFFFAOYSA-N CC1=NC=C(CO)C=C1 Chemical compound CC1=NC=C(CO)C=C1 DJCJOWDAAZEMCI-UHFFFAOYSA-N 0.000 description 2
- GGSAMCDSFWBGCU-UHFFFAOYSA-N COC(C)(C)CC(C)N Chemical compound COC(C)(C)CC(C)N GGSAMCDSFWBGCU-UHFFFAOYSA-N 0.000 description 2
- GQPZJYLNBFBGKW-UHFFFAOYSA-N COC1=C(CN)C=CC(C)=N1 Chemical compound COC1=C(CN)C=CC(C)=N1 GQPZJYLNBFBGKW-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- QYQFPYXXMLVXIT-UHFFFAOYSA-N ClC=1C2=C(N=CN=1)N(C=C2)CC1=CC(=C(C=C1)OC)OC Chemical compound ClC=1C2=C(N=CN=1)N(C=C2)CC1=CC(=C(C=C1)OC)OC QYQFPYXXMLVXIT-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- CGDBGDLDSVYRRB-MRVPVSSYSA-N FC(C1=CC=C(C=N1)[C@@H]1NCCOC1)(F)F Chemical compound FC(C1=CC=C(C=N1)[C@@H]1NCCOC1)(F)F CGDBGDLDSVYRRB-MRVPVSSYSA-N 0.000 description 2
- HFACUOYDUGAVGJ-UHFFFAOYSA-N FC(F)(F)C1=CN=C(C2CCCC2)C=C1 Chemical compound FC(F)(F)C1=CN=C(C2CCCC2)C=C1 HFACUOYDUGAVGJ-UHFFFAOYSA-N 0.000 description 2
- LHKMMFZULDJJMU-UHFFFAOYSA-N FC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F Chemical compound FC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F LHKMMFZULDJJMU-UHFFFAOYSA-N 0.000 description 2
- KGBCTJKMWIJMBC-UHFFFAOYSA-N FC=1C(=NC=NC=1F)OCC=1C=NC(=NC=1)CC(=O)OC Chemical compound FC=1C(=NC=NC=1F)OCC=1C=NC(=NC=1)CC(=O)OC KGBCTJKMWIJMBC-UHFFFAOYSA-N 0.000 description 2
- FDWTUSFXZZAMNR-JFUAUVDRSA-N FC=1C(=NC=NC=1N1C(CC(C1)C)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC1=CC=C(C=C1)F Chemical compound FC=1C(=NC=NC=1N1C(CC(C1)C)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC1=CC=C(C=C1)F FDWTUSFXZZAMNR-JFUAUVDRSA-N 0.000 description 2
- XLUJDGNXJNMXEN-UHFFFAOYSA-N FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)OCC=1C=NC(=NC=1)CC(=O)O Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)OCC=1C=NC(=NC=1)CC(=O)O XLUJDGNXJNMXEN-UHFFFAOYSA-N 0.000 description 2
- LDPQQIFSWGPJKI-UHFFFAOYSA-N FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)OCC=1C=NC(=NC=1)CC(=O)OC Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)OCC=1C=NC(=NC=1)CC(=O)OC LDPQQIFSWGPJKI-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101000686034 Homo sapiens Nuclear receptor ROR-gamma Proteins 0.000 description 2
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CSWCWWXADLHDIZ-UHFFFAOYSA-N N-(3,3-dimethylbutyl)-5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound CC(CCNC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)(C)C CSWCWWXADLHDIZ-UHFFFAOYSA-N 0.000 description 2
- YUTAYTDSZFZURL-UHFFFAOYSA-N N-(cyclobutylmethyl)-5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1(CCC1)CNC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F YUTAYTDSZFZURL-UHFFFAOYSA-N 0.000 description 2
- LFZUUXIUPTVBBP-QGZVFWFLSA-N N-(cyclopentylmethyl)-5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1(CCCC1)CNC1=NC=NC(=C1F)N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F LFZUUXIUPTVBBP-QGZVFWFLSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- JQGQFGGBTXLASY-XEVCZEQESA-N N-[(1R)-3,3-dimethyl-1-morpholin-2-ylbutyl]-5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound CC(C[C@H](C1CNCCO1)NC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)(C)C JQGQFGGBTXLASY-XEVCZEQESA-N 0.000 description 2
- LLOSNGJIKOEMDJ-UHFFFAOYSA-N N-[1-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)propyl]-5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound O1CCCOC2=C1C=CC(=C2)C(CC)NC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F LLOSNGJIKOEMDJ-UHFFFAOYSA-N 0.000 description 2
- JZCQQUYHZBDBTF-QGZVFWFLSA-N N-[1-[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]piperidin-4-yl]methanesulfonamide Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)N1CCC(CC1)NS(=O)(=O)C JZCQQUYHZBDBTF-QGZVFWFLSA-N 0.000 description 2
- YQAGCOJYOOAYQU-UHFFFAOYSA-N N-benzyl-5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C(C1=CC=CC=C1)NC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F YQAGCOJYOOAYQU-UHFFFAOYSA-N 0.000 description 2
- KULJJAAOTUQMCL-UHFFFAOYSA-N N-cyano-2-[4-[[[5-fluoro-6-[3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound C(#N)NC(CC1=CC=C(C=C1)CNC1=NC=NC(=C1F)N1C(COCC1)C1=CC=C(C=C1)C(F)(F)F)=O KULJJAAOTUQMCL-UHFFFAOYSA-N 0.000 description 2
- KPWSCCOAAYOAKW-UHFFFAOYSA-N N1N=NN=C1CC1CCC(CC1)CN Chemical compound N1N=NN=C1CC1CCC(CC1)CN KPWSCCOAAYOAKW-UHFFFAOYSA-N 0.000 description 2
- NPICNRYVDWYXDE-UHFFFAOYSA-N N1N=NN=C1CC1CCC(CC1)CNC(OC(C)(C)C)=O Chemical compound N1N=NN=C1CC1CCC(CC1)CNC(OC(C)(C)C)=O NPICNRYVDWYXDE-UHFFFAOYSA-N 0.000 description 2
- CSVYITCBZGOVBG-UHFFFAOYSA-N NCC1=CC=C(O)N=C1 Chemical compound NCC1=CC=C(O)N=C1 CSVYITCBZGOVBG-UHFFFAOYSA-N 0.000 description 2
- SIONSKXCPDFBFA-UHFFFAOYSA-N NCC1=CC=C(OCC2CCCO2)C=C1 Chemical compound NCC1=CC=C(OCC2CCCO2)C=C1 SIONSKXCPDFBFA-UHFFFAOYSA-N 0.000 description 2
- WCOCCXZFEJGHTC-UHFFFAOYSA-N O=C(O)CC1=CC=C(CBr)C=C1 Chemical compound O=C(O)CC1=CC=C(CBr)C=C1 WCOCCXZFEJGHTC-UHFFFAOYSA-N 0.000 description 2
- XSZAKZAFMXBHNX-UHFFFAOYSA-N O=C(O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound O=C(O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 XSZAKZAFMXBHNX-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000023984 PPAR alpha Human genes 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 108091008554 ROR receptors Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 2
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- KRZYJYZKRSUDLS-OAHLLOKOSA-N [1-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]cyclopropyl]methanol Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CC1)CO KRZYJYZKRSUDLS-OAHLLOKOSA-N 0.000 description 2
- VOUMVRKTHFMLOV-UHFFFAOYSA-N [3-[[[6-[4,4-difluoro-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]methyl]oxetan-3-yl]methanol Chemical compound FC1(CC(N(C1)C1=C(C(=NC=N1)NCC1(COC1)CO)F)C1=CC=C(C=C1)C(F)(F)F)F VOUMVRKTHFMLOV-UHFFFAOYSA-N 0.000 description 2
- NBYQWCMTKNOMBS-UHFFFAOYSA-N [4-(aminomethyl)phenyl]methanesulfonamide Chemical compound NCC1=CC=C(CS(N)(=O)=O)C=C1 NBYQWCMTKNOMBS-UHFFFAOYSA-N 0.000 description 2
- UVIGZMZSEKYQAZ-UHFFFAOYSA-N [4-(imidazol-1-ylmethyl)phenyl]methanamine Chemical compound C1=CC(CN)=CC=C1CN1C=NC=C1 UVIGZMZSEKYQAZ-UHFFFAOYSA-N 0.000 description 2
- AXGOYOIFQSGSED-UHFFFAOYSA-N [4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]-morpholin-4-ylmethanone Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)C(=O)N1CCOCC1 AXGOYOIFQSGSED-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical compound C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 125000004474 heteroalkylene group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 102000047214 human RORC Human genes 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 229940097275 indigo Drugs 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- IQZZFVDIZRWADY-UHFFFAOYSA-N isocoumarin Chemical compound C1=CC=C2C(=O)OC=CC2=C1 IQZZFVDIZRWADY-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 208000027905 limb weakness Diseases 0.000 description 2
- 231100000861 limb weakness Toxicity 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- LLDQUDYCTIKKFV-UHFFFAOYSA-N methyl 2-[4-(hydroxymethyl)phenyl]acetate Chemical compound COC(=O)CC1=CC=C(CO)C=C1 LLDQUDYCTIKKFV-UHFFFAOYSA-N 0.000 description 2
- QORBVHBFCPNNBF-UHFFFAOYSA-N methyl 4-[[[5-fluoro-6-[3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]oxane-4-carboxylate Chemical compound FC=1C(=NC=NC=1N1C(COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)C(=O)OC QORBVHBFCPNNBF-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- ZYUJVRGNPLWRLU-UHFFFAOYSA-N n-[4-(aminomethyl)cyclohexyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1CCC(CN)CC1 ZYUJVRGNPLWRLU-UHFFFAOYSA-N 0.000 description 2
- RMOMEZIIKPPAFX-UHFFFAOYSA-N n-[4-(aminomethyl)phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound NCC1=CC=C(NS(=O)(=O)C(F)(F)F)C=C1 RMOMEZIIKPPAFX-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108091008726 retinoic acid receptors α Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- RJSSWEFFQSAFSI-UHFFFAOYSA-N tert-butyl n-[(1-oxidopyridin-1-ium-3-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C[N+]([O-])=C1 RJSSWEFFQSAFSI-UHFFFAOYSA-N 0.000 description 2
- HUDXPALPFZECBF-UHFFFAOYSA-N tert-butyl n-[(1-oxidopyridin-1-ium-4-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=[N+]([O-])C=C1 HUDXPALPFZECBF-UHFFFAOYSA-N 0.000 description 2
- QBENUNRDGNUPQJ-UHFFFAOYSA-N tert-butyl n-[(4-fluoropiperidin-4-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1(F)CCNCC1 QBENUNRDGNUPQJ-UHFFFAOYSA-N 0.000 description 2
- DSHSAPVSNPCWLW-UHFFFAOYSA-N tert-butyl n-[[4-(cyanomethyl)cyclohexyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCC(CC#N)CC1 DSHSAPVSNPCWLW-UHFFFAOYSA-N 0.000 description 2
- KSXPGASLEFGROT-UHFFFAOYSA-N tert-butyl n-[[4-(hydroxymethyl)cyclohexyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCC(CO)CC1 KSXPGASLEFGROT-UHFFFAOYSA-N 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 108091008763 thyroid hormone receptors α Proteins 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 102000009310 vitamin D receptors Human genes 0.000 description 2
- 108050000156 vitamin D receptors Proteins 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- YJPBMPPMCQRVHC-UHFFFAOYSA-N (2-methylthiolan-2-yl)methanamine Chemical compound NCC1(C)CCCS1 YJPBMPPMCQRVHC-UHFFFAOYSA-N 0.000 description 1
- SEOQZGKOJIMEHW-CVEARBPZSA-N (2R)-2-[[5-fluoro-6-[(2S)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound FC=1C(=NC=NC=1N1[C@@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)N[C@@H](C(=O)N)CC(C)(C)C SEOQZGKOJIMEHW-CVEARBPZSA-N 0.000 description 1
- GHENBBJRNNWWKY-AAFJCEBUSA-N (2R)-2-[[6-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound O1CCOC2=C1C=CC(=C2)C1N(CCC1)C1=C(C(=NC=N1)N[C@@H](C(=O)N)CC(C)(C)C)F GHENBBJRNNWWKY-AAFJCEBUSA-N 0.000 description 1
- XIODODFTWTTWQZ-MRTLOADZSA-N (2R)-2-[[6-[2-(4-tert-butylphenyl)pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]-4,4-dimethylpentanamide Chemical compound C(C)(C)(C)C1=CC=C(C=C1)C1N(CCC1)C1=C(C(=NC=N1)N[C@@H](C(=O)N)CC(C)(C)C)F XIODODFTWTTWQZ-MRTLOADZSA-N 0.000 description 1
- VVHJGRYLRCCJNN-SNVBAGLBSA-N (3S)-3-[2-fluoro-4-(trifluoromethoxy)phenyl]morpholine Chemical compound FC1=C(C=CC(=C1)OC(F)(F)F)[C@@H]1NCCOC1 VVHJGRYLRCCJNN-SNVBAGLBSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- JYDKRSKRMGGEBM-UHFFFAOYSA-N (4-methylsulfonylmorpholin-2-yl)methanamine Chemical compound CS(=O)(=O)N1CCOC(CN)C1 JYDKRSKRMGGEBM-UHFFFAOYSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- HPARLNRMYDSBNO-UHFFFAOYSA-N 1,4-benzodioxine Chemical compound C1=CC=C2OC=COC2=C1 HPARLNRMYDSBNO-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- WRDHCSRNQXUDMV-UHFFFAOYSA-N 1-(oxan-4-yl)propan-2-amine;hydrochloride Chemical compound Cl.CC(N)CC1CCOCC1 WRDHCSRNQXUDMV-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical class CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- YIWHMEKRMSMXGK-UHFFFAOYSA-N 1-[3-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]pyrrolidin-2-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=C(C=CC=1)N1C(CCC1)=O YIWHMEKRMSMXGK-UHFFFAOYSA-N 0.000 description 1
- KYNQNPSFWOHXJI-UHFFFAOYSA-N 1-[4-(aminomethyl)-4-fluoropiperidin-1-yl]ethanone hydrochloride Chemical compound Cl.CC(=O)N1CCC(F)(CN)CC1 KYNQNPSFWOHXJI-UHFFFAOYSA-N 0.000 description 1
- VOZXFEHDLWMUMH-LJQANCHMSA-N 1-[4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]piperidin-1-yl]ethanone Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCN(CC1)C(C)=O VOZXFEHDLWMUMH-LJQANCHMSA-N 0.000 description 1
- FGDCPELTKCHPGO-UHFFFAOYSA-N 1-[4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]piperidine-3-carboxamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)N1CC(CCC1)C(=O)N FGDCPELTKCHPGO-UHFFFAOYSA-N 0.000 description 1
- YNOPXVNOXLUZIO-UHFFFAOYSA-N 1-[4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]pyrrolidin-2-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)N1C(CCC1)=O YNOPXVNOXLUZIO-UHFFFAOYSA-N 0.000 description 1
- VBNXPZNSYNTVDD-UHFFFAOYSA-N 1-[6-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]-2-methylpyridin-3-yl]ethanol Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C(=N1)C)C(C)O VBNXPZNSYNTVDD-UHFFFAOYSA-N 0.000 description 1
- YMYHGUQDKAUZCO-UHFFFAOYSA-N 1-[[4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]methyl]pyrrolidin-2-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CN1C(CCC1)=O YMYHGUQDKAUZCO-UHFFFAOYSA-N 0.000 description 1
- YXRAGXSNAROKLF-GOSISDBHSA-N 1-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]cycloheptan-1-ol Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCCCCC1)O YXRAGXSNAROKLF-GOSISDBHSA-N 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- 150000003970 1-benzazocines Chemical class 0.000 description 1
- RIVWKTGMEDRLLN-UHFFFAOYSA-N 1-cyclopentyl-4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]pyrrolidin-2-one Chemical compound C1(CCCC1)N1C(CC(C1)CNC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)=O RIVWKTGMEDRLLN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CXSRTRBJDQEIAY-UHFFFAOYSA-N 1-methyl-4-(methylaminomethyl)pyrrolidin-2-one Chemical compound CNCC1CN(C)C(=O)C1 CXSRTRBJDQEIAY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- FGFBEHFJSQBISW-UHFFFAOYSA-N 1h-cyclopenta[b]pyridine Chemical compound C1=CNC2=CC=CC2=C1 FGFBEHFJSQBISW-UHFFFAOYSA-N 0.000 description 1
- LTFBFZBWUKWXID-UHFFFAOYSA-N 1h-cyclopenta[d]pyrimidine Chemical compound N1=CNC2=CC=CC2=C1 LTFBFZBWUKWXID-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- CZOAFZLCFJBDSE-GXOAENINSA-N 2,2,2-trifluoro-N-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]cyclohexyl]ethanesulfonamide Chemical compound FC(CS(=O)(=O)NC1CCC(CC1)CNC1=NC=NC(=C1F)N1[C@H](COCC1)C1=CC=C(C=C1)OC(F)(F)F)(F)F CZOAFZLCFJBDSE-GXOAENINSA-N 0.000 description 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- RMQJFYAFGGOKQJ-UHFFFAOYSA-N 2-(2,4-dimethoxyphenyl)pyrrolidine Chemical compound COC1=CC(OC)=CC=C1C1NCCC1 RMQJFYAFGGOKQJ-UHFFFAOYSA-N 0.000 description 1
- FIRVFEHVSIYTIO-UHFFFAOYSA-N 2-(3-bromophenyl)pyrrolidine Chemical compound BrC1=CC=CC(C2NCCC2)=C1 FIRVFEHVSIYTIO-UHFFFAOYSA-N 0.000 description 1
- SRTPGDGQKPCDMC-UHFFFAOYSA-N 2-(3-chlorophenyl)pyrrolidine Chemical compound ClC1=CC=CC(C2NCCC2)=C1 SRTPGDGQKPCDMC-UHFFFAOYSA-N 0.000 description 1
- QGKFYRMABWIOIW-UHFFFAOYSA-N 2-(3-methoxyphenyl)pyrrolidine Chemical compound COC1=CC=CC(C2NCCC2)=C1 QGKFYRMABWIOIW-UHFFFAOYSA-N 0.000 description 1
- ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 description 1
- YCRDJNYYUAPJGA-UHFFFAOYSA-N 2-[1-[5-fluoro-6-[(1-methylsulfonylpiperidin-4-yl)methylamino]pyrimidin-4-yl]pyrrolidin-2-yl]-5-(trifluoromethyl)phenol Chemical compound FC=1C(=NC=NC=1NCC1CCN(CC1)S(=O)(=O)C)N1C(CCC1)C1=C(C=C(C=C1)C(F)(F)F)O YCRDJNYYUAPJGA-UHFFFAOYSA-N 0.000 description 1
- FZVTZVGYPJOLGS-UHFFFAOYSA-N 2-[2-methoxy-4-(trifluoromethyl)phenyl]pyrrolidine Chemical compound COC1=CC(C(F)(F)F)=CC=C1C1NCCC1 FZVTZVGYPJOLGS-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWZBPBKAANKOJQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenyl]acetic acid Chemical compound OCC1=CC=C(CC(O)=O)C=C1 FWZBPBKAANKOJQ-UHFFFAOYSA-N 0.000 description 1
- LXPQNTNSSNXGIN-UHFFFAOYSA-N 2-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]acetic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(CC(O)=O)C=C1 LXPQNTNSSNXGIN-UHFFFAOYSA-N 0.000 description 1
- ASXSZRPCBALSOV-UHFFFAOYSA-N 2-[4-[[5-fluoro-6-[[4-(trifluoromethyl)phenyl]methylamino]pyrimidin-4-yl]oxymethyl]phenyl]acetic acid Chemical compound FC=1C(=NC=NC=1NCC1=CC=C(C=C1)C(F)(F)F)OCC1=CC=C(C=C1)CC(=O)O ASXSZRPCBALSOV-UHFFFAOYSA-N 0.000 description 1
- HIKDOUMYWAHCCA-LJQANCHMSA-N 2-[4-[[[5-fluoro-6-[(2R)-2-[2-fluoro-4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=C(C=C(C=C1)C(F)(F)F)F)NCC1=CC=C(C=C1)CC(=O)N HIKDOUMYWAHCCA-LJQANCHMSA-N 0.000 description 1
- LBXNBXOPKWAYQZ-GOSISDBHSA-N 2-[4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]oxan-4-yl]ethanol Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)CCO LBXNBXOPKWAYQZ-GOSISDBHSA-N 0.000 description 1
- AJPHRYVIANBLJL-LJQANCHMSA-N 2-[4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)O AJPHRYVIANBLJL-LJQANCHMSA-N 0.000 description 1
- FGPDUHWVPMJPCC-RTBURBONSA-N 2-[4-[[[5-fluoro-6-[(2R,4R)-4-fluoro-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1[C@H](C[C@H](C1)F)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)N FGPDUHWVPMJPCC-RTBURBONSA-N 0.000 description 1
- FGPDUHWVPMJPCC-RBUKOAKNSA-N 2-[4-[[[5-fluoro-6-[(2R,4S)-4-fluoro-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1[C@H](C[C@@H](C1)F)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)N FGPDUHWVPMJPCC-RBUKOAKNSA-N 0.000 description 1
- AJPHRYVIANBLJL-IBGZPJMESA-N 2-[4-[[[5-fluoro-6-[(2S)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1[C@@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)O AJPHRYVIANBLJL-IBGZPJMESA-N 0.000 description 1
- BBUYJAYHBUEDHG-LADRWXRNSA-N 2-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]cyclohexyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)OC(F)(F)F)NCC1CCC(CC1)CC(=O)O BBUYJAYHBUEDHG-LADRWXRNSA-N 0.000 description 1
- XWANYTKJABUMFS-LJQANCHMSA-N 2-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)OC(F)(F)F)NCC1=CC=C(C=C1)CC(=O)N XWANYTKJABUMFS-LJQANCHMSA-N 0.000 description 1
- AQUQPPTUHXNEQQ-LADRWXRNSA-N 2-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]cyclohexyl]acetamide Chemical compound NC(=O)CC1CCC(CNC2=C(F)C(=NC=N2)N2CCOC[C@@H]2C2=CC=C(C=C2)C(F)(F)F)CC1 AQUQPPTUHXNEQQ-LADRWXRNSA-N 0.000 description 1
- WOCBSABIEQLEJC-LADRWXRNSA-N 2-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]cyclohexyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCC(CC1)CC(=O)O WOCBSABIEQLEJC-LADRWXRNSA-N 0.000 description 1
- OKECLIUEXFOGKH-LBXVMSDZSA-N 2-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]cyclohexyl]acetonitrile Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCC(CC1)CC#N OKECLIUEXFOGKH-LBXVMSDZSA-N 0.000 description 1
- RSHCUYMKMUGUND-GOSISDBHSA-N 2-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]oxan-4-yl]ethanol Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)CCO RSHCUYMKMUGUND-GOSISDBHSA-N 0.000 description 1
- IATNIOVCHFSFTA-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-(3-methoxyphenyl)pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC(=CC=C1)OC)NCC1=CC=C(C=C1)CC(=O)N IATNIOVCHFSFTA-UHFFFAOYSA-N 0.000 description 1
- JGWVPQMSLZQODU-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-(4-hydroxyphenyl)pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)O)NCC1=CC=C(C=C1)CC(=O)N JGWVPQMSLZQODU-UHFFFAOYSA-N 0.000 description 1
- ALKKURDGPRLYFX-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-(4-methylphenyl)pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C)NCC1=CC=C(C=C1)CC(=O)N ALKKURDGPRLYFX-UHFFFAOYSA-N 0.000 description 1
- HNCAEHSWEWEPSG-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-(4-propan-2-ylphenyl)pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(C)C)NCC1=CC=C(C=C1)CC(=O)N HNCAEHSWEWEPSG-UHFFFAOYSA-N 0.000 description 1
- UGVIBTVUDSUJDC-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=NOC(=N1)C)NCC1=CC=C(C=C1)CC(=O)N UGVIBTVUDSUJDC-UHFFFAOYSA-N 0.000 description 1
- KYSSXDQQZCGDBX-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-(5-methylfuran-2-yl)pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C=1OC(=CC=1)C)NCC1=CC=C(C=C1)CC(=O)N KYSSXDQQZCGDBX-UHFFFAOYSA-N 0.000 description 1
- FEAIWBGVRKOVTC-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-[2-hydroxy-4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=C(C=C(C=C1)C(F)(F)F)O)NCC1=CC=C(C=C1)CC(=O)N FEAIWBGVRKOVTC-UHFFFAOYSA-N 0.000 description 1
- YEZPOIUIJCDJQC-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]piperidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)N YEZPOIUIJCDJQC-UHFFFAOYSA-N 0.000 description 1
- IGDZGKSWZCVZEU-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]cyclohexyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCC(CC1)CC(=O)O IGDZGKSWZCVZEU-UHFFFAOYSA-N 0.000 description 1
- AJPHRYVIANBLJL-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)O AJPHRYVIANBLJL-UHFFFAOYSA-N 0.000 description 1
- OJRDMAZGCPLYSK-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]ethanol Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CCO OJRDMAZGCPLYSK-UHFFFAOYSA-N 0.000 description 1
- HJJWMARAXUXWSH-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[2-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)(C1=CC=C(C=C1)C(F)(F)F)C)NCC1=CC=C(C=C1)CC(=O)N HJJWMARAXUXWSH-UHFFFAOYSA-N 0.000 description 1
- NMEZNXCJKHMXQI-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[3-[4-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1C(COCC1)C1=CC=C(C=C1)OC(F)(F)F)NCC1=CC=C(C=C1)CC(=O)O NMEZNXCJKHMXQI-UHFFFAOYSA-N 0.000 description 1
- QTCKMQOQJMGLFF-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetic acid Chemical compound FC=1C(=NC=NC=1N1C(COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)O QTCKMQOQJMGLFF-UHFFFAOYSA-N 0.000 description 1
- YSKDAIRVRGXQDD-UHFFFAOYSA-N 2-[4-[[[5-fluoro-6-[4-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CC(C1)C)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CC(=O)N YSKDAIRVRGXQDD-UHFFFAOYSA-N 0.000 description 1
- QBKYQEWCZFFVGY-UHFFFAOYSA-N 2-[4-[[[6-[2-(1,3-benzothiazol-2-yl)pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound S1C(=NC2=C1C=CC=C2)C1N(CCC1)C1=C(C(=NC=N1)NCC1=CC=C(C=C1)CC(=O)N)F QBKYQEWCZFFVGY-UHFFFAOYSA-N 0.000 description 1
- LLXVHOKUSUSGAB-UHFFFAOYSA-N 2-[4-[[[6-[2-(1,3-dimethylpyrazol-4-yl)pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound CN1N=C(C(=C1)C1N(CCC1)C1=C(C(=NC=N1)NCC1=CC=C(C=C1)CC(=O)N)F)C LLXVHOKUSUSGAB-UHFFFAOYSA-N 0.000 description 1
- HNHAQURUMYKPEB-UHFFFAOYSA-N 2-[4-[[[6-[2-(3-bromophenyl)pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound BrC=1C=C(C=CC=1)C1N(CCC1)C1=C(C(=NC=N1)NCC1=CC=C(C=C1)CC(=O)N)F HNHAQURUMYKPEB-UHFFFAOYSA-N 0.000 description 1
- SJWFJJMVFXHDFV-UHFFFAOYSA-N 2-[4-[[[6-[2-(3-chlorophenyl)pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound ClC=1C=C(C=CC=1)C1N(CCC1)C1=C(C(=NC=N1)NCC1=CC=C(C=C1)CC(=O)N)F SJWFJJMVFXHDFV-UHFFFAOYSA-N 0.000 description 1
- UWNAZOAYLQYFEL-UHFFFAOYSA-N 2-[4-[[[6-[2-(4-ethoxyphenyl)pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound C(C)OC1=CC=C(C=C1)C1N(CCC1)C1=C(C(=NC=N1)NCC1=CC=C(C=C1)CC(=O)N)F UWNAZOAYLQYFEL-UHFFFAOYSA-N 0.000 description 1
- PXJNPYRFKUPRBK-UHFFFAOYSA-N 2-[4-[[[6-[2-(5-ethylfuran-2-yl)pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound C(C)C1=CC=C(O1)C1N(CCC1)C1=C(C(=NC=N1)NCC1=CC=C(C=C1)CC(=O)N)F PXJNPYRFKUPRBK-UHFFFAOYSA-N 0.000 description 1
- UMPRHQCTZDBDDC-UHFFFAOYSA-N 2-[4-[[[6-[4,4-difluoro-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]-5-fluoropyrimidin-4-yl]amino]methyl]phenyl]acetamide Chemical compound FC1(CC(N(C1)C1=C(C(=NC=N1)NCC1=CC=C(C=C1)CC(=O)N)F)C1=CC=C(C=C1)C(F)(F)F)F UMPRHQCTZDBDDC-UHFFFAOYSA-N 0.000 description 1
- XXMYSHXIIUGTIE-QGZVFWFLSA-N 2-[5-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]thiophen-2-yl]acetic acid Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(S1)CC(=O)O XXMYSHXIIUGTIE-QGZVFWFLSA-N 0.000 description 1
- OOFXMLGLUUTOTD-UHFFFAOYSA-N 2-[5-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]pyrimidin-2-yl]acetamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=NC(=NC=1)CC(=O)N OOFXMLGLUUTOTD-UHFFFAOYSA-N 0.000 description 1
- QUKOHVGDEMUVTL-IIIMJFFVSA-N 2-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]cyclohexan-1-ol Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1C(CCCC1)O QUKOHVGDEMUVTL-IIIMJFFVSA-N 0.000 description 1
- GBFCYTZHLLASSZ-PDDLGQBUSA-N 2-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]-2-methylcyclohexan-1-ol Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(C(CCCC1)O)C GBFCYTZHLLASSZ-PDDLGQBUSA-N 0.000 description 1
- QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- NEURYOYRKPFLKH-UHFFFAOYSA-N 2-chloro-1-isocyanato-4-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC=C(N=C=O)C(Cl)=C1 NEURYOYRKPFLKH-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- JUTDHSGANMHVIC-UHFFFAOYSA-N 2-phenylpyrrolidine Chemical compound C1CCNC1C1=CC=CC=C1 JUTDHSGANMHVIC-UHFFFAOYSA-N 0.000 description 1
- ZCZJZHBJWUIBJR-UHFFFAOYSA-N 2-pyrrolidin-2-yl-5-(trifluoromethyl)pyridine Chemical compound N1C(CCC1)C1=NC=C(C=C1)C(F)(F)F ZCZJZHBJWUIBJR-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical compound C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- FEAVXMPFTQROEI-UHFFFAOYSA-N 2h-pyrano[3,2-b]pyridine Chemical compound C1=CN=C2C=CCOC2=C1 FEAVXMPFTQROEI-UHFFFAOYSA-N 0.000 description 1
- SHASOVNNKCSWPT-UHFFFAOYSA-N 2h-pyrido[2,3-e]oxazine Chemical compound C1=CN=C2C=CNOC2=C1 SHASOVNNKCSWPT-UHFFFAOYSA-N 0.000 description 1
- WQEBRZKYXXZALY-UHFFFAOYSA-N 2h-pyrido[2,3-e]thiazine Chemical compound C1=CN=C2C=CNSC2=C1 WQEBRZKYXXZALY-UHFFFAOYSA-N 0.000 description 1
- SQMFHXCAROIIPN-UHFFFAOYSA-N 2h-pyrido[2,3-h][1,2]benzothiazine Chemical compound C1=CC2=NC=CC=C2C2=C1C=CNS2 SQMFHXCAROIIPN-UHFFFAOYSA-N 0.000 description 1
- UOYFHFMEIJQMDL-UHFFFAOYSA-N 2h-pyrimido[4,5-e]oxazine Chemical compound N1=CN=C2C=CNOC2=C1 UOYFHFMEIJQMDL-UHFFFAOYSA-N 0.000 description 1
- LATZNTJAPMNLAZ-UHFFFAOYSA-N 2h-pyrimido[4,5-e]thiazine Chemical compound N1=CN=C2C=CNSC2=C1 LATZNTJAPMNLAZ-UHFFFAOYSA-N 0.000 description 1
- ONJRTQUWKRDCTA-UHFFFAOYSA-N 2h-thiochromene Chemical compound C1=CC=C2C=CCSC2=C1 ONJRTQUWKRDCTA-UHFFFAOYSA-N 0.000 description 1
- CBHTTYDJRXOHHL-UHFFFAOYSA-N 2h-triazolo[4,5-c]pyridazine Chemical compound N1=NC=CC2=C1N=NN2 CBHTTYDJRXOHHL-UHFFFAOYSA-N 0.000 description 1
- WPWNEKFMGCWNPR-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene Chemical compound C1=CC=C2CCCSC2=C1 WPWNEKFMGCWNPR-UHFFFAOYSA-N 0.000 description 1
- HBXMNLJLIGPTDU-UHFFFAOYSA-N 3-[4-(trifluoromethoxy)phenyl]morpholine Chemical compound FC(OC1=CC=C(C=C1)C1NCCOC1)(F)F HBXMNLJLIGPTDU-UHFFFAOYSA-N 0.000 description 1
- JOXDCDWRPBYJIL-UHFFFAOYSA-N 3-[[4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]methyl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CN1C(NC(C1=O)(C)C)=O JOXDCDWRPBYJIL-UHFFFAOYSA-N 0.000 description 1
- JUDMBZXTZBFTJN-UHFFFAOYSA-N 3-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]-N,N-dimethylbenzamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=C(C(=O)N(C)C)C=CC=1 JUDMBZXTZBFTJN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LDQJLODBECTKKT-UHFFFAOYSA-N 3-fluoro-N-[(6-methylpyridin-3-yl)methyl]-4-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyridin-2-amine Chemical compound FC=1C(=NC=CC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=NC(=CC=1)C LDQJLODBECTKKT-UHFFFAOYSA-N 0.000 description 1
- AGSAKIVVCZROSV-UHFFFAOYSA-N 3-methyl-1-(2h-tetrazol-5-yl)butan-1-amine Chemical compound CC(C)CC(N)C=1N=NNN=1 AGSAKIVVCZROSV-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZOLNSECVOZFNLU-UHFFFAOYSA-N 3h-1,2-benzoxathiole Chemical compound C1=CC=C2CSOC2=C1 ZOLNSECVOZFNLU-UHFFFAOYSA-N 0.000 description 1
- VKOGKKXJOIMSPG-UHFFFAOYSA-N 3h-oxathiolo[4,3-b]pyridine Chemical compound C1=CN=C2COSC2=C1 VKOGKKXJOIMSPG-UHFFFAOYSA-N 0.000 description 1
- OHUHAOFESPFVBE-UHFFFAOYSA-N 3h-oxathiolo[4,3-d]pyrimidine Chemical compound N1=CN=C2COSC2=C1 OHUHAOFESPFVBE-UHFFFAOYSA-N 0.000 description 1
- CGPIFQOTBHKPNM-UHFFFAOYSA-N 4-(aminomethyl)oxan-4-ol Chemical compound NCC1(O)CCOCC1 CGPIFQOTBHKPNM-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- PPSATQATAPMFIW-UHFFFAOYSA-N 4-[4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]piperazin-2-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)N1CC(NCC1)=O PPSATQATAPMFIW-UHFFFAOYSA-N 0.000 description 1
- AZEKNJGFCSHZID-UHFFFAOYSA-N 4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]cyclohexane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NCC1CCC(C(O)=O)CC1 AZEKNJGFCSHZID-UHFFFAOYSA-N 0.000 description 1
- PPAKGYCMHBCBDN-GOSISDBHSA-N 4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]benzamide Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C(=O)N)C=C1 PPAKGYCMHBCBDN-GOSISDBHSA-N 0.000 description 1
- QTJHQIGMMZIBGZ-GOSISDBHSA-N 4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]benzenesulfonamide Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)S(=O)(=O)N QTJHQIGMMZIBGZ-GOSISDBHSA-N 0.000 description 1
- YFRAMJMDFIUCEH-GOSISDBHSA-N 4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]benzenesulfonic acid Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)S(=O)(=O)O YFRAMJMDFIUCEH-GOSISDBHSA-N 0.000 description 1
- VRNPGKSCAHOTFU-UHFFFAOYSA-N 4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]benzoic acid Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C(=O)O)C=C1 VRNPGKSCAHOTFU-UHFFFAOYSA-N 0.000 description 1
- MQSYACYPYHJPKJ-UHFFFAOYSA-N 4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]benzonitrile Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C#N)C=C1 MQSYACYPYHJPKJ-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- NIVJZQZGIBLJNB-UHFFFAOYSA-N 4-pyrrolidin-2-ylphenol Chemical compound C1=CC(O)=CC=C1C1NCCC1 NIVJZQZGIBLJNB-UHFFFAOYSA-N 0.000 description 1
- FOSKMRJXXHGXKB-UHFFFAOYSA-N 5-[4-(trifluoromethyl)phenyl]pyrrolidin-3-one Chemical compound FC(C1=CC=C(C=C1)C1CC(CN1)=O)(F)F FOSKMRJXXHGXKB-UHFFFAOYSA-N 0.000 description 1
- IMFJFCRAPYGWTH-UHFFFAOYSA-N 5-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]-1,3-dihydroindol-2-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=C2CC(NC2=CC=1)=O IMFJFCRAPYGWTH-UHFFFAOYSA-N 0.000 description 1
- UWOWFVMSZRCOQR-UHFFFAOYSA-N 5-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]-1H-pyridin-2-one Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=CC(=NC=1)O UWOWFVMSZRCOQR-UHFFFAOYSA-N 0.000 description 1
- PCMZTQMGFCJUQL-UHFFFAOYSA-N 5-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]-N,N-dimethyloxolane-2-carboxamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCC(O1)C(=O)N(C)C PCMZTQMGFCJUQL-UHFFFAOYSA-N 0.000 description 1
- CUTZHFRSCZZCIS-UHFFFAOYSA-N 5-fluoro-6-[2-(4-methoxyphenyl)pyrrolidin-1-yl]-N-[(6-methylpyridin-3-yl)methyl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)OC)NCC=1C=NC(=CC=1)C CUTZHFRSCZZCIS-UHFFFAOYSA-N 0.000 description 1
- CWDNLSYUBPIFFV-UHFFFAOYSA-N 5-fluoro-6-[2-(5-methylfuran-2-yl)pyrrolidin-1-yl]-N-[(6-methylpyridin-3-yl)methyl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C=1OC(=CC=1)C)NCC=1C=NC(=CC=1)C CWDNLSYUBPIFFV-UHFFFAOYSA-N 0.000 description 1
- NRCSJSNNGHNSKF-GOSISDBHSA-N 5-fluoro-N-[(1-methylsulfonylpiperidin-4-yl)methyl]-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCN(CC1)S(=O)(=O)C NRCSJSNNGHNSKF-GOSISDBHSA-N 0.000 description 1
- GFTMNFLPDOWNQG-GOSISDBHSA-N 5-fluoro-N-[(1-methylsulfonylpiperidin-4-yl)methyl]-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCN(CC1)S(=O)(=O)C GFTMNFLPDOWNQG-GOSISDBHSA-N 0.000 description 1
- QNHCXYGWAVBEEH-QGZVFWFLSA-N 5-fluoro-N-[(1-oxidopyridin-1-ium-4-yl)methyl]-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=[N+](C=C1)[O-] QNHCXYGWAVBEEH-QGZVFWFLSA-N 0.000 description 1
- QBMQUFWDKZJPCM-UHFFFAOYSA-N 5-fluoro-N-[(2-methoxy-6-methylpyridin-3-yl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C(=NC(=CC=1)C)OC QBMQUFWDKZJPCM-UHFFFAOYSA-N 0.000 description 1
- IFWCIKLKGGRFSU-UHFFFAOYSA-N 5-fluoro-N-[(2-methoxypyridin-4-yl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC(=NC=C1)OC IFWCIKLKGGRFSU-UHFFFAOYSA-N 0.000 description 1
- VOKOLTIQHVGHAO-UHFFFAOYSA-N 5-fluoro-N-[(3-methyloxetan-3-yl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(COC1)C VOKOLTIQHVGHAO-UHFFFAOYSA-N 0.000 description 1
- ADEOJEPWHLJNDN-UHFFFAOYSA-N 5-fluoro-N-[(4-methoxyoxan-4-yl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)OC ADEOJEPWHLJNDN-UHFFFAOYSA-N 0.000 description 1
- NZVGRJQPAXUURI-UHFFFAOYSA-N 5-fluoro-N-[(4-methoxypyridin-2-yl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=NC=CC(=C1)OC NZVGRJQPAXUURI-UHFFFAOYSA-N 0.000 description 1
- RMGVTLQMDWKEMC-QGZVFWFLSA-N 5-fluoro-N-[(4-methyloxan-4-yl)methyl]-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)C RMGVTLQMDWKEMC-QGZVFWFLSA-N 0.000 description 1
- XZLAEMCOHAELQG-LJQANCHMSA-N 5-fluoro-N-[(4-methylsulfonylphenyl)methyl]-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)S(=O)(=O)C XZLAEMCOHAELQG-LJQANCHMSA-N 0.000 description 1
- ZRTBXVXGVQWWEW-UHFFFAOYSA-N 5-fluoro-N-[(4-morpholin-4-ylphenyl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)N1CCOCC1 ZRTBXVXGVQWWEW-UHFFFAOYSA-N 0.000 description 1
- MJVHAOTVQRPOFM-WIXQSORDSA-N 5-fluoro-N-[(4-propan-2-ylcyclohexyl)methyl]-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCC(CC1)C(C)C MJVHAOTVQRPOFM-WIXQSORDSA-N 0.000 description 1
- XXYUEXXCUNESEI-UHFFFAOYSA-N 5-fluoro-N-[(6-methoxypyridin-3-yl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=NC(=CC=1)OC XXYUEXXCUNESEI-UHFFFAOYSA-N 0.000 description 1
- PACGUNMNJUGMHF-UHFFFAOYSA-N 5-fluoro-N-[(6-methylpyridin-2-yl)methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=NC(=CC=C1)C PACGUNMNJUGMHF-UHFFFAOYSA-N 0.000 description 1
- JJYFOOTWPUUNBR-UHFFFAOYSA-N 5-fluoro-N-[(6-methylpyridin-3-yl)methyl]-6-[5-[4-(trifluoromethyl)phenyl]triazol-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1N=NC=C1C1=CC=C(C=C1)C(F)(F)F)NCC=1C=NC(=CC=1)C JJYFOOTWPUUNBR-UHFFFAOYSA-N 0.000 description 1
- XUWFEXZRWAKPAH-UHFFFAOYSA-N 5-fluoro-N-[3-methyl-1-(2H-tetrazol-5-yl)butyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NC(CC(C)C)C1=NN=NN1 XUWFEXZRWAKPAH-UHFFFAOYSA-N 0.000 description 1
- HSVVLPOVGBCCRB-QGZVFWFLSA-N 5-fluoro-N-[[1-(methoxymethyl)cyclobutyl]methyl]-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCC1)COC HSVVLPOVGBCCRB-QGZVFWFLSA-N 0.000 description 1
- MXHJEOBMKJDRDU-UHFFFAOYSA-N 5-fluoro-N-[[3-(1,2,4-triazol-1-ylmethyl)phenyl]methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC(=CC=C1)CN1N=CN=C1 MXHJEOBMKJDRDU-UHFFFAOYSA-N 0.000 description 1
- URJGNHQOOXXUFG-UHFFFAOYSA-N 5-fluoro-N-[[3-(methoxymethyl)phenyl]methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC(=CC=C1)COC URJGNHQOOXXUFG-UHFFFAOYSA-N 0.000 description 1
- LNYIIQLGAWHKAZ-UHFFFAOYSA-N 5-fluoro-N-[[4-(1,2,4-triazol-1-ylmethyl)phenyl]methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CN1N=CN=C1 LNYIIQLGAWHKAZ-UHFFFAOYSA-N 0.000 description 1
- XNBUIXZHLSGPTJ-UHFFFAOYSA-N 5-fluoro-N-[[4-(2H-tetrazol-5-yl)phenyl]methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)C1=NN=NN1 XNBUIXZHLSGPTJ-UHFFFAOYSA-N 0.000 description 1
- UODSZXVKBOSOCE-LADRWXRNSA-N 5-fluoro-N-[[4-(2H-tetrazol-5-ylmethyl)cyclohexyl]methyl]-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCC(CC1)CC1=NN=NN1 UODSZXVKBOSOCE-LADRWXRNSA-N 0.000 description 1
- XNDKAFUEJJVVIM-LADRWXRNSA-N 5-fluoro-N-[[4-(2H-tetrazol-5-ylmethyl)cyclohexyl]methyl]-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1CCC(CC1)CC1=NN=NN1 XNDKAFUEJJVVIM-LADRWXRNSA-N 0.000 description 1
- VKJIJJVLIMEDIK-UHFFFAOYSA-N 5-fluoro-N-[[4-(imidazol-1-ylmethyl)phenyl]methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CN1C=NC=C1 VKJIJJVLIMEDIK-UHFFFAOYSA-N 0.000 description 1
- CETMZMGKDXUXJU-GOSISDBHSA-N 5-fluoro-N-[[4-(methylsulfonylmethyl)oxan-4-yl]methyl]-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1(CCOCC1)CS(=O)(=O)C CETMZMGKDXUXJU-GOSISDBHSA-N 0.000 description 1
- OOHNDLBHFMRNBA-UHFFFAOYSA-N 5-fluoro-N-[[4-(methylsulfonylmethyl)phenyl]methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CS(=O)(=O)C OOHNDLBHFMRNBA-UHFFFAOYSA-N 0.000 description 1
- BEHZGVTXDPJISI-UHFFFAOYSA-N 5-fluoro-N-[[4-(oxolan-2-ylmethoxy)phenyl]methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)OCC1OCCC1 BEHZGVTXDPJISI-UHFFFAOYSA-N 0.000 description 1
- ZGIFRGXLSAIPTK-UHFFFAOYSA-N 5-fluoro-N-[[4-(trifluoromethyl)phenyl]methyl]-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)C(F)(F)F ZGIFRGXLSAIPTK-UHFFFAOYSA-N 0.000 description 1
- HFTVJMFWJUFBNO-UHFFFAOYSA-N 5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC=CC2=N1 HFTVJMFWJUFBNO-UHFFFAOYSA-N 0.000 description 1
- LXJWTBIPBFBGFV-UHFFFAOYSA-N 6h-pyrano[3,2-d]pyrimidine Chemical compound N1=CN=C2C=CCOC2=C1 LXJWTBIPBFBGFV-UHFFFAOYSA-N 0.000 description 1
- PHQVXPYZZSPBHC-UHFFFAOYSA-N 6h-thiopyrano[3,2-d]pyrimidine Chemical compound N1=CN=C2C=CCSC2=C1 PHQVXPYZZSPBHC-UHFFFAOYSA-N 0.000 description 1
- CCDMBTCSHSROMD-UHFFFAOYSA-N 7h-thieno[3,2-c]diazepine Chemical compound C1=CN=NC2=CCSC2=C1 CCDMBTCSHSROMD-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- GMUKUOKRNXFJKD-UHFFFAOYSA-N C(C)(=O)N1CCC(CC1)(F)CNC(OC(C)(C)C)=O Chemical compound C(C)(=O)N1CCC(CC1)(F)CNC(OC(C)(C)C)=O GMUKUOKRNXFJKD-UHFFFAOYSA-N 0.000 description 1
- QHBYGJLVFNLHRB-UHFFFAOYSA-N C1=CC2=CC(C3CCCN3)=CC=C2N=C1 Chemical compound C1=CC2=CC(C3CCCN3)=CC=C2N=C1 QHBYGJLVFNLHRB-UHFFFAOYSA-N 0.000 description 1
- VFTXXPDSXZVEAD-UHFFFAOYSA-N C1=CC=C(C2=CC=C(C3CCCN3)C=C2)C=C1 Chemical compound C1=CC=C(C2=CC=C(C3CCCN3)C=C2)C=C1 VFTXXPDSXZVEAD-UHFFFAOYSA-N 0.000 description 1
- AVVPWXPJNPXAFS-UHFFFAOYSA-N C1=CC=C(C2CCCOC2)C=C1 Chemical compound C1=CC=C(C2CCCOC2)C=C1 AVVPWXPJNPXAFS-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- GZCNEVKOAPHDEZ-OAQYLSRUSA-N CC(=O)N1CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound CC(=O)N1CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 GZCNEVKOAPHDEZ-OAQYLSRUSA-N 0.000 description 1
- NLHYOWAZEDRLOI-OAQYLSRUSA-N CC(=O)N1CCC(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound CC(=O)N1CCC(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 NLHYOWAZEDRLOI-OAQYLSRUSA-N 0.000 description 1
- JFBLTILAHRPXNP-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C2CCCN2)C=C1 Chemical compound CC(C)(C)C1=CC=C(C2CCCN2)C=C1 JFBLTILAHRPXNP-UHFFFAOYSA-N 0.000 description 1
- SCHBQCYBYLZBQB-JRSYVHTFSA-N CC(C)(C)C1OCCCC1CCc1ncnc(N2CCC[C@@H]2c2ccc(C(F)(F)F)cc2)c1F Chemical compound CC(C)(C)C1OCCCC1CCc1ncnc(N2CCC[C@@H]2c2ccc(C(F)(F)F)cc2)c1F SCHBQCYBYLZBQB-JRSYVHTFSA-N 0.000 description 1
- GPWHFPWZAPOYNO-UHFFFAOYSA-N CC(C)(C)CCN Chemical compound CC(C)(C)CCN GPWHFPWZAPOYNO-UHFFFAOYSA-N 0.000 description 1
- LPBSHGLDBQBSPI-RXMQYKEDSA-N CC(C)(C)C[C@@H](N)C(=O)O Chemical compound CC(C)(C)C[C@@H](N)C(=O)O LPBSHGLDBQBSPI-RXMQYKEDSA-N 0.000 description 1
- YUXNIJKQMCWHNM-VEDVMXKPSA-N CC(C)(C)C[C@@H](N)C1CNCCO1 Chemical compound CC(C)(C)C[C@@H](N)C1CNCCO1 YUXNIJKQMCWHNM-VEDVMXKPSA-N 0.000 description 1
- OCJXWXGVDQCFJW-ZCFIWIBFSA-N CC(C)(C)C[C@@H](N)CO Chemical compound CC(C)(C)C[C@@H](N)CO OCJXWXGVDQCFJW-ZCFIWIBFSA-N 0.000 description 1
- QFOWQLCFQVQUKB-HZPDHXFCSA-N CC(C)(C)C[C@@H](NC1=NC=NC(N2CCC[C@@H]2C2=CC=C(C(F)(F)F)C=C2)=C1F)C(=O)O Chemical compound CC(C)(C)C[C@@H](NC1=NC=NC(N2CCC[C@@H]2C2=CC=C(C(F)(F)F)C=C2)=C1F)C(=O)O QFOWQLCFQVQUKB-HZPDHXFCSA-N 0.000 description 1
- SEOQZGKOJIMEHW-AAFJCEBUSA-N CC(C)(C)C[C@@H](Nc1ncnc(N2CCCC2c2ccc(C(F)(F)F)cc2)c1F)C(N)=O Chemical compound CC(C)(C)C[C@@H](Nc1ncnc(N2CCCC2c2ccc(C(F)(F)F)cc2)c1F)C(N)=O SEOQZGKOJIMEHW-AAFJCEBUSA-N 0.000 description 1
- FSPIBWBEJPTYLM-AAFJCEBUSA-N CC(C)(C)C[C@@H](Nc1ncnc(N2CCCC2c2ccc(C(F)(F)F)cc2Cl)c1F)C(N)=O Chemical compound CC(C)(C)C[C@@H](Nc1ncnc(N2CCCC2c2ccc(C(F)(F)F)cc2Cl)c1F)C(N)=O FSPIBWBEJPTYLM-AAFJCEBUSA-N 0.000 description 1
- FBKLOZLXQUHYFE-MRTLOADZSA-N CC(C)(C)C[C@@H](Nc1ncnc(N2CCCC2c2ccc(OC(C)(C)C)cc2)c1F)C(N)=O Chemical compound CC(C)(C)C[C@@H](Nc1ncnc(N2CCCC2c2ccc(OC(C)(C)C)cc2)c1F)C(N)=O FBKLOZLXQUHYFE-MRTLOADZSA-N 0.000 description 1
- LWPCHAFTUFHFBK-GVBTYQQHSA-N CC(C)(C)C[C@H](C(N)=O)NC(C1F)NC[N]2(CCCCCCCCC2)C1N(CCC1)C1c(ccc(Cl)c1)c1Cl Chemical compound CC(C)(C)C[C@H](C(N)=O)NC(C1F)NC[N]2(CCCCCCCCC2)C1N(CCC1)C1c(ccc(Cl)c1)c1Cl LWPCHAFTUFHFBK-GVBTYQQHSA-N 0.000 description 1
- JBGWTRAYKKEYMW-SSDOTTSWSA-N CC(C)(C)C[C@H](C(NC)=O)NC Chemical compound CC(C)(C)C[C@H](C(NC)=O)NC JBGWTRAYKKEYMW-SSDOTTSWSA-N 0.000 description 1
- GHENBBJRNNWWKY-VYRBHSGPSA-N CC(C)(C)C[C@H](Nc1ncnc(N2CCCC2c2ccc3c(c2)OCCO3)c1F)C(N)=O Chemical compound CC(C)(C)C[C@H](Nc1ncnc(N2CCCC2c2ccc3c(c2)OCCO3)c1F)C(N)=O GHENBBJRNNWWKY-VYRBHSGPSA-N 0.000 description 1
- NPWGFVDIIRRGMF-OYKVQYDMSA-N CC(C)(C)C[C@H](Nc1ncnc(N2CCCC2c2ccc3ncccc3c2)c1F)C(N)=O Chemical compound CC(C)(C)C[C@H](Nc1ncnc(N2CCCC2c2ccc3ncccc3c2)c1F)C(N)=O NPWGFVDIIRRGMF-OYKVQYDMSA-N 0.000 description 1
- BMIFRZQKVYXCOV-XYPYZODXSA-N CC(C)(C)OC(=O)NC[C@H]1CC[C@@H](CC1)NS(C)(=O)=O Chemical compound CC(C)(C)OC(=O)NC[C@H]1CC[C@@H](CC1)NS(C)(=O)=O BMIFRZQKVYXCOV-XYPYZODXSA-N 0.000 description 1
- HMMYZMWDTDJTRR-MGCOHNPYSA-N CC(C)(C)OC(=O)NC[C@H]1CC[C@H](N)CC1 Chemical compound CC(C)(C)OC(=O)NC[C@H]1CC[C@H](N)CC1 HMMYZMWDTDJTRR-MGCOHNPYSA-N 0.000 description 1
- PTNPTHCYDRKKFE-LJQANCHMSA-N CC(C)(CCC1=NC=NC(N2CCOC[C@@H]2C2=CC=C(C(F)(F)F)C=C2)=C1F)CCS(C)(=O)=O Chemical compound CC(C)(CCC1=NC=NC(N2CCOC[C@@H]2C2=CC=C(C(F)(F)F)C=C2)=C1F)CCS(C)(=O)=O PTNPTHCYDRKKFE-LJQANCHMSA-N 0.000 description 1
- UCGKLGOIPDOLHS-UHFFFAOYSA-N CC(C)(O)CC1=CC=C(CN)C=C1 Chemical compound CC(C)(O)CC1=CC=C(CN)C=C1 UCGKLGOIPDOLHS-UHFFFAOYSA-N 0.000 description 1
- GBNJZPAZGIUDPV-UHFFFAOYSA-N CC(C)(O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound CC(C)(O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 GBNJZPAZGIUDPV-UHFFFAOYSA-N 0.000 description 1
- YABUYQBMDULANI-UHFFFAOYSA-N CC(C)C1=CC=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)C=C1 Chemical compound CC(C)C1=CC=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)C=C1 YABUYQBMDULANI-UHFFFAOYSA-N 0.000 description 1
- GRNDIBIKTPLNJB-MTNXOHHFSA-N CC(C)C1CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound CC(C)C1CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 GRNDIBIKTPLNJB-MTNXOHHFSA-N 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N CC(C)C[C@@H](N)C(=O)O Chemical compound CC(C)C[C@@H](N)C(=O)O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- CBPJQFCAFFNICX-LJQANCHMSA-N CC(C)C[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)O Chemical compound CC(C)C[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)O CBPJQFCAFFNICX-LJQANCHMSA-N 0.000 description 1
- MNUXNVHQAFKNGV-RXMQYKEDSA-N CC(C)C[C@@H](O)C(N)=O Chemical compound CC(C)C[C@@H](O)C(N)=O MNUXNVHQAFKNGV-RXMQYKEDSA-N 0.000 description 1
- MHTNJOZWNZZYOB-OAHLLOKOSA-N CC(C)C[C@@H](Oc1ncnc(-n2nccc2-c2ccc(C(F)(F)F)cc2)c1F)C(N)=O Chemical compound CC(C)C[C@@H](Oc1ncnc(-n2nccc2-c2ccc(C(F)(F)F)cc2)c1F)C(N)=O MHTNJOZWNZZYOB-OAHLLOKOSA-N 0.000 description 1
- HINHVILGTIXQTI-CFNKFPHESA-N CC(C)C[C@H](C(N)=O)OC(C1F)NC[N]2(CCCCCCCC2)C1N(CCC1)[C@H]1C(CC1)CCC1C(F)(F)F Chemical compound CC(C)C[C@H](C(N)=O)OC(C1F)NC[N]2(CCCCCCCC2)C1N(CCC1)[C@H]1C(CC1)CCC1C(F)(F)F HINHVILGTIXQTI-CFNKFPHESA-N 0.000 description 1
- FVGOEJLQWGPNKC-UHFFFAOYSA-N CC(CC1CCOCC1)NC1=NC=NC(N2CCCC2C2=CC=C(C(F)(F)F)C=C2)=C1F.FC(F)(F)C1=CC=C(C2CCCN2)C=C1.FC1=NC=NC(F)=C1F.FC1=NC=NC(N2CCCC2C2=CC=C(C(F)(F)F)C=C2)=C1F Chemical compound CC(CC1CCOCC1)NC1=NC=NC(N2CCCC2C2=CC=C(C(F)(F)F)C=C2)=C1F.FC(F)(F)C1=CC=C(C2CCCN2)C=C1.FC1=NC=NC(F)=C1F.FC1=NC=NC(N2CCCC2C2=CC=C(C(F)(F)F)C=C2)=C1F FVGOEJLQWGPNKC-UHFFFAOYSA-N 0.000 description 1
- JONFVTZYOPDAGN-QDUOAJAYSA-N CC(CC1c2ccc(C(F)(F)F)cc2)CN1C(C1=[F])=NC=NC1N[C@H](CC(C)(C)C)C(N)=O Chemical compound CC(CC1c2ccc(C(F)(F)F)cc2)CN1C(C1=[F])=NC=NC1N[C@H](CC(C)(C)C)C(N)=O JONFVTZYOPDAGN-QDUOAJAYSA-N 0.000 description 1
- LZOLWEQBVPVDPR-YBMSBYLISA-N CC(OC(C)(C)C)[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)O Chemical compound CC(OC(C)(C)C)[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)O LZOLWEQBVPVDPR-YBMSBYLISA-N 0.000 description 1
- WCZPBHIIODFKOT-OAQYLSRUSA-N CC1(C)CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound CC1(C)CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 WCZPBHIIODFKOT-OAQYLSRUSA-N 0.000 description 1
- KTGFXZBCBZTEKN-UHFFFAOYSA-N CC1(C)NC(=O)N(CC2=CC=C(CN)C=C2)C1=O Chemical compound CC1(C)NC(=O)N(CC2=CC=C(CN)C=C2)C1=O KTGFXZBCBZTEKN-UHFFFAOYSA-N 0.000 description 1
- RERPFXGFWORZOO-UHFFFAOYSA-N CC1(C)NC(=O)N(Cc2ccc(CCc3ncnc(N4CCCC4c4ccc(C(F)(F)F)cc4)c3F)cc2)C1=O Chemical compound CC1(C)NC(=O)N(Cc2ccc(CCc3ncnc(N4CCCC4c4ccc(C(F)(F)F)cc4)c3F)cc2)C1=O RERPFXGFWORZOO-UHFFFAOYSA-N 0.000 description 1
- RSOIBHFJHXTOQC-RZFJCUDFSA-N CC1(CCC2=NC=NC(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=C2F)CCCCC1O Chemical compound CC1(CCC2=NC=NC(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=C2F)CCCCC1O RSOIBHFJHXTOQC-RZFJCUDFSA-N 0.000 description 1
- ZSKHDLRRKMDEEF-LJQANCHMSA-N CC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 Chemical compound CC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 ZSKHDLRRKMDEEF-LJQANCHMSA-N 0.000 description 1
- DHLFXGDKYWINSI-QRIPLOBPSA-N CC1(CNc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCCS1 Chemical compound CC1(CNc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCCS1 DHLFXGDKYWINSI-QRIPLOBPSA-N 0.000 description 1
- VOKOLTIQHVGHAO-OAHLLOKOSA-N CC1(CNc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)COC1 Chemical compound CC1(CNc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)COC1 VOKOLTIQHVGHAO-OAHLLOKOSA-N 0.000 description 1
- PJHVXGXZXHUIDP-UHFFFAOYSA-N CC1(c2ccc(C(F)(F)F)cc2)CCCN1c1ncnc(CCc2ccc(CC(N)=O)cc2)c1F Chemical compound CC1(c2ccc(C(F)(F)F)cc2)CCCN1c1ncnc(CCc2ccc(CC(N)=O)cc2)c1F PJHVXGXZXHUIDP-UHFFFAOYSA-N 0.000 description 1
- FJIZSGSZCDMMMY-UHFFFAOYSA-N CC1=C(F)N=CN=C1F Chemical compound CC1=C(F)N=CN=C1F FJIZSGSZCDMMMY-UHFFFAOYSA-N 0.000 description 1
- KWWSDWVNXSBXPM-UHFFFAOYSA-N CC1=CC=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)C=C1 Chemical compound CC1=CC=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)C=C1 KWWSDWVNXSBXPM-UHFFFAOYSA-N 0.000 description 1
- MLURESJNPWTVOS-UHFFFAOYSA-N CC1=CC=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)O1 Chemical compound CC1=CC=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)O1 MLURESJNPWTVOS-UHFFFAOYSA-N 0.000 description 1
- YSEAGSCGERFGBL-UHFFFAOYSA-N CC1=CC=C(CN)O1 Chemical compound CC1=CC=C(CN)O1 YSEAGSCGERFGBL-UHFFFAOYSA-N 0.000 description 1
- AUDFBTUUQAVBBD-UHFFFAOYSA-N CC1=NC(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)=NO1 Chemical compound CC1=NC(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)=NO1 AUDFBTUUQAVBBD-UHFFFAOYSA-N 0.000 description 1
- CSRMECUKFDYXJZ-UHFFFAOYSA-N CC1=NC(F)=C(C)C(F)=N1 Chemical compound CC1=NC(F)=C(C)C(F)=N1 CSRMECUKFDYXJZ-UHFFFAOYSA-N 0.000 description 1
- WMOBNOCVMZFPEN-UHFFFAOYSA-N CC1=NC2=C(C=C(Cl)C(Cl)=C2)N1 Chemical compound CC1=NC2=C(C=C(Cl)C(Cl)=C2)N1 WMOBNOCVMZFPEN-UHFFFAOYSA-N 0.000 description 1
- RPDPRRSOGASZNP-UHFFFAOYSA-N CC1=NN(C)C=C1C1CCCN1C1=NC=NC(CCC2=CC=C(CC(N)=O)C=C2)=C1F Chemical compound CC1=NN(C)C=C1C1CCCN1C1=NC=NC(CCC2=CC=C(CC(N)=O)C=C2)=C1F RPDPRRSOGASZNP-UHFFFAOYSA-N 0.000 description 1
- JKQYFIMAXVUXEH-UHFFFAOYSA-N CC1=NN=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)O1 Chemical compound CC1=NN=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)O1 JKQYFIMAXVUXEH-UHFFFAOYSA-N 0.000 description 1
- UZVPZCCMSNSPDA-UHFFFAOYSA-N CC1CC(C2=CC=C(C(F)(F)F)C=C2)N(C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)C1 Chemical compound CC1CC(C2=CC=C(C(F)(F)F)C=C2)N(C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)C1 UZVPZCCMSNSPDA-UHFFFAOYSA-N 0.000 description 1
- SCJJLHQPDXMANK-YMKLAINNSA-N CC1CC(C2=CC=C(C(F)(F)F)C=C2)N(C2=NC=NC(N[C@H](CC3=CC=C(F)C=C3)C(=O)[Re])=C2F)C1.CC1CC(C2=CC=C(C(F)(F)F)C=C2)N(C2=NC=NC(N[C@H](CC3=CC=C(F)C=C3)C(N)=O)=C2F)C1.N[C@H](CC1=CC=C(F)C=C1)C(=O)[Re].O=C(N[C@H](CC1=CC=C(F)C=C1)C(=O)[Re])OCC1C2=C(C=CC=C2)C2=C1C=CC=C2.O=C([Re])[C@@H](CC1=CC=C(F)C=C1)NC1=C(F)C(F)=NC=N1 Chemical compound CC1CC(C2=CC=C(C(F)(F)F)C=C2)N(C2=NC=NC(N[C@H](CC3=CC=C(F)C=C3)C(=O)[Re])=C2F)C1.CC1CC(C2=CC=C(C(F)(F)F)C=C2)N(C2=NC=NC(N[C@H](CC3=CC=C(F)C=C3)C(N)=O)=C2F)C1.N[C@H](CC1=CC=C(F)C=C1)C(=O)[Re].O=C(N[C@H](CC1=CC=C(F)C=C1)C(=O)[Re])OCC1C2=C(C=CC=C2)C2=C1C=CC=C2.O=C([Re])[C@@H](CC1=CC=C(F)C=C1)NC1=C(F)C(F)=NC=N1 SCJJLHQPDXMANK-YMKLAINNSA-N 0.000 description 1
- ROKGHQVTAKRJIB-TUAABQIMSA-N CC1CC(c2ccc(C(F)(F)F)cc2)N(c2ncnc(C[C@H](Cc3ccc(F)cc3)C(N)=O)c2F)C1 Chemical compound CC1CC(c2ccc(C(F)(F)F)cc2)N(c2ncnc(C[C@H](Cc3ccc(F)cc3)C(N)=O)c2F)C1 ROKGHQVTAKRJIB-TUAABQIMSA-N 0.000 description 1
- QJOMDDCPCCDXKS-UHFFFAOYSA-N CC1CCC(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound CC1CCC(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CC1 QJOMDDCPCCDXKS-UHFFFAOYSA-N 0.000 description 1
- ZMKGMRDHYTYLDH-UHFFFAOYSA-N CC1CCC(CN)CC1 Chemical compound CC1CCC(CN)CC1 ZMKGMRDHYTYLDH-UHFFFAOYSA-N 0.000 description 1
- SZKSMGYUQBSYES-UHFFFAOYSA-N CC1CCNC1C1=CC=C(C(F)(F)F)C=C1 Chemical compound CC1CCNC1C1=CC=C(C(F)(F)F)C=C1 SZKSMGYUQBSYES-UHFFFAOYSA-N 0.000 description 1
- ZYVJVWMLGGONOT-MRVPVSSYSA-N CCC(=O)[C@@H](CC(C)(C)C)NC Chemical compound CCC(=O)[C@@H](CC(C)(C)C)NC ZYVJVWMLGGONOT-MRVPVSSYSA-N 0.000 description 1
- FAXSITDEZGKGMC-UHFFFAOYSA-N CCC(=O)c1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1 Chemical compound CCC(=O)c1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1 FAXSITDEZGKGMC-UHFFFAOYSA-N 0.000 description 1
- QQKDFOZSHPKBEB-UHFFFAOYSA-N CCC(Br)C(=O)NCC1=C(C(=O)O)OC=C1 Chemical compound CCC(Br)C(=O)NCC1=C(C(=O)O)OC=C1 QQKDFOZSHPKBEB-UHFFFAOYSA-N 0.000 description 1
- VRVWCZCOCYUYGR-UHFFFAOYSA-N CCC(N)C1=CC2=C(C=C1)OCCCO2 Chemical compound CCC(N)C1=CC2=C(C=C1)OCCCO2 VRVWCZCOCYUYGR-UHFFFAOYSA-N 0.000 description 1
- KBQOSLWTKHIAAQ-UHFFFAOYSA-N CCC(Nc1ncnc(N2CCCC2c2ccc(C(F)(F)F)cc2)c1F)c1noc(C)n1 Chemical compound CCC(Nc1ncnc(N2CCCC2c2ccc(C(F)(F)F)cc2)c1F)c1noc(C)n1 KBQOSLWTKHIAAQ-UHFFFAOYSA-N 0.000 description 1
- XWFUGMNJIKDPKF-UHFFFAOYSA-N CCC1=CC=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)O1 Chemical compound CCC1=CC=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)O1 XWFUGMNJIKDPKF-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- VVPYJZGUNIMQIB-UHFFFAOYSA-N CCOC1=CC=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)C=C1 Chemical compound CCOC1=CC=C(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)C=C1 VVPYJZGUNIMQIB-UHFFFAOYSA-N 0.000 description 1
- KJSIEMSDXBNBIM-UHFFFAOYSA-N CCc1ccc(CN(C)c2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)nc1 Chemical compound CCc1ccc(CN(C)c2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)nc1 KJSIEMSDXBNBIM-UHFFFAOYSA-N 0.000 description 1
- JJZWGWDCPSBQQB-UHFFFAOYSA-N CN(C)C(=O)C1CCC(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)O1 Chemical compound CN(C)C(=O)C1CCC(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)O1 JJZWGWDCPSBQQB-UHFFFAOYSA-N 0.000 description 1
- BKFIAAKZWQTGHE-UHFFFAOYSA-N CN(C)C(=O)C1CCC(CN)O1 Chemical compound CN(C)C(=O)C1CCC(CN)O1 BKFIAAKZWQTGHE-UHFFFAOYSA-N 0.000 description 1
- RNFGDJAPVUUNFY-UHFFFAOYSA-N CN(C)C(=O)c1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1 Chemical compound CN(C)C(=O)c1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1 RNFGDJAPVUUNFY-UHFFFAOYSA-N 0.000 description 1
- KFTRXTSNTQSGNE-UHFFFAOYSA-N CN1C=C(CN)C=N1 Chemical compound CN1C=C(CN)C=N1 KFTRXTSNTQSGNE-UHFFFAOYSA-N 0.000 description 1
- ZAOLDHBNVDOBDU-UHFFFAOYSA-N CN1C=CC(CN)=C1 Chemical compound CN1C=CC(CN)=C1 ZAOLDHBNVDOBDU-UHFFFAOYSA-N 0.000 description 1
- ALIKXWNRKBRKKO-UHFFFAOYSA-N CN1CC(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CC1=O Chemical compound CN1CC(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CC1=O ALIKXWNRKBRKKO-UHFFFAOYSA-N 0.000 description 1
- RYPUQUNUTILSAZ-UHFFFAOYSA-N CN1CC(CN)CC1=O Chemical compound CN1CC(CN)CC1=O RYPUQUNUTILSAZ-UHFFFAOYSA-N 0.000 description 1
- XLJQPXVBQNJNLW-UHFFFAOYSA-N CN1CC1 Chemical compound CN1CC1 XLJQPXVBQNJNLW-UHFFFAOYSA-N 0.000 description 1
- OCICDTOQZOSSQU-UHFFFAOYSA-N COC(=O)CC1=CC=C(CN)C=C1 Chemical compound COC(=O)CC1=CC=C(CN)C=C1 OCICDTOQZOSSQU-UHFFFAOYSA-N 0.000 description 1
- SLBOTDTZZFCSBJ-UHFFFAOYSA-N COC(=O)Cc1ccc(CNc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound COC(=O)Cc1ccc(CNc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 SLBOTDTZZFCSBJ-UHFFFAOYSA-N 0.000 description 1
- GHGZTLUTZZRPQQ-UHFFFAOYSA-N COC1(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 Chemical compound COC1(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 GHGZTLUTZZRPQQ-UHFFFAOYSA-N 0.000 description 1
- YXCIOIMITUAHSX-UHFFFAOYSA-N COC1=C(C2CCCC2)C=CC(C(F)(F)F)=C1 Chemical compound COC1=C(C2CCCC2)C=CC(C(F)(F)F)=C1 YXCIOIMITUAHSX-UHFFFAOYSA-N 0.000 description 1
- AFSIRXYDEPECQT-UHFFFAOYSA-N COC1=C(CO)C=CC(CN2C=CC3=C(C4CCCC4C4=CC=C(C(F)(F)F)C=C4)N=CN=C32)=C1.COC1=C(CO)C=CC(CN2C=CC3=C(Cl)N=CN=C32)=C1.COC1=C(OC)C=C(CBr)C=C1.ClC1=C2C=CNC2=NC=N1 Chemical compound COC1=C(CO)C=CC(CN2C=CC3=C(C4CCCC4C4=CC=C(C(F)(F)F)C=C4)N=CN=C32)=C1.COC1=C(CO)C=CC(CN2C=CC3=C(Cl)N=CN=C32)=C1.COC1=C(OC)C=C(CBr)C=C1.ClC1=C2C=CNC2=NC=N1 AFSIRXYDEPECQT-UHFFFAOYSA-N 0.000 description 1
- LVMPWFJVYMXSNY-UHFFFAOYSA-N COC1=C(OC)C(CN)=CC=C1 Chemical compound COC1=C(OC)C(CN)=CC=C1 LVMPWFJVYMXSNY-UHFFFAOYSA-N 0.000 description 1
- DIVNUTGTTIRPQA-UHFFFAOYSA-N COC1=C(OC)C=C(CN)C=C1 Chemical compound COC1=C(OC)C=C(CN)C=C1 DIVNUTGTTIRPQA-UHFFFAOYSA-N 0.000 description 1
- PFKQNUNIMXUZGO-UHFFFAOYSA-N COC1=CC(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)=CC=C1 Chemical compound COC1=CC(C2CCCN2C2=NC=NC(CCC3=CC=C(CC(N)=O)C=C3)=C2F)=CC=C1 PFKQNUNIMXUZGO-UHFFFAOYSA-N 0.000 description 1
- GVLHBFBFUSPHJO-SECBINFHSA-N COC1=CC=C(C[C@@H](N)CO)C=C1 Chemical compound COC1=CC=C(C[C@@H](N)CO)C=C1 GVLHBFBFUSPHJO-SECBINFHSA-N 0.000 description 1
- JYQODLWFOPCSCS-HSZRJFAPSA-N COC1=CC=C(C[C@@H](NC(=O)OCC2C3=C(C=CC=C3)C3=C2C=CC=C3)C(=O)O)C=C1 Chemical compound COC1=CC=C(C[C@@H](NC(=O)OCC2C3=C(C=CC=C3)C3=C2C=CC=C3)C(=O)O)C=C1 JYQODLWFOPCSCS-HSZRJFAPSA-N 0.000 description 1
- UYPXKIANVWQRFM-TWMPVWRBSA-N COC1CCCCC1CCc1ncnc(N2CCC[C@@H]2c2ccc(C(F)(F)F)cc2)c1F Chemical compound COC1CCCCC1CCc1ncnc(N2CCC[C@@H]2c2ccc(C(F)(F)F)cc2)c1F UYPXKIANVWQRFM-TWMPVWRBSA-N 0.000 description 1
- CBEALPAKAUIYSJ-LJQANCHMSA-N COCC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCC1 Chemical compound COCC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCC1 CBEALPAKAUIYSJ-LJQANCHMSA-N 0.000 description 1
- ZPGCPCXHWGZGSX-HSZRJFAPSA-N COCCNS(=O)(=O)C1=CC=C(CCC2=NC=NC(N3CCC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=C2F)C=C1 Chemical compound COCCNS(=O)(=O)C1=CC=C(CCC2=NC=NC(N3CCC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=C2F)C=C1 ZPGCPCXHWGZGSX-HSZRJFAPSA-N 0.000 description 1
- RNYHHVIQBGQTMT-UHFFFAOYSA-N COCc1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1 Chemical compound COCc1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1 RNYHHVIQBGQTMT-UHFFFAOYSA-N 0.000 description 1
- VMPQYRZKZWWMGM-UHFFFAOYSA-N COc1cc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc(OC)c1 Chemical compound COc1cc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc(OC)c1 VMPQYRZKZWWMGM-UHFFFAOYSA-N 0.000 description 1
- XTQSLIRNWSXVPT-UHFFFAOYSA-N COc1cc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)ccn1 Chemical compound COc1cc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)ccn1 XTQSLIRNWSXVPT-UHFFFAOYSA-N 0.000 description 1
- WCLCSXJAZPMXDY-UHFFFAOYSA-N COc1ccc(C2CCCN2c2ncnc(CCc3ccc(C)nc3)c2F)cc1 Chemical compound COc1ccc(C2CCCN2c2ncnc(CCc3ccc(C)nc3)c2F)cc1 WCLCSXJAZPMXDY-UHFFFAOYSA-N 0.000 description 1
- DXXCGZXTELHVRD-UHFFFAOYSA-N COc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1OC Chemical compound COc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1OC DXXCGZXTELHVRD-UHFFFAOYSA-N 0.000 description 1
- JAWQABKXJKFJAK-UHFFFAOYSA-N COc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 Chemical compound COc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 JAWQABKXJKFJAK-UHFFFAOYSA-N 0.000 description 1
- IGLWJTWVASSDEH-UHFFFAOYSA-N COc1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1OC Chemical compound COc1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1OC IGLWJTWVASSDEH-UHFFFAOYSA-N 0.000 description 1
- BMZWEIZHPFGRRK-UHFFFAOYSA-N COc1ccnc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1 Chemical compound COc1ccnc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1 BMZWEIZHPFGRRK-UHFFFAOYSA-N 0.000 description 1
- HULMGYYOKAEGJX-UHFFFAOYSA-N COc1nc(C)ccc1CCc1ncnc(N2CCCC2c2ccc(C(F)(F)F)cc2)c1F Chemical compound COc1nc(C)ccc1CCc1ncnc(N2CCCC2c2ccc(C(F)(F)F)cc2)c1F HULMGYYOKAEGJX-UHFFFAOYSA-N 0.000 description 1
- DDUPPYNRMUFZQX-UHFFFAOYSA-N CS(=O)(=O)C1=CN=C(CCl)C=C1 Chemical compound CS(=O)(=O)C1=CN=C(CCl)C=C1 DDUPPYNRMUFZQX-UHFFFAOYSA-N 0.000 description 1
- CQEIGYJXWSWUIY-UHFFFAOYSA-N CS(=O)(=O)C1=NC=C(CCl)C=C1 Chemical compound CS(=O)(=O)C1=NC=C(CCl)C=C1 CQEIGYJXWSWUIY-UHFFFAOYSA-N 0.000 description 1
- LLZSHFKSAFZIMB-HXUWFJFHSA-N CS(=O)(=O)CC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 Chemical compound CS(=O)(=O)CC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 LLZSHFKSAFZIMB-HXUWFJFHSA-N 0.000 description 1
- SZHQMBFLAZHRLB-UHFFFAOYSA-N CS(=O)(=O)CC1=CC=C(CN)C=C1 Chemical compound CS(=O)(=O)CC1=CC=C(CN)C=C1 SZHQMBFLAZHRLB-UHFFFAOYSA-N 0.000 description 1
- AXMVKVXJPNOOAC-GOSISDBHSA-N CS(=O)(=O)CC1CCN(C2=NC=NC(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=C2F)CC1 Chemical compound CS(=O)(=O)CC1CCN(C2=NC=NC(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=C2F)CC1 AXMVKVXJPNOOAC-GOSISDBHSA-N 0.000 description 1
- JSLSHVXOTBITNL-UHFFFAOYSA-N CS(=O)(=O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound CS(=O)(=O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 JSLSHVXOTBITNL-UHFFFAOYSA-N 0.000 description 1
- NMYFYYODSVISGN-UHFFFAOYSA-N CS(=O)(=O)N1CCC(CBr)CC1 Chemical compound CS(=O)(=O)N1CCC(CBr)CC1 NMYFYYODSVISGN-UHFFFAOYSA-N 0.000 description 1
- RPUKTUIFRWDMCH-UHFFFAOYSA-N CS(=O)(=O)N1CCC(CCC2=NC=NC(N3CCCC3C3=C(O)C=C(C(F)(F)F)C=C3)=C2F)CC1 Chemical compound CS(=O)(=O)N1CCC(CCC2=NC=NC(N3CCCC3C3=C(O)C=C(C(F)(F)F)C=C3)=C2F)CC1 RPUKTUIFRWDMCH-UHFFFAOYSA-N 0.000 description 1
- IJOJHMCQCGOZCF-HXUWFJFHSA-N CS(=O)(=O)N1CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound CS(=O)(=O)N1CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 IJOJHMCQCGOZCF-HXUWFJFHSA-N 0.000 description 1
- LXAKARRRPXWNRC-HXUWFJFHSA-N CS(=O)(=O)N1CCC(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound CS(=O)(=O)N1CCC(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 LXAKARRRPXWNRC-HXUWFJFHSA-N 0.000 description 1
- FOVPVEVEEUDDQE-OAQYLSRUSA-N CS(=O)(=O)N1CCC(CN2C=CC3=C2N=CN=C3N2CCOC[C@@H]2C2=CC=C(OC(F)(F)F)C=C2)CC1 Chemical compound CS(=O)(=O)N1CCC(CN2C=CC3=C2N=CN=C3N2CCOC[C@@H]2C2=CC=C(OC(F)(F)F)C=C2)CC1 FOVPVEVEEUDDQE-OAQYLSRUSA-N 0.000 description 1
- BAPRRIYCNSOIRA-PKUWUEBNSA-N CS(=O)(=O)NC1CCCC1CCC1=C(F)C(N2CCOC[C@@H]2C2=CC=C(C(F)(F)F)C=C2)=NC=N1 Chemical compound CS(=O)(=O)NC1CCCC1CCC1=C(F)C(N2CCOC[C@@H]2C2=CC=C(C(F)(F)F)C=C2)=NC=N1 BAPRRIYCNSOIRA-PKUWUEBNSA-N 0.000 description 1
- YTNUGXHMCJYOKI-SZVBFZGTSA-N CS(=O)(=O)N[C@H]1CC[C@H](CNC2=NC=NC(N3CCOC[C@@H]3C3=CC=C(OC(F)(F)F)C=C3)=C2F)CC1 Chemical compound CS(=O)(=O)N[C@H]1CC[C@H](CNC2=NC=NC(N3CCOC[C@@H]3C3=CC=C(OC(F)(F)F)C=C3)=C2F)CC1 YTNUGXHMCJYOKI-SZVBFZGTSA-N 0.000 description 1
- XZPSMBLJLXWEHR-OAQYLSRUSA-N CS(=O)(=O)c1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound CS(=O)(=O)c1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 XZPSMBLJLXWEHR-OAQYLSRUSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZZDJPXNTXOTHTO-QNSVNVJESA-N Cc1c(N[C@H](CC(C)(C)C)C(N)=O)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 Chemical compound Cc1c(N[C@H](CC(C)(C)C)C(N)=O)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 ZZDJPXNTXOTHTO-QNSVNVJESA-N 0.000 description 1
- GGMIUKDSWCAKFJ-UHFFFAOYSA-N Cc1ccc(CCc2nccc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 Chemical compound Cc1ccc(CCc2nccc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 GGMIUKDSWCAKFJ-UHFFFAOYSA-N 0.000 description 1
- DNXBBYLIBGCUKM-UHFFFAOYSA-N Cc1ccc(CCc2ncnc(-n3nncc3-c3ccc(C(F)(F)F)cc3)c2F)cn1 Chemical compound Cc1ccc(CCc2ncnc(-n3nncc3-c3ccc(C(F)(F)F)cc3)c2F)cn1 DNXBBYLIBGCUKM-UHFFFAOYSA-N 0.000 description 1
- MZPYNQRVNROOPY-UHFFFAOYSA-N Cc1ccc(CCc2ncnc(N3CCCC3(C)c3ccc(C(F)(F)F)cc3)c2F)cn1 Chemical compound Cc1ccc(CCc2ncnc(N3CCCC3(C)c3ccc(C(F)(F)F)cc3)c2F)cn1 MZPYNQRVNROOPY-UHFFFAOYSA-N 0.000 description 1
- WEQWNAXJSGFLQU-UHFFFAOYSA-N Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 Chemical compound Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 WEQWNAXJSGFLQU-UHFFFAOYSA-N 0.000 description 1
- HALQIFBVOPQOAC-UHFFFAOYSA-N Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C)o3)c2F)cn1 Chemical compound Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C)o3)c2F)cn1 HALQIFBVOPQOAC-UHFFFAOYSA-N 0.000 description 1
- QQTYXBYTBFCISP-UHFFFAOYSA-N Cc1ccc(CNc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3O)c2F)cn1 Chemical compound Cc1ccc(CNc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3O)c2F)cn1 QQTYXBYTBFCISP-UHFFFAOYSA-N 0.000 description 1
- WMVDVHDHVYPIBB-UHFFFAOYSA-N Cc1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)n1 Chemical compound Cc1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)n1 WMVDVHDHVYPIBB-UHFFFAOYSA-N 0.000 description 1
- BYVJEVZTOQNYTA-UHFFFAOYSA-N Cc1nc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)ccc1C(C)O Chemical compound Cc1nc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)ccc1C(C)O BYVJEVZTOQNYTA-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- SDULKWWJRROVEN-UHFFFAOYSA-N Cl.CS(=O)(=O)N1CCC(F)(CN)CC1 Chemical compound Cl.CS(=O)(=O)N1CCC(F)(CN)CC1 SDULKWWJRROVEN-UHFFFAOYSA-N 0.000 description 1
- WMPOSKBNUUSPFN-UHFFFAOYSA-N Cl.NCc1ccc(CC(=O)NC#N)cc1 Chemical compound Cl.NCc1ccc(CC(=O)NC#N)cc1 WMPOSKBNUUSPFN-UHFFFAOYSA-N 0.000 description 1
- HNTZVGMWXCFCTA-UHFFFAOYSA-N ClC1=C2/C=C\NC2=NC=C1 Chemical compound ClC1=C2/C=C\NC2=NC=C1 HNTZVGMWXCFCTA-UHFFFAOYSA-N 0.000 description 1
- HIWDMCGEUIPKTK-UHFFFAOYSA-N Clc(c(Cl)c1)cc([nH]2)c1nc2I Chemical compound Clc(c(Cl)c1)cc([nH]2)c1nc2I HIWDMCGEUIPKTK-UHFFFAOYSA-N 0.000 description 1
- VBGQXLFGHNOYJT-UHFFFAOYSA-N Cn1cc(CNc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 Chemical compound Cn1cc(CNc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 VBGQXLFGHNOYJT-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- UELKHVSAEJVYMV-UHFFFAOYSA-N FC(F)(F)C1=CC=C(C2=CC=NC2)C=C1 Chemical compound FC(F)(F)C1=CC=C(C2=CC=NC2)C=C1 UELKHVSAEJVYMV-UHFFFAOYSA-N 0.000 description 1
- NCZGZQWRTIFQKA-UHFFFAOYSA-N FC(F)(F)C1=CC=C(C2=CN=NN2)C=C1 Chemical compound FC(F)(F)C1=CC=C(C2=CN=NN2)C=C1 NCZGZQWRTIFQKA-UHFFFAOYSA-N 0.000 description 1
- CKCJOQMDMYPVKX-UHFFFAOYSA-N FC(F)(F)C1=CC=C(C2COCCN2)C=C1 Chemical compound FC(F)(F)C1=CC=C(C2COCCN2)C=C1 CKCJOQMDMYPVKX-UHFFFAOYSA-N 0.000 description 1
- XCKVCAOSVNOPOM-UHFFFAOYSA-N FC(F)(F)OC1=CC=C(C2CCCN2)C=C1 Chemical compound FC(F)(F)OC1=CC=C(C2CCCN2)C=C1 XCKVCAOSVNOPOM-UHFFFAOYSA-N 0.000 description 1
- XDMSYEGDWCCLPL-UHFFFAOYSA-N FC(F)(F)OC1=CC=C(C2CCCOC2)C=C1 Chemical compound FC(F)(F)OC1=CC=C(C2CCCOC2)C=C1 XDMSYEGDWCCLPL-UHFFFAOYSA-N 0.000 description 1
- MCVYDTZVOSPMJU-UHFFFAOYSA-N FC1(CCN(CC1)S(=O)(=O)C)CN Chemical compound FC1(CCN(CC1)S(=O)(=O)C)CN MCVYDTZVOSPMJU-UHFFFAOYSA-N 0.000 description 1
- NBIDRFMBAGQGTL-UHFFFAOYSA-N FC1(CCN(CC1)S(=O)(=O)C)CNC(OC(C)(C)C)=O Chemical compound FC1(CCN(CC1)S(=O)(=O)C)CNC(OC(C)(C)C)=O NBIDRFMBAGQGTL-UHFFFAOYSA-N 0.000 description 1
- KWFMVKFSWMRDFJ-UHFFFAOYSA-N FC1=C(C(F)(F)F)C=CC(C2CCCC2)=C1 Chemical compound FC1=C(C(F)(F)F)C=CC(C2CCCC2)=C1 KWFMVKFSWMRDFJ-UHFFFAOYSA-N 0.000 description 1
- XNDKAFUEJJVVIM-GPMSIDNRSA-N FC1=C(NC[C@H]2CC[C@H](CC3=NN=NN3)CC2)N=CN=C1N1CCOC[C@@H]1C1=CC=C(C(F)(F)F)C=C1 Chemical compound FC1=C(NC[C@H]2CC[C@H](CC3=NN=NN3)CC2)N=CN=C1N1CCOC[C@@H]1C1=CC=C(C(F)(F)F)C=C1 XNDKAFUEJJVVIM-GPMSIDNRSA-N 0.000 description 1
- MCLDVUCSDZGNRR-UHFFFAOYSA-N FC1=CC(F)=NC=N1 Chemical compound FC1=CC(F)=NC=N1 MCLDVUCSDZGNRR-UHFFFAOYSA-N 0.000 description 1
- BRGQXGPRBQQRNM-UHFFFAOYSA-N FC1=NC(C(F)(F)F)=NC(F)=C1F Chemical compound FC1=NC(C(F)(F)F)=NC(F)=C1F BRGQXGPRBQQRNM-UHFFFAOYSA-N 0.000 description 1
- JZUKIPMHFMTJPI-UHFFFAOYSA-N Fc1c(CCc2ccc(C(F)(F)F)cc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 Chemical compound Fc1c(CCc2ccc(C(F)(F)F)cc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 JZUKIPMHFMTJPI-UHFFFAOYSA-N 0.000 description 1
- GWZCEKWMYNFQHJ-UHFFFAOYSA-N Fc1c(CCc2ccc(C(F)(F)F)nc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 Chemical compound Fc1c(CCc2ccc(C(F)(F)F)nc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 GWZCEKWMYNFQHJ-UHFFFAOYSA-N 0.000 description 1
- GSFFLIGKFDCEFY-GOSISDBHSA-N Fc1c(CCc2ccc(Cl)nc2)ncnc1N1CCC[C@@H]1c1ccc(C(F)(F)F)cc1 Chemical compound Fc1c(CCc2ccc(Cl)nc2)ncnc1N1CCC[C@@H]1c1ccc(C(F)(F)F)cc1 GSFFLIGKFDCEFY-GOSISDBHSA-N 0.000 description 1
- REEJAGZCPRXRCU-UHFFFAOYSA-N Fc1c(CCc2ccc(Cn3ccnc3)cc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 Chemical compound Fc1c(CCc2ccc(Cn3ccnc3)cc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 REEJAGZCPRXRCU-UHFFFAOYSA-N 0.000 description 1
- DDXLJBZCTHMILL-UHFFFAOYSA-N Fc1c(CCc2ccc(Cn3cncn3)cc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 Chemical compound Fc1c(CCc2ccc(Cn3cncn3)cc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 DDXLJBZCTHMILL-UHFFFAOYSA-N 0.000 description 1
- KNLUSOAPJARRGP-UHFFFAOYSA-N Fc1c(CCc2ccc(N3CCOCC3)cc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 Chemical compound Fc1c(CCc2ccc(N3CCOCC3)cc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 KNLUSOAPJARRGP-UHFFFAOYSA-N 0.000 description 1
- YFXNBFOXBDPGKJ-UHFFFAOYSA-N Fc1c(CCc2ccc(OCC3CCCO3)cc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 Chemical compound Fc1c(CCc2ccc(OCC3CCCO3)cc2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 YFXNBFOXBDPGKJ-UHFFFAOYSA-N 0.000 description 1
- NPCFGGMBZLXJPX-UHFFFAOYSA-N Fc1c(CCc2cccc(Cn3cncn3)c2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 Chemical compound Fc1c(CCc2cccc(Cn3cncn3)c2)ncnc1N1CCCC1c1ccc(C(F)(F)F)cc1 NPCFGGMBZLXJPX-UHFFFAOYSA-N 0.000 description 1
- DQPLSUCIVBMAMH-FQNRMIAFSA-N Fc1c(NCC2CCOC2)ncnc1N1CCC[C@@H]1c1ccc(C(F)(F)F)cc1 Chemical compound Fc1c(NCC2CCOC2)ncnc1N1CCC[C@@H]1c1ccc(C(F)(F)F)cc1 DQPLSUCIVBMAMH-FQNRMIAFSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- MEOBGMGTJFDBQD-QGZVFWFLSA-N N#CC1(CNC2=C(F)C(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)CCOCC1 Chemical compound N#CC1(CNC2=C(F)C(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)CCOCC1 MEOBGMGTJFDBQD-QGZVFWFLSA-N 0.000 description 1
- LFIWXXXFJFOECP-UHFFFAOYSA-N N#CC1=CC=C(CN)C=C1 Chemical compound N#CC1=CC=C(CN)C=C1 LFIWXXXFJFOECP-UHFFFAOYSA-N 0.000 description 1
- OKECLIUEXFOGKH-MBOZVWFJSA-N N#CC[C@H]1CC[C@H](CNC2=C(F)C(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)CC1 Chemical compound N#CC[C@H]1CC[C@H](CNC2=C(F)C(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)CC1 OKECLIUEXFOGKH-MBOZVWFJSA-N 0.000 description 1
- KZRNFNYNZIILOM-UHFFFAOYSA-N N#Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound N#Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 KZRNFNYNZIILOM-UHFFFAOYSA-N 0.000 description 1
- NLPTWFAEQUQZJH-QGZVFWFLSA-N N-(2,2-dimethyl-4-methylsulfonylbutyl)-5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-amine Chemical compound CC(CNC1=NC=NC(=C1F)N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F)(CCS(=O)(=O)C)C NLPTWFAEQUQZJH-QGZVFWFLSA-N 0.000 description 1
- OWHVQAOFKMCXHA-GOSISDBHSA-N N-(2-aminoethyl)-4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]oxane-4-carboxamide Chemical compound NCCNC(=O)C1(CCOCC1)CNC1=NC=NC(=C1F)N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F OWHVQAOFKMCXHA-GOSISDBHSA-N 0.000 description 1
- OMORXHJRWVAFOL-QGZVFWFLSA-N N-[(1,1-dioxothian-4-yl)methyl]-5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound O=S1(CCC(CC1)CNC1=NC=NC(=C1F)N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)=O OMORXHJRWVAFOL-QGZVFWFLSA-N 0.000 description 1
- JYKHYULVPUOKSQ-OEMAIJDKSA-N N-[(1,1-dioxothiolan-2-yl)methyl]-5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound O=S1(C(CCC1)CNC1=NC=NC(=C1F)N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)=O JYKHYULVPUOKSQ-OEMAIJDKSA-N 0.000 description 1
- COCDONWMOJIYDY-MOMVYJMYSA-N N-[(2-tert-butyloxan-3-yl)methyl]-5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C(C)(C)(C)C1OCCCC1CNC1=NC=NC(=C1F)N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F COCDONWMOJIYDY-MOMVYJMYSA-N 0.000 description 1
- JTQQWKDGNOWHDR-UHFFFAOYSA-N N-[(3,4-dimethoxyphenyl)methyl]-5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound COC=1C=C(C=CC=1OC)CNC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F JTQQWKDGNOWHDR-UHFFFAOYSA-N 0.000 description 1
- PEFSEACMNLXBQW-UHFFFAOYSA-N N-[(3,5-dimethoxyphenyl)methyl]-5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound COC=1C=C(C=C(C=1)OC)CNC1=NC=NC(=C1F)N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F PEFSEACMNLXBQW-UHFFFAOYSA-N 0.000 description 1
- RLCXSQCIKYQULG-LJQANCHMSA-N N-[(4,4-dimethylcyclohexyl)methyl]-5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound CC1(CCC(CC1)CNC1=NC=NC(=C1F)N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)C RLCXSQCIKYQULG-LJQANCHMSA-N 0.000 description 1
- TWGJHXAICVLZOA-OEMAIJDKSA-N N-[(4,4-dioxo-1,4-oxathian-2-yl)methyl]-5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound O=S1(CC(OCC1)CNC1=NC=NC(=C1F)N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)=O TWGJHXAICVLZOA-OEMAIJDKSA-N 0.000 description 1
- KWCXNTAKURXUTH-MRXNPFEDSA-N N-[(6-chloropyridin-3-yl)methyl]-5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound ClC1=CC=C(C=N1)CNC1=NC=NC(=C1F)N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F KWCXNTAKURXUTH-MRXNPFEDSA-N 0.000 description 1
- BATYUDJRAQISFL-VMWRSERWSA-N N-[2-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]cyclopentyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1C(CCC1)CNC1=NC=NC(=C1F)N1[C@H](COCC1)C1=CC=C(C=C1)C(F)(F)F BATYUDJRAQISFL-VMWRSERWSA-N 0.000 description 1
- ZZHWVJHGPRMBPE-UHFFFAOYSA-N N-[4-(aminomethyl)cyclohexyl]-2,2,2-trifluoroethanesulfonamide Chemical compound NCC1CCC(CC1)NS(=O)(=O)CC(F)(F)F ZZHWVJHGPRMBPE-UHFFFAOYSA-N 0.000 description 1
- YTNUGXHMCJYOKI-GXOAENINSA-N N-[4-[[[5-fluoro-6-[(3S)-3-[4-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrimidin-4-yl]amino]methyl]cyclohexyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1CCC(CC1)CNC1=NC=NC(=C1F)N1[C@H](COCC1)C1=CC=C(C=C1)OC(F)(F)F YTNUGXHMCJYOKI-GXOAENINSA-N 0.000 description 1
- ILIMLQZOAAXVQS-OAQYLSRUSA-N N-cyclopropyl-4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]benzenesulfonamide Chemical compound C1(CC1)NS(=O)(=O)C1=CC=C(C=C1)CNC1=NC=NC(=C1F)N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F ILIMLQZOAAXVQS-OAQYLSRUSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- UKCMHITXYFGBIX-MRXNPFEDSA-N NC(=O)C1(CNC2=C(F)C(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)CCCC1 Chemical compound NC(=O)C1(CNC2=C(F)C(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)CCCC1 UKCMHITXYFGBIX-MRXNPFEDSA-N 0.000 description 1
- DVPLRGQYQGIGSP-UHFFFAOYSA-N NC(=O)C1CCCN(c2ccc(CCc3ncnc(N4CCCC4c4ccc(C(F)(F)F)cc4)c3F)cc2)C1 Chemical compound NC(=O)C1CCCN(c2ccc(CCc3ncnc(N4CCCC4c4ccc(C(F)(F)F)cc4)c3F)cc2)C1 DVPLRGQYQGIGSP-UHFFFAOYSA-N 0.000 description 1
- YLOZOVUUFCLOOF-UHFFFAOYSA-N NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3/C3=N/C4=C(C=CC=C4)S3)=NC=N2)C=C1 Chemical compound NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3/C3=N/C4=C(C=CC=C4)S3)=NC=N2)C=C1 YLOZOVUUFCLOOF-UHFFFAOYSA-N 0.000 description 1
- GQLOBPHKHDHWBQ-UHFFFAOYSA-N NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3C3=C4C=CC=CC4=CC=C3)=NC=N2)C=C1 Chemical compound NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3C3=C4C=CC=CC4=CC=C3)=NC=N2)C=C1 GQLOBPHKHDHWBQ-UHFFFAOYSA-N 0.000 description 1
- ZSVHQKHCTYLMCV-UHFFFAOYSA-N NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3C3=CC=C(O)C=C3)=NC=N2)C=C1 Chemical compound NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3C3=CC=C(O)C=C3)=NC=N2)C=C1 ZSVHQKHCTYLMCV-UHFFFAOYSA-N 0.000 description 1
- HOQQIFIAGARFMB-UHFFFAOYSA-N NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3C3=CC=C4C=CC=CC4=C3)=NC=N2)C=C1 Chemical compound NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3C3=CC=C4C=CC=CC4=C3)=NC=N2)C=C1 HOQQIFIAGARFMB-UHFFFAOYSA-N 0.000 description 1
- ZXSRJJKRIWVJTI-UHFFFAOYSA-N NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3C3=CC=CC(Br)=C3)=NC=N2)C=C1 Chemical compound NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3C3=CC=CC(Br)=C3)=NC=N2)C=C1 ZXSRJJKRIWVJTI-UHFFFAOYSA-N 0.000 description 1
- BMSJJSVKPORIFS-UHFFFAOYSA-N NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3C3=CC=CC(Cl)=C3)=NC=N2)C=C1 Chemical compound NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCC3C3=CC=CC(Cl)=C3)=NC=N2)C=C1 BMSJJSVKPORIFS-UHFFFAOYSA-N 0.000 description 1
- CYHZWWKQMGBTLN-UHFFFAOYSA-N NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCCC3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)C=C1 Chemical compound NC(=O)CC1=CC=C(CCC2=C(F)C(N3CCCCC3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)C=C1 CYHZWWKQMGBTLN-UHFFFAOYSA-N 0.000 description 1
- VBPTVEQUBHWADU-UHFFFAOYSA-N NC(=O)CC1=CC=C(CCC2=NC=NC(N3CCCC3C3=C(O)C=C(C(F)(F)F)C=C3)=C2F)C=C1 Chemical compound NC(=O)CC1=CC=C(CCC2=NC=NC(N3CCCC3C3=C(O)C=C(C(F)(F)F)C=C3)=C2F)C=C1 VBPTVEQUBHWADU-UHFFFAOYSA-N 0.000 description 1
- MDBOPJLXEBZIMC-JOCHJYFZSA-N NC(=O)CC1=CC=C(CN2CCC3=C2N=CN=C3N2CCC[C@@H]2C2=CC=C(C(F)(F)F)C=C2)C=C1 Chemical compound NC(=O)CC1=CC=C(CN2CCC3=C2N=CN=C3N2CCC[C@@H]2C2=CC=C(C(F)(F)F)C=C2)C=C1 MDBOPJLXEBZIMC-JOCHJYFZSA-N 0.000 description 1
- JTANKSSORRCUAD-UHFFFAOYSA-N NC(=O)CC1=CC=C(CNC2=C(F)C(N3CC(=O)CC3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)C=C1 Chemical compound NC(=O)CC1=CC=C(CNC2=C(F)C(N3CC(=O)CC3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)C=C1 JTANKSSORRCUAD-UHFFFAOYSA-N 0.000 description 1
- QKCGYRVRYPZGGU-UHFFFAOYSA-N NC(=O)CC1=CC=C(CNC2=C(F)C(N3CCC3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)C=C1 Chemical compound NC(=O)CC1=CC=C(CNC2=C(F)C(N3CCC3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)C=C1 QKCGYRVRYPZGGU-UHFFFAOYSA-N 0.000 description 1
- WDLQQBGZUFKXJG-UHFFFAOYSA-N NC(=O)CC1=CC=C(CNC2=C(F)C(N3CCCC3C3=CC4=C(C=C3)OCO4)=NC=N2)C=C1 Chemical compound NC(=O)CC1=CC=C(CNC2=C(F)C(N3CCCC3C3=CC4=C(C=C3)OCO4)=NC=N2)C=C1 WDLQQBGZUFKXJG-UHFFFAOYSA-N 0.000 description 1
- NQGASMOVPQXRKJ-MYKUNDNFSA-N NC(=O)CC1CCC(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound NC(=O)CC1CCC(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 NQGASMOVPQXRKJ-MYKUNDNFSA-N 0.000 description 1
- DGKCJCUCNXIICH-UHFFFAOYSA-N NC(=O)Cc1ccc(CCc2ncnc(N3CC(F)(F)CC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound NC(=O)Cc1ccc(CCc2ncnc(N3CC(F)(F)CC3c3ccc(C(F)(F)F)cc3)c2F)cc1 DGKCJCUCNXIICH-UHFFFAOYSA-N 0.000 description 1
- QTOZPRANAQJOBO-UHFFFAOYSA-N NC(=O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound NC(=O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 QTOZPRANAQJOBO-UHFFFAOYSA-N 0.000 description 1
- ZZHAUBUKWYFUOJ-OAQYLSRUSA-N NC(=O)Cc1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3F)c2F)cc1 Chemical compound NC(=O)Cc1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3F)c2F)cc1 ZZHAUBUKWYFUOJ-OAQYLSRUSA-N 0.000 description 1
- MFBRRNMDJNSUAW-OAQYLSRUSA-N NC(=O)Cc1ccc(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound NC(=O)Cc1ccc(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 MFBRRNMDJNSUAW-OAQYLSRUSA-N 0.000 description 1
- ZAFRCKGRPQHTNT-OAQYLSRUSA-N NC(=O)Cc1ccc(CCc2ncnc(N3CCOC[C@@H]3c3ccc(OC(F)(F)F)cc3)c2F)cc1 Chemical compound NC(=O)Cc1ccc(CCc2ncnc(N3CCOC[C@@H]3c3ccc(OC(F)(F)F)cc3)c2F)cc1 ZAFRCKGRPQHTNT-OAQYLSRUSA-N 0.000 description 1
- WGSKBYHNSJOWCL-PZJWPPBQSA-N NC(=O)Cc1ccc(CCc2ncnc(N3C[C@@H](F)C[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound NC(=O)Cc1ccc(CCc2ncnc(N3C[C@@H](F)C[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 WGSKBYHNSJOWCL-PZJWPPBQSA-N 0.000 description 1
- WGSKBYHNSJOWCL-FPOVZHCZSA-N NC(=O)Cc1ccc(CCc2ncnc(N3C[C@@H](F)C[C@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound NC(=O)Cc1ccc(CCc2ncnc(N3C[C@@H](F)C[C@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 WGSKBYHNSJOWCL-FPOVZHCZSA-N 0.000 description 1
- WGSKBYHNSJOWCL-TZIWHRDSSA-N NC(=O)Cc1ccc(CCc2ncnc(N3C[C@H](F)C[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound NC(=O)Cc1ccc(CCc2ncnc(N3C[C@H](F)C[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 WGSKBYHNSJOWCL-TZIWHRDSSA-N 0.000 description 1
- WGSKBYHNSJOWCL-CTNGQTDRSA-N NC(=O)Cc1ccc(CCc2ncnc(N3C[C@H](F)C[C@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound NC(=O)Cc1ccc(CCc2ncnc(N3C[C@H](F)C[C@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 WGSKBYHNSJOWCL-CTNGQTDRSA-N 0.000 description 1
- MDZLEOSZDRFDJR-UHFFFAOYSA-N NC(=O)Cc1ncc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 Chemical compound NC(=O)Cc1ncc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 MDZLEOSZDRFDJR-UHFFFAOYSA-N 0.000 description 1
- OCFNPFQCGGFIMA-QNSVNVJESA-N NC(=O)[C@@H](Cc1cc(F)c(F)cc1F)Nc1ncnc(N2CCCC2c2nc3ccccc3s2)c1F Chemical compound NC(=O)[C@@H](Cc1cc(F)c(F)cc1F)Nc1ncnc(N2CCCC2c2nc3ccccc3s2)c1F OCFNPFQCGGFIMA-QNSVNVJESA-N 0.000 description 1
- WHJBXBYOTJGLMT-HXUWFJFHSA-N NC(=O)c1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound NC(=O)c1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 WHJBXBYOTJGLMT-HXUWFJFHSA-N 0.000 description 1
- PMMHAQAYBFLFEM-UHFFFAOYSA-N NCC1(CCN(CC1)C(C)=O)F Chemical compound NCC1(CCN(CC1)C(C)=O)F PMMHAQAYBFLFEM-UHFFFAOYSA-N 0.000 description 1
- HNCQITIOVQUUQB-UHFFFAOYSA-N NCC1=CC=C(C(=O)N2CCOCC2)C=C1 Chemical compound NCC1=CC=C(C(=O)N2CCOCC2)C=C1 HNCQITIOVQUUQB-UHFFFAOYSA-N 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N NCC1=CC=C(C(=O)O)C=C1 Chemical compound NCC1=CC=C(C(=O)O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- PRDBLLIPPDOICK-UHFFFAOYSA-N NCC1=CC=C(C(F)(F)F)C=C1 Chemical compound NCC1=CC=C(C(F)(F)F)C=C1 PRDBLLIPPDOICK-UHFFFAOYSA-N 0.000 description 1
- GZPXIKSDIBYLTC-UHFFFAOYSA-N NCC1=CC=C(C=C1)CC(=O)NC#N Chemical compound NCC1=CC=C(C=C1)CC(=O)NC#N GZPXIKSDIBYLTC-UHFFFAOYSA-N 0.000 description 1
- YTLTVQZZOODNAT-UHFFFAOYSA-N NCC1=CC=C(N2CCCC(C(N)=O)C2)C=C1 Chemical compound NCC1=CC=C(N2CCCC(C(N)=O)C2)C=C1 YTLTVQZZOODNAT-UHFFFAOYSA-N 0.000 description 1
- HHTYQKRMCZUXLU-UHFFFAOYSA-N NCC1=CC=C(N2CCNC(=O)C2)C=C1 Chemical compound NCC1=CC=C(N2CCNC(=O)C2)C=C1 HHTYQKRMCZUXLU-UHFFFAOYSA-N 0.000 description 1
- LTILPSKZXNIITC-UHFFFAOYSA-N NCC1=CC=C(N2CCOCC2)C=C1 Chemical compound NCC1=CC=C(N2CCOCC2)C=C1 LTILPSKZXNIITC-UHFFFAOYSA-N 0.000 description 1
- GUABVDOVRIITCB-UHFFFAOYSA-N NCC1=CN=C(N2CCC(CO)CC2)C=C1 Chemical compound NCC1=CN=C(N2CCC(CO)CC2)C=C1 GUABVDOVRIITCB-UHFFFAOYSA-N 0.000 description 1
- GFOAHABINHRDKL-UHFFFAOYSA-N NCC1CCC(=O)N1 Chemical compound NCC1CCC(=O)N1 GFOAHABINHRDKL-UHFFFAOYSA-N 0.000 description 1
- KGMHFAGSWBNXEY-LJQANCHMSA-N NCCCC(=O)C1(CNC2=C(F)C(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)CCOCC1 Chemical compound NCCCC(=O)C1(CNC2=C(F)C(N3CCOC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=NC=N2)CCOCC1 KGMHFAGSWBNXEY-LJQANCHMSA-N 0.000 description 1
- ZYUJVRGNPLWRLU-ZKCHVHJHSA-N NC[C@@H]1CC[C@H](CC1)NS(=O)(=O)C Chemical compound NC[C@@H]1CC[C@H](CC1)NS(=O)(=O)C ZYUJVRGNPLWRLU-ZKCHVHJHSA-N 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- YPSSCEVOSCAKLY-UHFFFAOYSA-N NS(=O)(=O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound NS(=O)(=O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 YPSSCEVOSCAKLY-UHFFFAOYSA-N 0.000 description 1
- USJHUKGWUQLERB-HXUWFJFHSA-N NS(=O)(=O)c1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound NS(=O)(=O)c1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 USJHUKGWUQLERB-HXUWFJFHSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- FKPJZZHDPQRHIL-UHFFFAOYSA-N O=C(CC(CNC(C1F)NC2(CCCCCCCC2)NC1N(CCC1)C1C(CC1)CCC1C(F)(F)F)C1)N1C1CCCC1 Chemical compound O=C(CC(CNC(C1F)NC2(CCCCCCCC2)NC1N(CCC1)C1C(CC1)CCC1C(F)(F)F)C1)N1C1CCCC1 FKPJZZHDPQRHIL-UHFFFAOYSA-N 0.000 description 1
- OTSLNZOUQHIKJU-LOACHALJSA-N O=C(C[C@H](CC1CCNC1=O)C(=O)O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2 Chemical compound O=C(C[C@H](CC1CCNC1=O)C(=O)O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2 OTSLNZOUQHIKJU-LOACHALJSA-N 0.000 description 1
- YAHKXQSXDLBLDX-JOCHJYFZSA-N O=C(N[C@H](CC1=CC(F)=C(F)C=C1F)C(=O)O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2 Chemical compound O=C(N[C@H](CC1=CC(F)=C(F)C=C1F)C(=O)O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2 YAHKXQSXDLBLDX-JOCHJYFZSA-N 0.000 description 1
- GHWBOWNFASFNHK-OAQYLSRUSA-N O=C(N[C@H](CC1CCOCC1)C(=O)O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2 Chemical compound O=C(N[C@H](CC1CCOCC1)C(=O)O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2 GHWBOWNFASFNHK-OAQYLSRUSA-N 0.000 description 1
- MFDDNUPUOKTLSP-UHFFFAOYSA-N O=C(O)CC1CCC(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound O=C(O)CC1CCC(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CC1 MFDDNUPUOKTLSP-UHFFFAOYSA-N 0.000 description 1
- XDTGWRDUAQYUBG-MYKUNDNFSA-N O=C(O)CC1CCC(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound O=C(O)CC1CCC(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 XDTGWRDUAQYUBG-MYKUNDNFSA-N 0.000 description 1
- FSWVPSKZCQWTMK-CBGDNZLLSA-N O=C(O)C[C@H]1CC[C@H](CCc2ncnc(N3CCOC[C@@H]3c3ccc(OC(F)(F)F)cc3)c2F)CC1 Chemical compound O=C(O)C[C@H]1CC[C@H](CCc2ncnc(N3CCOC[C@@H]3c3ccc(OC(F)(F)F)cc3)c2F)CC1 FSWVPSKZCQWTMK-CBGDNZLLSA-N 0.000 description 1
- PWRYIDYONPKPLX-UHFFFAOYSA-N O=C(O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(OC(F)(F)F)cc3)c2F)cc1 Chemical compound O=C(O)Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(OC(F)(F)F)cc3)c2F)cc1 PWRYIDYONPKPLX-UHFFFAOYSA-N 0.000 description 1
- XSZAKZAFMXBHNX-OAQYLSRUSA-N O=C(O)Cc1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound O=C(O)Cc1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 XSZAKZAFMXBHNX-OAQYLSRUSA-N 0.000 description 1
- FLNFRLDHPYYKTH-LJQANCHMSA-N O=C(O)Cc1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)s1 Chemical compound O=C(O)Cc1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)s1 FLNFRLDHPYYKTH-LJQANCHMSA-N 0.000 description 1
- XSZAKZAFMXBHNX-NRFANRHFSA-N O=C(O)Cc1ccc(CCc2ncnc(N3CCC[C@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound O=C(O)Cc1ccc(CCc2ncnc(N3CCC[C@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 XSZAKZAFMXBHNX-NRFANRHFSA-N 0.000 description 1
- WGIBJKQZKJSOAW-UHFFFAOYSA-N O=C(O)Cc1ccc(CCc2ncnc(N3CCOCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound O=C(O)Cc1ccc(CCc2ncnc(N3CCOCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 WGIBJKQZKJSOAW-UHFFFAOYSA-N 0.000 description 1
- GZVSMSYQOPHWKS-UHFFFAOYSA-N O=C(O)Cc1ccc(CCc2ncnc(N3CCOCC3c3ccc(OC(F)(F)F)cc3)c2F)cc1 Chemical compound O=C(O)Cc1ccc(CCc2ncnc(N3CCOCC3c3ccc(OC(F)(F)F)cc3)c2F)cc1 GZVSMSYQOPHWKS-UHFFFAOYSA-N 0.000 description 1
- UOYQYFUQMYMBOH-UHFFFAOYSA-N O=C(O)Cc1ccc(COc2ncnc(CCc3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound O=C(O)Cc1ccc(COc2ncnc(CCc3ccc(C(F)(F)F)cc3)c2F)cc1 UOYQYFUQMYMBOH-UHFFFAOYSA-N 0.000 description 1
- FESLFHKFABODKM-UHFFFAOYSA-N O=C(O)c1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound O=C(O)c1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 FESLFHKFABODKM-UHFFFAOYSA-N 0.000 description 1
- IYNKYJSCJGELPH-UHFFFAOYSA-N O=C(c1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1)N1CCOCC1 Chemical compound O=C(c1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1)N1CCOCC1 IYNKYJSCJGELPH-UHFFFAOYSA-N 0.000 description 1
- HAGBRTBBLNHBNR-UHFFFAOYSA-N O=C(c1ccncc1)N1CCC(Cc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)C1 Chemical compound O=C(c1ccncc1)N1CCC(Cc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)C1 HAGBRTBBLNHBNR-UHFFFAOYSA-N 0.000 description 1
- OZFWIKJTNDKYJB-UHFFFAOYSA-N O=C1CC(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CN1C1CCCC1 Chemical compound O=C1CC(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CN1C1CCCC1 OZFWIKJTNDKYJB-UHFFFAOYSA-N 0.000 description 1
- YHYVGTQLLPJMLJ-UHFFFAOYSA-N O=C1CCCN1Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound O=C1CCCN1Cc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 YHYVGTQLLPJMLJ-UHFFFAOYSA-N 0.000 description 1
- RRCGDNBEXRBVHD-UHFFFAOYSA-N O=C1CCCN1c1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound O=C1CCCN1c1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 RRCGDNBEXRBVHD-UHFFFAOYSA-N 0.000 description 1
- ZVECNOOHTSRLFN-UHFFFAOYSA-N O=C1CCCN1c1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1 Chemical compound O=C1CCCN1c1cccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)c1 ZVECNOOHTSRLFN-UHFFFAOYSA-N 0.000 description 1
- RJOVFFAOCLBGFH-UHFFFAOYSA-N O=C1CN(c2ccc(CCc3ncnc(N4CCCC4c4ccc(C(F)(F)F)cc4)c3F)cc2)CCN1 Chemical compound O=C1CN(c2ccc(CCc3ncnc(N4CCCC4c4ccc(C(F)(F)F)cc4)c3F)cc2)CCN1 RJOVFFAOCLBGFH-UHFFFAOYSA-N 0.000 description 1
- BDHREJWNNLPANL-UHFFFAOYSA-N O=C1Cc2ccc(CCc3ncnc(N4CCCC4c4ccc(C(F)(F)F)cc4)c3F)cc2C1 Chemical compound O=C1Cc2ccc(CCc3ncnc(N4CCCC4c4ccc(C(F)(F)F)cc4)c3F)cc2C1 BDHREJWNNLPANL-UHFFFAOYSA-N 0.000 description 1
- CZOAFZLCFJBDSE-SZVBFZGTSA-N O=S(=O)(CC(F)(F)F)N[C@H]1CC[C@H](CNC2=C(F)C(N3CCOC[C@@H]3C3=CC=C(OC(F)(F)F)C=C3)=NC=N2)CC1 Chemical compound O=S(=O)(CC(F)(F)F)N[C@H]1CC[C@H](CNC2=C(F)C(N3CCOC[C@@H]3C3=CC=C(OC(F)(F)F)C=C3)=NC=N2)CC1 CZOAFZLCFJBDSE-SZVBFZGTSA-N 0.000 description 1
- RJLDQFXMWKAKQN-XMMPIXPASA-N O=S(=O)(CC1CC1)c1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound O=S(=O)(CC1CC1)c1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 RJLDQFXMWKAKQN-XMMPIXPASA-N 0.000 description 1
- VJUGSXFZKAGXNT-XMMPIXPASA-N O=S(=O)(CC1CC1)c1ccc(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound O=S(=O)(CC1CC1)c1ccc(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 VJUGSXFZKAGXNT-XMMPIXPASA-N 0.000 description 1
- LHFVYBXHIPJXAV-HXUWFJFHSA-N O=S(=O)(O)C1=CC=C(CCC2=NC=NC(N3CCC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=C2F)C=C1 Chemical compound O=S(=O)(O)C1=CC=C(CCC2=NC=NC(N3CCC[C@@H]3C3=CC=C(C(F)(F)F)C=C3)=C2F)C=C1 LHFVYBXHIPJXAV-HXUWFJFHSA-N 0.000 description 1
- IGJXVJUBYKQRRS-XPKAQORNSA-N O=S1(=O)CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)C1 Chemical compound O=S1(=O)CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)C1 IGJXVJUBYKQRRS-XPKAQORNSA-N 0.000 description 1
- YEDQHMQEZDNRBS-LJQANCHMSA-N O=S1(=O)CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound O=S1(=O)CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 YEDQHMQEZDNRBS-LJQANCHMSA-N 0.000 description 1
- SJARQBVLYXZXQA-UHUGOGIASA-N O=S1(=O)CCCC1CCc1ncnc(N2CCC[C@@H]2c2ccc(C(F)(F)F)cc2)c1F Chemical compound O=S1(=O)CCCC1CCc1ncnc(N2CCC[C@@H]2c2ccc(C(F)(F)F)cc2)c1F SJARQBVLYXZXQA-UHUGOGIASA-N 0.000 description 1
- HKOLEXUOLBRNHQ-UHUGOGIASA-N O=S1(=O)CCOC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)C1 Chemical compound O=S1(=O)CCOC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)C1 HKOLEXUOLBRNHQ-UHUGOGIASA-N 0.000 description 1
- IKLHERHJBIUMCC-UHFFFAOYSA-N OC1(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 Chemical compound OC1(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 IKLHERHJBIUMCC-UHFFFAOYSA-N 0.000 description 1
- AGDZMWKMXUAHCB-HXUWFJFHSA-N OC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCCCCC1 Chemical compound OC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCCCCC1 AGDZMWKMXUAHCB-HXUWFJFHSA-N 0.000 description 1
- MCXWTGSCXBONER-GOSISDBHSA-N OC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCSCC1 Chemical compound OC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCSCC1 MCXWTGSCXBONER-GOSISDBHSA-N 0.000 description 1
- IYMKXAUWSXTLMW-UHFFFAOYSA-N OC1=C(C2CCCN2)C=CC(C(F)(F)F)=C1 Chemical compound OC1=C(C2CCCN2)C=CC(C(F)(F)F)=C1 IYMKXAUWSXTLMW-UHFFFAOYSA-N 0.000 description 1
- VZLDEDIQHSWHKK-NQKNOSNGSA-N OC1CCCCC1CCc1ncnc(N2CCC[C@@H]2c2ccc(C(F)(F)F)cc2)c1F Chemical compound OC1CCCCC1CCc1ncnc(N2CCC[C@@H]2c2ccc(C(F)(F)F)cc2)c1F VZLDEDIQHSWHKK-NQKNOSNGSA-N 0.000 description 1
- VHKIYWZHPPYXAN-OAHLLOKOSA-N OCC1(CNc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)COC1 Chemical compound OCC1(CNc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)COC1 VHKIYWZHPPYXAN-OAHLLOKOSA-N 0.000 description 1
- ULSMVZMHUHLQIZ-MYKUNDNFSA-N OCC1CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 Chemical compound OCC1CCC(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CC1 ULSMVZMHUHLQIZ-MYKUNDNFSA-N 0.000 description 1
- MDYPQPRIEKWCRY-UHFFFAOYSA-N OCC1CCN(c2ccc(CCc3ncnc(N4CCCC4c4ccc(C(F)(F)F)cc4)c3F)cn2)CC1 Chemical compound OCC1CCN(c2ccc(CCc3ncnc(N4CCCC4c4ccc(C(F)(F)F)cc4)c3F)cn2)CC1 MDYPQPRIEKWCRY-UHFFFAOYSA-N 0.000 description 1
- HUYZLDPAYDYELC-UHFFFAOYSA-N OCC=1C=NC(=NC=1)CC(=O)OC Chemical compound OCC=1C=NC(=NC=1)CC(=O)OC HUYZLDPAYDYELC-UHFFFAOYSA-N 0.000 description 1
- VVRYBHGLWQGVNM-HXUWFJFHSA-N OCCC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 Chemical compound OCCC1(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 VVRYBHGLWQGVNM-HXUWFJFHSA-N 0.000 description 1
- ZTMDXJIIADVQHH-HXUWFJFHSA-N OCCC1(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 Chemical compound OCCC1(CCc2ncnc(N3CCOC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)CCOCC1 ZTMDXJIIADVQHH-HXUWFJFHSA-N 0.000 description 1
- XISBVTZBNJPKID-UHFFFAOYSA-N OCCc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound OCCc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cc1 XISBVTZBNJPKID-UHFFFAOYSA-N 0.000 description 1
- SRQCAPZFKUYSMN-OAQYLSRUSA-N OCc1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound OCc1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 SRQCAPZFKUYSMN-OAQYLSRUSA-N 0.000 description 1
- GEQYDQQBBLONGD-OAQYLSRUSA-N OCc1cccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)c1 Chemical compound OCc1cccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)c1 GEQYDQQBBLONGD-OAQYLSRUSA-N 0.000 description 1
- JHUQMCKRBSYJBR-LJQANCHMSA-N O[n+]1cccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)c1 Chemical compound O[n+]1cccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)c1 JHUQMCKRBSYJBR-LJQANCHMSA-N 0.000 description 1
- NYLPVYNVMSECKN-UHFFFAOYSA-N Oc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 Chemical compound Oc1ccc(CCc2ncnc(N3CCCC3c3ccc(C(F)(F)F)cc3)c2F)cn1 NYLPVYNVMSECKN-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- YIIOTOBXQVQGSV-UHFFFAOYSA-N [1,3]dioxolo[4,5-b]pyridine Chemical compound C1=CN=C2OCOC2=C1 YIIOTOBXQVQGSV-UHFFFAOYSA-N 0.000 description 1
- ACNORCPEAPJSND-UHFFFAOYSA-N [1,3]dioxolo[4,5-d]pyrimidine Chemical compound N1=CN=C2OCOC2=C1 ACNORCPEAPJSND-UHFFFAOYSA-N 0.000 description 1
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 description 1
- BRIOKNPDCPJCOD-UHFFFAOYSA-N [1,3]oxazolo[5,4-d]pyrimidine Chemical compound N1=CN=C2OC=NC2=C1 BRIOKNPDCPJCOD-UHFFFAOYSA-N 0.000 description 1
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 description 1
- YTWTYOFYJMRQGA-UHFFFAOYSA-N [1-[5-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]pyridin-2-yl]piperidin-4-yl]methanol Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC=1C=CC(=NC=1)N1CCC(CC1)CO YTWTYOFYJMRQGA-UHFFFAOYSA-N 0.000 description 1
- XBNOLLGBUPOQSE-UHFFFAOYSA-N [3-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]pyrrolidin-1-yl]-pyridin-4-ylmethanone Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NC1CN(CC1)C(=O)C1=CC=NC=C1 XBNOLLGBUPOQSE-UHFFFAOYSA-N 0.000 description 1
- ICABDHJZHGYFPZ-UHFFFAOYSA-N [4-(methylsulfonylmethyl)oxan-4-yl]methanamine Chemical compound CS(=O)(=O)CC1(CN)CCOCC1 ICABDHJZHGYFPZ-UHFFFAOYSA-N 0.000 description 1
- FYWMIBHWPBJNOB-LJQANCHMSA-N [4-[[[5-fluoro-6-[(2R)-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]methanol Chemical compound FC=1C(=NC=NC=1N1[C@H](CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CO FYWMIBHWPBJNOB-LJQANCHMSA-N 0.000 description 1
- XXHFFDJTANLDOU-UHFFFAOYSA-N [4-[[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]methyl]phenyl]methanesulfonamide Chemical compound FC=1C(=NC=NC=1N1C(CCC1)C1=CC=C(C=C1)C(F)(F)F)NCC1=CC=C(C=C1)CS(=O)(=O)N XXHFFDJTANLDOU-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- JHAOZNVZXDWVBN-UHFFFAOYSA-N [O-]C(=O)C(F)(F)F.[NH3+]CC1CCC(Cc2nn[nH]n2)CC1 Chemical compound [O-]C(=O)C(F)(F)F.[NH3+]CC1CCC(Cc2nn[nH]n2)CC1 JHAOZNVZXDWVBN-UHFFFAOYSA-N 0.000 description 1
- NHEWUIDQIPZVTC-LJQANCHMSA-N [O-][n+]1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 Chemical compound [O-][n+]1ccc(CCc2ncnc(N3CCC[C@@H]3c3ccc(C(F)(F)F)cc3)c2F)cc1 NHEWUIDQIPZVTC-LJQANCHMSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- HAVZTGSQJIEKPI-UHFFFAOYSA-N benzothiadiazine Chemical compound C1=CC=C2C=NNSC2=C1 HAVZTGSQJIEKPI-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XRLDSWLMHUQECH-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- MHPUGCYGQWGLJL-UHFFFAOYSA-N dimethyl pentanoic acid Natural products CC(C)CCCC(O)=O MHPUGCYGQWGLJL-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- ZTYYDUBWJTUMHW-UHFFFAOYSA-N furo[3,2-b]furan Chemical compound O1C=CC2=C1C=CO2 ZTYYDUBWJTUMHW-UHFFFAOYSA-N 0.000 description 1
- JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical compound C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000010651 grapefruit oil Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000005237 imidazopyrimidines Chemical class 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002478 indolizines Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000008372 isochromenes Chemical class 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- OXDGVVQFGUAOIK-UHFFFAOYSA-N n-[2-(aminomethyl)cyclopentyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1CCCC1CN OXDGVVQFGUAOIK-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- NCCHARWOCKOHIH-UHFFFAOYSA-N n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1 NCCHARWOCKOHIH-UHFFFAOYSA-N 0.000 description 1
- 125000001326 naphthylalkyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000005474 octanoate group Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000005430 oxychloro group Chemical group 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 208000010713 partial hind limb paralysis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- XYEVREOOMFVLLS-UHFFFAOYSA-N pyrazolo[4,3-c]diazepine Chemical class C1=CC=NN=C2C=NN=C21 XYEVREOOMFVLLS-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- MHOZZUICEDXVGD-UHFFFAOYSA-N pyrrolo[2,3-d]imidazole Chemical compound C1=NC2=CC=NC2=N1 MHOZZUICEDXVGD-UHFFFAOYSA-N 0.000 description 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- LJPZHJUSICYOIX-UHFFFAOYSA-N quinolizidine Chemical compound C1CCCC2CCCCN21 LJPZHJUSICYOIX-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- PHQXGCNECRISKB-UHFFFAOYSA-N tert-butyl n-(pyridin-3-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CN=C1 PHQXGCNECRISKB-UHFFFAOYSA-N 0.000 description 1
- KXCFJDZVQLRYSI-UHFFFAOYSA-N tert-butyl n-(pyridin-4-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=NC=C1 KXCFJDZVQLRYSI-UHFFFAOYSA-N 0.000 description 1
- UXWQXBSQQHAGMG-UHFFFAOYSA-N tert-butyl n-[(4-aminophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(N)C=C1 UXWQXBSQQHAGMG-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 150000008634 thiazolopyrimidines Chemical class 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 description 1
- 229940125670 thienopyridine Drugs 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical compound NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical compound BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Definitions
- aspects and embodiments described herein relate to compounds active towards nuclear receptors, pharmaceutical compositions comprising the compounds, and methods of treating inflammatory, metabolic, oncologic and autoimmune diseases or disorders using the compounds.
- Nuclear receptors are a family of transcription factors involved in the regulation of physiological functions, such as cell differentiation, embryonic development, and organ physiology. Nuclear receptors have also been identified as important pathological regulators in diseases such as cancer, diabetes, and autoimmune disorders.
- nuclear receptors examples include the nuclear retinoic acid receptor-related orphan receptors (RORs).
- RORs contain four principal domains: an N-terminal A/B domain, a DNA-binding domain, a hinge domain and a ligand binding domain. Binding of ligands to the ligand-binding domain is believed to cause conformational changes in the domain resulting in downstream actions. Different isoforms exist and these isoforms differ in their N-terminal A/B domain only.
- RORs consist of three members, namely ROR alpha (ROR ⁇ ), ROR beta (ROR ⁇ ) and ROR gamma (ROR ⁇ or RORc).
- ROR ⁇ is expressed in many tissues such as cerebellar Purkinje cells, the liver, thymus, skeletal muscle, skin, lung, adipose tissue and kidney.
- ROR ⁇ also has a broad expression pattern and was the most recently discovered of the three members. To date, five splice variants have been recorded for ROR ⁇ coding for two different protein isoforms: ROR ⁇ 1 and ROR ⁇ 2 (ROR ⁇ 2 is also known as ROR ⁇ t). Generally ROR ⁇ is used to describe ROR ⁇ 1 and/or ROR ⁇ t. ROR ⁇ 1 is expressed in many tissues and is predominantly expressed in the kidneys, liver, and skeletal muscle. In contrast, expression of ROR ⁇ t is restricted to lymphoid organs such as the thymus. ROR ⁇ t has been identified as a key regulator of Th17 cell differentiation.
- Th17 cells are a subset of T helper cells which preferentially produce the cytokines IL-17A, IL-17F, IL-21 and IL-22. Th17 cells and their products have been shown to be associated with the pathology of many human inflammatory and autoimmune disorders.
- Y is NR or O
- R is hydrogen or substituted or unsubstituted C 1-4 alkyl
- R 1 is selected from the group consisting of hydrogen, —OH, halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, and substituted or unsubstituted C 2-4 alkenyl;
- R 2 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, —CN, and —OH;
- R and R 2 are combined to form a substituted or unsubstituted fused ring;
- R 3 is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, oxo, —C( ⁇ O)R 10 ;
- R 4a is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C 1-6 alkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroaryl-C 1-6 alkyl;
- R 4b is selected from the group consisting of hydrogen, halogen, oxo, —OH, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, and —C( ⁇ O)R 10 ;
- R 5 is selected from the group consisting of —(CR 8 R 9 )pOR 12 , —(CR 8 R 9 )p-CR 13 R 14 R 15 , —(CR 8 R 9 )p-C( ⁇ O)OR 7 , and —(CR 8 R 9 )p-C( ⁇ O)NR 8 R 9 ;
- n, m, and p are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
- R 6a , R 6b are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 1-6 heteroalkyl, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, substituted or unsubstituted C 2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, or R 6a and R 6b are taken together to form an oxo group or a ring system selected from substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicycly
- R 7 , R 8 , R 9 , and R 12 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicyclyl;
- R 10 is selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy, —OH, —NH 2 , —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , and C 3-7 cycloalkyl;
- R 13 is absent, or selected from the group consisting of hydrogen, —OH, —CN substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, and —(CR 8 R 9 )p-C( ⁇ O)OR 7 , —(CR 8 R 9 )p-SO 2 R 7 and —(CR 8 R 9 )p-C( ⁇ O)NR 8 R 9 ;
- R 14 and R 15 are independently selected from the group consisting of hydrogen, and substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicyclyl; or
- R 14 and R 15 are combined to form a ring system selected from the group consisting of substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, substituted or unsubstituted C 2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- B is a ring system selected from the group consisting of aryl, heteroaryl, and bicyclic heteroalicyclyl, provided that it is not 5,6-dichloro-1H-benzo[d]imidazol-2-yl when R 1 and R 2 both are hydrogen;
- C is a ring system selected from C 2-9 heteroalicyclyl
- R and R 2 are combined to form a fused ring.
- R 5 is —(CR 8 R 9 )p-C( ⁇ O)OR 7 , or —(CR 8 R 9 )p-C( ⁇ O)NR 8 R 9 .
- R 5 is —(CR 8 R 9 )p-CR 13 R 14 R 15 wherein R 14 and R 15 are combined to form a ring system.
- composition comprising a compound of the herein above described type and at least one pharmaceutical acceptable excipient.
- the herein above described compound or pharmaceutical composition are for use in therapy.
- the herein above described compound or pharmaceutical composition are for use in the treatment and/or prevention of inflammatory, metabolic and autoimmune diseases or disorders.
- the herein above described compound or pharmaceutical composition are for modulating the activity of a retinoic acid receptor-related orphan receptor (ROR).
- ROR retinoic acid receptor-related orphan receptor
- any “R” group(s) such as, without limitation, R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , and R 10 , represent substituents that can be attached to the indicated atom.
- R groups includes but is not limited to hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and heteroalicyclyl.
- R a and R b of an NR a R b group are indicated to be “taken together” or “combined”, it means that they are covalently bonded to one another at their terminal atoms to form a ring that includes the nitrogen:
- any given group disclosed herein may comprise further hydrogen(s) than the one(s) provided by a R-group, being hydrogen, attached to the group.
- the substituent(s) (which may be present one or more times, such as 1, 2, 3 or 4 times) are independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, s
- substituent on a group is deemed to be “substituted,” the substitutent itself is substituted with one or more of the indicated substitutents.
- substituted it is meant that one or more hydrogen atoms on the referenced substituent may be replaced with a group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfon
- C m to C n refers to the number of carbon atoms in the relevant group. That is, the group can contain from “m” to “n”, inclusive, carbon atoms.
- a “C 1 to C 6 alkyl” group refers to all alkyl groups having from 1 to 6 carbons, that is, CH 3 —, CH 3 CH 2 —, CH 3 CH 2 CH 2 —, (CH 3 ) 2 CH—, CH 3 CH 2 CH 2 CH 2 —, CH 3 CH 2 CH(CH 3 )—, CH 3 CH(CH) 3 CH 2 —, CH 3 CH(CH) 3 CH 2 — and (CH 3 ) 3 C—. If no “m” and “n” are designated with regard to a group, the broadest range described in these definitions is to be assumed.
- alkyl refers to a straight or branched hydrocarbon chain group that is fully saturated (no double or triple bonds).
- the alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., “1 to 20 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated).
- the alkyl group may also be a medium size alkyl having 1 to 10 carbon atoms, such as “C 1-6 ”.
- the alkyl group could also be a lower alkyl having 1 to 4 carbon atoms.
- the alkyl group of the compounds may be designated as “C 1 -C 4 alkyl,” “C 1-4 alkyl” or similar designations.
- “C 1 -C 4 alkyl” or “C 1-4 alkyl” indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
- Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like.
- the substituent group(s) is(are) one or more group(s) individually and independently selected from alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl
- alkenyl refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more double bonds. If more than one double bond is present, the double bonds may be conjugated or not conjugated.
- the alkenyl group may have 2 to 20 carbon atoms (whenever it appears herein, a numerical range such as “2 to 20” refers to each integer in the given range; e.g., “2 to 20 carbon atoms” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated).
- the substituent group(s) is(are) one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, mercapto, alkylthio, cyano, halogen, nitro, haloalkyl, haloalkoxy, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof.
- alkynyl refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more triple bonds.
- the alkynyl group may have 2 to 20 carbon atoms (whenever it appears herein, a numerical range such as “2 to 20” refers to each integer in the given range; e.g., “2 to 20 carbon atoms” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated).
- An alkynyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups disclosed above with regard to alkenyl group substitution.
- hetero may be attached to a group and refers to one or more carbon atom(s) and the associated hydrogen atom(s) in the attached group have been independently replaced with the same or different heteroatoms selected from nitrogen, oxygen, phosphorus and sulfur.
- heteroalkyl refers to a straight or branched alkyl group consisting of the stated number of carbon atoms, where one or more carbon atom(s), such as 1, 2, 3 or 4 carbon atom(s), and the associated hydrogen atom(s) have been independently replaced with the same or different heteroatoms selected from nitrogen, oxygen and sulfur.
- the carbon atom(s) being replace may be in the middle or at the end of the alkyl group.
- heteroalkyl include, but are not limited to, —S-alkyl, —O-alkyl, —NH-alkyl, -alkylene-O-alkyl, etc
- aryl refers to a carbocyclic (all carbon) ring or two or more fused rings (rings that share two adjacent carbon atoms) that have a fully delocalized pi-electron system.
- aryl groups include, but are not limited to, benzene, naphthalene and azulene. An aryl group may be substituted.
- substituent group(s) that is(are) one or more group(s) independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihal
- substituents on an aryl group may form a non-aromatic ring fused to the aryl group, including a cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl.
- heteroaryl refers to a monocyclic or multicyclic aromatic ring system (a ring system with fully delocalized pi-electron system), in which at least one of the atoms in the ring system is a heteroatom, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur.
- Examples of monocyclic “heteroaryl” include, but are not limited to, furan, thiophene, phthalazine, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, triazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, tetrazole, and triazine.
- Examples of multicyclic “heteroaryl” include, but are not limited to, quinoline, isoquinoline, quinazoline, quinoxaline, indole, purines, benzofuran, benzothiophene, benzopyranones (e.g.
- a heteroaryl may be substituted.
- hydrogen atoms are replaced by substituent group(s) that is(are) one or more group(s) independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl,
- substituents on a heteroayl group may form a non-aromatic ring fused to the aryl group, including a cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl.
- aralkyl or “arylalkyl” is an aryl group connected, as a substituent, via an alkylene group.
- the alkylene and aryl group of an aralkyl may be substituted. Examples include but are not limited to benzyl, substituted benzyl, 2-phenylethyl, 3-phenylpropyl, and naphthylalkyl.
- the alkylene group is a lower alkylene group.
- heteroarylkyl or “heteroarylalkyl” is heteroaryl group connected, as a substituent, via an alkylene group.
- the alkylene and heteroaryl group of heteroaralkyl may be substituted. Examples include but are not limited to 2-thienylmethyl, 3-thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, pyrazolylalkyl and imidazolylalkyl, and their substituted as well as benzo-fused analogs.
- the alkylene group is a lower alkylene group.
- alkylene is a straight-chained tethering group, forming bonds to connect molecular fragments via their terminal carbon atoms.
- the alkylene may have 1 to 20 carbon atoms.
- the alkylene may also be a medium size alkylene having 1 to 10 carbon atoms, such as “C 1-6 ”
- the alkylene could also be a lower alkylene having 1 to 4 carbon atoms.
- the alkylene may be designated as “C 1 -C 4 alkylene”, “C 1-4 alkylene” or similar designations.
- Non-limiting examples include, methylene (—CH 2 —), ethylene (—CH 2 CH 2 —), propylene (—CH 2 CH 2 CH 2 —), and butylene (—(CH 2 ) 4 —) groups.
- methylene ethylene
- ethylene —CH 2 CH 2 —
- propylene —CH 2 CH 2 CH 2 —
- butylene —(CH 2 ) 4 —
- the two connected fragments are connected to the same carbon atom.
- a lower alkylene group may be substituted.
- heteroalkylene by itself or in combination with another term refers to an alkylene group consisting of the stated number of carbon atoms in which one or more of the carbon atoms, such as 1, 2, 3 or 4 carbon atom(s), are independently replaced with the same or different heteroatoms selected from oxygen, sulfur and nitrogen.
- heteroalkylene examples include, but not limited to —CH 2 —O—, —CH 2 —CH 2 —O—, —CH 2 —CH 2 —CH 2 —O—, —CH 2 —NH—, —CH 2 —CH 2 —NH—, —CH 2 —CH 2 —NH—, —CH 2 —CH 2 —NH—, —CH 2 —CH 2 —, —O—CH 2 —CH 2 —O—CH 2 —CH 2 —O—, —O—CH 2 —CH 2 —O—CH 2 —CH 2 —, and the like.
- alkylidene refers to a divalent group, such as ⁇ CR′R′′, which is attached to one carbon of another group, forming a double bond.
- Alkylidene groups include, but are not limited to, methylidene ( ⁇ CH 2 ) and ethylidene ( ⁇ CHCH 3 ).
- arylalkylidene refers to an alkylidene group in which either R′ or R′′ is an aryl group. An alkylidene group may be substituted.
- alkoxy refers to the group —OR wherein R is an alkyl, e.g. methoxy, ethoxy, n-propoxy, cyclopropoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, amoxy, tert-amoxy and the like. An alkoxy may be substituted.
- alkylthio refers to the formula —SR wherein R is an alkyl is defined as above, e.g. methylmercapto, ethylmercapto, n-propylmercapto, 1-methylethylmercapto (isopropylmercapto), n-butylmercapto, iso-butylmercapto, sec-butylmercapto, tert-butylmercapto, and the like.
- An alkylthio may be substituted.
- aryloxy and arylthio refers to RO— and RS—, in which R is an aryl as defined above, e.g., phenoxy, naphthalenyloxy, azulenyloxy, anthracenyloxy, naphthalenylthio, phenylthio and the like. Both an aryloxy and arylthio may be substituted.
- alkenyloxy refers to the formula —OR wherein R is an alkenyl as defined above, e.g., vinyloxy, propenyloxy, n-butenyloxy, iso-butenyloxy, sec-pentenyloxy, tert-pentenyloxy, and the like.
- the alkenyloxy may be substituted.
- acyl refers to a hydrogen, alkyl, alkenyl, alkynyl, or aryl connected, as substituents, via a carbonyl group. Examples include formyl, acetyl, propanoyl, benzoyl, and acryl. An acyl may be substituted.
- cycloalkyl refers to a completely saturated (no double bonds) mono- or multi-cyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro-connected fashion. Cycloalkyl groups may range from C 3 to C 10 , such as from C 3 to C 6 . A cycloalkyl group may be unsubstituted or substituted. Typical cycloalkyl groups include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- the substituent(s) may be an alkyl or selected from those indicated above with regard to substitution of an alkyl group unless otherwise indicated.
- substituents on a cycloalkyl group may form an aromatic ring fused to the cycloalkyl group, including an aryl and a heteroaryl.
- cycloalkenyl refers to a cycloalkyl group that contains one or more double bonds in the ring although, if there is more than one, they cannot form a fully delocalized pi-electron system in the ring (otherwise the group would be “aryl,” as defined herein). When composed of two or more rings, the rings may be connected together in a fused, bridged or spiro-connected fashion. Cycloalkenyl groups may range from C 3 to C 10 , such as from C 5 to C 10 . A cycloalkenyl group may be unsubstituted or substituted.
- substituent(s) When substituted, the substituent(s) may be an alkyl or selected from the groups disclosed above with regard to alkyl group substitution unless otherwise indicated.
- substituents on a cycloalkenyl group When substituted, substituents on a cycloalkenyl group may form an aromatic ring fused to the cycloalkenyl group, including an aryl and a heteroaryl.
- cycloalkynyl refers to a cycloalkyl group that contains one or more triple bonds in the ring. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro-connected fashion. Cycloalkynyl groups may range from C 8 to C 12 . A cycloalkynyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be an alkyl or selected from the groups disclosed above with regard to alkyl group substitution unless otherwise indicated. When substituted, substituents on a cycloalkynyl group may form an aromatic ring fused to the cycloalkynyl group, including an aryl and a heteroaryl.
- heteroalicyclic or “heteroalicyclyl” refers to a 3- to 18 membered ring which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
- the heteroalicyclic or heteroalicyclyl groups may range from C 2 to C 10 , in some embodiments it may range from C 2 to C 9 , and in other embodiments it may range from C 2 to C 8 .
- heteroalicyclic or “heteroalicyclyl” may be monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be joined together in a fused, bridged or spiro-connected fashion; and the nitrogen, carbon and sulfur atoms in the “heteroalicyclic” or “heteroalicyclyl” may be oxidized; the nitrogen may be quaternized; and the rings may also contain one or more double bonds provided that they do not form a fully delocalized pi-electron system throughout all the rings, examples are 2H-benzo[b][1,4]oxazin-3(4H)-one, 3,4-dihydroquinolin-2(1H)-one, 1,2,3,4-tetrahydroquino line, 3,4-dihydro-2H-benzo[b][1,4]oxazine, 2,3-dihydrobenzo[d]oxazole, 2,3-dihydro-1H-benz
- Heteroalicyclyl groups may be unsubstituted or substituted.
- the substituent(s) may be one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, C-amido, N-amido, S-sulfonamido, N-sulfonamido, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, haloalkyl, haloalkoxy, trihalomethan
- heteroalicyclic or “heteroalicyclyl” include but are not limited to, azepinyl, dioxolanyl, imidazolinyl, morpholinyl, oxetanyl, oxiranyl, piperidinyl N-Oxide, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, 4-piperidonyl, pyrazolidinyl, 2-oxopyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl sulfoxide, and thiamorpholinyl sulfone.
- substituents on a heteroalicyclyl group may form an aromatic ring fused to the heteroalicyclyl group, including an aryl and a heteroaryl.
- a “(cycloalkyl)alkyl” is a cycloalkyl group connected, as a substituent, via an alkylene group.
- the alkylene and cycloalkyl of a (cycloalkyl)alkyl may be substituted. Examples include but are not limited cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like.
- the alkylene group is a lower alkylene group.
- a “(cycloalkenyl)alkyl” is a cycloalkenyl group connected, as a substituent, via an alkylene group.
- the alkylene and cycloalkenyl of a (cycloalkenyl)alkyl may be substituted.
- the alkylene group is a lower alkylene group.
- a “(cycloalkynyl)alkyl” is a cycloalkynyl group connected, as a substituent, via an alkylene group.
- the alkylene and cycloalkynyl of a (cycloalkynyl)alkyl may be substituted.
- the alkylene group is a lower alkylene group.
- halo or “halogen” refers to F (fluoro), Cl (chloro), Br (bromo) or I (iodo).
- haloalkyl refers to an alkyl group in which one or more of the hydrogen atoms are replaced by halogen. Such groups include but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl and 1-chloro-2-fluoromethyl, 2-fluoroisobutyl. A haloalkyl may be substituted.
- haloalkoxy refers to a RO-group in which R is a haloalkyl group.
- groups include but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy and 1-chloro-2-fluoromethoxy, 2-fluoroisobutyoxy.
- a haloalkoxy may be substituted.
- O-carboxy refers to a “RC( ⁇ O)O—” group in which R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined herein.
- R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined herein.
- An O-carboxy may be substituted.
- C-carboxy refers to a “—C( ⁇ O)OR” group in which R can be the same as defined with respect to O-carboxy.
- a C-carboxy may be substituted.
- a “trihalomethanesulfonyl” group refers to an “X 3 CSO 2 —” group” wherein X is a halogen.
- a dashed bond represents an optional unsaturation between the atoms forming the bond. This bond may be unsaturated (e.g. C ⁇ C, C ⁇ N, C ⁇ O) or saturated (e.g. C—C, C—N, C—O). When a dashed bond is present in a ring system it may form part of an aromatic ring system.
- a “nitro” group refers to a “—NO 2 ” group
- a “cyano” group refers to a “—CN” group.
- a “cyanato” group refers to an “—OCN” group.
- An “isocyanato” group refers to a “—NCO” group.
- a “thiocyanato” group refers to a “—SCN” group.
- a “carbonyl” group refers to a “—C( ⁇ O)—” group.
- a “thiocarbonyl” group refers to a “—C( ⁇ S)—” group.
- An “oxo” group refers to a “ ⁇ O” group.
- a “hydroxy” group or “hydroxyl” group refers to an “—OH” group.
- An “isothiocyanato” group refers to an “—NCS” group.
- a “sulfinyl” group refers to an “—S( ⁇ O)—R” group in which R can be the same as defined with respect to O-carboxy.
- a sulfinyl may be substituted.
- a “sulfonyl” group refers to an “SO 2 R” group in which R can be the same as defined with respect to O-carboxy. A sulfonyl may be substituted.
- S-sulfonamido refers to a “—SO 2 NR A R B ” group in which R A and R B independently of each other can be the same as defined with respect to the R group as defined for O-carboxy, or combined to form a ring system selected from the group consisting of substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl substituted or unsubstituted heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- a S-sulfonamido may be substituted.
- N-sulfonamido refers to a “RSO 2 N(R A )—” group in which R and R A independently of each other can be the same as defined with respect to the R group as defined for O-carboxy. An N-sulfonamido may be substituted.
- a “trihalomethanesulfonamido” group refers to an “X 3 CSO 2 N(R)—” group with X as halogen and R can be the same as defined with respect to O-carboxy.
- a trihalomethanesulfonamido may be substituted.
- a “C-amido” group refers to a “—C( ⁇ O)NR A R B ” group in which R A and R B independently of each other can be the same as defined with respect to the R group as defined for O-carboxy, or combined to form a ring system selected from the group consisting of substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl substituted or unsubstituted heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- a C-amido may be substituted.
- N-amido refers to a “RC( ⁇ O)NR A —” group in which R and R A independently of each other can be the same as defined with respect to the R group as defined for O-carboxy. An N-amido may be substituted.
- esters refers to a “—C( ⁇ O)OR” group in which R can be the same as defined with respect to O-carboxy. An ester may be substituted.
- a lower alkoxyalkyl refers to an alkoxy group connected via a lower alkylene group.
- a lower alkoxyalkyl may be substituted.
- amine refers to “RNH 2 ” (a primary amine), “R 2 NH” (a secondary amine), “R 3 N” (a tertiary amine). An amino group may be substituted.
- a lower aminoalkyl refers to an amino group connected via a lower alkylene group.
- a lower aminoalkyl may be substituted.
- Any unsubstituted or monosubstituted amine group on a compound herein can be converted to an amide, any hydroxyl group can be converted to an ester and any carboxyl group can be converted to either an amide or ester using techniques well-known to those skilled in the art (see, for example, Greene and Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons, New York, N.Y., 1999).
- each center may independently be of R-configuration or S-configuration or a mixture thereof.
- the compounds provided herein may be enatiomerically pure or be stereoisomeric mixtures.
- compounds provided herein may be scalemic mixtures.
- each double bond may independently be E or Z or a mixture thereof.
- all tautomeric forms are also intended to be included.
- tautomer and “tautomeric” refer to alternate forms of a compound disclosed herein that differ in the position of a proton.
- Non-limiting examples include enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring —NH— moiety and a ring ⁇ N— moiety such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.
- isotopes may be present in the compounds described herein.
- Each chemical element as represented in a compound structure may include any isotope of said element.
- a hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen-1 (protium) and hydrogen-2 (deuterium).
- reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.
- “pharmaceutically acceptable salt” refers to a salt of a compound that does not abrogate the biological activity and properties of the compound.
- Pharmaceutical salts can be obtained by reaction of a compound disclosed herein with an acid or base.
- Base-formed salts include, without limitation, ammonium salt (NH 4 + ); alkali metal, such as, without limitation, sodium or potassium, salts; alkaline earth, such as, without limitation, calcium or magnesium, salts; salts of organic bases such as, without limitation, dicyclohexylamine, piperidine, piperazine, methylpiperazine, N-methyl-D-glucamine, diethylamine, ethylenediamine, tris(hydroxymethyl)methylamine; and salts with the amino group of amino acids such as, without limitation, arginine and lysine.
- Useful acid-based salts include, without limitation, acetates, adipates, aspartates, ascorbates, benzoates, butyrates, caparate, caproate, caprylate, camsylates, citrates, decanoates, formates, fumarates, gluconates, glutarate, glycolates, hexanoates, laurates, lactates, maleates, nitrates, oleates, oxalates, octanoates, propanoates, palmitates, phosphates, sebacates, succinates, stearates, sulfates, sulfonates, such as methanesulfonates, ethanesulfonates, p-toluenesulfonates, salicylates, tartrates, and tosylates.
- solvates and hydrates are complexes of a compound with one or more solvent of water molecules, or 1 to about 100, or 1 to about 10, or one to about 2, 3 or 4, solvent or water molecules.
- a “prodrug” refers to a compound that may not be pharmaceutically active but that is converted into an active drug upon in vivo administration.
- the prodrug may be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug.
- Prodrugs are often useful because they may be easier to administer than the parent drug. They may, for example, be bioavailable by oral administration whereas the parent drug is not.
- the prodrug may also have better solubility than the active parent drug in pharmaceutical compositions.
- prodrug a compound disclosed herein, which is administered as an ester (the “prodrug”) to facilitate absorption through a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to a carboxylic acid (the active entity) once inside the cell where water-solubility is beneficial.
- prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized in vivo to release the active parent compound.
- Anti-drug refers to a compound or composition acting against or opposing illicit drugs or their use. Compounds of the present application may act as anti-drugs.
- to “modulate” the activity of a receptor means either to activate it, i.e., to increase its cellular function over the base level measured in the particular environment in which it is found, or deactivate it, i.e., decrease its cellular function to less than the measured base level in the environment in which it is found and/or render it unable to perform its cellular function at all, even in the presence of a natural binding partner.
- a natural binding partner is an endogenous molecule that is an agonist for the receptor.
- An “agonist” is defined as a compound that increases the basal activity of a receptor (i.e. signal transduction mediated by the receptor).
- partial agonist refers to a compound that has an affinity for a receptor but, unlike an agonist, when bound to the receptor it elicits only a fractional degree of the pharmacological response normally associated with the receptor even if a large number of receptors are occupied by the compound.
- An “inverse agonist” is defined as a compound, which reduces, or suppresses the basal activity of a receptor, such that the compound is not technically an antagonist but, rather, is an agonist with negative intrinsic activity.
- antagonist refers to a compound that binds to a receptor to form a complex that does not give rise to any response, as if the receptor was unoccupied.
- An antagonist attenuates the action of an agonist on a receptor.
- An antagonist may bind reversibly or irreversibly, effectively eliminating the activity of the receptor permanently or at least until the antagonist is metabolized or dissociates or is otherwise removed by a physical or biological process.
- a “subject” refers to an animal that is the object of treatment, observation or experiment.
- Animal includes cold- and warm-blooded vertebrates and invertebrates such as birds, fish, shellfish, reptiles and, in particular, mammals.
- “Mammal” includes, without limitation, mice; rats; rabbits; guinea pigs; dogs; cats; sheep; goats; cows; horses; primates, such as monkeys, chimpanzees, and apes, and, in particular, humans.
- a “patient” refers to a subject that is being treated by a medical professional such as an M.D. or a D.V.M. to attempt to cure, or at least ameliorate the effects of, a particular disease or disorder or to prevent the disease or disorder from occurring in the first place.
- a “carrier” refers to a compound that facilitates the incorporation of a compound into cells or tissues.
- DMSO dimethyl sulfoxide
- a “diluent” refers to an ingredient in a pharmaceutical composition that lacks pharmacological activity but may be pharmaceutically necessary or desirable.
- a diluent may be used to increase the bulk of a potent drug whose mass is too small for manufacture or administration. It may also be a liquid for the dissolution of a drug to be administered by injection, ingestion or inhalation.
- a common form of diluent in the art is a buffered aqueous solution such as, without limitation, phosphate buffered saline that mimics the composition of human blood.
- an “excipient” refers to an inert substance that is added to a pharmaceutical composition to provide, without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability etc., to the composition.
- a “diluent” is a type of excipient.
- a “receptor” is intended to include any molecule present inside or on the surface of a cell that may affect cellular physiology when it is inhibited or stimulated by a ligand.
- a receptor comprises an extracellular domain with ligand-binding properties, a transmembrane domain that anchors the receptor in the cell membrane, and a cytoplasmic domain that generates a cellular signal in response to ligand binding (“signal transduction”).
- a receptor also includes any intracellular molecule that in response to ligation generates a signal.
- a receptor also includes any molecule having the characteristic structure of a receptor, but with no identifiable ligand.
- a receptor includes a truncated, modified, mutated receptor, or any molecule comprising partial or all of the sequences of a receptor.
- Ligand is intended to include any substance that interacts with a receptor.
- “Selective” or “selectivity” is defined as a compound's ability to generate a desired response from a particular receptor type, subtype, class or subclass while generating less or little response from other receptor types. “Selective” or “selectivity” of one or more particular subtypes of a receptor means a compound's ability to increase the activity of the subtypes while causing less, little or no increase in the activity of other subtypes.
- coadministration refers to the delivery of two or more separate chemical entities, whether in vitro or in vivo. Coadministration means the simultaneous delivery of separate agents; the simultaneous delivery of a mixture of agents; as well as the delivery of one agent followed by delivery of a second agent or additional agents. Agents that are coadministered are typically intended to work in conjunction with each other.
- an effective amount means an amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation or palliation of the symptoms of the disease being treated.
- prevent/preventing should not be construed to mean that a condition and/or a disease never might occur again after use of a compound or pharmaceutical composition according to embodiments disclosed herein to achieve prevention. Further, the term should neither be construed to mean that a condition not might occur, at least to some extent, after such use to prevent said condition. Rather, “prevent/preventing” is intended to mean that the condition to be prevented, if occurring despite such use, will be less severe than without such use.
- Y is NR or O
- R is hydrogen or substituted or unsubstituted C 1-4 alkyl
- R 1 is selected from the group consisting of hydrogen, —OH, halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, and substituted or unsubstituted C 2-4 alkenyl;
- R 2 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, —CN, and —OH;
- R and R 2 are combined to form a substituted or unsubstituted fused ring;
- R 3 is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, oxo, —C( ⁇ O)R 10 ;
- R 4a is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C 1-6 alkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroaryl-C 1-6 alkyl;
- R 4b is selected from the group consisting of hydrogen, halogen, oxo, —OH, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, and —C( ⁇ O)R 10 ;
- R 5 is selected from the group consisting of —(CR 8 R 9 )pOR 12 , —(CR 8 R 9 )p-CR 13 R 14 R 15 , —(CR 8 R 9 )p-C( ⁇ O)OR 7 , and —(CR 8 R 9 )p-C( ⁇ O)NR 8 R 9 ;
- n, m, and p are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
- R 6a , R 6b are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 1-6 heteroalkyl, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, substituted or unsubstituted C 2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, or R 6a and R 6b are taken together to form an oxo group or a ring system selected from substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicycly
- R 7 , R 8 , R 9 , and R 12 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicyclyl;
- R 10 is selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy, —OH, —NH 2 , —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , and C 3-7 cycloalkyl;
- R 13 if not to be taken together with R 6a , is absent, or selected from the group consisting of hydrogen, —OH, —CN substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, and —(CR 8 R 9 )p-C( ⁇ O)OR 7 , —(CR 8 R 9 )p-SO 2 R 7 and —(CR 8 R 9 )p-C( ⁇ O)NR 8 R 9 ;
- R 14 and R 15 are independently selected from the group consisting of hydrogen, and substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicyclyl; or
- R 14 and R 15 are combined to form a ring system selected from the group consisting of substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, substituted or unsubstituted C 2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- B is a ring system selected from the group consisting of aryl, heteroaryl, and bicyclic heteroalicyclyl, provided that it is not 5,6-dichloro-1H-benzo[d]imidazol-2-yl when R 1 and R 2 both are hydrogen;
- C is a ring system selected from C 2-9 heteroalicyclyl
- variables of the compounds of Formula (I) may be particularly useful in their end use application.
- R and R 2 in combination with the pyrimidine ring form a ring system selected from pyrrolo[2,3-d]pyrimidine and 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine.
- the ring system may be pyrrolo[2,3-d]pyrimidine.
- B is a ring system selected from the group consisting of aryl, heteroaryl, and bicyclic heteroalicyclyl, provided that it is not 5,6-dichloro-1H-benzo[d]imidazole-2-yl; i.e.
- B is a ring system selected from the group consisting of aryl, monocyclic heteroaryl, and bicyclic heteroalicyclyl.
- R and R 2 in combination with the pyrimidine ring form a pyrrolo[2,3-d]pyrimidine or 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine.
- the compounds of Formula (I) may also have the Formula (IIa):
- R 4e and R 4d are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, and —OH.
- R 4e and R 4d may be independently selected from the group consisting of hydrogen, methyl, and fluorine.
- the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe) as disclosed herein below have R 5 being —(CR 8 R 9 )p-C( ⁇ O)OR 7 or —(CR 8 R 9 )p-C( ⁇ O)NR 8 R 9 , unless otherwise specified.
- the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe) have R 5 being —(CR 8 R 9 ) p OR 12 .
- R 7 , R 8 , R 9 , and R 12 are independently selected of each other from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted aryl-C 1-6 alkyl and substituted or unsubstituted aryl.
- Preferred groups of R 7 , R 8 , R 9 , and R 12 are selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, and aryl, while even more preferred groups are selected from hydrogen, methyl, ethyl and tert-butyl.
- the integer p is preferably selected from 0, 1 or 2. In some embodiments, p is 0.
- R 5 is —(CR 8 R 9 )p-CR 13 R 14 R 15 .
- R 14 and R 15 are combined to form a ring system.
- the integer “p” may be 0 (zero), or 1. While it is not intended that the ring system be particular limited, preferred ring systems are selected from the group consisting of substituted or unsubstituted C 3-7 cycloalkyl, substituted or unsubstituted C 3-7 cycloalkenyl, substituted or unsubstituted C 2-6 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R 14 and R 15 may be combined to form a ring system selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, azetidinyl, thietanyl, pyrrolyl, pyrazolyl imidazolyl, pyrrolidinyl, imidazolinyl, pyrazolidinyl, thiazolidinyl, isothiazolidinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, oxathianyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, piperidinyl, piperazinyl, morpholinyl,
- R 14 and R 15 are combined to form a ring system selected from the group consisting of cycloheptyl, cyclohexyl, cyclopentyl, dioxanyl, furyl, imidazolyl, isothiazolyl, isoxazolyl, morpholinyl, oxazolyl, oxetanyl, oxathianyl, phenyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidinyl, pyrrolyl, tetrahydrofuryl, tetrahydropyranyl, tetrazolyl, thianyl, thiazolyl, thienyl, thiomorpholinyl, thiopyryl, and triazolyl, all of which may be unsubstituted or substituted.
- Some embodiments relate to the ring system formed being phenyl, pyridyl, cyclopentyl, cyclohexyl, piperidyl, pyrrolidinyl, oxetanyl, and tetrahydropyranyl, all which may be substituted by (CH 2 ) q (R 5a ) as defined herein. Some embodiments relate to the ring system being phenyl, pyridyl, piperidinyl oxetanyl, or cyclohexyl. In embodiments wherein R 14 and R 15 are combined to form an aromatic ring system, R 13 is absent.
- the ring system formed by the combination of R 14 and R 15 is substituted with —(CH 2 )q(R 5a ) wherein R 5a is independently selected from the group consisting of —CH 2 COOR 20 , —CH 2 CONR 21 R 22 , —CN, C 1-6 alkyl, —CH 2 -imidazolyl, —CH 2 —SO 2 R 20 , —CH 2 C(CH 3 ) 2 (OR 20 ), —OCH 3 , —CH 2 -triazolyl, —CF 3 , dimethyl substituted-imidazolyl-2,4-dione, —CH 2 —SO 2 NR 21 R 22 , morpholinyl, —C( ⁇ O)-morpholinyl, piperidyl-CH 2 OR 20 , —OCH 2 -tetrahydrofuryl, piperazinonyl, piperidinyl-CONR 21 R 22 , —OH, —CONR 21 R
- R 20 , R 21 , and R 22 are independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, —CN, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 2-6 heteroalicyclyl; and
- q is an integer selected from 0, 1 or 2.
- ring system formed by the combination of R 14 and R 15 may, in alternative embodiments, be substituted with groups other than —(CH 2 )q(R 5a ).
- R 13 is selected from the group consisting of hydrogen, —CN, CH 3 , fluorine, —OH, —CH 2 OH, —OCH 3 , —CH 2 CH 2 OH, —CO 2 H, —CO 2 —C 1-4 alkyl, —CH 2 SO 2 R 20 and —CONR 8 R 9 wherein R 8 and R 9 are independently of each other selected from hydrogen, C 1-4 alkyl and C 1-4 aminoalkyl or R 8 and R 9 are combined to form a C 2 -C 6 heteroalicyclyl.
- Some embodiments relate to R 13 taken together with R 6a to form a ring system selected from the group consisting of substituted or unsubstituted C 3-6 cycloalkyl and substituted or unsubstituted C 2-5 heteroalicyclyl.
- R 13 is absent or hydrogen.
- Y is NR.
- R may be selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 hydroxyalkyl. In one embodiment R is hydrogen.
- R 1 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-4 alkyl, and substituted or unsubstituted C 1-4 alkoxy. R 1 may thus include C 1-4 haloalkyl and C 1-4 hydroxyalkyl groups. In some embodiments, R 1 is hydrogen or CF 3 .
- R 2 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 hydroxyalkyl. In some embodiments, R 2 is a halogen such as fluorine.
- the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein may have an R 3 group selected from hydrogen, halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, oxo, C 1-4 alkoxy and C 1-4 haloalkoxy, unless otherwise specified.
- R 3 is selected from the group consisting of hydrogen, methyl, fluorine, chlorine and oxo. In some embodiments, R 3 is hydrogen.
- the integer m is selected from 2, 3, or 4, and at least two of the R 3 groups present are bound to the same atom of ring system C.
- R 3 is flouro, such as geminally arranged fluoro atoms.
- R 4a is selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1 -C 6 alkoxy, C 1-6 haloalkoxy, heteroaryl and aryl.
- R 4a groups are selected from the group consisting of methyl, ethyl, propyl, iso-propyl, tert-butyl, chlorine, bromine, fluorine, methoxy, ethoxy, C 1-2 haloalkyl, C 1-2 haloalkoxy and triazolyl.
- R 4a groups are —CF 3 , —CF 2 CF 3 , —CHF 2 , —OCF 3 , —OCF 2 CF 3 , and —OCHF 2 .
- R 4a is selected from the group consisting of isopropyl, halogen, ethoxy, CF 3 , —OCF 3 .
- R 4a is arranged in the para- or meta-position, in relation to the carbon carrying ring system C.
- R 4b is selected from hydrogen, oxo, halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1 -C 4 alkoxy, and C 1-4 haloalkoxy.
- R 4b may be further selected from methyl, ethyl, propyl, iso-propyl, tert-butyl, chlorine, bromine, fluorine, methoxy, ethoxy, —OH, C 1-2 haloalkyl, and C 1-2 haloalkoxy.
- R 4b groups comprise —CF 3 , —CHF 2 , —OCF 3 , and —OCHF 2 .
- R 4b is hydrogen.
- R 4a being selected from the group consisting of methyl, ethyl, propyl, iso-propyl, tert-butyl, chlorine, bromine, fluorine, methoxy, ethoxy, C 1-2 haloalkyl, C 1-2 haloalkoxy, and triazolyl arranged in the above mentioned para- or meta-position, and R 4b being hydrogen.
- R 6a is selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkoxy, and substituted or unsubstituted aryl, or R 6a and R 13 are taken together to form a ring system selected from substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicyclyl.
- R 6a are selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, and aryl. It is preferred however, that R 6a is hydrogen.
- R 6b is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted aryl-C 1-6 alkyl, substituted or unsubstituted C 2-9 heteroalicyclyl-C 1-6 alkyl, and substituted or unsubstituted aryl in the compounds of Formula (I).
- R 6b may be hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1 -C 6 alkoxy, C 1-6 haloalkoxy, C 1-6 -alkoxy-C 1-6 -alkyl-, aryl-C 1-6 alkyl-, C 2-9 heteroalicyclyl-C 1-4 alkyl-, C 1-6 -alkoxy-aryl-, haloaryl, and aryl.
- Particular examples of compounds of Formula (I) have an R 6b group selected from hydrogen, —(CH 2 )C(CH 3 ) 3 , —(CH 2 )CONH 2 , phenyl, phenyl substituted with 1 to 3 halogens, —CH(CH 3 )OC(CH 3 ) 3 , —CH 2 -phenyl-OCH 3 ,-phenyl-OCH 3 , —CH 2 -pyridyl, CH 2 -cyclohexyl-CH 2 CO 2 H, —CH 2 -cyclohexyl-CH 2 CONH 2 , CH 2 -cyclohexyl-CH 2 -tetrazolyl, —CH 2 -cyclohexyl-CH 2 OH, —CH 2 -cyclohexyl-NHSO 2 CH 3 , —CH 2 -cyclohexyl-NHSO 2 CH 2 CF 3 , —CH 2 -cyclohexyl-
- R 6a and R 6b being taken together to form a ring system selected from substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 2-9 heteroalicyclyl.
- Ring system B in compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein is not intended to be particularly limited, unless otherwise indicated.
- ring system B is a mono- or bicyclic aryl, a mono- or bicyclic heteroaryl, or a bicyclic heteroalicyclyl. Further, ring system B may be a monocyclic heteroalicyclyl. Ring system B may, but need not, be substituted with at least one of R 4a or R 4b that is a non-hydrogen substituent.
- ring system B is a mono-cyclic, 6-membered aryl or heteroaryl substituted with R 4a .
- ring system B is selected from the group consisting of phenyl, pyridyl, pyridazinyl, pyrimidinyl, naphthyl and furanyl, such as from the group consisting of phenyl, pyridyl, and pyrimidinyl.
- ring system B is selected from the group consisting of phenyl, and pyridyl.
- n is an integer selected from 1, 2, 3 and 4. Alternatively, n may be 0 meaning that R 4a will be the only substituent on ring system B.
- the ring B is a bicyclic ring system, such as bicyclic aryl, bicyclic heteroaryl, or bicyclic heteroalicyclyl ring systems, e.g. benzazepine, benzazocines, benzimidazole, benzimidazoline, benzodioxin, benzodioxole, benzofuran, benzoisothiazole, benzothiadiazine, benzothiadiazole, benzothiazepine, benzothiazine, benzothiazole, benzothiophene, benzotriazole, benzoxadiazole, benzoxathiole, benzoxazepine, benzoxazine, benzoxazole, benzisoxazole, benzodioxole, chromane, chromene, coumarin, cyclopentapyridine, cyclopentapyrimidine, diazanaphthalene, dioxolopyridine
- ring system C in compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein, is not intended to be particularly limited in scope, unless otherwise specified.
- ring system C is a C 2-9 heteroalicyclyl
- ring system C is a 4-7-membered heteroalicyclyl.
- ring system C may be pyrrolidinyl or morpholinyl.
- n and m may take any particular combination.
- m is 1 or 2.
- m may be 0 (zero) meaning that the ring system C is unsubstituted.
- n is an integer selected from 1, 2, 3 and 4.
- n may be 0 meaning that R 4a will be the only substituent on ring system B.
- n may be 0 and R 4a hydrogen, i.e. the ring system B is unsubstituted.
- the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein have R 5 being —(CR 8 R 9 )p-C( ⁇ O)NR 8 R 9 ; R 8 and R 9 are independently of each other selected from H and substituted or unsubstituted C 1-6 alkyl; p is 0; and R 6b is hydrogen or —(CH 2 )C(CH 3 ) 3 .
- Compounds disclosed herein may also comprise compounds of Formula (IIb):
- C is a pyrrolidine ring or a morpholine ring
- R1 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-4 alkyl, and substituted or unsubstituted C 1-4 alkoxy; some compounds of Formula (IIb) have an R1 that is hydrogen or —CF 3 ;
- R 3 is independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-4 alkyl, and halogen;
- R 4a is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C 1-6 alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl-C 1-6 alkyl; some compounds of Formula (IIb) have an R 4a that is selected from the group consisting of halogen, —CF 3 , —OCF 3 , iso-propyl, tert-butyl, —C 1-6 alkoxy, C 1-6 alkoxy substituted with one or more halogens, and phenyl;
- R 4b is independently selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, —C( ⁇ O)R 10 ;
- R 5 is selected from the group consisting of substituted or unsubstituted C 3-7 cycloalkyl, substituted or unsubstituted C 3-7 cycloalkenyl, substituted or unsubstituted C 2-6 heteroalicyclyl, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl;
- R 6a are R 6b are independently selected from the group consisting of hydrogen and substituted or unsubstituted C 1-6 alkyl;
- n is an integer independently selected from the group consisting of 1, 2, and 3;
- n is an integer independently selected from the group consisting of 1, 2, 3, and 4.
- R 5 may be selected from the group consisting of substituted or unsubstituted C 4-7 cycloalkyl, substituted or unsubstituted C 6-12 membered aryl, substituted or unsubstituted 4-membered heteroalicyclyl, substituted or unsubstituted 5-membered heteroaryl, substituted or unsubstituted 5-membered heteroalicyclyl, substituted or unsubstituted 6-membered heteroaryl, a substituted or unsubstituted 6-membered heteroalicyclyl, substituted or unsubstituted 7-membered heteroaryl, and a substituted or unsubstituted 7-membered heteroalicyclyl.
- R 5 may be selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, azetidinyl, thietanyl, pyrrolyl, pyrazoleyl imidazolyl, pyrrolidinyl, imidazolinyl, pyrazolidinyl, thiazolidinyl, isothiazolidinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, oxathianyl thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diox
- R 5 may be selected from the group consisting of cycloheptyl, cyclohexyl, cyclopentyl, dioxanyl, furyl, imidazolyl, isothiazolyl, isoxazolyl, morpholinyl, oxazolyl, oxetanyl, oxathianyl, phenyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidinyl, pyrrolyl, tetrahydrofuryl, tetrahydropyranyl, tetrazolyl, thianyl, thiazolyl, thienyl, thiomorpholinyl, thiopyryl, and triazolyl, any of which may be substituted or unsubstituted.
- R 5 may be substituted with —(CH 2 )q(R 5a ), wherein R 5a is independently selected from the group consisting of —CH 2 COOR 20 , —CH 2 CONR 21 R 22 , oxo, —CN, —CH 2 —CN, C 1-6 alkyl, —CH 2 -imidazolyl, —CH 2 —SO 2 R 20 , —CH 2 C(CH 3 ) 2 (OR 20 ), —OR 20 , —CH 2 -triazolyl, —CF 3 , dimethyl substituted-imidazolyl-2,4-dione, —CH 2 —SO 2 NR 21 R 22 , morpholinyl, —C( ⁇ O)-morpholinyl, piperidyl-CH 2 OR 20 , —OCH 2 -tetrahydrofuryl, piperazinonyl, piperidinyl-CONR 21 R 22 , —OH, —CONR 21 R 22
- R 20 , R 21 , and R 22 are independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, —CN, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 2-6 heteroalicyclyl; and
- q is an integer selected from 0, 1 or 2.
- R 5 may be selected from the group consisting of unsubstituted aryl, unsubstituted heteroaryl, aryl substituted with one or more C 1-6 alkoxy, aryl substituted with —CH 2 COOC 1-6 alkyl, aryl substituted with —CH 2 CONH—(C 1-6 alkyl), aryl substituted with CH 2 CON(C 1-6 alkyl) 2 , —(CH 2 )—C( ⁇ O)OR 7 , —C( ⁇ O)OR 7 , —(CH 2 )—C( ⁇ O)NR 8 R 9 or —C( ⁇ O)NR 8 R 9 , heteroaryl substituted with —(CH 2 )—C( ⁇ O)NR 8 R 9 or SO 2 R 7 , and C 2-9 heteroalicyclyl substituted with —(CH 2 )—C( ⁇ O)NR 8 R 9 or SO 2 R 7 ;
- R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, and C 1-6 alkylene substituted with furanyl.
- Compounds disclosed herein may also comprise compounds of Formula (IIc):
- R 3 is hydrogen, fluorine or methyl
- R 4a is selected from the group consisting of hydrogen, fluorine, chlorine, —C(CH 3 ) 3 , —CH 2 (CH 3 ) 2 , —CF 3 , —OCH 3 , —OC(CH 3 ) 3 , and —OCF 3 ;
- R 4b is selected from the group consisting of hydrogen, fluorine, chlorine, and —OCH 3 ;
- n and n are integers independently selected from 1 or 2;
- Y is OR 7 or NR 8 R 9 ;
- R 7 , R 8 , and R 9 are independently selected from H and C 1-6 alkyl
- B is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, 2-benzothiazolyl, quinolinyl, and 1,4-benzodioxanyl;
- C is pyrrolidinyl or morpholinyl.
- Compounds disclosed herein may also comprise compounds of Formula (IId):
- B is selected from phenyl, pyridyl and pyrimidyl
- C is pyrrolidinyl or morpholinyl
- R 4a is a substituent arrange in para- or meta-position compared to the carbon atom in the ring system C, and selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl (for example —CF 3 ), C 1-4 haloalkoxy (for example —OCF 3 ), and heteroaryl;
- R 5 is a ring selected from the group consisting of phenyl, pyrimidinyl, pyridyl, pyridinyl-N-oxide, cyclohexyl, pyrrolyl, pyrazolyl, furanyl, pyrrolidonyl, tetrahydrofuranyl, tetrahydropyranyl, benzopyrrolidonyl, cyclobutyl, oxetanyl, tetrahydrothiophenyl, tetrahydro-2H-thiopyranyl, cyclopentyl, cycloheptanyl, tetrahydrothiophenyl-1,1-dioxide, tetrahydro-2H-thiopyranyl-1,1-dioxide, 1,4-oxathianyl-4,4-dioxide, and piperidinyl, any of which may be unsubstituted or substituted with (R 5b )t;
- R 5b when present, is independently selected from the group consisting of —CH 2 COOR 20 , —CH 2 CONR 21 R 22 , oxo, —CN, —CH 2 —CN, —C 1-6 alkyl, —CH 2 -imidazolyl, —CH 2 —SO 2 R 20 , —CH 2 C(CH 3 ) 2 (OR 20 ), —OR 20 , —CH 2 -triazolyl, —CF 3 , dimethyl substituted-imidazolidinyl-2,4-dione, —CH 2 —SO 2 NR 21 R 22 , morpholinyl, —C( ⁇ O)-morpholinyl, piperazinonyl, piperidinyl-CONR 21 R 22 , —OH, —COR 20 , —CONR 21 R 22 , —CH(OR 20 )CH 3 , —COOR 20 , —CH 2 -pyrrolidonyl, —C
- R 20 , R 21 , and R 22 are independently selected from H, —C 1-6 alkyl, —C 1-6 haloalkyl, —C 3-6 cycloalkyl, and —C 1-6 heteroalicyclyl; and
- t is an integer selected from 1 or 2.
- Compounds disclosed herein may also comprise compounds of Formula (IIe):
- n, p and v are an integer selected from 0, 1 and 2;
- R is hydrogen or C 1-4 alkyl
- R 1 is selected from the group consisting of hydrogen, —OH, halogen, substituted or unsubstituted C 1-4 alkyl, and substituted or unsubstituted C 1-4 alkoxy;
- R 2 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 hydroxyalkyl;
- R and R 2 are combined to form a fused ring
- R 3 is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, oxo, and —C( ⁇ O)R 10 ;
- R 4a is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C 1-6 alkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroaryl-C 1-6 alkyl;
- R 4b is selected from the group consisting of hydrogen, oxo, halogen, —OH, substituted or unsubstituted C 1-4 alkyl, and substituted or unsubstituted C 1-4 alkoxy, —C( ⁇ O)R 10 ;
- R 5a is selected from the group consisting of hydrogen, halogen, oxo, —CN, —OH, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C 1-6 alkyl, substituted or unsubstituted C 2 -C 8 heteroalicyclyl, substituted or unsubstituted C 2 -C 8 heteroalicyclyl-C 1-6 alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl-C 1-6 alkyl, —(CH 2 ) q CO 2 R 20 , —(CH 2
- q is an integer selected from 0 or 1;
- R 20 , R 21 , and R 22 are independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, —CN, substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-6 heteroalicyclyl, or R 21 and R 22 are combined to form a C 3-6 cycloalkyl;
- R 6a , R 6b are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 1-6 heteroalkyl, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, substituted or unsubstituted C 2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, or R 6a and R 6b are taken together to form and oxo group or a ring system selected from substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicyclyl, or R
- R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicyclyl;
- R 10 is selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy, —OH, —NH 2 , —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , and C 3-7 cycloalkyl;
- R 13 if not to be taken together with R 6a , is absent, or selected from the group consisting of hydrogen, —CN, —OH, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, and —(CR 8 R 9 )p-C( ⁇ O)OR 7 , —(CR 8 R 9 )p-SO 2 R 7 and —(CR 8 R 9 )p-C( ⁇ O)NR 8 R 9 ;
- B is a ring system selected from the group consisting of aryl, heteroaryl, and, C 2 -C 9 bicyclic heteroalicyclyl;
- D is a ring system selected from the group consisting of aryl, heteroaryl, C 3-8 cycloalkyl and, C 2 -C 9 heteroalicyclyl,
- C is a ring system selected from C 2-9 heteroalicyclyl
- R 3 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, oxo, C 1-4 alkoxy and C 1-4 haloalkoxy;
- R 4a is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, and heteroaryl;
- R 4b is selected from the group consisting of hydrogen, oxo, halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxy, and C 1-4 haloalkoxy;
- R 6a is selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R 6b is selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, C 1-6 haloalkoxy, aryl-C 1-6 alkyl, substituted or unsubstituted C 2-9 heteroalicyclyl-C 1-6 alkyl, and substituted or unsubstituted aryl;
- R 6a and R 6b are taken together to form and oxo group or a ring system selected from substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicyclyl,
- R 6a and R 13 are taken together to form a ring system selected from substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-5 heteroalicyclyl;
- B is aryl or heteroaryl, for example phenyl, pyridyl, pyrazolyl, pyridazinyl, pyrimidinyl, naphthyl and furanyl, unless otherwise specified.
- Some embodiments relates to B being phenyl, pyrimidyl or pyridyl.
- B is a 6-membered aryl substituted with R 4a in the para-position or meta-position, a 6-membered heteroaryl substituted with R 4a in the para-position or meta-position, or a 5-membered heteroaryl substituted with R 4a in 2- or 3-position, unless otherwise specified.
- the 6-membered aryl is phenyl and the 6-membered heteroaryl is pyridyl or pyrimidinyl.
- R 4a being selected from the group consisting of halogen, —CN, C 1-4 alkyl, C 1-4 haloalkyl, C 1 -C 4 alkoxy, C 1-4 haloalkoxy and heteroaryl, for example isopropyl, —CN, ethoxy, CF 3 , and —OCF 3 .
- R 4b being selected from the group consisting of hydrogen, oxo, halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1 -C 4 alkoxy, C 1-4 haloalkoxy, and heteroaryl.
- R 4a being selected from the group consisting of halogen, —CN, C 1-4 alkyl, C 1-4 haloalkyl, C 1 -C 4 alkoxy, and C 1-4 haloalkoxy, for example isopropyl, ethoxy, —CF 3 , —CHF 2 , —OCF 3 , and —OCHF 2 and R 4b being selected from the group consisting of hydrogen, halogen, and —OH.
- D is selected from the group consisting of aryl, such as phenyl; heteroaryl, such as pyridyl, and pyrimidyl; C 3-8 cycloalkyl, such as cyclohexyl; and C 2-8 heteroalicyclyl, such as piperidyl, tetrahydro-2H-pyranyl, thiopyranyl, tetrahydro-2H-thiopyranyl, tetrahydro-2H-thiopyranyl-1,1-dioxide, pyrrolidinyl, thianyl and oxetanyl, all which may be substituted with one or more R 5a .
- aryl such as phenyl
- heteroaryl such as pyridyl, and pyrimidyl
- C 3-8 cycloalkyl such as cyclohexyl
- C 2-8 heteroalicyclyl such as piperidyl, tetrahydro-2H-pyranyl,
- R 5a being selected from hydrogen, C 1-6 alkyl, such as methyl and ethyl; C 1-6 hydroxyalkyl, such as methanol and ethanol; —(CH 2 ) q —CN; —(CH 2 ) q —CO 2 R 20 ; —(CH 2 ) q —C 1-6 alkoxy, such as methoxy and ethoxy and methoxyethyl; oxo, —(CH 2 ) q -heteroaryl, such as —(CH 2 —) q -tetrazolyl, —(CH 2 —) q -imidazolyl, —(CH 2 —) q -triazolyl; —(CH 2 —) q —CONR 20 R 21 ; —(CH 2 —) q —COR 20 ; —(CH 2 —) q —SO 2 R 20 ; —(CH 2 —) q
- R 20 , R 21 , and R 22 are independently of each other selected from the group consisting of hydrogen, —OH, substituted or unsubstituted C 1-6 alkyl, —CN, substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-6 heteroalicyclyl, or R 21 and R 22 are combined to form a C 3-6 cycloalkyl; and
- q is an integer selected from 0 or 1.
- the ring system D may comprise further hydrogen(s) than the one(s) provided by R 5a being hydrogen.
- R 20 , R 21 , and R 22 are independently of each other selected from the group consisting of hydrogen, methyl, ethyl, cyclopropyl, —CF 3 , and —CHF 2 ,
- R 13 is absent, or selected from the group consisting of hydrogen, —OH, —CN, C 1-4 hydroxyalkyl, C 1-6 haloalkyl, —(CH 2 —) q CO 2 H, —(CH 2 —) q —SO 2 R 20 , —(CH 2 —) q —NR 21 SO 2 R 20 and C 1-6 alkoxy, or R 13 combined with the atom to which it is attached and an adjacent R 5a to form a C 3-5 cycloalkyl, or C 2-4 heteroalicyclyl.
- R 6a is hydrogen, or combined with R 5a , R 6b or R 13 to form ring system such as a C 3-6 cycloalkyl or C 2-5 -heteroalicyclyl; R 6b is hydrogen or absent. In some embodiments both R 6a and R 6b are hydrogen.
- R is hydrogen;
- R 2 is selected from Cl or F; or R and R 2 are combined to form a pyrrolo[2,3-d]pyrimidine, 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine;
- n is an integer selected from 0, 1 and 2;
- n is an integer selected from 0 and 1;
- v is an integer selected from 0 and 1;
- R 3 is hydrogen or fluoro
- B is aryl or heteroaryl, for example phenyl, pyridyl, pyrazolyl, pyridazinyl, pyrimidinyl, naphthyl or furanyl;
- C is C 2-9 heteroalicyclyl, for example pyrrolidinyl or morpholinyl;
- R 4a is selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1 -C 4 alkoxy, C 1-4 haloalkoxy and heteroaryl, for example —CF 3 , —CHF 2 , —OCF 3 , —OCHF 2 , and triazolyl;
- R 4b is selected from the group consisting of hydrogen, —OH, oxo, halogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1 -C 4 alkoxy, C 1-4 haloalkoxy, and heteroaryl.
- D is selected from the group consisting of aryl, such as phenyl; heteroaryl, such as pyridyl, and pyrimidyl; C 3-8 cycloalkyl, such as cyclopentyl and cyclohexyl; and C 2-8 heteroalicyclyl, such as a mono-cyclic or a bridged C 2-8 heteroalicyclyl, such as piperidyl, tetrahydro-2H-pyranyl, thiopyranyl, tetrahydro-2H-thiopyranyl, tetrahydro-2H-thiopyranyl-1,1-dioxide, oxetanyl, tropanyl, and pyrrolidinyl, all which may be substituted with one or more R 5a ;
- R 5a is selected from halogen, C 1-6 alkyl, such as methyl and ethyl; C 1-6 hydroxyalkyl, such as methanol and ethanol; C 1-6 haloalkyl, such as —CF 3 , —(CH 2 ) q —CN; —(CH 2 ) q -acyl; —(CH 2 ) q —C 1-6 alkoxy, such as methoxy and ethoxy and methoxyethyl; —(CH 2 ) q -heteroaryl, such as —(CH 2 —) q -tetrazolyl, —(CH 2 —) q -imidazolyl, —(CH 2 —) q -triazolyl; —(CH 2 —) q —CONR 20 R 21 ; —(CH 2 —) q —COR 20 ; —(CH 2 —) q —SO 2 R 20
- R 20 , R 21 , and R 22 are independently of each other selected from the group consisting of hydrogen, —OH, substituted or unsubstituted C 1-6 alkyl, —CN, substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-6 heteroalicyclyl, or R 21 and R 22 are combined to form a C 3-6 cycloalkyl; and
- q is an integer selected from 0 or 1;
- R 13 is absent, or selected from the group consisting of hydrogen, —OH, —CN, C 1-4 hydroxyalkyl, C 1-6 haloalkyl, —(CH 2 —) q —SO 2 R 20 , —(CH 2 —) q —NR 21 SO 2 R 20 and C 1-6 alkoxy, or R 13 combined with the atom to which it is attached and an adjacent R 5a to form a C 3-5 cycloalkyl, or C 2-4 heteroalicyclyl; In some embodiments R 13 is absent or hydrogen.
- R 6a is hydrogen, or combined with R 5a , R 6b or R 13 to form ring system such as a C 3-6 cycloalkyl or C 2-5 -heteroalicyclyl; R 6b is hydrogen or absent; for example both R 6a and R 6b are hydrogen.
- B may be phenyl or pyridyl. Further, B may be phenyl with R 4a in the para-position or meta-position, or a 6-membered heteroaryl substituted with R 4a in the para-position or meta-position, or a 5-membered heteroaryl substituted with R 4a in 2- or 3-position, wherein R 4a is selected from a group other than hydrogen.
- Y 1 is NR or O
- Y 2 is N or C
- R is hydrogen or substituted or unsubstituted C 1-4 alkyl
- R 1 is selected from the group consisting of hydrogen, —OH, halogen, —CN, —NO 2 , —NH 2 , alkylamino, amide, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, carbonyl, thisocarbonyl, C amido, N amido, S-sulfonamido, N sulfonamide, silyl, sulfenyl, sulfinyl, sulfonyl, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 1-6 heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsub
- R 2 is selected from the group consisting of hydrogen, —OH, halogen, —CN, —NO 2 , —NH 2 , alkylamino, amide, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, carbonyl, thisocarbonyl, C amido, N amido, S-sulfonamido, N sulfonamide, silyl, sulfenyl, sulfinyl, sulfonyl, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 1-6 heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsub
- R and R 2 are combined to form a fused ring
- R 4a is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C 1-6 alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl-C 1-6 alkyl;
- R 3 and R 4b are independently selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, —C( ⁇ O)R 10 ;
- R 5 is selected from the group consisting of —(CR 8 R 9 )pOR 12 , —(CR 8 R 9 )p-CR 13 R 14 R 15 , —(CR 8 R 9 )p-C( ⁇ O)OR 7 , and —(CR 8 R 9 )p-C( ⁇ O)NR 8 R 9 ;
- n, m, and p are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
- R 6a , R 6b are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 1-6 alkynyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 1-6 heteroalkyl, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, substituted or unsubstituted C 2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- R 7 , R 8 , R 9 , and R 12 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted C 2-9 heteroalicyclyl;
- R 10 is selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy, —NH 2 , —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , and C 3-7 cycloalkyl;
- R 13 is absent, or selected from the group consisting of hydrogen, —OH, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted C 1-6 alkoxy, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, and —(CR 8 R 9 )p-C( ⁇ O)OR 7 , and —(CR 8 R 9 )p-C( ⁇ O)NR 8 R 9 ;
- R 14 and R 15 are independently selected from the group consisting of hydrogen, and substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 2-9 heteroalicyclyl; or
- R 14 and R 15 are combined to form a ring system selected from the group consisting of substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl, substituted or unsubstituted C 3-8 cycloalkyl, substituted or unsubstituted C 3-8 cycloalkenyl substituted or unsubstituted C 2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- A, B and C are independently of each other a ring system selected from the group consisting of aryl, heteroaryl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, and C 2-9 heteroaliyclyl.
- A is selected from the group consisting of phenyl, pyridyl, pyrrolyl, furyl, pyranyl, thiopyranyl, thienyl, pyrazinyl, pyrimidinyl, triazinyl, naphthyl, indolyl, iso-indolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, and oxazolyl.
- A is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, and wherein R 1 is arranged in position 1 of the 6 membered ring, R 1 is arranged in position 4 of the 6 membered ring, Y 1 arranged in position 3 of the 6 membered ring, Y 2 arranged in position 5 of the 6 membered ring.
- R 1 is selected from the group consisting of hydrogen, —OH, halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, and substituted or unsubstituted C 2-4 alkenyl; and R 2 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 1-4 alkoxy, —CN, —OH and —NO 2 ; or R and R 2 are combined to form a fused ring;
- B is a ring system selected from the group consisting of aryl, heteroaryl, and bicyclic heteroalicyclyl
- C is a ring system selected from the group consisting of C 2-9 heteroalicyclyl and heteroaryl; wherein B is attached to a carbon atom adjacent the N atom of ring system C.
- halogen is selected from fluoro or chloro.
- FIG. 1 illustrates the TAMRA-labelled probe.
- FIG. 2 illustrates the characterisation of the Fluorescence Polarization (FP) assay with the TAMRA-labelled probe used in the FP assay.
- FP Fluorescence Polarization
- FIG. 3 depicts the assay results of example no. 89 in (A) Fluorescence Polarization Assay, (B) ROR ⁇ Reporter Assay (Gal4), and (C) Th17 Assay. Specific examples of compounds are disclosed in Table 1 below.
- the present disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising physiologically acceptable surface active agents, carriers, diluents, excipients, smoothing agents, suspension agents, film forming substances, and coating assistants, or a combination thereof; and a compound of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein.
- the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), included in the pharmaceutical composition may also be any compound of the preferred embodiments described above.
- the present disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising physiologically acceptable surface active agents, carriers, diluents, excipients, smoothing agents, suspension agents, film forming substances, and coating assistants, or a combination thereof; and a compound of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe).
- Acceptable carriers or diluents, as well as other additives to be combined with a compound of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein to provide a pharmaceutical composition, for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa. (1990), which is incorporated herein by reference in its entirety.
- Preservatives, stabilizers, dyes, sweeteners, fragrances, flavoring agents, taste masking agents, and the like may be provided in the pharmaceutical composition.
- sodium benzoate, ascorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives.
- antioxidants and suspending agents may be used.
- alcohols, esters, sulfated aliphatic alcohols, and the like may be used as surface active agents; sucrose, glucose, lactose, starch, crystallized cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium methasilicate aluminate, synthetic aluminum silicate, calcium carbonate, sodium acid carbonate, calcium hydrogen phosphate, calcium carboxymethyl cellulose, and the like may be used as excipients; magnesium stearate, talc, hardened oil and the like may be used as smoothing agents; coconut oil, olive oil, sesame oil, peanut oil, soya may be used as suspension agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate such as cellulose or sugar, or methylacetate-meth
- composition refers to a mixture of a compound disclosed herein with other chemical components, such as diluents or carriers.
- the pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to, oral, injection, aerosol, parenteral, and topical administration.
- Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Similar, pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic bases, such as ammonia, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, and the like.
- carrier defines a chemical compound that facilitates the incorporation of a compound into cells or tissues.
- DMSO dimethyl sulfoxide
- carrier facilitates the uptake of many organic compounds into the cells or tissues of an organism.
- diot defines chemical compounds diluted in water that will dissolve the compound of interest as well as stabilize the biologically active form of the compound. Salts dissolved in buffered solutions are utilized as diluents in the art.
- One commonly used buffered solution is phosphate buffered saline because it mimics the salt conditions of human blood. Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound.
- physiologically acceptable defines a carrier or diluent that does not abrogate the biological activity and properties of the compound.
- compositions described herein can be administered to a human patient per se, or in pharmaceutical compositions where they are mixed with other active ingredients, as in combination therapy, or suitable carriers or excipient(s).
- suitable carriers or excipient(s) suitable carriers or excipient(s).
- Suitable routes of administration may, for example, include oral, rectal, transmucosal, topical, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.
- parenteral delivery including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.
- the compounds can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.
- compositions may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tabletting processes.
- compositions for use as described herein may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Pharmaceutical Sciences, above.
- Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
- Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like.
- the injectable pharmaceutical compositions may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like.
- Physiologically compatible buffers include, but are not limited to, Hanks's solution, Ringer's solution, or physiological saline buffer. If desired, absorption enhancing preparations (for example, liposomes), may be utilized.
- penetrants appropriate to the barrier to be permeated may be used in the formulation.
- compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or other organic oils such as soybean, grapefruit or almond oils, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
- Such carriers enable the compounds disclosed herein to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
- Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the compounds for use as described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- Topical ophthalmic compositions may be formulated as a solution in water buffered at a pH of 5.0 to 8.0.
- ingredients that may be desirable to use in the ophthalmic preparations include preservatives (such as benzalkonium chloride, stabilized oxychloro complex, which is sold as PuriteTM, or stabilized chlorine dioxide), cosolvents (such as polysorbate 20, 60 and 80, Pluronic® F-68, F-84 and P-103, cyclodextrin, or Solutol) and viscosity-building agents (such as polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, or hydroxypropyl cellulose).
- preservatives such as benzalkonium chloride, stabilized oxychloro complex, which is sold as PuriteTM, or stabilized chlorine dioxide
- cosolvents such as polysorbate 20, 60 and 80, Pluronic® F-68, F-84 and P-103, cyclodextrin, or Solutol
- compositions for intraocular delivery include aqueous ophthalmic solutions of the active compounds in water-soluble form, such as eyedrops, or in gellan gum (Shedden et al., Clin. Ther., 23(3):440-50 (2001)) or hydrogels (Mayer et al., Ophthalmologica, 210(2):101-3 (1996)); ophthalmic ointments; ophthalmic suspensions, such as microparticulates, drug-containing small polymeric particles that are suspended in a liquid carrier medium (Joshi, A., J. Ocul.
- lipid-soluble formulations Alm et al., Prog. Clin. Biol. Res., 312:447-58 (1989)
- microspheres Microspheres
- ocular inserts All of the above-mentioned references, are incorporated herein by reference in their entireties.
- Such suitable pharmaceutical formulations for intraocular delivery are most often and preferably formulated to be sterile, isotonic and buffered for stability and comfort.
- Pharmaceutical compositions for intranasal delivery may also include drops and sprays often prepared to simulate in many respects nasal secretions to ensure maintenance of normal ciliary action.
- suitable formulations are most often and preferably isotonic, slightly buffered to maintain a pH of 5.5 to 6.5, and most often and preferably include antimicrobial preservatives and appropriate drug stabilizers.
- Pharmaceutical formulations for intraauricular delivery include suspensions and ointments for topical application in the ear. Common solvents for such aural formulations include glycerin and water.
- the compounds disclosed herein may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- a suitable pharmaceutical carrier may be a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase.
- a common cosolvent system used is the VPD co-solvent system, which is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80TM, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
- VPD co-solvent system is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80TM, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
- the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics.
- co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of POLYSORBATE 80TM; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.
- hydrophobic pharmaceutical compounds may be employed.
- Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs.
- Certain organic solvents such as dimethylsulfoxide also may be employed.
- the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
- sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days.
- additional strategies for protein stabilization may be employed.
- Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art.
- such agents may be encapsulated into liposomes. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior.
- the liposomal contents are both protected from the external micro-environment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm.
- the liposome may be coated with a tissue-specific antibody. The liposomes will be targeted to and taken up selectively by the desired organ.
- small hydrophobic organic molecules may be directly administered intracellularly.
- compositions may be combined with other compositions that contain other therapeutic or diagnostic agents.
- the compounds or pharmaceutical compositions disclosed herein as described above may be used to modulate the activity of a retinoic acid receptor-related orphan receptor (ROR), such as a ROR ⁇ , ROR ⁇ and/or ROR ⁇ (RORc) receptor.
- ROR retinoic acid receptor-related orphan receptor
- ROR ⁇ ROR ⁇
- RORc ROR ⁇
- Modulators of ROR ⁇ have been reviewed by B. Fauber and S. Magnuson in J. Med. Chem., Feb. 6, 2014, which hereby is incorporated by reference in its entirety.
- ROR ⁇ receptors are ROR ⁇ 1 and ROR ⁇ t receptors.
- the compounds or pharmaceutical compositions as described above may also display selective modulation of a particular ROR receptor relative to a different ROR receptor.
- some compounds or pharmaceutical compositions modulate the activity of an ROR ⁇ receptor to a larger extent than they modulate the activity of ROR ⁇ and/or ROR ⁇ receptors.
- the compounds or pharmaceutical compositions disclosed herein may also be used to modulate the activity of regulatory T cells (Tregs).
- Tregs regulatory T cells
- the compounds or pharmaceutical compositions disclosed herein may also be used to modulate the activity of cells producing IL17 in a ROR ⁇ t dependent manner, for example, ⁇ T cells, Th17 cells and ILC3 cells.
- the compounds or pharmaceutical compositions as described herein and above may also be used in therapy or may be used to treat inflammatory, metabolic, oncologic and autoimmune diseases or disorders.
- diseases or disorders are inflammatory, metabolic, oncologic and autoimmune diseases or disorders mediated or affected by IL17 and/or ROR ⁇ (RORc).
- RORc ROR ⁇
- the role of ROR ⁇ in the pathogenesis of autoimmune or inflammatory diseases has been disclosed in Immunity 2007, 26, 643-654; Nat. Rev. Immunol. 2006, 6, 205-217; J. Immunol. 2009, 183, 7169-7177; Brain Pathol. 2004, 14, 164-174; Brain 2007, 130, 1089-1104; and Nat Rev. Immunol. 2008, 8, 183-192 all of which are hereby incorporated by reference in their entirety.
- diseases or disorders include asthma, chronic obstructive pulmonary disease (COPD), bronchitis, atherosclerosis, helicobacter pylori infection, allergic diseases including allergic rhinitis, allergic conjunctivitis and uveitis, sprue and food allergy, atopic dermatitis, cystic fibrosis, lung allograph rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, steatosis, steatohepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), lupus erythematosus, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune ocular disease, ulcerative colitis, colitis, Crohn's disease, inflammatory bowel disease (IBD),
- compounds or pharmaceutical compositions having an antagonistic or inverse agonistic effect on ROR ⁇ may be used to reduce levels of IL17 and/or other gene products, such as interleukins, and cytokines, regulated ROR ⁇ .
- This may for example be in subjects suffering from for example, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, atherosclerosis, helicobacter pylori infection, allergic diseases including allergic rhinitis, allergic conjunctivitis and uveitis, sprue and food allergy, atopic dermatitis, cystic fibrosis, lung allograph rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, steatosis, steatohepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis
- compounds or pharmaceutical compositions having an agonistic effect on ROR ⁇ may be used to increase IL17 levels.
- Increasing IL17 levels may be particularly useful in immune compromised conditions or boosting the immune system response for example during infections and in cancer.
- the compounds or pharmaceutical compositions may be administered to the patient by any suitable means.
- methods of administration include, among others, (a) administration though oral pathways, which administration includes administration in capsule, tablet, granule, spray, syrup, or other such forms; (b) administration through non-oral pathways such as rectal, vaginal, intraurethral, intraocular, intranasal, or intraauricular, which administration includes administration as an aqueous suspension, an oily preparation or the like or as a drip, spray, suppository, salve, ointment or the like; (c) administration via injection, subcutaneously, intraperitoneally, intravenously, intramuscularly, intradermally, intraorbitally, intracapsularly, intraspinally, intrasternally, or the like, including infusion pump delivery; (d) administration locally such as by injection directly in the renal or cardiac area, e.g., by depot implantation, by intratumoral injection, or by intra-lymph node injection; (e) administration topically; as well
- compositions suitable for administration include compositions where the active ingredients are contained in an amount effective to achieve its intended purpose.
- the therapeutically effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including mammal, e.g. human, being treated, and the physical characteristics of the specific animal under consideration.
- the dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.
- a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed.
- the determination of effective dosage levels can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.
- dosages may be between about 10 microgram/kg and 100 mg/kg body weight, preferably between about 100 microgram/kg and 10 mg/kg body weight.
- dosages may be based and calculated upon the surface area of the patient, as understood by those of skill in the art.
- the exact formulation, route of administration and dosage for the pharmaceutical compositions disclosed herein can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl et al. 1975, in “The Pharmacological Basis of Therapeutics”, which is hereby incorporated herein by reference in its entirety, with particular reference to Ch. 1, p. 1).
- the dose range of the composition administered to the patient can be from about 0.5 to 1000 mg/kg of the patient's body weight.
- the dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the patient.
- human dosages for compounds have been established for at least some condition, those same dosages may be used, or dosages that are between about 0.1% and 500%, more preferably between about 25% and 250% of the established human dosage.
- a suitable human dosage can be inferred from ED 50 or ID 50 values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
- the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity).
- the magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps the dose frequency will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
- the daily dosage regimen for an adult human patient may be, for example, an oral dose of between 0.1 mg and 2000 mg of each active ingredient, preferably between 1 mg and 500 mg, e.g. 5 to 200 mg.
- An ocular eye drop may range in concentration between 0.005 and 5 percent. In one embodiment, an eye drop may range between 0.01 and 1 percent, or between 0.01 and 0.3 percent in another embodiment.
- an intravenous, subcutaneous, or intramuscular dose of each active ingredient of between 0.01 mg and 100 mg, preferably between 0.1 mg and 60 mg, e.g. 1 to 40 mg is used.
- dosages may be calculated as the free base.
- the composition is administered 1 to 4 times per day.
- the compositions disclosed herein may be administered by continuous intravenous infusion, preferably at a dose of each active ingredient up to 1000 mg per day.
- the compounds disclosed herein in certain situations it may be necessary to administer the compounds disclosed herein in amounts that exceed, or even far exceed, the above-stated, preferred dosage range or frequency in order to effectively and aggressively treat particularly aggressive diseases or infections.
- the compounds will be administered for a period of continuous therapy, for example for a week or more, or for months or years.
- Dosage amount and interval may be adjusted individually to provide plasma or tissue levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC).
- MEC minimal effective concentration
- the MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.
- Dosage intervals can also be determined using MEC value.
- Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.
- the effective local concentration of the drug may not be related to plasma concentration.
- the amount of composition administered may be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
- the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties may be established by determining in vitro toxicity towards a cell line, such as a mammalian, and preferably human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans.
- a cell line such as a mammalian, and preferably human, cell line.
- the results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans.
- the toxicity of particular compounds in an animal model such as mice, rats, rabbits, or monkeys, may be determined using known methods.
- the efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials.
- compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack may for example comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- the pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert.
- Compositions comprising a compound disclosed herein formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- the term “comprises/comprising” does not exclude the presence of other species or steps. Additionally, although individual features may be included in different claims, these may possibly advantageously be combined, and the inclusion in different claims does not imply that a combination of features is not feasible and/or advantageous. In addition, singular references do not exclude a plurality.
- the terms “a”, “an”, “first”, “second” etc. do not preclude a plurality.
- the phrases “at least one” or “one or more” refer to 1 or a number greater than 1, such as to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- starting materials were obtained from commercial suppliers, such as (but not limited to); ABchem, ABCR, Alfa Aesar, Anaspec, Anichem, Apollo Scientific, ASDI-Inter, Asiba Pharmatech, Astatech, Bachem, Chem-Impex, ChemCollect, Chembridge, Combi-Blocks, Enamine, Fluka, Fluorochem, Frontier Scientific, HDH Pharma, InFarmatik, InterBioScreen, Life Chemicals, Manchester organics, Matrix, MercaChem, NetChem, Oakwood Chemical, PepTech, Pharmcore, PrincetonBio, Sigma-Aldrich, TRC, Tyger Scientific and Ukrorgsyn.
- N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and dichloromethane (DCM) were dried over molecular sieves.
- Analytical HPLC was performed on a Waters Acquity system using a C18 reverse phase column (Merck Chromolith Speedrod RP-18E) with a linear gradient of the binary solvent system water/acetonitrile/formic acid (A: 100/0/0.1% and B: 0/100/0.1%) with a flow rate of 3.0 mL/min and UV detection at 254 nm at room temperature, combined with MS detection on a Waters Micromass QZ Quadrupole Mass Spectrometer instrument using electron spray ionization, or on a Shimadzu Nexera X2 system using a C18 reverse phase column (Acquity UPLC BEH C18 1.7 ⁇ m, 2.1 ⁇ 50 mm), with a linear gradient of the binary solvent system water/methanol/formic acid (A: 100/0/
- Preparative HPLC was performed on a Waters Acquity system using a C18 reverse phase column (Supelco ASCENTIS C18 581358-U, 15 cm ⁇ 21.2 mm), with a linear gradient of the binary solvent system water/acetonitrile/formic acid (A: 100/0/0.1% and B: 0/100/0.1%) with a flow rate of 15 mL/min and UV detection at 254 nm, combined with MS detection on a Waters Micromass QZ Quadrupole Mass Spectrometer instrument using electron spray ionization.
- the compounds disclosed herein may be made by one of the following four general methods. Further, additional guidance for preparing building blocks to be used in providing compounds disclosed herein is present in the co-pending international application PCT/EP2015/067692 also claiming priority from SE 1450920-2 and SE 1451406-1.
- a fluorenylmethyloxycarbonyl (Fmoc) protected amino acid was coupled to a Rink resin to produce 1a using the coupling reagents 1-hydroxy-7-azabenzotriazol (HOAt) and N,N′-diisopropylcarbodiimide (DIC) in the presence of a suitable base, e.g. ethyldiisopropylamine (DIPEA), in DCM/DMF (e.g. in a 1:1 ratio).
- DIPEA ethyldiisopropylamine
- DCM/DMF e.g. in a 1:1 ratio
- the mixture was agitated at a suitable temperature until complete conversion of the starting materials was observed, typically overnight at room temperature (i.e. 20-25° C.).
- the Fmoc group was removed from 1a by treatment with a base, e.g.
- a rink amide resin (0.88 g, 0.68 mmol/g, 0.6 mmol) was swelled in dry DMF (8 mL) for 15 minutes. The resin was drained and treated twice with 20% piperidine in DMF (2 ⁇ 8 mL) for 30 minutes each. The resin was drained and washed with DMF (3 ⁇ 8 mL), methanol (2 ⁇ 8 mL), DMF (2 ⁇ 8 mL) and DCM (3 ⁇ 8 mL). The resin was swelled in dry DCM (8 mL) for 15 minutes and drained.
- the resin was swelled in dry DCM (8 mL) for 15 minutes and drained.
- a solution of acetic anhydride (0.57 mL, 6 mmol) and pyridine (0.97 mL, 12 mmol) dissolved in DCM (8 mL) was added and the mixture was agitated at room temperature for 1 hour.
- the resin was drained and washed with DCM (3 ⁇ 8 mL), DMF (3 ⁇ 8 mL) and DCM (3 ⁇ 8 mL).
- the resin was swelled in dry DMSO (8 mL) for 15 minutes and drained.
- a halogenated pyrrolopyrimidine 2b e.g. 6-chloro-7-deazapurine
- an alkyl halide 2a e.g. 4-(bromomethyl)-1,2-dimethoxy-benzene
- a suitable solvent e.g. cesium carbonate in dry dioxane or sodium hydride in dry tetrahydrofuran.
- the mixture was stirred at room temperature until completion of reaction, typically overnight.
- the reaction may for example be monitored by thin layer chromatography.
- the reaction may for example be monitored by thin layer chromatography.
- the desired product was obtained upon work-up, e.g.
- 2-(4-trifluoromethyl-phenyl)-pyrrolidine and a suitable base in an appropriate solvent, e.g. cesium carbonate in dry DMSO.
- an appropriate solvent e.g. cesium carbonate in dry DMSO.
- the reaction was achieved by microwave irradiation at elevated temperatures for a period of time, e.g. at 100-150° C. for 1 hour. The reaction may for example be monitored by thin layer chromatography.
- the desired compound 2d was obtained upon work-up, for example by extraction with EtOAc, washing with water at a suitable pH and brine, drying over an appropriate drying agent, e.g. Na 2 SO 4 , and purification by flash column chromatrography (CC) using an appropriate eluent combination on a suitable column material, e.g. heptane/EtOAc or DCM/MeOH on silica gel, or recrystallization from a suitable solvent or solvent mixture, e.g. toluene/heptan
- 6-Chloro-7-deazapurine (77 mg, 0.5 mmol) and 4-(bromomethyl)-1,2-dimethoxy-benzene (127 mg, 0.55 mmol) were dissolved in dry dioxane (5 mL) and cesium carbonate (325 mg, 1.0 mmol) was added. The mixture was stirred overnight at room temperature, concentrated in vacuo, redissolved in water, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo.
- a compound containing a free amino or hydroxyl group 3a e.g. 1-tetrahydropyran-4-ylpropan-2-amine
- a fluorinated aromatic compound 3b e.g. 4,5,6-trifluoro-pyrimidine
- a suitable base e.g. DIPEA or cesium carbonate in dry DMSO or dioxane.
- Conversion to 3c was typically achieved after stirring at room temperature overnight.
- the reaction may for example be monitored by thin layer chromatography.
- the reaction may for example be monitored by thin layer chromatography.
- the desired product was obtained upon work-up, e.g.
- An example of such treatment is cesium carbonate in dry DMSO, heated under microwave irradiation during a period of time, e.g. at 80-150° C. for 1 hour.
- the reaction may for example be monitored by thin layer chromatography.
- the desired compound 3d was obtained upon work-up, for example by extraction with EtOAc, washing with water at a suitable pH and brine, drying over an appropriate drying agent, e.g. Na 2 SO 4 , and purification by flash column chromatrography (CC) using an appropriate eluent combination on a suitable column material, e.g. heptane/EtOAc or DCM/MeOH on silica gel, or recrystallization from a suitable solvent or solvent mixture, e.g. toluene/heptane.
- CC flash column chromatrography
- 4,5,6-Trifluoro-pyrimidine (0.27 g, 2.0 mmol) and 2-(4-trifluoromethyl-phenyl)-pyrrolidine (0.43 g, 2.0 mmol) were dissolved in dry DMSO (4 mL) and DIPEA (0.7 mL, 4.0 mmol) was added. The reaction was stirred at room temperature overnight, poured into 3M aq. calcium chloride, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo.
- tert-butyl 4-(trifluoromethylsulfonamido) benzylcarbamate (1.3 g, 41%) as pale yellow solid.
- N-[4-(aminomethyl)phenyl]-1,1,1-trifluoro-methanesulfonamide was isolated after BOC deprotection, as described for tert-butyl (((trans)-4-(methylsulfonamido) cyclohexyl)methyl) carbamate.
- the initial two steps of general method 4 may be performed in accordance with general method 3.
- the methyl ester 4a was subsequently hydrolyzed to yield 4b, e.g. by treatment with 1M lithium hydroxide in an appropriate solvent combination, e.g. water/tetrahydrofuran/methanol (e.g. in a ratio of 1:1:1). Hydrolysis was typically achieved after stirring at room temperature overnight.
- the reaction may for example be monitored by thin layer chromatography
- the reaction may for example be monitored by thin layer chromatography.
- the desired product was obtained upon work-up, e.g. by extraction with EtOAc, washing with water at a suitable pH and brine, drying over an appropriate drying agent, e.g.
- Amide analogues 4c were prepared by treatment of 4b with ammonium chloride, HOAt, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and DIPEA in an appropriate solvent, e.g. DMF, followed by stirring at room temperature overnight.
- a suitable column material e.g. heptane/EtOAc or DCM/MeOH on silica gel
- a suitable solvent or solvent mixture e.g. toluene/heptane.
- Amide analogues 4c were prepared by treatment of 4b with ammonium chloride, HOAt, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and DIPEA in an appropriate solvent, e.g. DMF, followed by stirring at room temperature overnight.
- EDC N-(3-dimethylaminopropyl)
- the reaction may for example be monitored by thin layer chromatography.
- the desired compound 4c was obtained upon work-up, for example by extraction with EtOAc, washing with water at a suitable pH and brine, drying over an appropriate drying agent, e.g. Na 2 SO 4 , and purification by flash column chromatrography (CC) using an appropriate eluent combination on a suitable column material, e.g. heptane/EtOAc or DCM/MeOH on silica gel, or recrystallization from a suitable solvent or solvent mixture, e.g. toluene/heptane.
- CC flash column chromatrography
- the activity of the compounds was evaluated using a Fluorescence Polarization (FP) Assay and, in most cases, a Th17 Assay and/or ROR ⁇ Reporter assay (also referred to as Gal4 assay).
- FP assay Fluorescence Polarization
- the FP assay is an in vitro assay monitoring binding within the ligand binding pocket.
- the ROR ⁇ and the Th17 assays are both cell-based assays monitoring functional activity of the compound assayed.
- a buffer containing 10 mM Hepes, 150 mM NaCl, 1 mM DTT, 0.05% Pluronic F-127 detergent (all from Sigma), and 100 nM human ROR ⁇ t (Ligand Binding Domain obtained from Crelux (Planegg, Germany), batch no PC5032-1) was complemented with 1 ⁇ l test compounds diluted in 100% DMSO. The total volume was 25 ⁇ l, in a black Perkin Elmer OptiPlate. As negative control, 1 ⁇ l DMSO was used. Samples were incubated at room temperature for 30 min, followed by addition 5 ⁇ l of probe diluted in assay buffer to a concentration of 125 nM (final concentration of probe is 25 nM).
- the probe is a fluorescently labeled (TAMRA) ROR ⁇ t ligand identified by Nuevolution with a total molecular weight of 910 g/mole as shown in Graph A in FIG. 1 .
- Graph (B) in FIG. 2 shows the polarization signal rises with increasing concentration of human ROR ⁇ t (LBD), using 50 nM TAMRA-labelled probe concentration.
- ROR ⁇ t inhibitor SR2211 (1,1,1,3,3,3-hexafluoro-2-(2-fluoro-4′-((4-(pyridin-4-ylmethyl)piperazin-1-yl)methyl)-[1,1′-biphenyl]-4-yl)propan-2-ol; see Kumar et al, ACS Chem. Biol., 2012, 7 (4), pp 672-677) inhibits the probe from binding ROR ⁇ t with an IC50 of 0.36 ⁇ M, which is close to the value reported in the literature.
- the plate was incubated for 10 min at room temperature and fluorescence polarization was read using an Envision 2102 plate reader (Perkin Elmer) with the TAMRA FP optical module installed.
- PBMCs Human peripheral blood mononuclear cells
- BD Pharmingen 5 ⁇ g/ml coated 96-well plates (400,000 cells/well, 160 ⁇ l RPMI 1640+10% Fetal Bovine Serum) containing 5
- Test compounds were tested in triplicates, diluted 1000-fold in medium (final DMSO concentration is 0.1%). Incubated for seven days at 37° C., 5% CO 2 , 95% humidity, and 2-fluoro-4′-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]- ⁇ , ⁇ -bis(trifluoromethyl)-[1,1′-biphenyl]-4-methanol (SR2211 Calbiochem, Cat. No. 557353) was used as positive control.
- ROR ⁇ functional assays were performed using a commercially available assay product (INDIGO Biosciences, State College, Pa., USA; product #IB04001).
- the ROR ⁇ reporter cells are HEK293t cells transfected with one vector that provides high level constitutive expression of a hybrid protein comprised of the yeast Gal4-DNA binding domain fused to the ligand binding domain of human ROR ⁇ , and a second vector comprising the firefly luciferase cDNA functionally linked to the upstream activation sequence (UAS) of yeast Gal4.
- UAS upstream activation sequence
- a suspension of ROR ⁇ Reporter Cells was prepared using the protocol and culture medium provided in the kit product, and 100 ⁇ l of the Reporter Cell suspension was then dispensed into wells of a white, collagen-treated, 96-well assay plate.
- Concentrated stocks of test compounds were prepared in DMSO, then further diluted using media provided in the kit to generate ‘2 ⁇ -concentration’ treatment media.
- 100 ⁇ l of medium for each respective treatment concentration dispensed into triplicate assay wells, thereby combining with the reporter cells. All media formulations contained 10% charcoal stripped Fetal Bovine Serum, but are otherwise proprietary to INDIGO Biosciences.
- Final treatment concentrations for each test compound were 1,000 nM and 100 nM, each with 0.1% residual DMSO.
- ROR ⁇ may be of interest to provide compounds with selective modulation of ROR ⁇ for example compounds that are selective to ROR ⁇ over ROR ⁇ , compounds that are selective for ROR ⁇ versus ROR ⁇ , and compounds that are selective for ROR ⁇ versus BOTH ROR ⁇ and ROR ⁇ . It may also be of interest to provide compounds that are selective for ROR ⁇ versus further nuclear hormone receptors such as CAR1, FXR, GR, LXR ⁇ , LXR ⁇ , PPAR ⁇ , PXR, RAR ⁇ , RXR ⁇ , TR ⁇ , VDR. It is apparent to those skilled in the art that these nuclear hormone receptors are merely examples, and that selectivity against other nuclear receptors may also be of interest.
- nuclear hormone receptors are merely examples, and that selectivity against other nuclear receptors may also be of interest.
- ROR ⁇ and one or more further nuclear hormone receptors may for example be of interest to provide compounds that modulate ROR ⁇ and one or more further nuclear hormone receptors, as well as compounds that modulate both ROR ⁇ and ROR ⁇ , or ROR ⁇ and RORP. It may also be of interest to provide compounds that modulate ROR ⁇ and BOTH ROR ⁇ and ROR ⁇ , as well as compounds that modulate both ROR ⁇ and one or more further nuclear hormone receptors such as CAR1, FXR, GR, LXR ⁇ , LXR ⁇ , PPAR ⁇ , PXR, RAR ⁇ , RXR ⁇ , TR ⁇ , VDR. It is apparent to those skilled in the art that these nuclear hormone receptors are merely examples, and that modulation of even other nuclear receptors may also be of interest.
- the reporter assay may be modified to provide activity data for compounds against said other nuclear hormone receptor.
- the reporter assay may be modified to provide activity data for compounds against said other nuclear hormone receptor.
- Those skilled in the art know how to accomplish such modification.
- the selectivity of a compound towards ROR ⁇ versus said other nuclear hormone receptor can be established.
- a compound may be said to be selective for ROR ⁇ versus another nuclear hormone receptor if the activity of the compound against ROR ⁇ is greater than 5, 10, 20, or 100 fold higher for ROR ⁇ than for said other nuclear receptor.
- the compound(s) or pharmaceutical composition(s) described herein may modulate the activity of an ROR ⁇ receptor to a larger extent than it modulates the activity of ROR ⁇ and/or ROR ⁇ receptors.
- FIG. 3 graphically illustrates the assay results of example no. 89.
- compounds having inhibition values of greater than 80% in both an ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay are disclosed herein. According to an embodiment the compounds have inhibition values of greater than 80% in both a ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 1000 nM, such as less than 500 nM.
- the compounds are having inhibition values of greater than 80% in at least one of a ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay. According to an embodiment the compounds have inhibition values of greater than 80% in at least one of a ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 1000 nM, such as less than 500 nM.
- the compounds are having inhibition values of greater than 50% in both an ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay. According to an embodiment the compounds have inhibition values of greater than 50% in both a ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 1000 nM, such as less than 500 nM.
- the compounds are having inhibition values of greater than 50% in at least one of a ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay. According to an embodiment the compounds have inhibition values of greater than 50% in at least one of a ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 2000 nM, such as less than 1000 nM, such as less than 500 nM.
- the compounds are having inhibition values of greater than 20% in both an ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay. According to an embodiment the compounds have inhibition values of greater than 20% in both a ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 2000 nM, such as less than 1000 nM, such as less than 500 nM.
- the compounds are having inhibition values of greater than 50% in a ROR ⁇ Reporter Assay (Gal4) at 1 ⁇ M and inhibition values of greater than 20% in a ROR ⁇ Reporter Assay (Gal4) at 0.1 ⁇ M.
- the compounds are having inhibition values of greater than 50% in a ROR ⁇ Reporter Assay (Gal4) at 1 ⁇ M and inhibition values of greater than 20% in a ROR ⁇ Reporter Assay (Gal4) at 0.1 ⁇ M, and a FP activity range less than 2000 nM, such as less than 1000 nM, such as less than 500 nM.
- the compounds are having inhibition values of greater than 20% in at least one of a ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay. According to an embodiment the compounds have inhibition values of greater than 20% in at least one of a ROR ⁇ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 2000 nM, such as less than 1000 nM, such as less than 500 nM.
- EAE is an animal model for multiple sclerosis used to evaluate the efficacy of test compounds.
- EAE was induced at WuXi AppTec (Shanghai) in female C57BL/6 mice obtained from SLAC Laboratories, Shanghai by injection of 100 ⁇ l (100 ⁇ g MOG 35-55 peptide in complete Freund's adjuvant containing 200 ⁇ g M. tuberculosis /mouse) emulsion (with a 25-G needle) subcutaneously in the shaved back of the mouse.
- Each mouse was also given 200 ng PTX in 200 ⁇ l of PBS by intraperitoneal injection at 0 and 48 hours after immunization.
- compound or vehicle (2% DMSO, 10% HP- ⁇ -CD in MilliQ water) was given orally twice daily at various doses selected from 3, 10, and 30 mg/kg, beginning at the day of EAE induction. Treatment lasted for 25 days, and the animals were scored daily for EAE symptoms using the following scoring system: 0, Normal mouse; no overt signs of disease; 1, Limp tail or hind limb weakness but not both; 2 Limp tail and hind limb weakness; 3 Partial hind limb paralysis; 4 Complete hind limb paralysis; 5 Moribund state; death by EAE: sacrifice for humane reasons.
- the clinical score can be expressed as the mean score for each treatment group+/ ⁇ S.E.M.
- Example 204 was tested in the EAE study at 10 and 30 mg/kg. Example 204 was shown to delay onset and lower clinical score at both doses.
- Collagen-induced arthritis is an animal model of rheumatoid arthritis used to evaluate the efficacy of test compounds.
- CIA was induced at Washington Biotechnology Inc. (Baltimore) in male DBA/1J mice (Jackson Laboratories) by subcutaneous injection at the base of the tail with 50 ⁇ l of a bovine collagen/complete Freund's adjuvant emulsion. After 21 days, the mice were further boosted by a further subcutaneous injection of 50 ⁇ l of a collagen/incomplete Freund's adjuvant emulsion.
- compound or vehicle 2% DMSO, 10% HP- ⁇ -CD in MilliQ water
- compound or vehicle 2% DMSO, 10% HP- ⁇ -CD in MilliQ water
- treatment lasted until day 41, and the animals were scored three times weekly. Each paw was scored and the sum of all four scores was recorded as the Arthritic Index (AI).
- AI Arthritic Index
- the Arthritis Index for each treatment can be expressed as the mean score for each treatment group+/ ⁇ S.E.M.
- Example 204 was tested in the CIA study at 10 and 30 mg/kg in prophylactic setting and at 30 mg/kg in therapeutic setting. Example 204 was shown to significantly reduce disease severity at both prophylactic doses. Example 204 was shown to arrest disease development in the therapeutic setting.
- compounds disclosed herein have been found to at least modulate the activity of ROR ⁇ . Additionally it has been found that compounds disclosed herein have in vivo usefulness, and could consequently be useful in treating inflammatory, metabolic and autoimmune diseases.
Abstract
Description
- Aspects and embodiments described herein relate to compounds active towards nuclear receptors, pharmaceutical compositions comprising the compounds, and methods of treating inflammatory, metabolic, oncologic and autoimmune diseases or disorders using the compounds.
- Nuclear receptors are a family of transcription factors involved in the regulation of physiological functions, such as cell differentiation, embryonic development, and organ physiology. Nuclear receptors have also been identified as important pathological regulators in diseases such as cancer, diabetes, and autoimmune disorders.
- Examples of nuclear receptors include the nuclear retinoic acid receptor-related orphan receptors (RORs). RORs contain four principal domains: an N-terminal A/B domain, a DNA-binding domain, a hinge domain and a ligand binding domain. Binding of ligands to the ligand-binding domain is believed to cause conformational changes in the domain resulting in downstream actions. Different isoforms exist and these isoforms differ in their N-terminal A/B domain only.
- RORs consist of three members, namely ROR alpha (RORα), ROR beta (RORβ) and ROR gamma (RORγ or RORc).
- RORα is expressed in many tissues such as cerebellar Purkinje cells, the liver, thymus, skeletal muscle, skin, lung, adipose tissue and kidney.
- RORγ also has a broad expression pattern and was the most recently discovered of the three members. To date, five splice variants have been recorded for RORγ coding for two different protein isoforms: RORγ1 and RORγ2 (RORγ2 is also known as RORγt). Generally RORγ is used to describe RORγ1 and/or RORγt. RORγ1 is expressed in many tissues and is predominantly expressed in the kidneys, liver, and skeletal muscle. In contrast, expression of RORγt is restricted to lymphoid organs such as the thymus. RORγt has been identified as a key regulator of Th17 cell differentiation. Th17 cells are a subset of T helper cells which preferentially produce the cytokines IL-17A, IL-17F, IL-21 and IL-22. Th17 cells and their products have been shown to be associated with the pathology of many human inflammatory and autoimmune disorders.
- There is thus evidence that RORα and RORγ play a role in the pathogenesis of many diseases.
- It would be desirable to provide compounds that modulate the activity of RORα and/or RORγ for use in treating inflammatory, metabolic and autoimmune diseases.
- In one aspect provided herein are compounds of Formula (I)
- or pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and stereoisomers thereof, wherein:
- Y is NR or O;
- R is hydrogen or substituted or unsubstituted C1-4 alkyl;
- R1 is selected from the group consisting of hydrogen, —OH, halogen, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, and substituted or unsubstituted C2-4 alkenyl;
- R2 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, —CN, and —OH;
- or R and R2 are combined to form a substituted or unsubstituted fused ring;
- R3 is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, oxo, —C(═O)R10;
- R4a is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C1-6 alkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroaryl-C1-6 alkyl;
- R4b is selected from the group consisting of hydrogen, halogen, oxo, —OH, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, and —C(═O)R10;
- R5 is selected from the group consisting of —(CR8R9)pOR12, —(CR8R9)p-CR13R14R15, —(CR8R9)p-C(═O)OR7, and —(CR8R9)p-C(═O)NR8R9;
- n, m, and p are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
- R6a, R6b are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C1-6 heteroalkyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, or R6a and R6b are taken together to form an oxo group or a ring system selected from substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl, or R6a and R13 are taken together to form a ring system selected from substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-5 heteroalicyclyl;
- R7, R8, R9, and R12, are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl;
- R10 is selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, —OH, —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, and C3-7 cycloalkyl;
- R13 is absent, or selected from the group consisting of hydrogen, —OH, —CN substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, and —(CR8R9)p-C(═O)OR7, —(CR8R9)p-SO2R7 and —(CR8R9)p-C(═O)NR8R9;
- R14 and R15 are independently selected from the group consisting of hydrogen, and substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl; or
- R14 and R15 are combined to form a ring system selected from the group consisting of substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- B is a ring system selected from the group consisting of aryl, heteroaryl, and bicyclic heteroalicyclyl, provided that it is not 5,6-dichloro-1H-benzo[d]imidazol-2-yl when R1 and R2 both are hydrogen;
- C is a ring system selected from C2-9 heteroalicyclyl;
- wherein B is attached to a carbon atom adjacent the N atom of ring system C; and
- with the proviso the compound is not:
- According to a further aspect, R and R2 are combined to form a fused ring. In another aspect, R5 is —(CR8R9)p-C(═O)OR7, or —(CR8R9)p-C(═O)NR8R9. Alternatively, R5 is —(CR8R9)p-CR13R14R15 wherein R14 and R15 are combined to form a ring system.
- According to another aspect, there is provided a pharmaceutical composition comprising a compound of the herein above described type and at least one pharmaceutical acceptable excipient.
- According to yet another aspect, the herein above described compound or pharmaceutical composition are for use in therapy.
- According to another aspect, the herein above described compound or pharmaceutical composition are for use in the treatment and/or prevention of inflammatory, metabolic and autoimmune diseases or disorders.
- In another aspect, the herein above described compound or pharmaceutical composition are for modulating the activity of a retinoic acid receptor-related orphan receptor (ROR).
- Further, advantageous features of various embodiments are defined in the dependent claims and within the detailed description below.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications referenced herein are incorporated by reference in their entirety. In the event that there are a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.
- As used herein, any “R” group(s) such as, without limitation, R1, R2, R3, R4, R5, R8, R9, and R10, represent substituents that can be attached to the indicated atom. A non-limiting list of R groups includes but is not limited to hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and heteroalicyclyl. If two “R” groups are covalently bonded to the same atom or to adjacent atoms, then they may be “taken together” or “combined” as defined herein to form a cycloalkyl, aryl, heteroaryl or heteroalicyclyl group. For example, without limitation, if Ra and Rb of an NRaRb group are indicated to be “taken together” or “combined”, it means that they are covalently bonded to one another at their terminal atoms to form a ring that includes the nitrogen:
- As readily recognized by the skilled person, any given group disclosed herein may comprise further hydrogen(s) than the one(s) provided by a R-group, being hydrogen, attached to the group.
- Whenever a group is described as being “unsubstituted or substituted,” if substituted, the substituent(s) (which may be present one or more times, such as 1, 2, 3 or 4 times) are independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof.
- When a substituent on a group is deemed to be “substituted,” the substitutent itself is substituted with one or more of the indicated substitutents. When the referenced substituent is substituted, it is meant that one or more hydrogen atoms on the referenced substituent may be replaced with a group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. The protecting groups that may form the protective derivatives of the above substituents are known to those of skill in the art and may be found in references Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, N.Y., 1999, which is hereby incorporated by reference in its entirety.
- As used herein, “Cm to Cn,” “Cm-Cn” or “Cm-n” in which “m” and “n” are integers refers to the number of carbon atoms in the relevant group. That is, the group can contain from “m” to “n”, inclusive, carbon atoms. Thus, for example, a “C1 to C6 alkyl” group refers to all alkyl groups having from 1 to 6 carbons, that is, CH3—, CH3CH2—, CH3CH2CH2—, (CH3)2CH—, CH3CH2CH2CH2—, CH3CH2CH(CH3)—, CH3CH(CH)3CH2—, CH3CH(CH)3CH2— and (CH3)3C—. If no “m” and “n” are designated with regard to a group, the broadest range described in these definitions is to be assumed.
- As used herein, “alkyl” refers to a straight or branched hydrocarbon chain group that is fully saturated (no double or triple bonds). The alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., “1 to 20 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated). The alkyl group may also be a medium size alkyl having 1 to 10 carbon atoms, such as “C1-6”. The alkyl group could also be a lower alkyl having 1 to 4 carbon atoms. The alkyl group of the compounds may be designated as “C1-C4 alkyl,” “C1-4 alkyl” or similar designations. By way of example only, “C1-C4 alkyl” or “C1-4 alkyl” indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like. When substituted, the substituent group(s) is(are) one or more group(s) individually and independently selected from alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof.
- As used herein, “alkenyl” refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more double bonds. If more than one double bond is present, the double bonds may be conjugated or not conjugated. The alkenyl group may have 2 to 20 carbon atoms (whenever it appears herein, a numerical range such as “2 to 20” refers to each integer in the given range; e.g., “2 to 20 carbon atoms” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated). When substituted, the substituent group(s) is(are) one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, mercapto, alkylthio, cyano, halogen, nitro, haloalkyl, haloalkoxy, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof.
- As used herein, “alkynyl” refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more triple bonds. The alkynyl group may have 2 to 20 carbon atoms (whenever it appears herein, a numerical range such as “2 to 20” refers to each integer in the given range; e.g., “2 to 20 carbon atoms” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated). An alkynyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be selected from the same groups disclosed above with regard to alkenyl group substitution.
- As used herein, “hetero” may be attached to a group and refers to one or more carbon atom(s) and the associated hydrogen atom(s) in the attached group have been independently replaced with the same or different heteroatoms selected from nitrogen, oxygen, phosphorus and sulfur.
- As used herein, “heteroalkyl,” by itself or in combination with another term, refers to a straight or branched alkyl group consisting of the stated number of carbon atoms, where one or more carbon atom(s), such as 1, 2, 3 or 4 carbon atom(s), and the associated hydrogen atom(s) have been independently replaced with the same or different heteroatoms selected from nitrogen, oxygen and sulfur. The carbon atom(s) being replace may be in the middle or at the end of the alkyl group. Examples of heteroalkyl include, but are not limited to, —S-alkyl, —O-alkyl, —NH-alkyl, -alkylene-O-alkyl, etc
- As used herein, “aryl” refers to a carbocyclic (all carbon) ring or two or more fused rings (rings that share two adjacent carbon atoms) that have a fully delocalized pi-electron system. Examples of aryl groups include, but are not limited to, benzene, naphthalene and azulene. An aryl group may be substituted. When substituted, hydrogen atoms are replaced by substituent group(s) that is(are) one or more group(s) independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. When substituted, substituents on an aryl group may form a non-aromatic ring fused to the aryl group, including a cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl.
- As used herein, “heteroaryl” refers to a monocyclic or multicyclic aromatic ring system (a ring system with fully delocalized pi-electron system), in which at least one of the atoms in the ring system is a heteroatom, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur. Examples of monocyclic “heteroaryl” include, but are not limited to, furan, thiophene, phthalazine, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, triazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, tetrazole, and triazine. Examples of multicyclic “heteroaryl” include, but are not limited to, quinoline, isoquinoline, quinazoline, quinoxaline, indole, purines, benzofuran, benzothiophene, benzopyranones (e.g. coumarin, chromone, and isocoumarin). A heteroaryl may be substituted. When substituted, hydrogen atoms are replaced by substituent group(s) that is(are) one or more group(s) independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. When substituted, substituents on a heteroayl group may form a non-aromatic ring fused to the aryl group, including a cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl.
- An “aralkyl” or “arylalkyl” is an aryl group connected, as a substituent, via an alkylene group. The alkylene and aryl group of an aralkyl may be substituted. Examples include but are not limited to benzyl, substituted benzyl, 2-phenylethyl, 3-phenylpropyl, and naphthylalkyl. In some cases, the alkylene group is a lower alkylene group.
- A “heteroaralkyl” or “heteroarylalkyl” is heteroaryl group connected, as a substituent, via an alkylene group. The alkylene and heteroaryl group of heteroaralkyl may be substituted. Examples include but are not limited to 2-thienylmethyl, 3-thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, pyrazolylalkyl and imidazolylalkyl, and their substituted as well as benzo-fused analogs. In some cases, the alkylene group is a lower alkylene group.
- An “alkylene” is a straight-chained tethering group, forming bonds to connect molecular fragments via their terminal carbon atoms. The alkylene may have 1 to 20 carbon atoms. The alkylene may also be a medium size alkylene having 1 to 10 carbon atoms, such as “C1-6” The alkylene could also be a lower alkylene having 1 to 4 carbon atoms. The alkylene may be designated as “C1-C4 alkylene”, “C1-4 alkylene” or similar designations. Non-limiting examples include, methylene (—CH2—), ethylene (—CH2CH2—), propylene (—CH2CH2CH2—), and butylene (—(CH2)4—) groups. In the case of methylene, the two connected fragments are connected to the same carbon atom. A lower alkylene group may be substituted.
- As used herein, “heteroalkylene” by itself or in combination with another term refers to an alkylene group consisting of the stated number of carbon atoms in which one or more of the carbon atoms, such as 1, 2, 3 or 4 carbon atom(s), are independently replaced with the same or different heteroatoms selected from oxygen, sulfur and nitrogen. Examples of heteroalkylene include, but not limited to —CH2—O—, —CH2—CH2—O—, —CH2—CH2—CH2—O—, —CH2—NH—, —CH2—CH2—NH—, —CH2—CH2—CH2—NH—, —CH2—CH2—NH—CH2—, —O—CH2—CH2—O—CH2—CH2—O—, —O—CH2—CH2—O—CH2—CH2—, and the like.
- As used herein, “alkylidene” refers to a divalent group, such as ═CR′R″, which is attached to one carbon of another group, forming a double bond. Alkylidene groups include, but are not limited to, methylidene (═CH2) and ethylidene (═CHCH3). As used herein, “arylalkylidene” refers to an alkylidene group in which either R′ or R″ is an aryl group. An alkylidene group may be substituted.
- As used herein, “alkoxy” refers to the group —OR wherein R is an alkyl, e.g. methoxy, ethoxy, n-propoxy, cyclopropoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, amoxy, tert-amoxy and the like. An alkoxy may be substituted.
- As used herein, “alkylthio” refers to the formula —SR wherein R is an alkyl is defined as above, e.g. methylmercapto, ethylmercapto, n-propylmercapto, 1-methylethylmercapto (isopropylmercapto), n-butylmercapto, iso-butylmercapto, sec-butylmercapto, tert-butylmercapto, and the like. An alkylthio may be substituted.
- As used herein, “aryloxy” and “arylthio” refers to RO— and RS—, in which R is an aryl as defined above, e.g., phenoxy, naphthalenyloxy, azulenyloxy, anthracenyloxy, naphthalenylthio, phenylthio and the like. Both an aryloxy and arylthio may be substituted.
- As used herein, “alkenyloxy” refers to the formula —OR wherein R is an alkenyl as defined above, e.g., vinyloxy, propenyloxy, n-butenyloxy, iso-butenyloxy, sec-pentenyloxy, tert-pentenyloxy, and the like. The alkenyloxy may be substituted.
- As used herein, “acyl” refers to a hydrogen, alkyl, alkenyl, alkynyl, or aryl connected, as substituents, via a carbonyl group. Examples include formyl, acetyl, propanoyl, benzoyl, and acryl. An acyl may be substituted.
- As used herein, “cycloalkyl” refers to a completely saturated (no double bonds) mono- or multi-cyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro-connected fashion. Cycloalkyl groups may range from C3 to C10, such as from C3 to C6. A cycloalkyl group may be unsubstituted or substituted. Typical cycloalkyl groups include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. If substituted, the substituent(s) may be an alkyl or selected from those indicated above with regard to substitution of an alkyl group unless otherwise indicated. When substituted, substituents on a cycloalkyl group may form an aromatic ring fused to the cycloalkyl group, including an aryl and a heteroaryl.
- As used herein, “cycloalkenyl” refers to a cycloalkyl group that contains one or more double bonds in the ring although, if there is more than one, they cannot form a fully delocalized pi-electron system in the ring (otherwise the group would be “aryl,” as defined herein). When composed of two or more rings, the rings may be connected together in a fused, bridged or spiro-connected fashion. Cycloalkenyl groups may range from C3 to C10, such as from C5 to C10. A cycloalkenyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be an alkyl or selected from the groups disclosed above with regard to alkyl group substitution unless otherwise indicated. When substituted, substituents on a cycloalkenyl group may form an aromatic ring fused to the cycloalkenyl group, including an aryl and a heteroaryl.
- As used herein, “cycloalkynyl” refers to a cycloalkyl group that contains one or more triple bonds in the ring. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro-connected fashion. Cycloalkynyl groups may range from C8 to C12. A cycloalkynyl group may be unsubstituted or substituted. When substituted, the substituent(s) may be an alkyl or selected from the groups disclosed above with regard to alkyl group substitution unless otherwise indicated. When substituted, substituents on a cycloalkynyl group may form an aromatic ring fused to the cycloalkynyl group, including an aryl and a heteroaryl.
- As used herein, “heteroalicyclic” or “heteroalicyclyl” refers to a 3- to 18 membered ring which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. The heteroalicyclic or heteroalicyclyl groups may range from C2 to C10, in some embodiments it may range from C2 to C9, and in other embodiments it may range from C2 to C8. The “heteroalicyclic” or “heteroalicyclyl” may be monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be joined together in a fused, bridged or spiro-connected fashion; and the nitrogen, carbon and sulfur atoms in the “heteroalicyclic” or “heteroalicyclyl” may be oxidized; the nitrogen may be quaternized; and the rings may also contain one or more double bonds provided that they do not form a fully delocalized pi-electron system throughout all the rings, examples are 2H-benzo[b][1,4]oxazin-3(4H)-one, 3,4-dihydroquinolin-2(1H)-one, 1,2,3,4-tetrahydroquino line, 3,4-dihydro-2H-benzo[b][1,4]oxazine, 2,3-dihydrobenzo[d]oxazole, 2,3-dihydro-1H-benzo[d]imidazole, indoline, and 1,3-dihydro-2H-benzo[d]imidazol-2-one, and benzo[d]oxazol-2(3H)-one. Heteroalicyclyl groups may be unsubstituted or substituted. When substituted, the substituent(s) may be one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, oxo, alkoxy, aryloxy, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, cyano, halogen, C-amido, N-amido, S-sulfonamido, N-sulfonamido, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. Examples of such “heteroalicyclic” or “heteroalicyclyl” include but are not limited to, azepinyl, dioxolanyl, imidazolinyl, morpholinyl, oxetanyl, oxiranyl, piperidinyl N-Oxide, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, 4-piperidonyl, pyrazolidinyl, 2-oxopyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl sulfoxide, and thiamorpholinyl sulfone. When substituted, substituents on a heteroalicyclyl group may form an aromatic ring fused to the heteroalicyclyl group, including an aryl and a heteroaryl.
- A “(cycloalkyl)alkyl” is a cycloalkyl group connected, as a substituent, via an alkylene group. The alkylene and cycloalkyl of a (cycloalkyl)alkyl may be substituted. Examples include but are not limited cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like. In some cases, the alkylene group is a lower alkylene group.
- A “(cycloalkenyl)alkyl” is a cycloalkenyl group connected, as a substituent, via an alkylene group. The alkylene and cycloalkenyl of a (cycloalkenyl)alkyl may be substituted. In some cases, the alkylene group is a lower alkylene group.
- A “(cycloalkynyl)alkyl” is a cycloalkynyl group connected, as a substituent, via an alkylene group. The alkylene and cycloalkynyl of a (cycloalkynyl)alkyl may be substituted. In some cases, the alkylene group is a lower alkylene group.
- As used herein, “halo” or “halogen” refers to F (fluoro), Cl (chloro), Br (bromo) or I (iodo).
- As used herein, “haloalkyl” refers to an alkyl group in which one or more of the hydrogen atoms are replaced by halogen. Such groups include but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl and 1-chloro-2-fluoromethyl, 2-fluoroisobutyl. A haloalkyl may be substituted.
- As used herein, “haloalkoxy” refers to a RO-group in which R is a haloalkyl group. Such groups include but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy and 1-chloro-2-fluoromethoxy, 2-fluoroisobutyoxy. A haloalkoxy may be substituted.
- An “O-carboxy” group refers to a “RC(═O)O—” group in which R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined herein. An O-carboxy may be substituted.
- A “C-carboxy” group refers to a “—C(═O)OR” group in which R can be the same as defined with respect to O-carboxy. A C-carboxy may be substituted.
- A “trihalomethanesulfonyl” group refers to an “X3CSO2—” group” wherein X is a halogen.
-
- A “nitro” group refers to a “—NO2” group
- A “cyano” group refers to a “—CN” group.
- A “cyanato” group refers to an “—OCN” group.
- An “isocyanato” group refers to a “—NCO” group.
- A “thiocyanato” group refers to a “—SCN” group.
- A “carbonyl” group refers to a “—C(═O)—” group.
- A “thiocarbonyl” group refers to a “—C(═S)—” group.
- An “oxo” group refers to a “═O” group.
- A “hydroxy” group or “hydroxyl” group refers to an “—OH” group.
- An “isothiocyanato” group refers to an “—NCS” group.
- A “sulfinyl” group refers to an “—S(═O)—R” group in which R can be the same as defined with respect to O-carboxy. A sulfinyl may be substituted.
- A “sulfonyl” group refers to an “SO2R” group in which R can be the same as defined with respect to O-carboxy. A sulfonyl may be substituted.
- An “S-sulfonamido” group refers to a “—SO2NRARB” group in which RA and RB independently of each other can be the same as defined with respect to the R group as defined for O-carboxy, or combined to form a ring system selected from the group consisting of substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl substituted or unsubstituted heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. A S-sulfonamido may be substituted.
- An “N-sulfonamido” group refers to a “RSO2N(RA)—” group in which R and RA independently of each other can be the same as defined with respect to the R group as defined for O-carboxy. An N-sulfonamido may be substituted.
- A “trihalomethanesulfonamido” group refers to an “X3CSO2N(R)—” group with X as halogen and R can be the same as defined with respect to O-carboxy. A trihalomethanesulfonamido may be substituted.
- A “C-amido” group refers to a “—C(═O)NRARB” group in which RA and RB independently of each other can be the same as defined with respect to the R group as defined for O-carboxy, or combined to form a ring system selected from the group consisting of substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl substituted or unsubstituted heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. A C-amido may be substituted.
- An “N-amido” group refers to a “RC(═O)NRA—” group in which R and RA independently of each other can be the same as defined with respect to the R group as defined for O-carboxy. An N-amido may be substituted.
- An “ester” refers to a “—C(═O)OR” group in which R can be the same as defined with respect to O-carboxy. An ester may be substituted.
- A lower alkoxyalkyl refers to an alkoxy group connected via a lower alkylene group. A lower alkoxyalkyl may be substituted.
- An “amine” or “amino” refers to “RNH2” (a primary amine), “R2NH” (a secondary amine), “R3N” (a tertiary amine). An amino group may be substituted.
- A lower aminoalkyl refers to an amino group connected via a lower alkylene group. A lower aminoalkyl may be substituted.
- Any unsubstituted or monosubstituted amine group on a compound herein can be converted to an amide, any hydroxyl group can be converted to an ester and any carboxyl group can be converted to either an amide or ester using techniques well-known to those skilled in the art (see, for example, Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, N.Y., 1999).
- As used herein, the abbreviations for any protective groups, amino acids and other compounds, are, unless indicated otherwise, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (See, Biochem. 11:942-944 (1972)).
- As employed herein, the following terms have their accepted meaning in the chemical literature.
- CDCl3 deuterated chloroform
- DCM dichloromethane or CH2Cl2
- DIPEA N,N-diisopropylethylamine
- DMF N,N-dimethylformamide
- DMSO dimethyl sulfoxide
- EtOAc ethyl acetate
- h hour(s)
- MeOH methanol
- TFA trifluoroacetic acid
- It is understood that, in any compound disclosed herein having one or more chiral centers, if an absolute stereochemistry is not expressly indicated, then each center may independently be of R-configuration or S-configuration or a mixture thereof. Thus, the compounds provided herein may be enatiomerically pure or be stereoisomeric mixtures. Further, compounds provided herein may be scalemic mixtures. In addition, it is understood that in any compound having one or more double bond(s) generating geometrical isomers that can be defined as E or Z each double bond may independently be E or Z or a mixture thereof. Likewise, all tautomeric forms are also intended to be included.
- As used herein, “tautomer” and “tautomeric” refer to alternate forms of a compound disclosed herein that differ in the position of a proton. Non-limiting examples include enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring —NH— moiety and a ring ═N— moiety such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.
- It is understood that isotopes may be present in the compounds described herein. Each chemical element as represented in a compound structure may include any isotope of said element. For example, in a compound described herein a hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen-1 (protium) and hydrogen-2 (deuterium). Thus, reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.
- As used herein, “pharmaceutically acceptable salt” refers to a salt of a compound that does not abrogate the biological activity and properties of the compound. Pharmaceutical salts can be obtained by reaction of a compound disclosed herein with an acid or base. Base-formed salts include, without limitation, ammonium salt (NH4 +); alkali metal, such as, without limitation, sodium or potassium, salts; alkaline earth, such as, without limitation, calcium or magnesium, salts; salts of organic bases such as, without limitation, dicyclohexylamine, piperidine, piperazine, methylpiperazine, N-methyl-D-glucamine, diethylamine, ethylenediamine, tris(hydroxymethyl)methylamine; and salts with the amino group of amino acids such as, without limitation, arginine and lysine. Useful acid-based salts include, without limitation, acetates, adipates, aspartates, ascorbates, benzoates, butyrates, caparate, caproate, caprylate, camsylates, citrates, decanoates, formates, fumarates, gluconates, glutarate, glycolates, hexanoates, laurates, lactates, maleates, nitrates, oleates, oxalates, octanoates, propanoates, palmitates, phosphates, sebacates, succinates, stearates, sulfates, sulfonates, such as methanesulfonates, ethanesulfonates, p-toluenesulfonates, salicylates, tartrates, and tosylates.
- Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more solvent of water molecules, or 1 to about 100, or 1 to about 10, or one to about 2, 3 or 4, solvent or water molecules.
- As used herein, a “prodrug” refers to a compound that may not be pharmaceutically active but that is converted into an active drug upon in vivo administration. The prodrug may be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. Prodrugs are often useful because they may be easier to administer than the parent drug. They may, for example, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have better solubility than the active parent drug in pharmaceutical compositions. An example, without limitation, of a prodrug would be a compound disclosed herein, which is administered as an ester (the “prodrug”) to facilitate absorption through a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to a carboxylic acid (the active entity) once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized in vivo to release the active parent compound. By virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, those skilled in the art, once a pharmaceutically active compound is known, can design prodrugs of the compound (see, e.g. Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392).
- “Anti-drug” refers to a compound or composition acting against or opposing illicit drugs or their use. Compounds of the present application may act as anti-drugs.
- As used herein, to “modulate” the activity of a receptor means either to activate it, i.e., to increase its cellular function over the base level measured in the particular environment in which it is found, or deactivate it, i.e., decrease its cellular function to less than the measured base level in the environment in which it is found and/or render it unable to perform its cellular function at all, even in the presence of a natural binding partner. A natural binding partner is an endogenous molecule that is an agonist for the receptor.
- An “agonist” is defined as a compound that increases the basal activity of a receptor (i.e. signal transduction mediated by the receptor).
- As used herein, “partial agonist” refers to a compound that has an affinity for a receptor but, unlike an agonist, when bound to the receptor it elicits only a fractional degree of the pharmacological response normally associated with the receptor even if a large number of receptors are occupied by the compound.
- An “inverse agonist” is defined as a compound, which reduces, or suppresses the basal activity of a receptor, such that the compound is not technically an antagonist but, rather, is an agonist with negative intrinsic activity.
- As used herein, “antagonist” refers to a compound that binds to a receptor to form a complex that does not give rise to any response, as if the receptor was unoccupied. An antagonist attenuates the action of an agonist on a receptor. An antagonist may bind reversibly or irreversibly, effectively eliminating the activity of the receptor permanently or at least until the antagonist is metabolized or dissociates or is otherwise removed by a physical or biological process.
- As used herein, a “subject” refers to an animal that is the object of treatment, observation or experiment. “Animal” includes cold- and warm-blooded vertebrates and invertebrates such as birds, fish, shellfish, reptiles and, in particular, mammals. “Mammal” includes, without limitation, mice; rats; rabbits; guinea pigs; dogs; cats; sheep; goats; cows; horses; primates, such as monkeys, chimpanzees, and apes, and, in particular, humans.
- As used herein, a “patient” refers to a subject that is being treated by a medical professional such as an M.D. or a D.V.M. to attempt to cure, or at least ameliorate the effects of, a particular disease or disorder or to prevent the disease or disorder from occurring in the first place.
- As used herein, a “carrier” refers to a compound that facilitates the incorporation of a compound into cells or tissues. For example, without limitation, dimethyl sulfoxide (DMSO) is a commonly utilized carrier that facilitates the uptake of many organic compounds into cells or tissues of a subject.
- As used herein, a “diluent” refers to an ingredient in a pharmaceutical composition that lacks pharmacological activity but may be pharmaceutically necessary or desirable. For example, a diluent may be used to increase the bulk of a potent drug whose mass is too small for manufacture or administration. It may also be a liquid for the dissolution of a drug to be administered by injection, ingestion or inhalation. A common form of diluent in the art is a buffered aqueous solution such as, without limitation, phosphate buffered saline that mimics the composition of human blood.
- As used herein, an “excipient” refers to an inert substance that is added to a pharmaceutical composition to provide, without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability etc., to the composition. A “diluent” is a type of excipient.
- A “receptor” is intended to include any molecule present inside or on the surface of a cell that may affect cellular physiology when it is inhibited or stimulated by a ligand. Typically, a receptor comprises an extracellular domain with ligand-binding properties, a transmembrane domain that anchors the receptor in the cell membrane, and a cytoplasmic domain that generates a cellular signal in response to ligand binding (“signal transduction”). A receptor also includes any intracellular molecule that in response to ligation generates a signal. A receptor also includes any molecule having the characteristic structure of a receptor, but with no identifiable ligand. In addition, a receptor includes a truncated, modified, mutated receptor, or any molecule comprising partial or all of the sequences of a receptor.
- “Ligand” is intended to include any substance that interacts with a receptor.
- “Selective” or “selectivity” is defined as a compound's ability to generate a desired response from a particular receptor type, subtype, class or subclass while generating less or little response from other receptor types. “Selective” or “selectivity” of one or more particular subtypes of a receptor means a compound's ability to increase the activity of the subtypes while causing less, little or no increase in the activity of other subtypes.
- As used herein, “coadministration” of pharmacologically active compounds refers to the delivery of two or more separate chemical entities, whether in vitro or in vivo. Coadministration means the simultaneous delivery of separate agents; the simultaneous delivery of a mixture of agents; as well as the delivery of one agent followed by delivery of a second agent or additional agents. Agents that are coadministered are typically intended to work in conjunction with each other.
- The term “an effective amount” as used herein means an amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation or palliation of the symptoms of the disease being treated.
- When used herein, “prevent/preventing” should not be construed to mean that a condition and/or a disease never might occur again after use of a compound or pharmaceutical composition according to embodiments disclosed herein to achieve prevention. Further, the term should neither be construed to mean that a condition not might occur, at least to some extent, after such use to prevent said condition. Rather, “prevent/preventing” is intended to mean that the condition to be prevented, if occurring despite such use, will be less severe than without such use.
- Compounds
- According to one aspect compounds of Formula (I)
- or pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and stereoisomers thereof, wherein:
- Y is NR or O;
- R is hydrogen or substituted or unsubstituted C1-4 alkyl;
- R1 is selected from the group consisting of hydrogen, —OH, halogen, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, and substituted or unsubstituted C2-4 alkenyl;
- R2 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, —CN, and —OH;
- or R and R2 are combined to form a substituted or unsubstituted fused ring;
- R3 is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, oxo, —C(═O)R10;
- R4a is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C1-6 alkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroaryl-C1-6 alkyl;
- R4b is selected from the group consisting of hydrogen, halogen, oxo, —OH, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, and —C(═O)R10;
- R5 is selected from the group consisting of —(CR8R9)pOR12, —(CR8R9)p-CR13R14R15, —(CR8R9)p-C(═O)OR7, and —(CR8R9)p-C(═O)NR8R9;
- n, m, and p are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
- R6a, R6b are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C1-6 heteroalkyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, or R6a and R6b are taken together to form an oxo group or a ring system selected from substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl, or R6a and R13 are taken together to form a ring system selected from substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-5 heteroalicyclyl;
- R7, R8, R9, and R12, are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl;
- R10 is selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, —OH, —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, and C3-7 cycloalkyl;
- R13, if not to be taken together with R6a, is absent, or selected from the group consisting of hydrogen, —OH, —CN substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, and —(CR8R9)p-C(═O)OR7, —(CR8R9)p-SO2R7 and —(CR8R9)p-C(═O)NR8R9;
- R14 and R15 are independently selected from the group consisting of hydrogen, and substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl; or
- R14 and R15 are combined to form a ring system selected from the group consisting of substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- B is a ring system selected from the group consisting of aryl, heteroaryl, and bicyclic heteroalicyclyl, provided that it is not 5,6-dichloro-1H-benzo[d]imidazol-2-yl when R1 and R2 both are hydrogen;
- C is a ring system selected from C2-9 heteroalicyclyl;
- wherein B is attached to a carbon atom adjacent the N atom of ring system C; and with the proviso the compound is not:
- are provided.
- As with any group of structurally related compounds which possess a particular utility, certain embodiments of variables of the compounds of Formula (I) may be particularly useful in their end use application.
- In some embodiments of the compounds of Formula (I), R and R2 in combination with the pyrimidine ring form a ring system selected from pyrrolo[2,3-d]pyrimidine and 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine. The ring system may be pyrrolo[2,3-d]pyrimidine.
- In some embodiments according to Formula (I) B is a ring system selected from the group consisting of aryl, heteroaryl, and bicyclic heteroalicyclyl, provided that it is not 5,6-dichloro-1H-benzo[d]imidazole-2-yl; i.e.
- In some further embodiments according to Formula (I), B is a ring system selected from the group consisting of aryl, monocyclic heteroaryl, and bicyclic heteroalicyclyl. In some embodiments of the compounds of Formula (I), R and R2 in combination with the pyrimidine ring form a pyrrolo[2,3-d]pyrimidine or 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine. The compounds of Formula (I) may also have the Formula (IIa):
- wherein R4e and R4d are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, and —OH. In preferred compounds of Formula (IIa), R4e and R4d may be independently selected from the group consisting of hydrogen, methyl, and fluorine.
- Embodiment disclosed herein below in relation to various groups, rings and substituents of compounds of Formula (I) are, as indicated, equally applicable to compounds of any one of the Formulae (IIa-IIe) provided below herein, provided that the relevant group, integer, ring and/or substituent is present in the Formula of concern, as readily appreciated by the skilled person.
- According to another embodiment, the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe) as disclosed herein below, have R5 being —(CR8R9)p-C(═O)OR7 or —(CR8R9)p-C(═O)NR8R9, unless otherwise specified. In an alternative embodiment, the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe) have R5 being —(CR8R9)pOR12. In these embodiments, R7, R8, R9, and R12 are independently selected of each other from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted aryl-C1-6 alkyl and substituted or unsubstituted aryl. Preferred groups of R7, R8, R9, and R12 are selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, and aryl, while even more preferred groups are selected from hydrogen, methyl, ethyl and tert-butyl. The integer p is preferably selected from 0, 1 or 2. In some embodiments, p is 0.
- According to yet another embodiment, R5 is —(CR8R9)p-CR13R14R15. In this embodiment it is preferred that R14 and R15 are combined to form a ring system. Further, the integer “p” may be 0 (zero), or 1. While it is not intended that the ring system be particular limited, preferred ring systems are selected from the group consisting of substituted or unsubstituted C3-7 cycloalkyl, substituted or unsubstituted C3-7 cycloalkenyl, substituted or unsubstituted C2-6 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. For example, R14 and R15 may be combined to form a ring system selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, azetidinyl, thietanyl, pyrrolyl, pyrazolyl imidazolyl, pyrrolidinyl, imidazolinyl, pyrazolidinyl, thiazolidinyl, isothiazolidinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, oxathianyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxolanyl, dioxanyl, furyl, dihydrofuranyl, furazanyl, tetrahydrofuryl, pyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, dithiolanyl, dithianyl, thiopyranyl, thianyl, thienyl, oxetanyl, quinolyl, isoquinolyl, indolyl, iso-indolyl, and tetrahydrothienyl, any of which may be substituted or unsubstituted. Preferably, R14 and R15 are combined to form a ring system selected from the group consisting of cycloheptyl, cyclohexyl, cyclopentyl, dioxanyl, furyl, imidazolyl, isothiazolyl, isoxazolyl, morpholinyl, oxazolyl, oxetanyl, oxathianyl, phenyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidinyl, pyrrolyl, tetrahydrofuryl, tetrahydropyranyl, tetrazolyl, thianyl, thiazolyl, thienyl, thiomorpholinyl, thiopyryl, and triazolyl, all of which may be unsubstituted or substituted. Some embodiments relate to the ring system formed being phenyl, pyridyl, cyclopentyl, cyclohexyl, piperidyl, pyrrolidinyl, oxetanyl, and tetrahydropyranyl, all which may be substituted by (CH2)q(R5a) as defined herein. Some embodiments relate to the ring system being phenyl, pyridyl, piperidinyl oxetanyl, or cyclohexyl. In embodiments wherein R14 and R15 are combined to form an aromatic ring system, R13 is absent.
- In a further embodiment, the ring system formed by the combination of R14 and R15 is substituted with —(CH2)q(R5a) wherein R5a is independently selected from the group consisting of —CH2COOR20, —CH2CONR21R22, —CN, C1-6 alkyl, —CH2-imidazolyl, —CH2—SO2R20, —CH2C(CH3)2(OR20), —OCH3, —CH2-triazolyl, —CF3, dimethyl substituted-imidazolyl-2,4-dione, —CH2—SO2NR21R22, morpholinyl, —C(═O)-morpholinyl, piperidyl-CH2OR20, —OCH2-tetrahydrofuryl, piperazinonyl, piperidinyl-CONR21R22, —OH, —CONR21R22, —CH(OR20)CH3, —COOR20, —CH2-pyrrolidyl, C1-6 alkylene-OH, cyclopentyl, pyrrolidonyl, tetrazolyl, —CH2— tetrazolyl, —CH2OR20, acyl, —SOR20, —SO2R20, —COR20, —NR21SO2R20, —SO2NR21R22, and halogen;
- R20, R21, and R22 are independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, —CN, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted C2-6 heteroalicyclyl; and
- q is an integer selected from 0, 1 or 2.
- Of course the ring system formed by the combination of R14 and R15 may, in alternative embodiments, be substituted with groups other than —(CH2)q(R5a).
- According to some embodiments, R13 is selected from the group consisting of hydrogen, —CN, CH3, fluorine, —OH, —CH2OH, —OCH3, —CH2CH2OH, —CO2H, —CO2—C1-4 alkyl, —CH2SO2R20 and —CONR8R9 wherein R8 and R9 are independently of each other selected from hydrogen, C1-4 alkyl and C1-4 aminoalkyl or R8 and R9 are combined to form a C2-C6 heteroalicyclyl. Some embodiments relate to R13 taken together with R6a to form a ring system selected from the group consisting of substituted or unsubstituted C3-6 cycloalkyl and substituted or unsubstituted C2-5 heteroalicyclyl.
- According to some embodiments, R13 is absent or hydrogen.
- In some embodiments of the compounds of Formula (I), Y is NR. Further, while R may be selected from the group consisting of hydrogen, C1-4 alkyl, C1-4 haloalkyl, and C1-4 hydroxyalkyl. In one embodiment R is hydrogen.
- According to some embodiments, R1 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, and substituted or unsubstituted C1-4 alkoxy. R1 may thus include C1-4 haloalkyl and C1-4 hydroxyalkyl groups. In some embodiments, R1 is hydrogen or CF3.
- According to some embodiments, R2 is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, and C1-4 hydroxyalkyl. In some embodiments, R2 is a halogen such as fluorine.
- In some embodiments, the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein may have an R3 group selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, oxo, C1-4 alkoxy and C1-4 haloalkoxy, unless otherwise specified. According to one embodiment R3 is selected from the group consisting of hydrogen, methyl, fluorine, chlorine and oxo. In some embodiments, R3 is hydrogen.
- In some compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein the integer m is selected from 2, 3, or 4, and at least two of the R3 groups present are bound to the same atom of ring system C. This embodiment provides compounds with one or two geminally substituted atoms that are part of ring system C. In some embodiments, R3 is flouro, such as geminally arranged fluoro atoms.
- According to some embodiments of the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein, R4a is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-C6 alkoxy, C1-6 haloalkoxy, heteroaryl and aryl. In some embodiments R4a groups are selected from the group consisting of methyl, ethyl, propyl, iso-propyl, tert-butyl, chlorine, bromine, fluorine, methoxy, ethoxy, C1-2 haloalkyl, C1-2 haloalkoxy and triazolyl. In some embodiments R4a groups are —CF3, —CF2CF3, —CHF2, —OCF3, —OCF2CF3, and —OCHF2. In some embodiments R4a is selected from the group consisting of isopropyl, halogen, ethoxy, CF3, —OCF3.
- In some embodiments, wherein the ring system B is 6-membered aryl or heteroaryl, R4a is arranged in the para- or meta-position, in relation to the carbon carrying ring system C.
- According to some embodiments, R4b is selected from hydrogen, oxo, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-C4 alkoxy, and C1-4 haloalkoxy. In this embodiment, R4b may be further selected from methyl, ethyl, propyl, iso-propyl, tert-butyl, chlorine, bromine, fluorine, methoxy, ethoxy, —OH, C1-2 haloalkyl, and C1-2 haloalkoxy. Examples of R4b groups comprise —CF3, —CHF2, —OCF3, and —OCHF2. In some embodiments R4b is hydrogen.
- Some embodiments relate to R4a being selected from the group consisting of methyl, ethyl, propyl, iso-propyl, tert-butyl, chlorine, bromine, fluorine, methoxy, ethoxy, C1-2 haloalkyl, C1-2 haloalkoxy, and triazolyl arranged in the above mentioned para- or meta-position, and R4b being hydrogen.
- In some embodiments of the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein, R6a is selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, and substituted or unsubstituted aryl, or R6a and R13 are taken together to form a ring system selected from substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl. Further examples of R6a are selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and aryl. It is preferred however, that R6a is hydrogen.
- According to some embodiments, R6b is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted aryl-C1-6 alkyl, substituted or unsubstituted C2-9 heteroalicyclyl-C1-6 alkyl, and substituted or unsubstituted aryl in the compounds of Formula (I). Thus, R6b may be hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-C6 alkoxy, C1-6 haloalkoxy, C1-6-alkoxy-C1-6-alkyl-, aryl-C1-6 alkyl-, C2-9 heteroalicyclyl-C1-4 alkyl-, C1-6-alkoxy-aryl-, haloaryl, and aryl. Particular examples of compounds of Formula (I) have an R6b group selected from hydrogen, —(CH2)C(CH3)3, —(CH2)CONH2, phenyl, phenyl substituted with 1 to 3 halogens, —CH(CH3)OC(CH3)3, —CH2-phenyl-OCH3,-phenyl-OCH3, —CH2-pyridyl, CH2-cyclohexyl-CH2CO2H, —CH2-cyclohexyl-CH2CONH2, CH2-cyclohexyl-CH2-tetrazolyl, —CH2-cyclohexyl-CH2OH, —CH2-cyclohexyl-NHSO2CH3, —CH2-cyclohexyl-NHSO2CH2CF3, —CH2-cyclohexyl-CH2CN, —CH2-phenyl-CH2CO2H, —CH2-phenyl-CH2CONH2, —CH2-phenyl-CH2CONH2CH3, —CH2-phenyl-CH2-tetrazolyl, —CH2-phenyl-CONH2, —CH2-phenyl-SO2NH-cyclopropyl, —CH2-phenyl-SO2CH3, —CH2-phenyl-NHSO2CF3, —CH2-phenyl-NHSO2CH3, —CH2-phenyl-NHSO2CHF2, —CH2-pyridyl-CH3, —CH2-pyridyl-SO2CH3, —CH2-pyridyl-CH2CONH2, —CH2-pyrimidyl-NHSO2CH3, —CH2-piperidyl-COCH3, —CH2-piperidyl-SO2CH3, —CH2-piperidyl-SO2CF3, —CH2-thienyl-CH2CO2H, —CH2-cyclobutyl-CH2CO2H, —CH2-cyclobutyl-CH2CONH2, —CH2-cyclobutyl-CO2H, —CH2-cyclobutyl-CONH2, —CH2-tetrahydrothiopyryl, —CH2-cyclopentyl, —CH2-cyclohexyl, —CH2-tetrahydrofuranyl, —CH2-tetrahydropyranyl, —CH2-oxetanyl, and —CH2-pyranyl.
- Some embodiments relate to R6a and R6b being taken together to form a ring system selected from substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted C2-9 heteroalicyclyl.
- Ring system B in compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein is not intended to be particularly limited, unless otherwise indicated. In some embodiments, ring system B is a mono- or bicyclic aryl, a mono- or bicyclic heteroaryl, or a bicyclic heteroalicyclyl. Further, ring system B may be a monocyclic heteroalicyclyl. Ring system B may, but need not, be substituted with at least one of R4a or R4b that is a non-hydrogen substituent. Compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein, may also have a ring system B that is a mono-cyclic, 6-membered aryl or heteroaryl substituted with R4a. In some embodiments ring system B is selected from the group consisting of phenyl, pyridyl, pyridazinyl, pyrimidinyl, naphthyl and furanyl, such as from the group consisting of phenyl, pyridyl, and pyrimidinyl. Some embodiments ring system B is selected from the group consisting of phenyl, and pyridyl. In some embodiments, n is an integer selected from 1, 2, 3 and 4. Alternatively, n may be 0 meaning that R4a will be the only substituent on ring system B.
- In some embodiments, the ring B is a bicyclic ring system, such as bicyclic aryl, bicyclic heteroaryl, or bicyclic heteroalicyclyl ring systems, e.g. benzazepine, benzazocines, benzimidazole, benzimidazoline, benzodioxin, benzodioxole, benzofuran, benzoisothiazole, benzothiadiazine, benzothiadiazole, benzothiazepine, benzothiazine, benzothiazole, benzothiophene, benzotriazole, benzoxadiazole, benzoxathiole, benzoxazepine, benzoxazine, benzoxazole, benzisoxazole, benzodioxole, chromane, chromene, coumarin, cyclopentapyridine, cyclopentapyrimidine, diazanaphthalene, dioxolopyridine, dioxolopyrimidine, dihydrobenzodioxine, dihydrobenzooxathiine, furofuran, furopyridine, furopyridine, furopyrimidine, imidazopyridine, imidazopyrimidines, indane, indazole, indene, indole, indoline, indolizines, isobenzofuran, isochromenes, isoindole, isoindoline, isoquinoline, naphthalene, naphthyridine, oxathiolopyridine, oxathiolopyrimidine, oxazolopyridine, oxazolopyrimidine, pteridine, purine, pyranopyridine, pyranopyrimidine, pyrazolodiazepines, pyrazolopyridine, pyrazolopyrimidine, pyridobenzthiazine, pyridodiazepene, pyridooxazine, pyridopyrazine, pyridopyrimidine, pyridothiazine, pyrimidooxazine, pyrimidopyrimidine, pyrimidothiazine, pyrrolizine, pyrroloimidazole, pyrrolopyrazine, pyrrolopyridine, pyrrolopyrimidine, quinazoline, quinoline, quinolone, quinolizidine, quinoxaline, tetralin, thiazolopyridine, thiazolopyrimidine, thienodiazepine, thienopyridine, thienopyrimidine, thiochromane, thiochromene, thiopyranopyridine, thiopyranopyrimidine, triazolopyridazine, triazolopyridine or triazolopyrimidine, all of which may be unsubstituted or substituted.
- Like ring system B, the ring system C in compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein, is not intended to be particularly limited in scope, unless otherwise specified. According to one embodiment, ring system C is a C2-9 heteroalicyclyl In some embodiments ring system C is a 4-7-membered heteroalicyclyl. For example, ring system C may be pyrrolidinyl or morpholinyl.
- The integer values of n and m may take any particular combination. In one embodiment, m is 1 or 2. Further, m may be 0 (zero) meaning that the ring system C is unsubstituted. In another embodiment, n is an integer selected from 1, 2, 3 and 4. Alternatively, n may be 0 meaning that R4a will be the only substituent on ring system B. Alternatively, n may be 0 and R4a hydrogen, i.e. the ring system B is unsubstituted.
- According to yet another embodiment, the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein, have R5 being —(CR8R9)p-C(═O)NR8R9; R8 and R9 are independently of each other selected from H and substituted or unsubstituted C1-6 alkyl; p is 0; and R6b is hydrogen or —(CH2)C(CH3)3.
- Compounds disclosed herein may also comprise compounds of Formula (IIb):
- wherein:
- C is a pyrrolidine ring or a morpholine ring;
- R1 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, and substituted or unsubstituted C1-4 alkoxy; some compounds of Formula (IIb) have an R1 that is hydrogen or —CF3;
- R3 is independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-4 alkyl, and halogen;
- R4a is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C1-6 alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl-C1-6 alkyl; some compounds of Formula (IIb) have an R4a that is selected from the group consisting of halogen, —CF3, —OCF3, iso-propyl, tert-butyl, —C1-6 alkoxy, C1-6 alkoxy substituted with one or more halogens, and phenyl;
- R4b is independently selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, —C(═O)R10;
- R5 is selected from the group consisting of substituted or unsubstituted C3-7 cycloalkyl, substituted or unsubstituted C3-7 cycloalkenyl, substituted or unsubstituted C2-6 heteroalicyclyl, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl;
- R6a are R6b are independently selected from the group consisting of hydrogen and substituted or unsubstituted C1-6 alkyl; and
- m is an integer independently selected from the group consisting of 1, 2, and 3; and
- n is an integer independently selected from the group consisting of 1, 2, 3, and 4.
- In compounds of Formula (IIb), R5 may be selected from the group consisting of substituted or unsubstituted C4-7 cycloalkyl, substituted or unsubstituted C6-12 membered aryl, substituted or unsubstituted 4-membered heteroalicyclyl, substituted or unsubstituted 5-membered heteroaryl, substituted or unsubstituted 5-membered heteroalicyclyl, substituted or unsubstituted 6-membered heteroaryl, a substituted or unsubstituted 6-membered heteroalicyclyl, substituted or unsubstituted 7-membered heteroaryl, and a substituted or unsubstituted 7-membered heteroalicyclyl. Thus, R5 may be selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, azetidinyl, thietanyl, pyrrolyl, pyrazoleyl imidazolyl, pyrrolidinyl, imidazolinyl, pyrazolidinyl, thiazolidinyl, isothiazolidinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, oxathianyl thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxolanyl, dioxanyl, furyl, dihydrofuranyl, furazanyl, tetrahydrofuryl, pyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, dithiolanyl, dithianyl, thiopyranyl, thianyl, thienyl, oxetanyl, quinolyl, isoquinolyl, indolyl, iso-indolyl, and tetrahydrothienyl, any of which may be substituted or unsubstituted. Especially, R5 may be selected from the group consisting of cycloheptyl, cyclohexyl, cyclopentyl, dioxanyl, furyl, imidazolyl, isothiazolyl, isoxazolyl, morpholinyl, oxazolyl, oxetanyl, oxathianyl, phenyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolidinyl, pyrrolyl, tetrahydrofuryl, tetrahydropyranyl, tetrazolyl, thianyl, thiazolyl, thienyl, thiomorpholinyl, thiopyryl, and triazolyl, any of which may be substituted or unsubstituted.
- If substituted, R5 may be substituted with —(CH2)q(R5a), wherein R5a is independently selected from the group consisting of —CH2COOR20, —CH2CONR21R22, oxo, —CN, —CH2—CN, C1-6 alkyl, —CH2-imidazolyl, —CH2—SO2R20, —CH2C(CH3)2(OR20), —OR20, —CH2-triazolyl, —CF3, dimethyl substituted-imidazolyl-2,4-dione, —CH2—SO2NR21R22, morpholinyl, —C(═O)-morpholinyl, piperidyl-CH2OR20, —OCH2-tetrahydrofuryl, piperazinonyl, piperidinyl-CONR21R22, —OH, —CONR21R22, —CH(OR20)CH3, —COOR20, —CH2-pyrrolidyl, C1-6 alkylene-OH, cyclopentyl, pyrrolidonyl, —NR21SO2R20, tetrazolyl, —CH2-tetrazolyl, —CH2OR20, acyl, —SOR20, —SO3R20, —SO2R20, —SO2NR21R22, and halogen;
- R20, R21, and R22 are independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, —CN, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted C2-6 heteroalicyclyl; and
- q is an integer selected from 0, 1 or 2.
- Further, R5 may be selected from the group consisting of unsubstituted aryl, unsubstituted heteroaryl, aryl substituted with one or more C1-6 alkoxy, aryl substituted with —CH2COOC1-6 alkyl, aryl substituted with —CH2CONH—(C1-6 alkyl), aryl substituted with CH2CON(C1-6 alkyl)2, —(CH2)—C(═O)OR7, —C(═O)OR7, —(CH2)—C(═O)NR8R9 or —C(═O)NR8R9, heteroaryl substituted with —(CH2)—C(═O)NR8R9 or SO2R7, and C2-9 heteroalicyclyl substituted with —(CH2)—C(═O)NR8R9 or SO2R7;
- R7, R8, and R9 are independently selected from the group consisting of hydrogen, unsubstituted C1-6 alkyl, and C1-6 alkylene substituted with furanyl.
- Compounds disclosed herein may also comprise compounds of Formula (IIc):
- wherein:
- R3 is hydrogen, fluorine or methyl;
- R4a is selected from the group consisting of hydrogen, fluorine, chlorine, —C(CH3)3, —CH2(CH3)2, —CF3, —OCH3, —OC(CH3)3, and —OCF3;
- R4b is selected from the group consisting of hydrogen, fluorine, chlorine, and —OCH3;
- m and n are integers independently selected from 1 or 2;
- Y is OR7 or NR8R9;
- R7, R8, and R9 are independently selected from H and C1-6 alkyl; and
- B is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, 2-benzothiazolyl, quinolinyl, and 1,4-benzodioxanyl; and
- C is pyrrolidinyl or morpholinyl.
- Compounds disclosed herein may also comprise compounds of Formula (IId):
- wherein:
- B is selected from phenyl, pyridyl and pyrimidyl;
- C is pyrrolidinyl or morpholinyl;
- R4a is a substituent arrange in para- or meta-position compared to the carbon atom in the ring system C, and selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl (for example —CF3), C1-4 haloalkoxy (for example —OCF3), and heteroaryl;
- R5 is a ring selected from the group consisting of phenyl, pyrimidinyl, pyridyl, pyridinyl-N-oxide, cyclohexyl, pyrrolyl, pyrazolyl, furanyl, pyrrolidonyl, tetrahydrofuranyl, tetrahydropyranyl, benzopyrrolidonyl, cyclobutyl, oxetanyl, tetrahydrothiophenyl, tetrahydro-2H-thiopyranyl, cyclopentyl, cycloheptanyl, tetrahydrothiophenyl-1,1-dioxide, tetrahydro-2H-thiopyranyl-1,1-dioxide, 1,4-oxathianyl-4,4-dioxide, and piperidinyl, any of which may be unsubstituted or substituted with (R5b)t;
- R5b, when present, is independently selected from the group consisting of —CH2COOR20, —CH2CONR21R22, oxo, —CN, —CH2—CN, —C1-6 alkyl, —CH2-imidazolyl, —CH2—SO2R20, —CH2C(CH3)2(OR20), —OR20, —CH2-triazolyl, —CF3, dimethyl substituted-imidazolidinyl-2,4-dione, —CH2—SO2NR21R22, morpholinyl, —C(═O)-morpholinyl, piperazinonyl, piperidinyl-CONR21R22, —OH, —COR20, —CONR21R22, —CH(OR20)CH3, —COOR20, —CH2-pyrrolidonyl, —C1-6-alkylene-OH, -cyclopentyl, -pyrrolidonyl, -tetrazolyl, —CH2-triazolyl, —CH2OR20, -acyl, —SOR20, —SO2R20, —SO2NR21R22, —NR21SO2R20, and halogen;
- R20, R21, and R22 are independently selected from H, —C1-6 alkyl, —C1-6 haloalkyl, —C3-6 cycloalkyl, and —C1-6 heteroalicyclyl; and
- t is an integer selected from 1 or 2.
- Compounds disclosed herein may also comprise compounds of Formula (IIe):
-
- or pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and stereoisomers thereof, wherein:
- n, p and v are an integer selected from 0, 1 and 2;
- R is hydrogen or C1-4 alkyl;
- R1 is selected from the group consisting of hydrogen, —OH, halogen, substituted or unsubstituted C1-4 alkyl, and substituted or unsubstituted C1-4 alkoxy;
- R2 is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, and C1-4 hydroxyalkyl;
- or R and R2 are combined to form a fused ring;
- R3 is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, oxo, and —C(═O)R10;
- R4a is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C1-6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroaryl-C1-6 alkyl;
- R4b is selected from the group consisting of hydrogen, oxo, halogen, —OH, substituted or unsubstituted C1-4 alkyl, and substituted or unsubstituted C1-4 alkoxy, —C(═O)R10;
- R5a is selected from the group consisting of hydrogen, halogen, oxo, —CN, —OH, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C1-6 alkyl, substituted or unsubstituted C2-C8 heteroalicyclyl, substituted or unsubstituted C2-C8 heteroalicyclyl-C1-6 alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl-C1-6 alkyl, —(CH2)qCO2R20, —(CH2)q—CONR20R21, —(CH2)q—SOR20, —(CH2)q—SO2R20, —(CH2)q—SO2NR21R22, and —(CH2)qNR21SO2R20;
- q is an integer selected from 0 or 1;
- R20, R21, and R22 are independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, —CN, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-6 heteroalicyclyl, or R21 and R22 are combined to form a C3-6 cycloalkyl;
- R6a, R6b are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C1-6 heteroalkyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, or R6a and R6b are taken together to form and oxo group or a ring system selected from substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl, or R6a and R13 are taken together to form a ring system selected from substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-5 heteroalicyclyl;
- R7, R8, and R9 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl;
- R10 is selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, —OH, —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, and C3-7 cycloalkyl;
- R13, if not to be taken together with R6a, is absent, or selected from the group consisting of hydrogen, —CN, —OH, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, and —(CR8R9)p-C(═O)OR7, —(CR8R9)p-SO2R7 and —(CR8R9)p-C(═O)NR8R9;
- B is a ring system selected from the group consisting of aryl, heteroaryl, and, C2-C9 bicyclic heteroalicyclyl;
- D is a ring system selected from the group consisting of aryl, heteroaryl, C3-8 cycloalkyl and, C2-C9 heteroalicyclyl,
- C is a ring system selected from C2-9 heteroalicyclyl, and
- with the proviso the compound is not:
- Some embodiments relates to the compound according to Formula (IIe) wherein
- R3 is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, oxo, C1-4 alkoxy and C1-4 haloalkoxy;
- R4a is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, and heteroaryl;
- R4b is selected from the group consisting of hydrogen, oxo, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, and C1-4 haloalkoxy;
- R6a is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, and C1-6 haloalkoxy;
- R6b is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, C1-6 haloalkoxy, aryl-C1-6 alkyl, substituted or unsubstituted C2-9 heteroalicyclyl-C1-6 alkyl, and substituted or unsubstituted aryl;
- or R6a and R6b are taken together to form and oxo group or a ring system selected from substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl,
- or R6a and R13 are taken together to form a ring system selected from substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-5 heteroalicyclyl;
- In some embodiments the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein, B is aryl or heteroaryl, for example phenyl, pyridyl, pyrazolyl, pyridazinyl, pyrimidinyl, naphthyl and furanyl, unless otherwise specified. Some embodiments relates to B being phenyl, pyrimidyl or pyridyl.
- In some embodiments the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein, B is a 6-membered aryl substituted with R4a in the para-position or meta-position, a 6-membered heteroaryl substituted with R4a in the para-position or meta-position, or a 5-membered heteroaryl substituted with R4a in 2- or 3-position, unless otherwise specified. In some embodiments the 6-membered aryl is phenyl and the 6-membered heteroaryl is pyridyl or pyrimidinyl. Some embodiments relate to R4a being selected from the group consisting of halogen, —CN, C1-4 alkyl, C1-4 haloalkyl, C1-C4 alkoxy, C1-4 haloalkoxy and heteroaryl, for example isopropyl, —CN, ethoxy, CF3, and —OCF3. Some embodiments relate to R4b being selected from the group consisting of hydrogen, oxo, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-C4 alkoxy, C1-4 haloalkoxy, and heteroaryl. Some embodiments relate to R4a being selected from the group consisting of halogen, —CN, C1-4 alkyl, C1-4 haloalkyl, C1-C4 alkoxy, and C1-4 haloalkoxy, for example isopropyl, ethoxy, —CF3, —CHF2, —OCF3, and —OCHF2 and R4b being selected from the group consisting of hydrogen, halogen, and —OH.
- In some embodiments the compounds of Formulae (IIe), D is selected from the group consisting of aryl, such as phenyl; heteroaryl, such as pyridyl, and pyrimidyl; C3-8 cycloalkyl, such as cyclohexyl; and C2-8 heteroalicyclyl, such as piperidyl, tetrahydro-2H-pyranyl, thiopyranyl, tetrahydro-2H-thiopyranyl, tetrahydro-2H-thiopyranyl-1,1-dioxide, pyrrolidinyl, thianyl and oxetanyl, all which may be substituted with one or more R5a. Some embodiments relates to R5a being selected from hydrogen, C1-6 alkyl, such as methyl and ethyl; C1-6 hydroxyalkyl, such as methanol and ethanol; —(CH2)q—CN; —(CH2)q—CO2R20; —(CH2)q—C1-6 alkoxy, such as methoxy and ethoxy and methoxyethyl; oxo, —(CH2)q-heteroaryl, such as —(CH2—)q-tetrazolyl, —(CH2—)q-imidazolyl, —(CH2—)q-triazolyl; —(CH2—)q—CONR20R21; —(CH2—)q—COR20; —(CH2—)q—SO2R20; —(CH2—)q—NR21SOR20; and —(CH2—)q—SO2NR21R22;
- R20, R21, and R22 are independently of each other selected from the group consisting of hydrogen, —OH, substituted or unsubstituted C1-6 alkyl, —CN, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-6 heteroalicyclyl, or R21 and R22 are combined to form a C3-6 cycloalkyl; and
- q is an integer selected from 0 or 1.
- As for any given group disclosed herein, the ring system D may comprise further hydrogen(s) than the one(s) provided by R5a being hydrogen.
- In some embodiments R20, R21, and R22 are independently of each other selected from the group consisting of hydrogen, methyl, ethyl, cyclopropyl, —CF3, and —CHF2,
- In some embodiments the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein, R13 is absent, or selected from the group consisting of hydrogen, —OH, —CN, C1-4 hydroxyalkyl, C1-6 haloalkyl, —(CH2—)qCO2H, —(CH2—)q—SO2R20, —(CH2—)q—NR21SO2R20 and C1-6 alkoxy, or R13 combined with the atom to which it is attached and an adjacent R5a to form a C3-5 cycloalkyl, or C2-4 heteroalicyclyl.
- In some embodiments the compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein, R6a is hydrogen, or combined with R5a, R6b or R13 to form ring system such as a C3-6 cycloalkyl or C2-5-heteroalicyclyl; R6b is hydrogen or absent. In some embodiments both R6a and R6b are hydrogen.
- In some embodiments the compounds according to Formula (IIe)
- R is hydrogen; R2 is selected from Cl or F; or R and R2 are combined to form a pyrrolo[2,3-d]pyrimidine, 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine;
- m is an integer selected from 0, 1 and 2;
- n is an integer selected from 0 and 1;
- v is an integer selected from 0 and 1;
- R3 is hydrogen or fluoro
- B is aryl or heteroaryl, for example phenyl, pyridyl, pyrazolyl, pyridazinyl, pyrimidinyl, naphthyl or furanyl;
- C is C2-9 heteroalicyclyl, for example pyrrolidinyl or morpholinyl;
- R4a is selected from the group consisting of halogen, C1-4 alkyl, C1-4 haloalkyl, C1-C4 alkoxy, C1-4 haloalkoxy and heteroaryl, for example —CF3, —CHF2, —OCF3, —OCHF2, and triazolyl;
- R4b is selected from the group consisting of hydrogen, —OH, oxo, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-C4 alkoxy, C1-4 haloalkoxy, and heteroaryl.
- D is selected from the group consisting of aryl, such as phenyl; heteroaryl, such as pyridyl, and pyrimidyl; C3-8 cycloalkyl, such as cyclopentyl and cyclohexyl; and C2-8 heteroalicyclyl, such as a mono-cyclic or a bridged C2-8 heteroalicyclyl, such as piperidyl, tetrahydro-2H-pyranyl, thiopyranyl, tetrahydro-2H-thiopyranyl, tetrahydro-2H-thiopyranyl-1,1-dioxide, oxetanyl, tropanyl, and pyrrolidinyl, all which may be substituted with one or more R5a;
- R5a is selected from halogen, C1-6 alkyl, such as methyl and ethyl; C1-6 hydroxyalkyl, such as methanol and ethanol; C1-6 haloalkyl, such as —CF3, —(CH2)q—CN; —(CH2)q-acyl; —(CH2)q—C1-6 alkoxy, such as methoxy and ethoxy and methoxyethyl; —(CH2)q-heteroaryl, such as —(CH2—)q-tetrazolyl, —(CH2—)q-imidazolyl, —(CH2—)q-triazolyl; —(CH2—)q—CONR20R21; —(CH2—)q—COR20; —(CH2—)q—SO2R20; —(CH2—)q—NR21SOR20; —(CH2—)q—SO2NR21R22;
- R20, R21, and R22 are independently of each other selected from the group consisting of hydrogen, —OH, substituted or unsubstituted C1-6 alkyl, —CN, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-6 heteroalicyclyl, or R21 and R22 are combined to form a C3-6 cycloalkyl; and
- q is an integer selected from 0 or 1;
- R13 is absent, or selected from the group consisting of hydrogen, —OH, —CN, C1-4 hydroxyalkyl, C1-6 haloalkyl, —(CH2—)q—SO2R20, —(CH2—)q—NR21SO2R20 and C1-6 alkoxy, or R13 combined with the atom to which it is attached and an adjacent R5a to form a C3-5 cycloalkyl, or C2-4 heteroalicyclyl; In some embodiments R13 is absent or hydrogen.
- R6a is hydrogen, or combined with R5a, R6b or R13 to form ring system such as a C3-6 cycloalkyl or C2-5-heteroalicyclyl; R6b is hydrogen or absent; for example both R6a and R6b are hydrogen.
- In such an embodiment, B may be phenyl or pyridyl. Further, B may be phenyl with R4a in the para-position or meta-position, or a 6-membered heteroaryl substituted with R4a in the para-position or meta-position, or a 5-membered heteroaryl substituted with R4a in 2- or 3-position, wherein R4a is selected from a group other than hydrogen.
- According to one aspect disclosed herein are compounds of Formula (X)
- or pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and stereoisomers thereof, wherein:
- Y1 is NR or O;
- Y2 is N or C;
- R is hydrogen or substituted or unsubstituted C1-4 alkyl;
- R1 is selected from the group consisting of hydrogen, —OH, halogen, —CN, —NO2, —NH2, alkylamino, amide, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, carbonyl, thisocarbonyl, C amido, N amido, S-sulfonamido, N sulfonamide, silyl, sulfenyl, sulfinyl, sulfonyl, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C1-6 heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C3-9 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C2-9 heteroaliyclyl;
- R2 is selected from the group consisting of hydrogen, —OH, halogen, —CN, —NO2, —NH2, alkylamino, amide, acyl, ester, O-carboxy, mercapto, alkylthio, arylthio, carbonyl, thisocarbonyl, C amido, N amido, S-sulfonamido, N sulfonamide, silyl, sulfenyl, sulfinyl, sulfonyl, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C1-6 heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C3-9 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C2-9 heteroaliyclyl;
- or R and R2 are combined to form a fused ring;
- R4a is selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl-C1-6 alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl-C1-6 alkyl;
- R3 and R4b are independently selected from the group consisting of hydrogen, halogen, —OH, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, —C(═O)R10;
- R5 is selected from the group consisting of —(CR8R9)pOR12, —(CR8R9)p-CR13R14R15, —(CR8R9)p-C(═O)OR7, and —(CR8R9)p-C(═O)NR8R9;
- n, m, and p are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
- R6a, R6b are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C1-6 alkynyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C1-6 heteroalkyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- R7, R8, R9, and R12, are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-6 cycloalkyl, and substituted or unsubstituted C2-9 heteroalicyclyl;
- R10 is selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, and C3-7 cycloalkyl;
- R13 is absent, or selected from the group consisting of hydrogen, —OH, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, and —(CR8R9)p-C(═O)OR7, and —(CR8R9)p-C(═O)NR8R9;
- R14 and R15 are independently selected from the group consisting of hydrogen, and substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted C2-9 heteroalicyclyl; or
- R14 and R15 are combined to form a ring system selected from the group consisting of substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl substituted or unsubstituted C2-9 heteroalicyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
- A, B and C are independently of each other a ring system selected from the group consisting of aryl, heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, and C2-9 heteroaliyclyl.
- In a related embodiment A is selected from the group consisting of phenyl, pyridyl, pyrrolyl, furyl, pyranyl, thiopyranyl, thienyl, pyrazinyl, pyrimidinyl, triazinyl, naphthyl, indolyl, iso-indolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, and oxazolyl. In yet a related embodiment A is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, and wherein R1 is arranged in position 1 of the 6 membered ring, R1 is arranged in
position 4 of the 6 membered ring, Y1 arranged in position 3 of the 6 membered ring, Y2 arranged inposition 5 of the 6 membered ring. In a related embodiment R1 is selected from the group consisting of hydrogen, —OH, halogen, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, and substituted or unsubstituted C2-4 alkenyl; and R2 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, —CN, —OH and —NO2; or R and R2 are combined to form a fused ring; - In yet a related embodiment B is a ring system selected from the group consisting of aryl, heteroaryl, and bicyclic heteroalicyclyl; C is a ring system selected from the group consisting of C2-9 heteroalicyclyl and heteroaryl; wherein B is attached to a carbon atom adjacent the N atom of ring system C.
- In some embodiments whenever a halogen is specified as a substituent the halogen is selected from fluoro or chloro.
-
FIG. 1 illustrates the TAMRA-labelled probe. -
FIG. 2 illustrates the characterisation of the Fluorescence Polarization (FP) assay with the TAMRA-labelled probe used in the FP assay. -
FIG. 3 depicts the assay results of example no. 89 in (A) Fluorescence Polarization Assay, (B) RORγ Reporter Assay (Gal4), and (C) Th17 Assay. Specific examples of compounds are disclosed in Table 1 below. -
-
TABLE 1 Example Compounds by Structure and Name. Ex. No. Structure Name 4 3-[[2-[4-[2-(4- phenylphenyl)pyrrolidin-1- yl]pyrrolo[2,3-d]pyrimidin-7- yl]butanoylamino]methyl]furan-2- carboxamide 5 (2R)-2-[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide or (2R)-2- [[5-fluoro-6-[(2S)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl- pentanamide 6 (2R)-4,4-dimethyl-2-[[6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino] pentanamide 9 (2R)-2-[[6-[2-(1,3-benzothiazo1-2- yl)pyrrolidin-1-yl]-5-fluoro- pyrimidin-4-yl]amino]-3-(2,4,5- trifluorophenyl)propanamide 11 (2R)-2-[[6-[2-(2,4- dichlorophenyl)pyrrolidin-1-yl]-5- fluoro-pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 13 (2R)-2-[[5-fluoro-2- (trifluoromethyl)-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 14 (2R)-4,4-dimethyl-2-[[5-methyl-6- [2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]pentanamide 15 (2R)-2-[[2,5-dimethyl-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 16 5-fluoro-N-(3-methoxy-1,3- dimethyl-butyl)-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 17 (2R)-2-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-3-(4- methoxyphenyl)propanamide 18 (2R)-2-[[5-fluoro-6-[4-methyl-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 19 (2R)-2-[[6-[2-(4-tert- butylphenyl)pyrrolidin-1-yl]-5- fluoro-pyrimidin-4-yl]amino]-4,4- dimethyl- pentanamide 20 (2R)-2-[[5-fluoro-6-[3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 21 N-(3,3-dimethylbutyl)-5-fluoro-6- [2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 23 (2R)-2-[[5-fluoro-6-[2-(6- quinolyl)pyrrolidin-1-yl]pyrimidin- 4-yl]amino]-4,4-dimethyl- pentanamide 24 (2R)-2-[[6-[2-(2,3-dihydro-1,4- benzodioxin-6-yl)pyrrolidin-1-yl]-5- fluoro-pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 29 (2R)-2-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-3-(4- methoxyphenyl)propan-1-ol 30 (2R)-2-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentan-1-ol 31 (2R)-2-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]-methyl- amino]-N,4,4-trimethyl- pentanamide 32 2-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetic acid 33 (2R)-2-[[5-fluoro-6-[4-methyl-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4- methyl-pentanoic acid 34 (2R)-2-[[5-fluoro-6-[4-methyl-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4- methyl-pentanamide 35 (2R)-2-[[6-[2-[2-chloro-4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-5-fluoro-pyrimidin-4- yl]amino]-4,4-dimethyl- pentanamide 36 (2R)-2-[[6-[2-[2-chloro-4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-5-fluoro-pyrimidin-4- yl]amino]-4,4-dimethyl-pentanoic acid 37 (2R)-2-[[5-fluoro-6-[4-methyl-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-3-(4- fluorophenyl)propanamide 38 (2R)-2-[[5-fluoro-6-[3-methyl-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 39 (2R)-2-[[3-fluoro-2-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-4-pyridyl]amino]-4,4- dimethyl- pentanamide 40 2-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 41 5-fluoro-N-(1-methyl-2- tetrahydropyran-4-yl-ethyl)-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 42 (2R)-2-[[5-fluoro-6-[2-[5- (trifluoromethyl)-2- pyridyl]pyrrolidin-1-yl]pyrimidin-4- yl]amino]-4,4-dimethyl- pentanamide 43 (2R)-2-[[6-[2-(4-tert- butoxyphenyl)pyrrolidin-1-yl]-5- fluoro-pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 44 4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]benzoic acid 45 3-[[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]methyl]- 5,5-dimethyl-imidazolidine-2,4- dione 46 [4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]methane- sulfonamide 48 5-fluoro-N-[[4- (trifluoromethyl)phenyl]methyl]-6- [2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 51 (2R)-3-tert-butoxy-2-[[5-fluoro-6- [2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]butanamide 52 (2R)-2-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-3- tetrahydropyran-4-yl-propanamide 53 N-[(3,4-dimethoxyphenyl)methyl]- 5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 54 N-[(2,3-dimethoxyphenyl)methyl]- 5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 55 N-[1-(3,4-dihydro-2H-1,5- benzodioxepin-7-yl)propyl]-5- fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 56 5-fluoro-N-[(4- morpholinophenyl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 57 [4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]- morpholino-methanone 58 [1-[5-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]methyl]- 2-pyridyl]-4-piperidyl]methanol 59 5-fluoro-N-[[4-(tetrahydrofuran-2- ylmethoxy)phenyl]methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- amine 60 4-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]piperazin- 2-one 61 1-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]piperidine- 3-carboxamide 62 (2R)-2-[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide or (2R)-2- [[5-fluoro-6-[(2S)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 63 (2R)-2-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-3-(2- oxopyrrolidin-3-yl)propanamide 64 N-[(1R)-3,3-dimethyl-1-morpholin- 2-yl-butyl]-5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 65 (2R)-2-[[5-fluoro-6-[2-[2-methoxy-4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 66 3-fluoro-N-[(6-methyl-3- pyridyl)methyl]-4-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyridin-2-amine 67 1-[(3,4-dimethoxyphenyl)methyl]-4- [2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrrolo[2,3-b]pyridine 68 (2R)-2-[[5-fluoro-6-[3-[4- (trifluoromethoxy)phenyl]morpholin- 4-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 69 7-[(3,4-dimethoxyphenyl)methyl]-4- [2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrrolo[2,3-d]pyrimidine 70 methyl 2-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetate 71 1-[2-[(1R)-1-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-3,3- dimethyl-butyl]morpholin-4- yl]ethanone 72 (2R)-2-[[5-fluoro-6-[2-[3-fluoro-4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanamide 73 5-fluoro-4-[2-[3-fluoro-4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-6-[(6-methyl-3- pyridyl)methoxy]pyrimidine 74 5-fluoro-4-[(6-methyl-3- pyridyl)methoxy]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidine 77 (2R)-2-[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]oxy-4-methyl- pentanamide or (2R)-2-[5-fluoro-6- [(2S)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]oxy-4-methyl- pentanamide 78 (2R)-2-[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]oxy-4-methyl- pentanamide or (2R)-2-[5-fluoro-6- [(2S)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]oxy-4-methyl- pentanamide 79 2-[4-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]oxymethyl]phenyl] acetic acid 80 (2R)-2-[5-fluoro-6-[5-[4- (trifluoromethyl)phenyl]pyrazol-1- yl]pyrimidin-4-yl]oxy-4-methyl- pentanamide 81 2-[4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetic acid 83 2-[4-[[5-fluoro-6-[[4- (trifluoromethyl)phenyl]methylamino] pyrimidin-4- yl]oxymethyl]phenyl]acetic acid 84 2-[4-[[5-fluoro-6-[2-[6- (trifluoromethyl)-3- pyridyl]pyrrolidin-1-yl]pyrimidin-4- yl]oxymethyl]phenyl]acetamide 85 2-[4-[[4-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrrolo[2,3-d]pyrimidin-7- yl]methyl]phenyl]acetic acid 86 2-[5-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]oxymethyl]pyrimidin-2- yl]acetamide 87 2-[5-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]pyrimidin-2- yl]acetamide 88 4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl] benzonitrile 89 5-fluoro-N-[(6-methyl-3- pyridyl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 90 5-fluoro-6-[2-(4- methoxyphenyl)pyrrolidin-1-yl]-N- [(6-methyl-3- pyridyl)methyl]pyrimidin-4-amine 91 2-[4-[[[5-fluoro-6-[3-[4- (trifluoromethoxy)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetic acid 93 5-fluoro-N-[(4- methylcyclohexyl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 94 5-fluoro-N-[[4-(imidazol-1- ylmethyl)phenyl]methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 95 5-fluoro-N-[[4- (methylsulfonylmethyl)phenyl] methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 96 5-fluoro-N-[(6-methyl-3- pyridyl)methyl]-6-[5-[4- (trifluoromethyl)phenyl]triazol-1- yl]pyrimidin-4-amine 97 5-fluoro-N-[(6-methyl-3- pyridyl)methyl]-6-[2-[4- (trifluoromethoxy)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 98 1-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]-2-methyl- propan-2-ol 99 5-fluoro-N-[(2-methoxy-6-methyl- 3-pyridyl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- amine 100 5-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]pyridin-2-ol 104 2-[1-[5-fluoro-6-[(6-methyl-3- pyridyl)methylamino]pyrimidin-4- yl]pyrrolidin-2-yl]-5- (trifluoromethyl)pheno1 105 5-fluoro-N-[(1-methylpyrrol-3- yl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 106 5-fluoro-N-[(1-methylpyrazo1-4- yl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 107 5-fluoro-N-[(5-methyl-2- furyl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 108 5-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]pyrrolidin-2-one 109 4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]methyl]- 1-methyl-pyrrolidin-2-one 110 5-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]methyl]- N,N-dimethyl-tetrahydrofuran-2- carboxamide 111 5-fluoro-N-[(4- methoxytetrahydropyran-4- yl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 112 1-[6-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]methyl]- 2-methyl-3-pyridyl]ethanol 113 5-fluoro-N-[(2-methoxy-4- pyridyl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 114 5-fluoro-N-[(6-methoxy-3- pyridyl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 115 5-fluoro-N-[[4-(1,2,4-triazol-1- ylmethyl)phenyl]methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 116 5-fluoro-N-[(6-methoxy-3- pyridyl)methyl]-N-methyl-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 117 2-[4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetic acid 118 2-[4-[[[5-fluoro-6-[(2S)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetic acid 119 2-[4-[[[5-fluoro-6-[3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetic acid 120 4-[2-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]ethyl]benzoic acid 121 [3-[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]pyrrolidin-1-yl]-(4- pyridyl)methanone 122 5-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]indolin-2-one 123 5-fluoro-N-[3-methyl-1-(1H- tetrazol-5-yl)butyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 124 1-[[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]methyl] pyrrolidin-2-one 126 5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-N-[[6-(trifluoromethyl)-3- pyridyl]methyl]pyrimidin-4-amine 128 2-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]ethanol 129 4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]tetrahydropyran- 4-ol 130 1-cyclopentyl-4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]pyrrolidin-2-one 131 5-fluoro-N-[(4-methoxy-2- pyridyl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 132 5-fluoro-N-[(6-methyl-2- pyridyl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 134 9-[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]-3,9- diazaspiro[4.5]decan-2-one 135 4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]-methyl- amino]methyl]-1-methyl-pyrrolidin- 2-one 136 N-[(5-ethyl-2-pyridyl)methyl]-5- fluoro-N-methyl-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 137 1-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]pyrrolidin- 2-one 138 5-fluoro-N-[[4-(1H-tetrazol-5- yl)phenyl]methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 139 N-benzyl-5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 140 5-fluoro-N-(4-pyridylmethyl)- 6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 141 5-fluoro-N-(3-pyridylmethyl)- 6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 142 N-[(3,5-dimethoxyphenyl)methyl]- 5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 143 1-[3-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]pyrrolidin- 2-one 144 3-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]methyl]- N-methyl-benzamide 145 3-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]methyl]- N,N-dimethyl-benzamide 146 5-fluoro-N-[[3-(1,2,4-triazol-1- ylmethyl)phenyl]methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 147 5-fluoro-N-[[3- (methoxymethyl)phenyl]methyl]-6- [2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 148 2-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]cyclohexyl] acetic acid 150 5-fluoro-6-[2-(5-methyl-2- furyl)pyrrolidin-1-yl]-N-[(6-methyl- 3-pyridyl)methyl]pyrimidin-4- amine 151 N-(cyclobutylmethyl)-5-fluoro- 6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 152 5-fluoro-N-[(1- methylcyclobutyl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 154 5-fluoro-N-(tetrahydrofuran-3- ylmethyl)-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 155 5-fluoro-N-(tetrahydropyran-2- ylmethyl)-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 159 5-fluoro-N-(tetrahydrothiophen-2- ylmethyl)-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 161 5-fluoro-N-[(4- methyltetrahydropyran-4- yl)methyl]-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 164 5-fluoro-N-(tetrahydrothiopyran-4- ylmethyl)-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 165 3-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]tetrahydrothiophen- 3-ol 166 N-[(4,4- dimethylcyclohexyl)methyl]-5- fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 167 1-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]cycloheptanol 168 5-fluoro-N-[(2- methoxycyclohexyl)methyl]-6- [(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 169 4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]tetrahydrothiopyran- 4-o1 170 N-[(1,1-dioxothiolan-2-yl)methyl]- 5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 175 N-[(2-tert-butyltetrahydropyran-3- yl)methyl]-5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 178 5-fluoro-N-[(4- isopropylcyclohexyl)methyl]-6- [(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 181 5-fluoro-N-(tetrahydrofuran-2- ylmethyl)-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 182 4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]benzenesulfonamide 183 N-[(6-chloro-3-pyridyl)methyl]-5- fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 184 N-[(1,1-dioxothiolan-3-yl)methyl]- 5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 185 5-fluoro-N-(3-thienylmethyl)-6- [(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 186 5-fluoro-N-(tetrahydropyran-3- ylmethyl)-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 188 5-fluoro-N-[[1- (methoxymethyl)cyclobutyl]methyl]- 6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 189 2-[4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]-N-methyl- acetamide 190 5-fluoro-N-[[4-(1H-tetrazol-5- ylmethyl)cyclohexyl]methyl]-6- [(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 191 1-[4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]methyl]- 1-piperidyl]ethanone 192 2-[4-[[[5-fluoro-6-[2-[4- (trifluoromethoxy)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetic acid 193 5-fluoro-N-[(1-oxidopyridin-1-ium- 3-yl)methyl]-6-[(2R)-2[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 194 5-fluoro-N-[(1-oxidopyridin-1-ium- 4-yl)methyl]-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 195 2-[4-[[4-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrrolo[2,3-d]pyrimidin-7- yl]methyl]phenyl]acetic acid 196 2-[4-[[4-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrrolo[2,3-d]pyrimidin-7- yl]methyl]phenyl]acetamide 197 5-fluoro-N-[(1-methylsulfonyl-4- piperidyl)methyl]-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 198 5-fluoro-N-[(3-methyloxetan-3- yl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 199 5-fluoro-N-[(2- methyltetrahydrofuran-2- yl)methyl]-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- amine 200 2-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]cyclohexanol 201 5-fluoro-N-[(2- methyltetrahydrothiophen-2- yl)methyl]-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 202 N-[(4,4-dioxo-1,4-oxathian-2- yl)methyl]-5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 203 5-fluoro-N-(2-thienylmethyl)-6- [(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 204 2-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 205 2-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]cyclohexyl]acetic acid 206 2-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]cyclohexyl] acetamide 207 2-[5-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]methyl]- 2-thienyl]acetic acid 208 5-fluoro-N-(tetrahydropyran-4- ylmethyl)-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 209 5-fluoro-N-[(6-methyl-3- pyridyl)methyl]-6-[2-methyl-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 210 5-fluoro-6-[(2R)-2-[2-fluoro-4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-N-[(6-methyl-3- pyridyl)methyl]pyrimidin-4-amine 211 5-fluoro-N-[(6-methyl-3- pyridyl)methyl]-6-[4-methyl-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 212 5-fluoro-6-[4-methoxy-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-N-[(6-methyl-3- pyridyl)methyl]pyrimidin-4-amine 213 5-fluoro-N-[(5-methyloxazol-2- yl)methyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 214 5-(((5-fluoro-6-(2-(4- (trifluoromethyl)phenyl)pyrrolidin- 1-yl)pyrimidin-4-yl)amino)methyl)- 1,3,4-oxadiazol-2-ol 215 5-fluoro-N-[1-(5-methyl-1,2,4- oxadiazo1-3-yl)propyl]-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 216 5-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]isoxazol-3-ol 217 [3-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]methanol 218 N-(cyclopentylmethyl)-5-fluoro-6- [(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 219 5-fluoro-N-[(4- methylsulfonylphenyl)methyl]-6- [(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 220 3-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]tetrahydrofuran- 3-ol 221 2-[4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]tetrahydropyran-4- yl]ethanol 222 N-[(1,1-dioxothian-4-yl)methyl]-5- fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-amine 223 4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]methyl]- 1,1-dioxo-thian-4-ol 224 N-cyclopropyl-4-[[[5-fluoro-6- [(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]benzenesulfonamide 225 [4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]cyclohexyl] methanol 226 4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]benzamide 227 [4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]methanol 228 [3-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]oxetan-3- yl]methano1 229 2-[4-[[[5-fluoro-6-[2-methyl-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 230 2-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethoxy)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 231 2-[4-[[[6-[4,4-difluoro-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-5-fluoro-pyrimidin-4- yl]amino]methyl]phenyl]acetamide 232 2-[4-[[[5-fluoro-6-[(2R)-2-[2- fluoro-4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 233 1-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-yl]amino]methyl]- 1-piperidyl]ethanone 234 4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-yl]amino]methyl]- 1,1-dioxo-thian-4-ol 235 5-fluoro-N-[(3-methyloxetan-3- yl)methyl]-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 236 N-cyclopropyl-4-[[[5-fluoro-6- [(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl] benzenesulfonamide 237 5-fluoro-N-[(1-methylsulfonyl-4- piperidyl)methyl]-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 238 3-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]tetrahydrofuran- 3-ol 239 2-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]tetrahydropyran- 4-yl]ethanol 240 5-fluoro-N-[[4- (methylsulfonylmethyl) tetrahydropyran-4-yl] methyl]-6-[(2R)-2-[4- (trifluoromethyl)phenyl] pyrrolidin- 1-yl]pyrimidin-4-amine 241 2-[4-[[[5-fluoro-6-[(2R,4R)-4- fluoro-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide AND 2-[4-[[[5-fluoro-6-[(2S,4S)- 4-fluoro-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 242 2-[4-[[[5-fluoro-6-[(2S,4R)-4- fluoro-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide AND 2-[4-[[[5-fluoro-6-[(2R,4S)-4- fluoro-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 243 2-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethoxy)phenyl] morpholin-4-yl]pyrimidin-4- yl]amino]methyl]cyclohexyl]acetic acid 244 2-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]phenyl]-N-methyl- acetamide 245 2-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethoxy)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]cyclohexyl] acetamide 246 5-fluoro-N-[[4-(1H-tetrazol-5- ylmethyl)phenyl]methyl]-6-[(3S)-3- [4-(trifluoromethoxy)phenyl] morpholin-4-yl]pyrimidin-4-amine 247 5-fluoro-N-(tetrahydropyran-4- ylmethyl)-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 248 2-[4-[[[5-fluoro-6-[4-methyl-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 249 1-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl] cyclopentanecarboxamide 250 1-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-yl]amino]methyl]- N,N-dimethyl- cyclopentanecarboxamide 251 N-[2-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]cyclopentyl] methanesulfonamide 252 2-[4-[[4-[(3S)-3-[4- (trifluoromethoxy)phenyl] morpholin-4-yl]pyrrolo[2,3-d] pyrimidin-7- yl]methyl]phenyl]acetamide 253 5-fluoro-N-[[4- (methylsulfonylmethyl) tetrahydropyran-4-yl]methyl]-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 254 methyl 4-[[[5-fluoro-6-[3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]tetrahydropyran- 4-carboxylate 255 4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]tetrahydropyran-4- carboxamide 256 N-(2-aminoethyl)-4-[[[5-fluoro-6- [(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]tetrahydropyran-4- carboxamide 257 4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]tetrahydropyran-4- carbonitrile 258 2-[4-[[[5-fluoro-6-[(3S)-3-[2-fluoro- 4-(trifluoromethoxy)phenyl] morpholin-4-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 259 6-[4,4-difluoro-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-5-fluoro-N-(tetrahydropyran- 4-ylmethyl)pyrimidin-4-amine 260 6-[4,4-difluoro-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-5-fluoro-N-[[4- (methylsulfonylmethyl) tetrahydropyran-4-yl] methyl]pyrimidin-4-amine 261 [3-[[[6-[4,4-difluoro-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-5-fluoro-pyrimidin-4- yl]amino]methyl]oxetan-3- yl]methanol 262 1-[4-fluoro-4-[[[5-fluoro-6- [(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-yl]amino]methyl]- 1-piperidyl]ethanone 263 5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]-N-[[1- (trifluoromethylsulfonyl)-4- piperidyl]methyl]pyrimidin-4-amine 264 5-fluoro-N-[(4- fluorotetrahydropyran-4-yl)methyl]- 6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 265 2-[4-[[4-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]-5,6-dihydropyrrolo[2,3- d]pyrimidin-7- yl]methyl]phenyl]acetamide 266 5-fluoro-N-[(4-fluoro-1- methylsulfonyl-4-piperidyl)methyl]- 6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 267 N-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethoxy)phenyl] morpholin-4-yl]pyrimidin-4- yl]amino]methyl]cyclohexyl] methanesulfonamide 268 4-[[[5-fluoro-6-[3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]tetrahydropyran-4- carboxylic acid 273 N-cyclopropyl-4-[[[5-fluoro-6-(3- phenylmorpholin-4-yl)pyrimidin-4- yl]amino]methyl] benzenesulfonamide 274 5-fluoro-N-[(1-methylsulfonyl-4- piperidyl)methyl]-6-(3- phenylmorpholin-4-yl)pyrimidin-4- amine 276 2-[4-[[[5-fluoro-6-(3- phenylmorpholin-4-yl)pyrimidin-4- yl]amino]methyl]phenyl]acetic acid 279 2-[4-[[[5-fluoro-6-(2- phenylpyrrolidin-1-yl)pyrimidin-4- yl]amino]methyl]phenyl]acetamide 280 2-[4-[[[5-fluoro-6-[4-oxo-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 282 2-[5-[[[5-fluoro-6-(3- phenylmorpholin-4-yl)pyrimidin-4- yl]amino]methyl]-2-thienyl]acetic acid 283 2-[5-[[[5-fluoro-6-(3- phenylmorpholin-4-yl)pyrimidin-4- yl]amino]methyl]-2- thienyl]acetamide 284 2-[4-[[4-(3-phenylmorpholin-4- yl)pyrrolo[2,3-d]pyrimidin-7- yl]methyl]phenyl]acetamide 285 2,2,2-trifluoro-N-[4-[[[5-fluoro-6- [(3S)-3-[4- (trifluoromethoxy)phenyl]morpholin- 4-yl]pyrimidin-4-yl]amino]methyl] cyclohexyl]ethane sulfonamide 286 4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-yl]amino]methyl]- N-methyl-tetrahydropyran-4- carboxamide 287 2-[4-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]cyclohexyl] acetonitrile 288 5-fluoro-N-[[4-(1H-tetrazol-5- ylmethyl)cyclohexyl]methyl]-6- [(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 290 (3S)-4-[7-[(1-methylsulfonyl-4- piperidyl)methyl]pyrrolo[2,3- d]pyrimidin-4-yl]-3-[4- (trifluoromethoxy)phenyl] morpholine 291 1,1,1-trifluoro-N-[4-[[[5-fluoro-6- [(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]phenyl] methanesulfonamide 292 N-cyano-2-[4-[[[5-fluoro-6-[3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 293 5-fluoro-N-[(6-methylsulfonyl-3- pyridyl)methyl]-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 294 N-(2,2-dimethyl-4-methylsulfonyl- butyl)-5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 295 2-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-yl]amino]methyl]- 2-methyl-cyclohexanol 296 [1-[[[5-fluoro-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4- yl]amino]methyl]cyclopropyl] methanol 297 N-[1-[5-fluoro-6-[(3 S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-yl]-4- piperidyl]methanesulfonamide 299 2-[4-[[[6-[2-(1,3-benzodioxol-5- yl)pyrrolidin-1-yl]-5-fluoro- pyrimidin-4- yl]amino]methyl]phenyl]acetamide 300 2-[4-[[[5-fluoro-6-[2-(4- hydroxyphenyl)pyrrolidin-1- yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 301 2-[4-[[[6-[2-(4- ethoxyphenyl)pyrrolidin-1-yl]-5- fluoro-pyrimidin-4- yl]amino]methyl]phenyl]acetamide 302 2-[4-[[[5-fluoro-6-[2-(p- tolyl)pyrrolidin-1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 303 2-[4-[[[5-fluoro-6-[2-(4- isopropylphenyl)pyrrolidin-1- yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 304 2-[4-[[[5-fluoro-6-[2-(3- methoxyphenyl)pyrrolidin-1- yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 305 2-[4-[[[6-[2-(3- bromophenyl)pyrrolidin-1-yl]-5- fluoro-pyrimidin-4- yl]amino]methyl]phenyl]acetamide 306 2-[4-[[[6-[2-(3- chlorophenyl)pyrrolidin-1-yl]-5- fluoro-pyrimidin-4- yl]amino]methyl]phenyl]acetamide 307 2-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]azetidin-1- yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 308 2-[4-[[[5-fluoro-6-[2-[4- (trifluoromethyl)phenyl]-1- piperidyl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 309 5-fluoro-N-[(4- methylsulfonylmorpholin-2- yl)methyl]-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 310 2-[4-[[[6-[2-(1,3-benzothiazol-2- yl)pyrrolidin-1-yl]-5-fluoro- pyrimidin-4- yl]amino]methyl]phenyl]acetamide 311 2-[4-[[[5-fluoro-6-[2-(1- naphthyl)pyrrolidin-1-yl]pyrimidin- 4- yl]amino]methyl]phenyl] acetamide 312 2-[4-[[[5-fluoro-6-[2-(2- naphthyl)pyrrolidin-1-yl]pyrimidin- 4-yl]amino]methyl]phenyl] acetamide 313 2-[4-[[[5-fluoro-6-[2-(5-methyl-2- furyl)pyrrolidin-1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 314 2-[4-[[[5-fluoro-6-[2-(5-methyl- 1,2,4-oxadiazol-3-yl)pyrrolidin-1- yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 315 2-[4-[[[5-fluoro-6-[2-(5-methyl- 1,3,4-oxadiazol-2-yl)pyrrolidin-1- yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 316 2-[4-[[[6-[2-(5-ethyl-2- furyl)pyrrolidin-1-yl]-5-fluoro- pyrimidin-4- yl]amino]methyl]phenyl]acetamide 317 2-[4-[[[6-[2-(1,3-dimethylpyrazol-4- yl)pyrrolidin-1-yl]-5-fluoro- pyrimidin-4- yl]amino]methyl]phenyl]acetamide 318 2-[4-[[[6-[2-(2,4- dimethoxyphenyl)pyrrolidin-1-yl]- 5-fluoro-pyrimidin-4- yl]amino]methyl]phenyl]acetamide 319 4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]benzenesulfonic acid 320 4-[[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino] methyl]-N-(2- methoxyethyl)benzenesulfonamide 323 2-[4-[[[5-fluoro-6-[2-[2-hydroxy-4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4- yl]amino]methyl]phenyl]acetamide 324 2-[1-[5-fluoro-6-[(1-methylsulfonyl- 4-piperidyl)methylamino]pyrimidin- 4-yl]pyrrolidin-2-yl]-5- (trifluoromethyl)phenol 325 (2R)-2-[[5-fluoro-6-[(2R)-2-[4- (trifluoromethyl)phenyl]pyrrolidin- 1-yl]pyrimidin-4-yl]amino]-4,4- dimethyl-pentanoic acid 326 2-[4-[[4-[(3S)-3-[6- (trifluoromethyl)-3- pyridyl]morpholin-4-yl]pyrrolo[2,3- d]pyrimidin-7- yl]methyl]phenyl]acetamide 327 5-fluoro-N-[(1- methylsulfonylpyrrolidin-3- yl)methyl]-6-[(3S)-3-[4- (trifluoromethyl)phenyl]morpholin- 4-yl]pyrimidin-4-amine 328 2-[4-[[4-[(3S)-3-[5- (trifluoromethyl)-2- pyridyl]morpholin-4-yl]pyrrolo[2,3- d]pyrimidin-7- yl]methyl]phenyl]acetamide 329 (3S)-4-[7-[(6-methylsulfonyl-3- pyridyl)methyl]pyrrolo[2,3- d]pyrimidin-4-yl]-3-[4- (trifluoromethoxy)phenyl] morpholine 330 (3S)-4-[7-[(5-methylsulfonyl-2- pyridyl)methyl]pyrrolo[2,3- d]pyrimidin-4-yl]-3-[4- (trifluoromethoxy)phenyl] morpholine - In a related aspect there is provided a prodrug of a compound of Formula (I) as described herein.
- Pharmaceutical Compositions
- In another aspect, the present disclosure relates to a pharmaceutical composition comprising physiologically acceptable surface active agents, carriers, diluents, excipients, smoothing agents, suspension agents, film forming substances, and coating assistants, or a combination thereof; and a compound of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein. The compounds of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), included in the pharmaceutical composition may also be any compound of the preferred embodiments described above. In another aspect, the present disclosure relates to a pharmaceutical composition comprising physiologically acceptable surface active agents, carriers, diluents, excipients, smoothing agents, suspension agents, film forming substances, and coating assistants, or a combination thereof; and a compound of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe). Acceptable carriers or diluents, as well as other additives to be combined with a compound of Formula (I), compounds of Formula (IIa), and compounds of any one of Formulae (IIb-IIe), as disclosed herein to provide a pharmaceutical composition, for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa. (1990), which is incorporated herein by reference in its entirety. Preservatives, stabilizers, dyes, sweeteners, fragrances, flavoring agents, taste masking agents, and the like may be provided in the pharmaceutical composition. For example, sodium benzoate, ascorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives. In addition, antioxidants and suspending agents may be used. In various embodiments, alcohols, esters, sulfated aliphatic alcohols, and the like may be used as surface active agents; sucrose, glucose, lactose, starch, crystallized cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium methasilicate aluminate, synthetic aluminum silicate, calcium carbonate, sodium acid carbonate, calcium hydrogen phosphate, calcium carboxymethyl cellulose, and the like may be used as excipients; magnesium stearate, talc, hardened oil and the like may be used as smoothing agents; coconut oil, olive oil, sesame oil, peanut oil, soya may be used as suspension agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate such as cellulose or sugar, or methylacetate-methacrylate copolymer as a derivative of polyvinyl may be used as suspension agents; and plasticizers such as ester phthalates and the like may be used as suspension agents.
- The term “pharmaceutical composition” refers to a mixture of a compound disclosed herein with other chemical components, such as diluents or carriers. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to, oral, injection, aerosol, parenteral, and topical administration. Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Similar, pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic bases, such as ammonia, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, and the like.
- The term “carrier” defines a chemical compound that facilitates the incorporation of a compound into cells or tissues. For example dimethyl sulfoxide (DMSO) is a commonly utilized carrier as it facilitates the uptake of many organic compounds into the cells or tissues of an organism.
- The term “diluent” defines chemical compounds diluted in water that will dissolve the compound of interest as well as stabilize the biologically active form of the compound. Salts dissolved in buffered solutions are utilized as diluents in the art. One commonly used buffered solution is phosphate buffered saline because it mimics the salt conditions of human blood. Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound.
- The term “physiologically acceptable” defines a carrier or diluent that does not abrogate the biological activity and properties of the compound.
- The pharmaceutical compositions described herein can be administered to a human patient per se, or in pharmaceutical compositions where they are mixed with other active ingredients, as in combination therapy, or suitable carriers or excipient(s). Techniques for formulation and administration of the compounds of the instant application may be found in “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., 18th edition, 1990.
- Suitable routes of administration may, for example, include oral, rectal, transmucosal, topical, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections. The compounds can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.
- The pharmaceutical compositions may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tabletting processes.
- Pharmaceutical compositions for use as described herein may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Pharmaceutical Sciences, above.
- Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like. In addition, if desired, the injectable pharmaceutical compositions may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like. Physiologically compatible buffers include, but are not limited to, Hanks's solution, Ringer's solution, or physiological saline buffer. If desired, absorption enhancing preparations (for example, liposomes), may be utilized.
- For transmucosal administration, penetrants appropriate to the barrier to be permeated may be used in the formulation.
- Pharmaceutical formulations for parenteral administration, e.g., by bolus injection or continuous infusion, include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or other organic oils such as soybean, grapefruit or almond oils, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds disclosed herein to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
- For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
- For administration by inhalation, the compounds for use as described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- Further disclosed herein are various pharmaceutical compositions well known in the pharmaceutical art for uses that include intraocular, intranasal, and intraauricular delivery. Suitable penetrants for these uses are generally known in the art. Topical ophthalmic compositions may be formulated as a solution in water buffered at a pH of 5.0 to 8.0. Other ingredients that may be desirable to use in the ophthalmic preparations include preservatives (such as benzalkonium chloride, stabilized oxychloro complex, which is sold as Purite™, or stabilized chlorine dioxide), cosolvents (such as
polysorbate - The compounds disclosed herein may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- For hydrophobic compounds, a suitable pharmaceutical carrier may be a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. A common cosolvent system used is the VPD co-solvent system, which is a solution of 3% w/v benzyl alcohol, 8% w/v of the
nonpolar surfactant Polysorbate 80™, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. - Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of POLYSORBATE 80™; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.
- Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
- Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external micro-environment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. The liposome may be coated with a tissue-specific antibody. The liposomes will be targeted to and taken up selectively by the desired organ. Alternatively, small hydrophobic organic molecules may be directly administered intracellularly.
- Additional therapeutic or diagnostic agents may be incorporated into the pharmaceutical compositions. Alternatively or additionally, pharmaceutical compositions may be combined with other compositions that contain other therapeutic or diagnostic agents.
- Uses
- The compounds or pharmaceutical compositions disclosed herein as described above may be used to modulate the activity of a retinoic acid receptor-related orphan receptor (ROR), such as a RORα, RORβ and/or RORγ (RORc) receptor. Modulators of RORγ have been reviewed by B. Fauber and S. Magnuson in J. Med. Chem., Feb. 6, 2014, which hereby is incorporated by reference in its entirety. Examples of RORγ receptors are RORγ1 and RORγt receptors. The compounds or pharmaceutical compositions as described above may also display selective modulation of a particular ROR receptor relative to a different ROR receptor. For example, according to some embodiments disclosed herein some compounds or pharmaceutical compositions modulate the activity of an RORγ receptor to a larger extent than they modulate the activity of RORα and/or RORβ receptors.
- The compounds or pharmaceutical compositions disclosed herein may also be used to modulate the activity of regulatory T cells (Tregs).
- The compounds or pharmaceutical compositions disclosed herein may also be used to modulate the activity of cells producing IL17 in a RORγt dependent manner, for example, γδT cells, Th17 cells and ILC3 cells.
- Publications providing useful background information are Arthritis & Rheumatism, 2014, 66, 579-588; Curr Top Microbial Immun, 2014, 378, 171-182; Drug Disc. Today, 2014, May; Nature Rev. Drug Disc. 2012, 11, 763-776, and Nature Rev. Drug Disc., 2014, 13, 197-216, all of which are hereby incorporated by reference in their entirety.
- The compounds or pharmaceutical compositions as described herein and above may also be used in therapy or may be used to treat inflammatory, metabolic, oncologic and autoimmune diseases or disorders. Examples of such diseases or disorders are inflammatory, metabolic, oncologic and autoimmune diseases or disorders mediated or affected by IL17 and/or RORγ (RORc). The role of RORγ in the pathogenesis of autoimmune or inflammatory diseases has been disclosed in Immunity 2007, 26, 643-654; Nat. Rev. Immunol. 2006, 6, 205-217; J. Immunol. 2009, 183, 7169-7177; Brain Pathol. 2004, 14, 164-174; Brain 2007, 130, 1089-1104; and Nat Rev. Immunol. 2008, 8, 183-192 all of which are hereby incorporated by reference in their entirety.
- More specific examples of diseases or disorders include asthma, chronic obstructive pulmonary disease (COPD), bronchitis, atherosclerosis, helicobacter pylori infection, allergic diseases including allergic rhinitis, allergic conjunctivitis and uveitis, sprue and food allergy, atopic dermatitis, cystic fibrosis, lung allograph rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, steatosis, steatohepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), lupus erythematosus, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune ocular disease, ulcerative colitis, colitis, Crohn's disease, inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), Sjogren's syndrome, optic neuritis, type I diabetes, neuromyelitis optica, Myasthenia Gravis, Guillain-Barre syndrome, Graves' disease, scleritis, obesity, obesity-induced insulin resistance and type II diabetes and cancer.
- More specifically, compounds or pharmaceutical compositions having an antagonistic or inverse agonistic effect on RORγ may be used to reduce levels of IL17 and/or other gene products, such as interleukins, and cytokines, regulated RORγ. This may for example be in subjects suffering from for example, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, atherosclerosis, helicobacter pylori infection, allergic diseases including allergic rhinitis, allergic conjunctivitis and uveitis, sprue and food allergy, atopic dermatitis, cystic fibrosis, lung allograph rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, steatosis, steatohepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), lupus erythematosus, Hashimoto's disease, pancreatitis, autoimmune diabetes, autoimmune ocular disease, ulcerative colitis, colitis, Crohn's disease, inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), Sjogren's syndrome, optic neuritis, type I diabetes, neuromyelitis optica, Myasthenia Gravis, Guillain-Barre syndrome, Graves' disease, scleritis, obesity, obesity-induced insulin resistance and type II diabetes.
- Conversely, compounds or pharmaceutical compositions having an agonistic effect on RORγ may be used to increase IL17 levels. Increasing IL17 levels may be particularly useful in immune compromised conditions or boosting the immune system response for example during infections and in cancer.
- Methods of Administration
- The compounds or pharmaceutical compositions may be administered to the patient by any suitable means. Non-limiting examples of methods of administration include, among others, (a) administration though oral pathways, which administration includes administration in capsule, tablet, granule, spray, syrup, or other such forms; (b) administration through non-oral pathways such as rectal, vaginal, intraurethral, intraocular, intranasal, or intraauricular, which administration includes administration as an aqueous suspension, an oily preparation or the like or as a drip, spray, suppository, salve, ointment or the like; (c) administration via injection, subcutaneously, intraperitoneally, intravenously, intramuscularly, intradermally, intraorbitally, intracapsularly, intraspinally, intrasternally, or the like, including infusion pump delivery; (d) administration locally such as by injection directly in the renal or cardiac area, e.g., by depot implantation, by intratumoral injection, or by intra-lymph node injection; (e) administration topically; as well as (f) administration to cells ex vivo followed by insertion of said cells into the patient; as deemed appropriate by those of skill in the art for bringing the compound disclosed herein into contact with living tissue.
- Pharmaceutical compositions suitable for administration include compositions where the active ingredients are contained in an amount effective to achieve its intended purpose. The therapeutically effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including mammal, e.g. human, being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- As will be readily apparent to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed. The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.
- In non-human animal studies, applications of potential products are commenced at higher dosage levels, with dosage being decreased until the desired effect is no longer achieved or adverse side effects disappear. The dosage may range broadly, depending upon the desired effects and the therapeutic indication.
- Typically, dosages may be between about 10 microgram/kg and 100 mg/kg body weight, preferably between about 100 microgram/kg and 10 mg/kg body weight. Alternatively dosages may be based and calculated upon the surface area of the patient, as understood by those of skill in the art.
- The exact formulation, route of administration and dosage for the pharmaceutical compositions disclosed herein can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl et al. 1975, in “The Pharmacological Basis of Therapeutics”, which is hereby incorporated herein by reference in its entirety, with particular reference to Ch. 1, p. 1). Typically, the dose range of the composition administered to the patient can be from about 0.5 to 1000 mg/kg of the patient's body weight. The dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the patient. In instances where human dosages for compounds have been established for at least some condition, those same dosages may be used, or dosages that are between about 0.1% and 500%, more preferably between about 25% and 250% of the established human dosage. Where no human dosage is established, as will be the case for newly-discovered pharmaceutical compounds, a suitable human dosage can be inferred from ED50 or ID50 values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
- It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps the dose frequency will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
- Although the exact dosage will be determined on a drug-by-drug basis, in most cases, some generalizations regarding the dosage can be made. The daily dosage regimen for an adult human patient may be, for example, an oral dose of between 0.1 mg and 2000 mg of each active ingredient, preferably between 1 mg and 500 mg, e.g. 5 to 200 mg. An ocular eye drop may range in concentration between 0.005 and 5 percent. In one embodiment, an eye drop may range between 0.01 and 1 percent, or between 0.01 and 0.3 percent in another embodiment. In other embodiments, an intravenous, subcutaneous, or intramuscular dose of each active ingredient of between 0.01 mg and 100 mg, preferably between 0.1 mg and 60 mg, e.g. 1 to 40 mg is used. In cases of administration of a pharmaceutically acceptable salt, dosages may be calculated as the free base. In some embodiments, the composition is administered 1 to 4 times per day. Alternatively the compositions disclosed herein may be administered by continuous intravenous infusion, preferably at a dose of each active ingredient up to 1000 mg per day. As will be understood by those of skill in the art, in certain situations it may be necessary to administer the compounds disclosed herein in amounts that exceed, or even far exceed, the above-stated, preferred dosage range or frequency in order to effectively and aggressively treat particularly aggressive diseases or infections. In some embodiments, the compounds will be administered for a period of continuous therapy, for example for a week or more, or for months or years.
- Dosage amount and interval may be adjusted individually to provide plasma or tissue levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.
- Dosage intervals can also be determined using MEC value. Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.
- In cases of local or ex vivo administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.
- The amount of composition administered may be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
- Compounds disclosed herein can be evaluated for efficacy and toxicity using known methods. For example, the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties, may be established by determining in vitro toxicity towards a cell line, such as a mammalian, and preferably human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans. Alternatively, the toxicity of particular compounds in an animal model, such as mice, rats, rabbits, or monkeys, may be determined using known methods. The efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials. Recognized in vitro models exist for nearly every class of condition, including but not limited to cancer, cardiovascular disease, and various immune dysfunction. Similarly, acceptable animal models may be used to establish efficacy of chemicals to treat such conditions. When selecting a model to determine efficacy, the skilled artisan can be guided by the state of the art to choose an appropriate model, dose, and route of administration, and regime. Of course, human clinical trials can also be used to determine the efficacy of a compound in humans.
- The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions comprising a compound disclosed herein formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- General Remarks
- As described above with reference to specific illustrative embodiments, it is not intended to be limited to the specific form set forth herein. Any combination of the above mentioned embodiments should be appreciated as being within the scope of the invention. Rather, the invention is limited only by the accompanying claims and other embodiments than the specific above are equally possible within the scope of these appended claims.
- In the claims, the term “comprises/comprising” does not exclude the presence of other species or steps. Additionally, although individual features may be included in different claims, these may possibly advantageously be combined, and the inclusion in different claims does not imply that a combination of features is not feasible and/or advantageous. In addition, singular references do not exclude a plurality. The terms “a”, “an”, “first”, “second” etc. do not preclude a plurality. The phrases “at least one” or “one or more” refer to 1 or a number greater than 1, such as to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- The following examples are mere examples and should by no mean be interpreted to limit the scope of the invention. Rather, the invention is limited only by the accompanying claims.
- General Chemical Procedures
- Unless otherwise stated, starting materials were obtained from commercial suppliers, such as (but not limited to); ABchem, ABCR, Alfa Aesar, Anaspec, Anichem, Apollo Scientific, ASDI-Inter, Asiba Pharmatech, Astatech, Bachem, Chem-Impex, ChemCollect, Chembridge, Combi-Blocks, Enamine, Fluka, Fluorochem, Frontier Scientific, HDH Pharma, InFarmatik, InterBioScreen, Life Chemicals, Manchester organics, Matrix, MercaChem, NetChem, Oakwood Chemical, PepTech, Pharmcore, PrincetonBio, Sigma-Aldrich, TRC, Tyger Scientific and Ukrorgsyn. N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and dichloromethane (DCM) were dried over molecular sieves. Analytical HPLC was performed on a Waters Acquity system using a C18 reverse phase column (Merck Chromolith Speedrod RP-18E) with a linear gradient of the binary solvent system water/acetonitrile/formic acid (A: 100/0/0.1% and B: 0/100/0.1%) with a flow rate of 3.0 mL/min and UV detection at 254 nm at room temperature, combined with MS detection on a Waters Micromass QZ Quadrupole Mass Spectrometer instrument using electron spray ionization, or on a Shimadzu Nexera X2 system using a C18 reverse phase column (Acquity UPLC BEH C18 1.7 μm, 2.1×50 mm), with a linear gradient of the binary solvent system water/methanol/formic acid (A: 100/0/0.1% and B: 0/100/0.1%) with a flow rate of 0.78 mL/min and UV detection at 254 nm, combined with MS detecting on a Shimadzu LCMS-2020 Spectrometer instrument using electron spray ionization. Preparative HPLC was performed on a Waters Acquity system using a C18 reverse phase column (Supelco ASCENTIS C18 581358-U, 15 cm×21.2 mm), with a linear gradient of the binary solvent system water/acetonitrile/formic acid (A: 100/0/0.1% and B: 0/100/0.1%) with a flow rate of 15 mL/min and UV detection at 254 nm, combined with MS detection on a Waters Micromass QZ Quadrupole Mass Spectrometer instrument using electron spray ionization. Chiral resolution was performed on a Lux Cellulose2 (250×21 mm) column using a mobile phase of 0.2% diethyamine in hexane/ethanol, with a flow of 20 mL/min and UV detection at 290 nm. 1H NMR spectra were recorded on a Bruker Avance 300 spectrometer (at 300 MHz), using CD3OD, CDCl3, DMSO-d6 or C6D6 solvents. Chemical shifts are reported in ppm (δ) using residual solvent as an internal standard; CDCl3: 7.26 ppm; CD3OD: 3.31; DMSO-d6: 2.50 ppm. Coupling constants (J) are given in Hz.
- Synthetic Methods
- The compounds disclosed herein may be made by one of the following four general methods. Further, additional guidance for preparing building blocks to be used in providing compounds disclosed herein is present in the co-pending international application PCT/EP2015/067692 also claiming priority from SE 1450920-2 and SE 1451406-1.
- A fluorenylmethyloxycarbonyl (Fmoc) protected amino acid was coupled to a Rink resin to produce 1a using the coupling reagents 1-hydroxy-7-azabenzotriazol (HOAt) and N,N′-diisopropylcarbodiimide (DIC) in the presence of a suitable base, e.g. ethyldiisopropylamine (DIPEA), in DCM/DMF (e.g. in a 1:1 ratio). The mixture was agitated at a suitable temperature until complete conversion of the starting materials was observed, typically overnight at room temperature (i.e. 20-25° C.). The Fmoc group was removed from 1a by treatment with a base, e.g. 20% piperidine in DMF for 30 minutes at room temperature, to yield 1b. An aromatic fluorinated building block, e.g. 4,5,6-trifluoro-pyrimidine, was coupled to a compound containing a free amino group in a nucleophilic aromatic substitution reaction to produce 1c. The reaction may for example be done by addition of DIPEA in dimethyl sulfoxide (DMSO) followed by agitation overnight at room temperature. An aromatic nucleophilic substitution reaction was subsequently performed by addition of a compound containing a free amine to 1c, in the presence of a suitable base, to yield 1d. An example the addition of 4-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidine and DIPEA in DMSO, followed by agitation overnight at elevated temperature, e.g. 80-100° C. The desired compound 1e was obtained by cleavage from the resin upon treatment of 1d with an acid, e.g. 2,2,2-trifluoroethanoic acid (TFA) as an 80% solution in DCM upon stirring for 1 hour at room temperature. The obtained mixture was concentrated in vacuo and purification by e.g. flash column chromatography (CC) using an appropriate eluent combination on a suitable column material, e.g. heptane/EtOAc on silica gel.
-
- A rink amide resin (0.88 g, 0.68 mmol/g, 0.6 mmol) was swelled in dry DMF (8 mL) for 15 minutes. The resin was drained and treated twice with 20% piperidine in DMF (2×8 mL) for 30 minutes each. The resin was drained and washed with DMF (3×8 mL), methanol (2×8 mL), DMF (2×8 mL) and DCM (3×8 mL). The resin was swelled in dry DCM (8 mL) for 15 minutes and drained. A solution of (2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-fluorophenyl)propanoic acid (0.49 g, 1.2 mol) and 1-hydroxy-7-azabenzotriazol (0.16 mg, 1.2 mmol) dissolved in DMF/DCM (1:1, 8 mL) was added, followed by DIPEA (0.31 mL, 3.6 mmol) and DIC (0.19 mL, 1.2 mmol). The reaction was agitated at room temperature overnight, drained and washed with DMF (3×8 mL), MeOH (2×8 mL), DMF (2×8 mL) and DCM (3×8 mL). The resin was swelled in dry DCM (8 mL) for 15 minutes and drained. A solution of acetic anhydride (0.57 mL, 6 mmol) and pyridine (0.97 mL, 12 mmol) dissolved in DCM (8 mL) was added and the mixture was agitated at room temperature for 1 hour. The resin was drained and washed with DCM (3×8 mL), DMF (3×8 mL) and DCM (3×8 mL). The resin was swelled in dry DMSO (8 mL) for 15 minutes and drained. A solution of 4,5,6-trifluoro-pyrimidine (0.16 g, 1.2 mmol) in dry DMSO (6 mL) was added, followed by DIPEA (0.26 mL, 3.0 mmol). The mixture was agitated overnight at room temperature, drained and washed with DCM (3×8 mL), DMF (3×8 mL) and DCM (3×8 mL). The resin was swelled in dry DMSO (8 mL) for 15 minutes and drained. A solution of 4-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidine (0.28, 1.2 mmol) in dry DMSO (6 mL) was added, followed by DIPEA (0.26 mL, 3.0 mmol). The mixture was agitated overnight at 80° C., drained and washed with DCM (3×8 mL), DMF (3×8 mL) and DCM (3×8 mL). The resin was swelled in dry DCM (8 mL) for 15 minutes and drained. A solution of 80% TFA in dry DCM (8 mL) was added and the mixture was agitated for 1 hour. The filtrate was collected and the treatment repeated once. The resin was washed with acetonitrile (ACN, 8 mL) and the filtrated collected. The pooled filtrates were concentrated in vacuo and purified by flash CC (eluent: DCM/MeOH, on silica gel) yielding (2R)-2-[[5-fluoro-6-[4-methyl-2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]amino]-3-(4-fluorophenyl)propanamide 37 (37 mg, 12% yield). 1H NMR (300 MHz, DMSO-d6) δ 7.70-7.55 (m, 2H), 7.50-7.45 (s, 1H), 7.43-7.36 (m, 2H), 7.33-7.23 (m, 2H), 7.10-7.00 (m, 2H), 5.22-5.18 (m, 1H), 4.67-4.55 (m, 1H), 4.02-3.92 (m, 1H), 3.43-3.38 (m, 1H), 3.05-2.96 (m, 1H), 2.57-2.52 (m, 1H), 2.31-2.28 (m, 1H), 1.35-1.29 (m, 1H), 1.02 (d, J=6.1 Hz, 3H). m/z 506 (M+H).
- General method 1 was used to prepare the following example numbers using the shown starting materials:
-
Ex. Aromatic fluorinated No. Fmoc protected amino acid building block Free amine 5 pyrrolidine 6 pyrrolidine 9 11 13 14 15 17 18 19 pyrrolidine 20 23 24 34 35 37 38 39 42 43 51 52 62 63 65 68 72 77 78 - A halogenated pyrrolopyrimidine 2b, e.g. 6-chloro-7-deazapurine, was N-alkylated by addition of an alkyl halide 2a, e.g. 4-(bromomethyl)-1,2-dimethoxy-benzene, and an appropriate base in a suitable solvent, e.g. cesium carbonate in dry dioxane or sodium hydride in dry tetrahydrofuran. The mixture was stirred at room temperature until completion of reaction, typically overnight. The reaction may for example be monitored by thin layer chromatography. The reaction may for example be monitored by thin layer chromatography. The desired product was obtained upon work-up, e.g. by extraction with EtOAc, washing with water at a suitable pH and brine, drying over an appropriate drying agent, e.g. Na2SO4, and purification by flash column chromatrography (CC) using an appropriate eluent combination on a suitable column material, e.g. heptane/EtOAc or DCM/MeOH on silica gel, or recrystallization from a suitable solvent or solvent mixture, e.g. toluene/heptane. Nucleophilic aromatic substitution of the halogen on intermediate 2c was achieved upon addition of a building block containing a free amino group, e.g. 2-(4-trifluoromethyl-phenyl)-pyrrolidine, and a suitable base in an appropriate solvent, e.g. cesium carbonate in dry DMSO. The reaction was achieved by microwave irradiation at elevated temperatures for a period of time, e.g. at 100-150° C. for 1 hour. The reaction may for example be monitored by thin layer chromatography. The desired compound 2d was obtained upon work-up, for example by extraction with EtOAc, washing with water at a suitable pH and brine, drying over an appropriate drying agent, e.g. Na2SO4, and purification by flash column chromatrography (CC) using an appropriate eluent combination on a suitable column material, e.g. heptane/EtOAc or DCM/MeOH on silica gel, or recrystallization from a suitable solvent or solvent mixture, e.g. toluene/heptane.
- Use of General Method 2 to Prepare Example No. 69:
- 6-Chloro-7-deazapurine (77 mg, 0.5 mmol) and 4-(bromomethyl)-1,2-dimethoxy-benzene (127 mg, 0.55 mmol) were dissolved in dry dioxane (5 mL) and cesium carbonate (325 mg, 1.0 mmol) was added. The mixture was stirred overnight at room temperature, concentrated in vacuo, redissolved in water, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by flash CC (eluent: DCM/MeOH, on silica gel) yielding 4-chloro-7-(3,4-dimethoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (65 mg, 43% yield).
- 4-Chloro-7-(3,4-dimethoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (63 mg, 0.21 mmol) and 2-(4-trifluoromethyl-phenyl)-pyrrolidine (45 mg, 0.21 mmol) were dissolved in dry DMSO (4 mL). Cesium carbonate (137 mg, 0.42 mmol) was added, and the mixture was heated at 150° C. for 30 minutes in a microwave reactor. The mixture was poured onto 3M aq. calcium chloride, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by preparative HPLC yielding 7-[(3,4-dimethoxyphenyl)methyl]-4-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrrolo[2,3-d]pyrimidine 69 (9 mg, 9% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.07 (s, 1H), 7.64 (d, J=8.1 Hz, 2H), 7.43 (d, J=8.0 Hz, 2H), 7.22 (s, 1H), 6.97 (s, 1H), 6.84 (d, J=8.3 Hz, 1H), 6.71 (d, J=8.1 Hz, 1H), 5.62 (s, 1H), 5.22 (s, 2H), 4.30-3.81 (m, 3H), 3.68 (s, 6H), 2.22-1.71 (m, 4H). m/z 483 (M+H).
- General method 2 was used to prepare the following example numbers using the shown starting materials:
-
Ex. Halogenated No. pyrrolopyrimidine Alkyl halide Free amine 4 67 69 85 195 196 252 265 284 290 326 328 329 330 - Synthesis of Selected Alkyl Halide
- To a solution of 2-(4-(hydroxymethyl) phenyl) acetic acid (20 g, 120.48 mmol) in MeOH:toluene (1:1) (200 mL) at 0° C. was added trimethylsilyldiazomethane (TMSCHN2, 27.51 g, 240 mmol), and the mixture was stirred at room temperature for 16 hours. After completion, the solvent was evaporated and the crude compound was purified by flash CC (Eluent: EtOAc/pet ether, on silica gel) to afford methyl 2-(4-(hydroxymethyl) phenyl) acetate (Compound-2) (18 g, 83%) as an off white solid.
- To a solution of methyl 2-(4-(hydroxymethyl) phenyl) acetate (3.4 g, 1.87 mmol) in MeOH (10 vol) was added aqueous NH3 (34 ml), and the mixture was heated at 90° C. for 16 hours in a sealed tube. After completion, the reaction mixture was allowed to room temperature, filtered and concentrated in vacuo to afford 2-(4-(hydroxymethyl) phenyl) acetamide (1.1 g, 35%) as an off white solid.
- To a solution of 2-(4-(hydroxymethyl) phenyl) acetamide (2 g, 12.12 mmol), Et3N (5.1 mL, 36.36 mmol) in DMF (20 mL) was added methane sulfonyl chloride (1.5 mL, 18.18 mmol), and the mixture was stirred at room temperature for 3 hours. After completion, the reaction mixture was poured into ice water and filtered the solid to afford 2-(4-(chloromethyl) phenyl) acetamide (1.2 g, 54%) as an off white solid.
- A compound containing a free amino or hydroxyl group 3a, e.g. 1-tetrahydropyran-4-ylpropan-2-amine, was coupled to a fluorinated aromatic compound 3b, e.g. 4,5,6-trifluoro-pyrimidine, upon treatment with a suitable base in an appropriate solvent, e.g. DIPEA or cesium carbonate in dry DMSO or dioxane. Conversion to 3c was typically achieved after stirring at room temperature overnight. The reaction may for example be monitored by thin layer chromatography. The reaction may for example be monitored by thin layer chromatography. The desired product was obtained upon work-up, e.g. by extraction with EtOAc, washing with water at a suitable pH and brine, drying over an appropriate drying agent, e.g. Na2SO4, and purification by flash column chromatrography (CC) using an appropriate eluent combination on a suitable column material, e.g. heptane/EtOAc or DCM/MeOH on silica gel, or recrystallization from a suitable solvent or solvent mixture, e.g. toluene/heptane. Subsequent nucleophilic aromatic substitution of 3c with a building block containing a free amino or hydroxyl group can be achieved upon treatment with a suitable base in an appropriate solvent. An example of such treatment is cesium carbonate in dry DMSO, heated under microwave irradiation during a period of time, e.g. at 80-150° C. for 1 hour. The reaction may for example be monitored by thin layer chromatography. The desired compound 3d was obtained upon work-up, for example by extraction with EtOAc, washing with water at a suitable pH and brine, drying over an appropriate drying agent, e.g. Na2SO4, and purification by flash column chromatrography (CC) using an appropriate eluent combination on a suitable column material, e.g. heptane/EtOAc or DCM/MeOH on silica gel, or recrystallization from a suitable solvent or solvent mixture, e.g. toluene/heptane.
- Use of General Method 3 to Prepare Example No. 41:
- 4,5,6-Trifluoro-pyrimidine (0.27 g, 2.0 mmol) and 2-(4-trifluoromethyl-phenyl)-pyrrolidine (0.43 g, 2.0 mmol) were dissolved in dry DMSO (4 mL) and DIPEA (0.7 mL, 4.0 mmol) was added. The reaction was stirred at room temperature overnight, poured into 3M aq. calcium chloride, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by flash CC (eluent: DCM/MeOH, on silica gel) yielding 4,5-difluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidine (0.58 g, 88% yield).
- 4,5-difluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidine (0.33 g, 1.0 mmol) and 1-tetrahydropyran-4-ylpropan-2-amine hydrochloride (0.18 g, 1.0 mmol) were dissolved in dry DMSO (2 mL) and cesium carbonate (0.65 g, 2.0 mmol) was added. The reaction was heated in a microwave reactor for 1 hour at 100° C., poured into 3M aq. calcium chloride, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by flash CC (eluent: DCM/MeOH, on silica gel), yielding 5-fluoro-N-(1-methyl-2-tetrahydropyran-4-yl-ethyl)-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-amine 41 (205 mg, 45% yield). 1H NMR (300 MHz, CDCl3) δ 7.90 (s, 1H), 7.58 (d, J=8.0 Hz, 2H), 7.33 (d, J=8.0 Hz, 2H), 5.40 (d, J=7.8 Hz, 1H), 4.28-4.24 (m, 2H), 4.05-4.00 (m, 1H), 4.00-3.91 (m, 2H), 3.86-3.79 (m, 1H), 3.39-3.25 (m, 2H), 2.39-2.25 (m, 1H), 1.99-1.83 (m, 3H), 1.76-1.64 (m, 2H), 1.41-1.18 (m, 7H). m/z 453 (M+H).
- General method 3 was used to prepare the following example numbers using the shown starting materials:
-
Ex. Fluorinated No. Free amine or alcohol (1) Free amine or alcohol (2) aromatic compound 16 21 29 30 31 33 36 41 44 45 46 48 53 54 55 56 57 58 59 trifluoropyrimidine 60 61 64 66 70 71 73 74 trifluoropyrimidine 80 88 trifluoropyrimidine 89 90 93 94 95 96 97 98 99 trifluoropyrimidine 100 104 105 106 107 108 109 110 111 112 113 114 115 116 120 121 122 123 124 126 128 129 130 131 132 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 trifluoropyrimidine 150 151 152 154 155 159 161 164 165 166 167 168 169 170 175 178 181 182 183 184 185 186 188 189 190 191 193 194 197 198 199 trifluoropyrimidine 200 201 202 203 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 trifluoropyrimidine 250 251 253 254 255 256 257 258 259 260 261 262 263 264 266 267 268 273 274 276 279 280 282 283 285 AND Enantiomer 286 287 288 291 292 293 294 295 296 297 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 324 325 327 - Synthesis of Selected Amines
- To 4-[(tert-butoxycarbonylamino)methyl]cyclohexanecarboxylic acid (0.84 g, 3.2 mmol) was added slowly solution of a BH3-THF solution in THF (16 mL, 1M). The reaction was allowed to stir for 2.5 hours, concentrated in vacuo, and the residue was redissolved and stirred with an aq. sodium hydroxide solution (1M, 30 mL) for 20 min. Ethyl acetate was added, and the mixture was allowed to stir for another 10 min. The phases were separated and the EtOAc phase was concentrated in vacuo and the crude product thereof was purified by flash CC (eluent: EtOAc/heptane, on silica gel) yielding tert-butyl N-[[4 (hydroxymethyl)cyclohexyl]methyl]carbamate (0.76 g, quant yield).
- Tert-butyl N-[[4-(hydroxymethyl)cyclohexyl]methyl]carbamate (0.60 g, 2.5 mmol) was dissolved in DCM (20 mL) and Et3N (1 mL) and then methanesulfonyl chloride was the added to the solution. The reaction was stirred over night at room temperature whereafter concentration under reduced pressure yielded a solid that was mixed with water and EtOAc. The EtOAc phase was separated and washed with brine and dried over sodium sulfate. Filtration and concentration in vacuo of the EtOAC phase gave a solid that was dissolved dry DMSO (10 mL). Potassium cyanide (0.36 g, 5.5 mmol) was added and the reaction was heated to 90° C. for 4 hours. The crude reaction was poured into water and the resulting mixture was extracted with EtOAc. The organic phase was dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by flash CC (eluent: EtOAc/heptane, on silica gel) yielding tert-butyl N-[[4-(cyanomethyl)cyclohexyl]methyl]carbamate (0.57 g, 88% yield).
- To a solution of tert-butyl N-[[4-(cyanomethyl)cyclohexyl]methyl]carbamate (160 mg, 0.60 mmol) in nitrobenzene was added triethylammonium chloride (160 mg, 1.2 mmol) and sodium azide (91 mg, 1.4 mmol). The resulting mixture was heated to 105° C. for 11 hours using microwave irradiation. Some more sodium azide (40 mg, 0.7 mmol) was added and the reaction was heated for another 45 min at 105° C. with microwave irradiation. The reaction was extracted with water and the water phase was washed with ether, made acidic with IM HCl and extracted with EtOAc. The EtOAc phase was dried using sodium sulfate, filtered and concentrated in vacuo and finally purified by flash CC (eluent: EtOAc/heptane, on silica gel) yielding tert-butyl N-[[4-(1H-tetrazol-5-ylmethyl)cyclohexyl]methyl]carbamate (33 mg, 18% yield).
- Tert-butyl N-[[4-(1H-tetrazol-5-ylmethyl)cyclohexyl]methyl]carbamate (33 mg, 0.11 mmol) was dissolved in DCM (2 mL), TFA (1 mL) was added, and the reaction was stirred for 2 hours. Concentration of the reaction mixture yielded [4-(1H-tetrazol-5-ylmethyl)cyclohexyl]methylammonium 2,2,2-trifluoroacetate that was used without further purification. Using an extra equivalent of the base in the General Method 3 gave [4-(1H-tetrazol-5-ylmethyl)cyclohexyl]methanamine in situ during the reaction.
- Tert-butyl N-(3-pyridylmethyl)carbamate (1.7 g, 8.4 mmol) was dissolved in DCM, meta-chloroperbenzoic acid (6.1 g, 25 mmol, 70%) was added, and the reaction was stirred at room temperature for 3 hours. After concentration in vacuo, the crude product was purified by flash CC (eluent: EtOAc/heptane followed by EtOAc/MeOH/ammonium hydroxide, on silica gel) to yield tert-butyl N-[(1-oxidopyridin-1-ium-3-yl)methyl]carbamate (1.9 g, 97% yield).
- Tert-butyl N-[(1-oxidopyridin-1-ium-3-yl)methyl]carbamate (1.9 g, 8.2 mmol) was dissolved in DCM (2 mL) followed by the addition of TFA. The reaction was heated to reflux overnight. After concentration in vacuo the residue was dissolved in a mixture of MEOH and DCM and the solution was then stirred together with Amberlite IRA-67 free base (7 g, washed and dried) for 30 min. The mixture was filtered with DCM and MeOH. Concentration of the filtrate gave 1-oxidopyridin-1-ium-3-yl)methanamine (0.91 g, 91% yield).
- Tert-butyl N-(4-pyridylmethyl)carbamate (100 mg, 0.48 mmol) was dissolved in DCM, meta-chloroperbenzoic acid (350 mg, 2.2 mmol, 70%) was added, and the reaction was stirred at room temperature for 4 hours. After concentration in vacuo the crude product was purified by flash CC (eluent: EtOAc/heptane followed by ethyl acetate/MeOH/ammonium hydroxide, on silica gel) to yield tert-butyl N-[(1-oxidopyridin-1-ium-4-yl)methyl]carbamate.
- Tert-butyl N-[(1-oxidopyridin-1-ium-4-yl)methyl]carbamate (80 mg, 0.64 mmol) was dissolved in DCM followed by the addition of TFA (0.19 mL). The reaction was heated to 60° C. by microwave irradiation for 30 min. After cooling, the solution was then stirred together with Amberlite IRA-67 free base (0.5 g, washed and dried) for 30 min. The mixture was filtered with DCM and MeOH. Concentration of the filtrate yielded 1-oxidopyridin-1-ium-4-yl)methanamine (48 mg, 61% yield).
- Tert-butyl N-[(4-fluoro-4-piperidyl)methyl]carbamate (232 mg, 1 mmol) was dissolved in 4 mL DCM and trimethylamine (TEA, 160 μL, 1.1 mmol) was added. The mixture was cooled to 0° C. and acetyl chloride (80 μL, 1.1 mmol) was added. The mixture was stirred for 1 hour while returning to room temperature. The mixture was poured into H2O, extracted with EtOAc, washed with brine, dried over Na2SO4, concentrated in vacuo and purified by flash CC (eluent: Heptane/EtOAc, on silica gel) yielding tert-butyl N-[(1-acetyl-4-fluoro-4-piperidyl)methyl]carbamate. The product was dissolved in 2 mL DCM and a solution of 4M HCl in dioxane (2 mL) was added. The mixture was stirred overnight at room temperature. The mixture was concentrated, and the crude 1-[4-(aminomethyl)-4-fluoro-1-piperidyl]ethanone hydrochloride was used in the next step without further purification (180 mg, 86%).
- Tert-butyl N-[(4-fluoro-4-piperidyl)methyl]carbamate (232 mg, 1 mmol) was dissolved in 4 mL DCM and TEA (160 μL, 1.1 mmol) was added. The mixture was cooled to 0° C. and methanesulfonyl chloride (90 μL, 1.1 mmol) was added. The mixture was stirred for 1 hour while returning to room temperature. The mixture was poured into H2O, extracted with EtOAc, washed with brine, dried over Na2SO4, concentrated in vacuo and purified by flash CC (eluent: Heptane/EtOAc) yielding tert-butyl N-[(4-fluoro-1-methylsulfonyl-4-piperidyl)methyl]carbamate. The product was dissolved in 2 mL DCM and a solution of 4M HCl in dioxane (2 mL) was added. The mixture was stirred overnight at room temperature. The mixture was concentrated, and the crude (4-fluoro-1-methylsulfonyl-4-piperidyl)methanamine hydrochloride was used in the next step without further purification (162 mg, 61%).
- To a solution of tert-butyl (((trans)-4-aminocyclohexyl)methyl)carbamate (2 g, 8.77 mmol) in CH2Cl2 (20 mL) at −78° C. was added DIPEA (2.26 g, 17.54 mmol), methane sulfonyl chloride (1 g, 8.77 mmol), and the mixture was stirred at room temperature for 4 hours. After completion, the reaction mixture was poured into ice water and extracted with CH2Cl2 (3×30 mL). The combined extracts were washed with water (2×20 mL), brine (20 mL), dried over anhydrous Na2SO4, filtered and evaporated. The crude compound was purified by flash CC (eluent: DCM/MeOH, on silica gel) to afford tert-butyl (((trans)-4-(methylsulfonamido)cyclohexyl)methyl)carbamate (230 mg) as yellow liquid.
- To a solution of tert-butyl (((trans)-4-(methylsulfonamido) cyclohexyl)methyl) carbamate (0.23 g, 0.751 mmol) in dioxane (1 mL) was added 4 N HCl in dioxane (2.3 mL), and the mixture was stirred at room temperature for 3 hours. After completion, the reaction mixture was evaporated to afford N-((trans)-4-(aminomethyl)cyclohexyl)methanesulfonamide (140 mg, 91%) as an off white solid.
- To a solution of tert-butyl 4-aminobenzylcarbamate (2 g, 9.0 mmol) in CH2Cl2 (20 mL) at −78° C. was added Et3N (1.8 g, 18.01 mmol), trifluoromethanesulfonic anhydride (2.54 g, 9.0 mmol), and the mixture was stirred at room temperature for 16 hours. After completion, the reaction mixture was diluted with CH2Cl2 (75 mL) and washed with saturated aq. NaHCO3 (40 mL), water (40 mL), brine (30 mL), dried over anhydrous Na2SO4, filtered and evaporated. The crude compound was purified by flash CC (Eluent: EtOAc/Pet ether, on silica gel) to afford tert-butyl 4-(trifluoromethylsulfonamido) benzylcarbamate (1.3 g, 41%) as pale yellow solid. N-[4-(aminomethyl)phenyl]-1,1,1-trifluoro-methanesulfonamide was isolated after BOC deprotection, as described for tert-butyl (((trans)-4-(methylsulfonamido) cyclohexyl)methyl) carbamate.
- 2-[4-[(tert-butoxycarbonylamino)methyl]phenyl]acetic acid (265 mg, 1.0 mmol), [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylene]-dimethyl-ammonium hexafluorophosphate (HATU, 380 mg, 1.0 mmol) and cyanamide (42 mg, 1.0 mmol) were dissolved in 5 mL dry DMF, and DIPEA (0.35 mL, 2.0 mmol) was added. The mixture was stirred at room temperature for 4 hours, poured into H2O, extracted with EtOAc, washed with brine, dried over Na2SO4, concentrated in vacuo and purified by flash CC (eluent: DCM/MeOH, on silica gel) yielding tert-butyl tert-butyl N-[[4-[2-(cyanoamino)-2-oxo-ethyl]phenyl]methyl]carbamate. The product was dissolved in 2 mL DCM and a solution of 4M HCl in dioxane (2 mL) was added. The mixture was stirred overnight at room temperature, concentrated, and the crude 2-[4-(aminomethyl)phenyl]-N-cyano-acetamide hydrochloride was used in the next step without further purification (120 mg, 53%).
- The initial two steps of
general method 4 may be performed in accordance with general method 3. The methyl ester 4a was subsequently hydrolyzed to yield 4b, e.g. by treatment with 1M lithium hydroxide in an appropriate solvent combination, e.g. water/tetrahydrofuran/methanol (e.g. in a ratio of 1:1:1). Hydrolysis was typically achieved after stirring at room temperature overnight. The reaction may for example be monitored by thin layer chromatography The reaction may for example be monitored by thin layer chromatography. The desired product was obtained upon work-up, e.g. by extraction with EtOAc, washing with water at a suitable pH and brine, drying over an appropriate drying agent, e.g. Na2SO4, and purification by flash column chromatrography (CC) using an appropriate eluent combination on a suitable column material, e.g. heptane/EtOAc or DCM/MeOH on silica gel, or recrystallization from a suitable solvent or solvent mixture, e.g. toluene/heptane. Amide analogues 4c were prepared by treatment of 4b with ammonium chloride, HOAt, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and DIPEA in an appropriate solvent, e.g. DMF, followed by stirring at room temperature overnight. The reaction may for example be monitored by thin layer chromatography. The desired compound 4c was obtained upon work-up, for example by extraction with EtOAc, washing with water at a suitable pH and brine, drying over an appropriate drying agent, e.g. Na2SO4, and purification by flash column chromatrography (CC) using an appropriate eluent combination on a suitable column material, e.g. heptane/EtOAc or DCM/MeOH on silica gel, or recrystallization from a suitable solvent or solvent mixture, e.g. toluene/heptane. - Use of General Method 4 to Prepare Example No. 86:
- Methyl 2-[5-(hydroxymethyl)pyrimidin-2-yl]acetate (0.36 g, 2.0 mmol) and 4,5,6-trifluoro-pyrimidine (0.27 g, 2.0 mmol) were dissolved in dry DMSO (4 mL) and DIPEA (0.7 mL, 4.0 mmol) was added. The reaction was stirred at room temperature overnight, poured into 3M aq. calcium chloride, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by flash CC (eluent: DCM/MeOH, on silica gel) yielding methyl 2-[5-[(5,6-difluoropyrimidin-4-yl)oxymethyl]pyrimidin-2-yl]acetate (0.39 g, 66% yield).
- Methyl 2-[5-[(5,6-difluoropyrimidin-4-yl)oxymethyl]pyrimidin-2-yl]acetate (0.30 g, 1.0 mmol) and 2-(4-trifluoromethyl-phenyl)-pyrrolidine (0.22 g, 1.0 mmol) were dissolved in dry DMSO (2 mL) and cesium carbonate (0.65 g, 2.0 mmol) was added. The reaction was heated in a microwave reactor for 1 hour at 100° C., poured into 3M aq. calcium chloride, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by flash CC (eluent: DCM/MeOH, on silica gel) yielding methyl 2-[5-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]oxymethyl]pyrimidin-2-yl]acetate (0.24 g, 49% yield).
- Methyl 2-[5-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]oxymethyl]pyrimidin-2-yl]acetate (0.20 g, 0.41 mmol) was dissolved in 2M aq. lithium hydroxide/tetrahydrofuran/methanol (1:1:1, 10 mL) and stirred at room temperature overnight. The solvents were removed in vacuo and the residue purified by preparative HPLC yielding 2-[5-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]oxymethyl]pyrimidin-2-yl]acetic acid (0.15 g, 76% yield).
- 2-[5-[[5-Fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]oxymethyl]pyrimidin-2-yl]acetic acid (0.12 g, 0.25 mmol), ammonium chloride (14 mg, 0.25 mmol), HOAt (31 mg, 0.25 mmol), EDC (39 mg, 0.25 mmol) and DIPEA (45 μL, 0.25 mmol) were dissolved in dry DMF (2 mL), and the reaction was stirred at room temperature overnight. The mixture was concentrated in vacuo, redissolved in EtOAc, washed with sat. aq. potassium carbonate, aq. potassium bisulfate (10%) and brine, dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash CC (eluent: eluent: DCM/MeOH, on silica gel) yielding 2-[5-[[5-fluoro-6-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyrimidin-4-yl]oxymethyl]pyrimidin-2-yl]acetamide 86 (68 mg, 56% yield). 1H NMR (300 MHz, CD3OD) δ 8.02 (s, 1H), 7.94-7.83 (m, 2H), 7.47 (d, J=8.1 Hz, 2H), 7.25 (d, J=8.0 Hz, 2H), 5.32 (d, J=7.7 Hz, 1H), 4.02-3.96 (m, 1H), 3.81-3.52 (m, 4H), 2.38-2.19 (m, 1H), 1.97-1.71 (m, 3H). m/z 477 (M+H).
-
General method 4 was used to prepare the following example numbers using the shown starting materials: -
Ex. No. 1H NMR or MS Data 4 m/z 589 (M + H) 5 1H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 1.9 Hz, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 6.46 (s, 1H), 5.41 (d, J = 7.9 Hz, 1H), 5.24 (s, 1H), 4.69 (s, 1H), 4.58 (s, 1H), 4.08-3.99 (m, 1H), 3.83-3.72 (m, 1H), 2.36 (dt, J = 15.4, 5.7 Hz, 1H), 2.05 (dd, J = 14.6, 3.6 Hz, 1H), 2.01-1.86 (m, 3H), 1.50 (dd, J = 14.7, 8.7 Hz, 1H), 0.96 (s, 9H). 6 1H NMR (300 MHz, CD3OD) δ 8.23 (s, 1H), 8.06-7.92 (m, 1H), 7.75-7.55 (m, 2H), 7.48-7.29 (m, 2H), 5.44-4.98 (m, 2H), 4.50-4.21 (m, 1H), 3.95-3.48 (m, 3H), 2.62-2.42 (m, 1H), 2.11-1.90 (m, 3H), 0.94 (s, 9H). 9 m/z 517 (M + H) 11 m/z 454 (M + H) 13 1H NMR (300 MHz, CDCl3) δ 7.57 (dd, J = 8.2, 3.3 Hz, 2H), 7.31 (dd, J = 8.0, 3.3 Hz, 2H), 5.46-5.30 (m, 1H), 4.69-4.51 (m, 1H), 4.17-4.00 (m, 1H), 3.91-3.77 (m, 1H), 2.54-2.25 (m, 1H), 2.12-1.87 (m, 4H), 1.64-1.46 (m, 1H), 1.04-0.77 (m, 9H). 14 m/z 450 (M + H) 15 m/z 464 (M + H) 16 1H NMR (300 MHz, CDCl3) δ 7.94 (d, J = 1.8 Hz, 1H), 7.65-7.50 (m, 2H), 7.35-7.28 (m, 2H), 5.62-5.47 (m, 1H), 5.42 (t, J = 8.8 Hz, 1H), 4.22-3.94 (m, 2H), 3.89-3.66 (m, 1H), 2.49-2.28 (m, 1H), 2.05-1.82 (m, 3H), 1.81-1.55 (m, 4H), 1.26 (dd, J = 6.3, 0.8 Hz, 3H), 1.23-1.15 (m, 4H), 1.11 (s, 2H). 17 1H NMR (300 MHz, CDCl3) δ 7.90 (dd, J = 3.2, 1.8 Hz, 1H), 7.63-7.52 (m, 2H), 7.35-7.25 (m, 2H), 7.23-7.11 (m, 2H), 6.90-6.76 (m, 2H), 5.41 (d, J = 8.0 Hz, 1H), 5.12-4.96 (m, 1H), 4.83-4.66 (m, 1H), 4.12-3.98 (m, 1H), 3.79 (s, 3H), 3.20-2.98 (m, J = 6.7 Hz, 2H), 2.46-2.27 (m, 1H), 2.04-1.83 (m, 3H). 18 1H NMR (300 MHz, DMSO-d6) δ 7.71-7.55 (m, 3H), 7.42 (t, J = 9.0 Hz, 2H), 7.15 (s, 1H), 6.89 (d, J = 6.9 Hz, 1H), 6.63-6.49 (m, 1H), 5.29-5.17 (m, 1H), 4.53-4.39 (m, 1H), 4.17-3.90 (m, 1H), 3.42 (t, J = 10.0 Hz, 2H), 2.66-2.53 (m, 1H), 2.41-2.18 (m, 1H), 1.75-1.54 (m, 2H), 1.42-1.28 (m, 1H), 1.10-0.99 (m, 3H), 0.85 (dd, J = 8.4, 3.7 Hz, 9H). 19 1H NMR (300 MHz, DMSO-d6) δ 7.75 (dd, J = 6.4, 1.9 Hz, 1H), 7.30 (dd, J = 8.1, 6.1 Hz, 2H), 7.18-7.01 (m, 3H), 6.87 (d, J = 14.0 Hz, 1H), 6.55-6.44 (m, 1H), 5.30 (d, J = 7.2 Hz, 1H), 4.46 (qd, J = 9.1, 3.4 Hz, 1H), 3.99-3.89 (m, 1H), 3.73-3.60 (m, 1H), 2.34-2.19 (m, 1H), 1.91-1.50 (m, 5H), 1.31-1.17 (m, 9H). 20 1H NMR (300 MHz, DMSO-d6) δ 7.93-7.83 (m, 1H), 7.71 (dd, J = 8.4, 2.5 Hz, 2H), 7.60 (d, J = 8.0 Hz, 2H), 7.22 (s, 1H), 6.93 (d, J = 6.6 Hz, 1H), 6.84 (d, J = 8.6 Hz, 1H), 5.46 (d, J = 3.3 Hz, 1H), 4.58-4.45 (m, 1H), 4.35-4.26 (m, 1H), 4.07-3.81 (m, 3H), 3.73-3.60 (m, 1H), 3.50-3.38 (m, 1H), 1.81-1.55 (m, 2H), 0.88 (d, J = 3.6 Hz, 9H). 21 1H NMR (300 MHz, CDCl3) δ 7.95 (s, 1H), 7.55 (d, J = 7.9 Hz, 2H), 7.29 (d, J = 7.4 Hz, 2H), 5.41 (d, J = 8.2 Hz, 1H), 4.44 (s, 1H), 4.12-3.96 (m, 1H), 3.88-3.69 (m, 1H), 3.53-3.31 (m, 2H), 2.48-2.28 (m, 1H), 2.06-1.81 (m, 3H), 1.56-1.40 (m, 2H), 0.95 (s, 9H). 23 m/z 437 (M + H) 24 m/z 444 (M + H) 29 1H NMR (300 MHz, DMSO-d6) δ 7.74-7.59 (m, 3H), 7.39 (d, J = 8.0 Hz, 2H), 7.10 (t, J = 8.0 Hz, 2H), 6.78 (dd, J = 8.4, 6.2 Hz, 2H), 6.46-6.31 (m, 1H), 5.34 (d, J = 7.7 Hz, 1H), 4.72 (t, J = 5.3 Hz, 1H), 4.21-4.07 (m, 1H), 4.02-3.86 (m, 1H), 3.68 (s, 3H), 2.88-2.58 (m, 2H), 2.41-2.21 (m, 1H), 1.98-1.68 (m, 3H), 1.05 (t, J = 7.0 Hz, 1H). 30 1H NMR (300 MHz, DMSO-d6) δ 7.77-7.58 (m, 3H), 7.46-7.32 (m, 2H), 6.29 (d, J = 8.6 Hz, 1H), 5.41-5.29 (m, 1H), 4.70-4.53 (m, 1H), 4.24-4.08 (m, 1H), 4.02-3.88 (m, 1H), 3.76-3.60 (m, 1H), 2.44-2.23 (m, 1H), 2.01-1.70 (m, 3H), 1.55-1.33 (m, 2H), 0.90-0.78 (m, 9H). 31 m/z 482 (M + H) 32 1H NMR (300 MHz, CD3OD) δ 7.72 (s, 1H), 7.60 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 7.32-7.17 (m, 4H), 5.49-5.37 (m, 1H), 4.61-4.45 (m, 2H), 4.13-3.96 (m, 1H), 3.90-3.72 (m, 1H), 3.57 (s, 2H), 2.54-2.35 (m, 1H), 2.08-1.85 (m, 3H). 33 1H NMR (300 MHz, CDCl3) δ 7.94-7.75 (m, 1H), 7.54 (d, J = 8.3 Hz, 2H), 7.32 (dd, J = 8.4, 2.8 Hz, 2H), 5.27 (t, J = 8.4 Hz, 1H), 4.93-4.79 (m, 1H), 4.66-4.48 (m, 1H), 4.21-4.04 (m, 1H), 3.53-3.38 (m, 1H), 2.68-2.51 (m, 1H), 2.48-2.27 (m, 1H), 1.90-1.57 (m, 3H), 1.12 (d, J = 6.4 Hz, 3H), 1.01-0.84 (m, 6H). 34 1H NMR (300 MHz, CDCl3) δ 7.89-7.77 (m, 1H), 7.54 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 5.27 (t, J = 8.7 Hz, 1H), 4.91-4.73 (m, 1H), 4.64-4.47 (m, 1H), 4.24-4.02 (m, 1H), 3.46 (t, J = 10.4 Hz, 1H), 2.71-2.50 (m, 1H), 2.46-2.29 (m, 1H), 1.89-1.58 (m, 3H), 1.17-1.04 (m, 3H), 1.01-0.90 (m, 6H). 35 1H NMR (300 MHz, CDCl3) δ 7.93 (dd, J = 5.7, 1.9 Hz, 1H), 7.70-7.64 (m, 1H), 7.44 (t, J = 7.2 Hz, 1H), 7.21 (dd, J = 8.1, 5.4 Hz, 1H), 5.59-5.44 (m, 1H), 4.76-4.68 (m, 1H), 4.64-4.50 (m, 1H), 3.89-3.74 (m, 1H), 2.52-2.36 (m, 1H), 2.13-1.80 (m, 4H), 1.58-1.43 (m, 1H), 1.02-0.89 (m, 9H). 36 1H NMR (300 MHz, CDCl3) δ 7.93 (d, J = 4.1 Hz, 1H), 7.67 (s, 1H), 7.45 (t, J = 6.4 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 5.72-5.60 (m, 1H), 4.83-4.70 (m, 1H), 4.61-4.46 (m, 1H), 4.16-4.02 (m, 1H), 3.92-3.74 (m, 1H), 2.53-2.36 (m, 1H), 2.12-1.81 (m, 4H), 1.62-1.47 (m, 1H), 1.03-0.93 (m, 9H). 37 1H NMR (300 MHz, DMSO-d6) δ 7.70-7.55 (m, 3H), 7.52-7.45 (m, 1H), 7.39 (d, J = 7.9 Hz, 2H), 7.35-7.20 (m, 2H), 7.08-6.99 (m, 2H), 5.29-5.10 (m, 1H), 3.48-3.37 (m, 1H), 2.98 (t, J = 11.9 Hz, 2H), 2.34-2.20 (m, 1H), 1.41-1.21 (m, 1H), 1.10-0.94 (m, 3H). 38 1H NMR (300 MHz, CDCl3) δ 7.95-7.85 (m, 1H), 7.62-7.50 (m, 2H), 7.35-7.29 (m, 1H), 7.26-7.17 (m, 1H), 5.33-5.23 (m, 1H), 4.15 (t, J = 9.9 Hz, 1H), 4.03-3.88 (m, 1H), 3.83-3.70 (m, 1H), 1.77-1.62 (m, 3H), 1.19 (d, J = 6.6 Hz, 2H), 1.01-0.87 (m, 12H). 39 m/z 453 (M + H) 40 1H NMR (300 MHz, DMSO-d6) δ 7.70 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 7.8 Hz, 2H), 7.23-7.08 (m, 4H), 6.92-6.75 (m, 1H), 5.37 (d, J = 7.9 Hz, 1H), 4.56-4.37 (m, 2H), 4.05-3.86 (m, 1H), 3.78-3.61 (m, 1H), 3.31-3.27 (m, 2H), 2.46-2.22 (m, 2H), 1.97-1.70 (m, 3H). 41 1H NMR (400 MHz, CDCl3) δ 7.90 (S, 1H), 7.56 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 8.6 Hz, 2H), 5.40 (d, J = 7.9 Hz, 1H), 4.25 (s, 2H), 4.07-3.97 (m, 1H), 3.91 (dd, J = 11.1, 4.3 Hz, 2H), 3.83-3.71 (m, 1H), 3.39-3.26 (m, 2H), 2.42-2.30 (m, 1H), 2.03-1.85 (m, 3H), 1.69 (d, J = 13.0 Hz, 2H), 1.49-1.20 (m, 4H), 1.19-1.13 (m, 3H). 42 1H NMR (400 MHz, DMSO-d6) δ 8.83-8.77 (m, 1H), 8.11 (d, J = 8.1 Hz, 1H), 8.05 (d, J = 6.2 Hz, 1H), 7.62-7.55 (m, 1H), 5.59 (s, 1H), 4.67-4.58 (m, 1H), 4.07 (t, J = 9.7 Hz, 1H), 3.92-3.81 (m, 1H), 2.56 (s, 1H), 2.21-1.95 (m, 4H), 1.89-1.73 (m, 2H), 0.97-0.87 (m, 9H). 43 1H NMR (400 MHz, CDCl3) δ 7.94 (dd, J = 6.4, 2.0 Hz, 1H), 7.03 (dd, J = 8.6, 4.2 Hz, 2H), 6.93-6.86 (m, 2H), 6.52 (s, 1H), 5.35 (s, 1H), 5.22 (s, 1H), 4.61 (s, 1H), 4.58-4.48 (m, 1H), 3.98 (s, 1H), 3.73 (t, J = 7.3 Hz, 1H), 2.38-2.22 (m, 1H), 2.06 (dt, J = 14.5, 3.0 Hz, 1H), 1.98-1.88 (m, 3H), 1.53-1.42 (m, 1H), 1.32 (dd, J = 5.6, 1.2 Hz, 9H), 0.93 (dd, J = 17.0, 3.0 Hz, 9H). 44 m/z 461 (M + H) 45 m/z 557 (M + H) 46 m/z 510 (M + H) 48 m/z 485 (M + H) 51 1H NMR (400 MHz, CDCl3) δ 7.92 (dd, J = 5.3, 2.0 Hz, 1H), 7.55 (t, J = 7.6 Hz, 2H), 7.26 (s, 2H), 6.23 (s, 1H), 5.45-5.31 (m, 2H), 5.18 (dd, J = 7.6, 2.3 Hz, 1H), 4.54-4.45 (m, 1H), 4.14-3.99 (m, 2H), 3.84-3.73 (m, 1H), 2.45-2.31 (m, 1H), 2.04-1.85 (m, 3H), 1.21 (d, J = 6.4 Hz, 3H), 1.16 (d, J = 22.8 Hz, 9H). 52 1H NMR (400 MHz, DMSO-d6) δ 7.75 (d, J = 8.6 Hz, 1H), 7.66 (dd, J = 8.5, 2.7 Hz, 2H), 7.46-7.39 (m, 2H), 7.34-7.29 (m, 1H), 6.95 (d, J = 11.9 Hz, 1H), 6.77 (d, J = 20.9 Hz, 1H), 5.38 (s, 1H), 4.52-4.37 (m, 1H), 3.97 (d, J = 8.1 Hz, 1H), 3.83-3.67 (m, 3H), 3.29-3.09 (m, 2H), 2.40-2.30 (m, 1H), 1.98-1.74 (m, 3H), 1.73-1.46 (m, 5H), 1.25-1.05 (m, 2H). 53 m/z 477 (M + H) 54 m/z 477 (M + H) 55 m/z 517 (M + H) 56 m/z 502 (M + H) 57 m/z 530 (M + H) 58 m/z 531 (M + H) 59 m/z 517 (M + H) 60 m/z 515 (M + H) 61 m/z 543 (M + H) 62 1H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 1.9 Hz, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 6.46 (s, 1H), 5.41 (d, J = 7.9 Hz, 1H), 5.24 (s, 1H), 4.69 (s, 1H), 4.58 (s, 1H), 4.08-3.99 (m, 1H), 3.83-3.72 (m, 1H), 2.36 (dt, J = 15.4, 5.7 Hz, 1H), 2.05 (dd, J = 14.6, 3.6 Hz, 1H), 2.01-1.86 (m, 3H), 1.50 (dd, J = 14.7, 8.7 Hz, 1H), 0.96 (s, 9H). 63 1H NMR (400 MHz, CDCl3) δ 7.88 (dd, J = 5.1, 2.0 Hz, 1H), 7.54 (d, J = 8.6 Hz, 2H), 7.28 (d, J = 8.3 Hz, 2H), 6.92 (d, J = 22.7 Hz, 1H), 6.71 (d, J = 3.7 Hz, 1H), 6.41 (s, 0H), 5.61 (d, J = 8.8 Hz, 1H), 5.47-5.29 (m, 2H), 4.81-4.56 (m, 1H), 4.09-3.98 (m, 1H), 3.84-3.71 (m, 1H), 3.44-3.28 (m, 2H), 2.59-2.47 (m, 1H), 2.46-2.29 (m, 2H), 2.25-2.10 (m, 1H), 2.09-1.81 (m, 6H). 64 1H NMR (300 MHz, DMSO-d6) δ 7.73 (dd, J = 7.1, 2.0 Hz, 1H), 7.64 (t, J = 7.3 Hz, 2H), 7.41 (dd, J = 7.8, 3.7 Hz, 2H), 6.51-6.22 (m, 1H), 5.35 (d, J = 7.5 Hz, 1H), 4.21 (s, 1H), 3.96 (s, 1H), 3.69 (d, J = 10.0 Hz, 2H), 3.35 (s, 1H), 3.27-3.05 (m, 1H), 2.69 (d, J = 11.7 Hz, 1H), 2.64-2.52 (m, 2H), 2.42-2.14 (m, 3H), 1.99-1.71 (m, 3H), 1.51 (d, J = 11.3 Hz, 1H), 1.47-1.32 (m, 1H), 0.79 (dd, J = 9.0, 4.2 Hz, 9H). 65 1H NMR (400 MHz, CDCl3) δ 7.93 (dd, J = 6.8, 1.7 Hz, 1H), 7.15-6.99 (m, 3H), 6.44 (s, 1H), 5.60 (d, J = 8.1 Hz, 1H), 5.20 (s, 1H), 4.66-4.51 (m, 2H), 4.02 (s, 1H), 3.93 (d, J = 2.4 Hz, 3H), 3.75 (t, J = 8.8 Hz, 1H), 2.30 (t, J = 7.3 Hz, 1H), 2.09-2.02 (m, 1H), 1.90 (dt, J = 27.6, 9.5 Hz, 3H), 1.47 (M, 1H), 0.93 (d, J = 17.1 Hz, 9H). 66 m/z 431 (M + H) 67 1H NMR (300 MHz, DMSO-d6) δ 8.15 (s, 1H), 7.76 (d, J = 5.6 Hz, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 7.7 Hz, 2H), 7.17 (d, J = 3.4 Hz, 1H), 6.96 (s, 1H), 6.82 (dd, J = 8.0, 1.4 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 6.44 (s, 1H), 5.90 (d, J = 5.6 Hz, 1H), 5.31 (d, J = 8.3 Hz, 1H), 5.26-5.14 (m, 2H), 4.19-4.02 (m, 1H), 3.92-3.76 (m, 1H), 3.70-3.63 (m, 6H), 2.47-2.37 (m, 1H), 2.09-1.79 (m, 3H). 68 1H NMR (300 MHz, CDCl3) δ 7.99 (d, J = 1.7 Hz, 1H), 7.58-7.47 (m, 2H), 7.22-7.13 (m, 2H), 6.36 (s, 1H), 5.57 (s, 1H), 5.29 (s, 1H), 4.89 (d, J = 7.5 Hz, 1H), 4.68-4.58 (m, 1H), 4.42-4.31 (m, 1H), 4.08-3.90 (m, 3H), 3.84-3.69 (m, 1H), 3.50-3.35 (m, 1H), 2.15-2.02 (m, 1H), 1.64-1.56 (m, 1H), 0.99 (s, 9H). 69 1H NMR (300 MHz, DMSO-d6) δ 7.71 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 7.8 Hz, 2H), 7.21-7.10 (m, 5H), 5.37 (d, J = 7.9 Hz, 1H), 4.55-4.38 (m, 2H), 4.05-3.87 (m, 1H), 3.81-3.65 (m, 1H), 3.64-3.53 (m, 5H), 2.39-2.21 (m, 1H), 1.99-1.67 (m, 3H). 70 1H NMR (300 MHz, DMSO-d6) δ 7.71 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 7.8 Hz, 2H), 7.21-7.10 (m, 5H), 5.37 (d, J = 7.9 Hz, 1H), 4.55-4.38 (m, 2H), 4.05-3.87 (m, 1H), 3.81-3.65 (m, 1H), 3.64-3.53 (m, 5H), 2.39-2.21 (m, 1H), 1.99-1.67 (m, 3H). 71 m/z 538 (M + H) 72 1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 5.4 Hz, 1H), 7.52 (q, J = 7.2 Hz, 1H), 7.10-6.97 (m, 2H), 6.41 (s, 1H), 5.36 (s, 1H), 5.22 (s, 1H), 4.70 (s, 1H), 4.58 (s, 1H), 4.03 (s, 1H), 3.78 (d, J = 10.8 Hz, 1H), 2.37 (s, 1H), 2.10-1.86 (m, 4H), 1.52-1.46 (m, 1H), 1.26 (s, 1H), 0.95 (d, J = 11.6 Hz, 8H). 73 1H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 2.4 Hz, 1H), 7.96 (s, 1H), 7.66 (dd, J = 7.8, 2.4 Hz, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.15 (d, J = 7.8 Hz, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.99 (d, J = 11.0 Hz, 1H), 5.44-5.32 (m, 3H), 4.06 (dt, J = 6.8, 3.9 Hz, 1H), 3.86-3.76 (m, 1H), 2.55 (s, 3H), 2.45-2.32 (m, 1H), 2.07-1.87 (m, 3H). 74 1H NMR (400 MHz, CDCl3) δ 8.56 (d, J = 2.4 Hz, 1H), 7.95 (s, 1H), 7.65 (dd, J = 7.9, 2.6 Hz, 1H), 7.54 (d, J = 8.3 Hz, 2H), 7.28 (s, 2H), 7.14 (d, J = 7.8 Hz, 1H), 5.46-5.31 (m, 3H), 4.12-4.02 (m, 1H), 3.86-3.77 (m, 1H), 2.55 (s, 3H), 2.43-2.32 (m, 1H), 2.03-1.87 (m, 3H). 77 1H NMR (300 MHz, CDCl3) δ 7.95 (s, 1H), 7.56 (d, J = 7.9 Hz, 2H), 7.28 (d, J = 9.8 Hz, 4H), 6.10 (s, 1H), 5.46 (dt, J = 8.1, 3.4 Hz, 2H), 5.30 (s, 1H), 4.15-4.01 (m, 1H), 3.92-3.75 (m, 1H), 2.47-2.31 (m, 1H), 2.07-1.72 (m, 7H), 1.02-0.86 (m, 6H). 78 1H NMR (300 MHz, CDCl3) δ 7.93 (s, 1H), 7.56 (d, J = 8.3 Hz, 2H), 7.26 (d, 4H), 6.17 (s, 1H), 5.53-5.32 (m, 3H), 4.09 (s, 1H), 3.91-3.78 (m, 1H), 2.48-2.31 (m, 1H), 2.08-1.48 (m, 7H), 0.92 (dd, J = 7.8, 6.1 Hz, 6H). 79 1H NMR (300 MHz, CDCl3) δ 7.96 (s, 1H), 7.54 (d, J = 8.3 Hz, 2H), 7.40 (d, J = 8.1 Hz, 2H), 7.27 (d, J = 8.1 Hz, 4H), 5.47-5.30 (m, 3H), 4.13-4.01 (m, 1H), 3.88-3.75 (m, 1H), 3.65 (s, 2H), 2.44-2.31 (m, 1H), 2.04-1.85 (m, 3H). 80 1H NMR (400 MHz, DMSO-d6) δ 10.46 (s, 0.3H), 8.77-8.73 (m, 0.64H), 8.69 (d, J = 2.9 Hz, 0.63H), 8.53 (s, 0.57H), 8.19 (dd, J = 8.1, 2.5 Hz, 2H), 7.86 (d, J = 8.4 Hz, 2H), 7.61 (s, 0.68H), 7.33 (dd, J = 8.8, 2.8 Hz, 1H), 7.22 (s, 0.67H), 5.81 (d, J = 6.0 Hz, 0.36H), 5.31 (dd, J = 9.6, 3.7 Hz, 0.71H), 4.27-4.20 (m, 0.42H), 1.95-1.79 (m, 2H), 1.79-1.66 (m, 1H), 1.59-1.51 (m, 1H), 1.01-0.89 (m, 6H). Note: Due to the presence of isomers the protons were integrated in decimals 81 1H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 1.8 Hz, 1H), 7.55 (d, J = 8.3 Hz, 2H), 7.31-7.21 (m, 6H), 5.41 (d, J = 7.9 Hz, 1H), 4.93 (s, 1H), 4.66-4.50 (m, 2H), 4.10-3.98 (m, 1H), 3.86-3.72 (m, 1H), 3.63 (s, 2H), 2.49-2.29 (m, 1H), 2.03-1.84 (m, 3H). 83 1H NMR (300 MHz, CDCl3) δ 8.10 (s, 1H), 7.61 (d, J = 8.0 Hz, 2H), 7.46 (dd, J = 8.3, 2.2 Hz, 4H), 7.37-7.29 (m, 2H), 5.46 (s, 2H), 4.79 (d, J = 6.1 Hz, 2H), 3.68 (s, 2H). 84 1H NMR (300 MHz, DMSO-d6) δ 8.74-8.60 (m, 1H), 8.01-7.84 (m, 2H), 7.80 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 7.24 (d, J = 8.2 Hz, 2H), 6.95-6.73 (m, 1H), 5.44 (d, J = 7.7 Hz, 1H), 5.40-5.24 (m, 2H), 4.17-3.95 (m, 1H), 3.86-3.67 (m, 1H), 3.36 (s, 2H), 2.46-2.29 (m, 1H), 2.04-1.76 (m, 3H). 85 1H NMR (300 MHz, DMSO-d6) δ 12.19 (s, 1H), 8.07 (s, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 7.16 (s, 5H), 6.80-6.55 (m, 1H), 5.61 (d, J = 7.8 Hz, 1H), 5.44-5.19 (m, 2H), 4.32-4.05 (m, 1H), 4.05-3.78 (m, 1H), 3.50 (s, 2H), 2.44-2.27 (m, 1H), 2.12-1.70 (m, 3H). 86 1H NMR (300 MHz, CD3OD) δ 8.02 (dd, J = 2.3, 1.2 Hz, 1H), 7.93-7.85 (m, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H), 5.32 (d, J = 7.7 Hz, 1H), 4.81 (d, J = 4.9 Hz, 2H), 4.04-3.92 (m, 1H), 3.72-3.55 (m, 3H), 2.40-2.19 (m, 1H), 1.95-1.70 (m, 3H). 87 1H NMR (300 MHz, CD3OD) δ 7.92 (s, 1H), 7.84-7.79 (m, 1H), 7.65 (t, J = 1.6 Hz, 1H), 7.48 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 8.0 Hz, 2H), 5.34-5.26 (m, 1H), 4.39-4.25 (m, 2H), 4.00-3.87 (m, 1H), 3.77-3.60 (m, 3H), 2.40-2.23 (m, 1H), 1.96-1.73 (m, 3H). 88 1H NMR (300 MHz, CD3OD) δ 7.70 (t, J = 1.7 Hz, 1H), 7.67-7.56 (m, 4H), 7.45 (dd, J = 8.2, 1.6 Hz, 2H), 7.38 (d, J = 7.9 Hz, 2H), 5.47-5.39 (m, 1H), 4.63 (s, 2H), 4.13-4.00 (m, 1H), 3.86-3.73 (m, 1H), 2.51-2.35 (m, 1H), 2.06-1.84 (m, 3H). 89 1H NMR (300 MHz, CD3OD) δ 8.35 (d, J = 2.2 Hz, 1H), 7.78-7.70 (m, 1H), 7.65 (dd, J = 8.0, 2.3 Hz, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 1H), 5.48-5.36 (m, 1H), 4.55 (d, J = 3.5 Hz, 2H), 4.13-3.95 (m, 1H), 3.89-3.70 (m, 1H), 2.47 (s, 3H), 2.46-2.31 (m, 1H), 2.04-1.81 (m, 3H). 90 1H NMR (300 MHz, CD3OD) δ 8.39-8.30 (m, 1H), 7.74 (d, J = 1.7 Hz, 1H), 7.63 (dd, J = 8.0, 2.3 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 7.07-7.01 (m, 2H), 6.84-6.77 (m, 2H), 5.36-5.24 (m, 1H), 4.53 (d, J = 3.8 Hz, 2H), 4.05-3.92 (m, 1H), 3.75-3.64 (m, 5H), 2.47 (s, 3H), 2.36-2.23 (m, 1H), 1.95-1.82 (m, 3H). 91 1H NMR (400 MHz, DMSO-d6) δ 12.20 (s, 1H), 7.84 (d, J = 2.0 Hz, 1H), 7.63 (q, J = 4.5 Hz, 1H), 7.53-7.47 (m, 2H), 7.33 (d, J = 8.6 Hz, 2H), 7.25-7.14 (m, 4H), 5.42 (s, 1H), 4.58-4.44 (m, 2H), 4.28 (dd, J = 12.1, 2.3 Hz, 1H), 4.01-3.81 (m, 3H), 3.65 (td, J = 11.2, 2.9 Hz, 2H), 3.51 (s, 2H), 3.30-3.24 (m, 1H). 93 1H NMR (300 MHz, CD3OD) δ 7.72 (t, J = 2.0 Hz, 1H), 7.58 (d, J = 8.1 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 5.44-5.37 (m, 1H), 4.10-3.99 (m, 1H), 3.84-3.72 (m, 1H), 3.31-3.25 (m, 1H), 3.16 (dd, J = 7.0, 5.2 Hz, 1H), 2.51-2.34 (m, 1H), 2.04-1.84 (m, 3H), 1.81-1.65 (m, 3H), 1.48-1.38 (m, 2H), 1.38-1.21 (m, 2H), 1.00-0.82 (m, 6H). 94 1H NMR (300 MHz, CD3OD) δ 7.70 (s, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 7.16 (d, J = 8.2 Hz, 2H), 7.06 (s, 1H), 6.96 (s, 1H), 5.44-5.38 (m, 1H), 4.55 (d, J = 4.7 Hz, 2H), 4.10-3.98 (m, 1H), 3.85-3.69 (m, 1H), 2.49-2.32 (m, 1H), 2.03-1.82 (m, 3H). 95 1H NMR (300 MHz, CD3OD) δ 7.72 (dd, J = 1.7, 0.7 Hz, 1H), 7.59 (d, J = 8.1 Hz, 2H), 7.43-7.29 (m, 6H), 5.46-5.39 (m, 1H), 4.65-4.52 (m, 2H), 4.37 (s, 2H), 4.11-4.00 (m, 1H), 3.80 (dtd, J = 10.4, 7.5, 2.8 Hz, 1H), 2.83 (s, 3H), 2.52-2.35 (m, 1H), 2.07-1.85 (m, 3H). 96 1H NMR (300 MHz, DMSO-d6) δ 9.46 (s, 1H), 8.90 (t, J = 5.9 Hz, 1H), 8.47 (d, J = 2.5 Hz, 1H), 8.38 (d, J = 1.2 Hz, 1H), 8.27 (d, J = 8.2 Hz, 2H), 7.87 (d, J = 8.6 Hz, 2H), 7.66 (dd, J = 8.0, 2.3 Hz, 1H), 7.22 (d, J = 8.0 Hz, 1H), 4.67 (d, J = 5.9 Hz, 2H), 2.44 (s, 3H). 97 1H NMR (300 MHz, DMSO-d6) δ 8.34 (d, J = 2.2 Hz, 1H), 7.73 (d, J = 2.0 Hz, 1H), 7.53 (dd, J = 8.0, 2.3 Hz, 1H), 7.44-7.34 (m, 1H), 7.33-7.22 (m, 4H), 7.14 (d, J = 7.9 Hz, 1H), 5.38-5.28 (m, 1H), 4.52-4.36 (m, 2H), 4.00-3.86 (m, 1H), 3.71-3.62 (m, 1H), 2.40 (s, 3H), 2.36-2.25 (m, 1H), 2.01-1.66 (m, 3H). 98 1H NMR (300 MHz, CD3OD) δ 7.72 (d, J = 1.7 Hz, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 7.25-7.09 (m, 4H), 5.51-5.37 (m, 1H), 4.63-4.46 (m, 2H), 4.12-4.00 (m, 1H), 3.86-3.73 (m, 1H), 2.72 (s, 2H), 2.54-2.38 (m, 1H), 2.04-1.86 (m, 3H), 1.15 (s, 6H). 99 1H NMR (300 MHz, CD3OD) δ 7.69 (t, J = 1.4 Hz, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.39-7.31 (m, 3H), 6.66 (d, J = 7.3 Hz, 1H), 5.40 (d, J = 7.7 Hz, 1H), 4.45 (s, 2H), 4.09-3.98 (m, 1H), 3.92 (d, J = 1.2 Hz, 3H), 3.85-3.69 (m, 1H), 2.50-2.33 (m, 4H), 2.05-1.81 (m, 3H). 100 m/z 434 (M + H) 104 1H NMR (300 MHz, DMSO-d6) δ 10.29 (s, 1H), 8.33 (d, J = 2.2 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.53 (dd, J = 7.9, 2.3 Hz, 1H), 7.44-7.29 (m, 1H), 7.14 (d, J = 8.0 Hz, 1H), 7.11-6.96 (m, 3H), 5.46 (d, J = 7.9 Hz, 1H), 4.51-4.33 (m, 2H), 4.04-3.86 (m, 1H), 3.76-3.56 (m, 1H), 2.40 (s, 3H), 2.31-2.10 (m, 1H), 2.01-1.83 (m, 1H), 1.83-1.60 (m, 2H). 105 m/z 420 (M + H) 106 m/z 421 (M + H) 107 m/z 421 (M + H) 108 m/z 424 (M + H) 109 m/z 438 (M + H) 110 m/z 482 (M + H) 111 m/z 455 (M + H) 112 m/z 476 (M + H) 113 1H NMR (300 MHz, CD3OD) δ 7.99 (dd, J = 5.3, 1.0 Hz, 1H), 7.71 (t, J = 1.3 Hz, 1H), 7.59 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 7.9 Hz, 2H), 6.86 (dt, J = 5.4, 1.2 Hz, 1H), 6.67 (s, 1H), 5.43 (d, J = 7.8 Hz, 1H), 4.63-4.46 (m, 2H), 4.13-3.98 (m, 1H), 3.90-3.75 (m, 4H), 2.52-2.35 (m, 1H), 2.06-1.84 (m, 3H). 114 1H NMR (300 MHz, DMSO-d6) δ 8.05 (dd, J = 2.4, 0.8 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.67-7.60 (m, 2H), 7.59 (d, J = 2.5 Hz, 0H), 7.39 (d, J = 8.2 Hz, 3H), 6.73 (dd, J = 8.5, 0.8 Hz, 1H), 5.36 (d, J = 7.8 Hz, 1H), 4.48-4.32 (m, 2H), 3.98-3.90 (m, 1H), 3.79 (s, 3H), 3.76-3.62 (m, 1H), 2.38-2.26 (m, 1H), 1.97-1.71 (m, 3H). 115 1H NMR (300 MHz, DMSO-d6) δ 8.62 (s, 1H), 7.94 (s, 1H), 7.71-7.61 (m, 3H), 7.46-7.35 (m, 3H), 7.30-7.13 (m, 4H), 5.35 (s, 3H), 4.54-4.33 (m, 2H), 3.98-3.89 (m, 1H), 3.77-3.61 (m, 1H), 2.42-2.27 (m, 1H), 1.95-1.70 (m, 3H). 116 1H NMR (300 MHz, CD3OD) δ 7.97 (s, 1H), 7.77 (s, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.48 (dd, J = 8.8, 1.6 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 6.69 (d, J = 8.6 Hz, 1H), 5.46-5.34 (m, 1H), 4.55 (q, J = 15.5 Hz, 2H), 4.11-3.97 (m, 1H), 3.86 (s, 3H), 3.85-3.68 (m, 1H), 2.95 (d, J = 3.7 Hz, 3H), 2.50-2.34 (m, 1H), 2.02-1.80 (m, 3H). 117 1H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 1.8 Hz, 1H), 7.55 (d, J = 8.3 Hz, 2H), 7.31-7.21 (m, 6H), 5.41 (d, J = 7.9 Hz, 1H), 4.93 (s, 1H), 4.66-4.50 (m, 2H), 4.10-3.98 (m, 1H), 3.86-3.72 (m, 1H), 3.63 (s, 2H), 2.49-2.29 (m, 1H), 2.03-1.84 (m, 3H). 118 m/z 475 (M + H) 119 1H NMR (300 MHz, DMSO-d6) δ 12.25 (s, 1H), 7.84 (d, J = 1.7 Hz, 1H), 7.75-7.56 (m, 5H), 7.27-7.11 (m, 4H), 5.46 (s, 1H), 4.51 (d, J = 6.1 Hz, 2H), 4.30 (dd, J = 12.1, 2.3 Hz, 1H), 4.08-3.81 (m, 4H), 3.66 (td, J = 11.0, 2.9 Hz, 1H), 3.51 (s, 2H). 120 m/z 475 (M + H) 121 m/z 501 (M + H) 122 m/z 472 (M + H) 123 m/z 465 (M + H) 124 m/z 514 (M + H) 126 1H NMR (300 MHz, DMSO-d6) δ 8.67 (s, 1H), 7.95-7.89 (m, 1H), 7.82 (dd, J = 7.8, 0.7 Hz, 1H), 7.72 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.54 (t, J = 6.0 Hz, 1H), 7.40 (d, J = 8.1 Hz, 2H), 5.37 (d, J = 8.0 Hz, 1H), 4.69-4.49 (m, 2H), 4.06-3.91 (m, 1H), 3.80-3.63 (m, 1H), 2.39-2.26 (m, 1H), 2.02-1.70 (m, 3H). 128 m/z 461 (M + H) 129 m/z 441 (M + H) 130 m/z 492 (M + H) 131 m/z 448 (M + H) 132 m/z 432 (M + H) 134 m/z 464 (M + H) 135 m/z 452 (M + H) 136 m/z 460 (M + H) 137 m/z 500 (M + H) 138 m/z 485 (M + H) 139 m/z 417 (M + H) 140 m/z 418 (M + H) 141 m/z 418 (M + H) 142 m/z 477 (M + H) 143 m/z 500 (M + H) 144 m/z 474 (M + H) 145 m/z 488 (M + H) 146 m/z 498 (M + H) 147 m/z 461 (M + H) 148 m/z 481 (M + H) 150 m/z 368 (M + H) 151 m/z 495 (M + H) 152 m/z 409 (M + H) 154 m/z 411 (M + H) 155 m/z 425 (M + H) 159 m/z 427 (M + H) 161 m/z 439 (M + H) 164 m/z 441 (M + H) 165 m/z 443 (M + H) 166 m/z 451 (M + H) 167 m/z 453 (M + H) 168 m/z 453 (M + H) 169 m/z 457 (M + H) 170 m/z 459 (M + H) 175 m/z 481 (M + H) 178 m/z 465 (M + H) 181 m/z 411 (M + H) 182 m/z 496 (M + H) 183 m/z 452 (M + H) 184 m/z 459 (M + H) 185 m/z 423 (M + H) 186 m/z 425 (M + H) 188 m/z 439 (M + H) 189 m/z 488 (M + H) 190 1H NMR (300 MHz, CD3OD) δ 7.71 (s (br), 1H), 7.59 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H), 5.41 (d, J = 7.9 Hz, 1H), 4.14-3.96 (m, 1H), 3.87-3.72 (m, 1H), 3.28-3.06 (m, 2H), 2.82 (d, J = 6.8 Hz, 2H), 2.57-2.33 (m, 1H), 2.07-1.85 (m, 3H), 1.85-1.63 (m, 5H), 1.63-1.42 (m, 1H), 1.17-0.81 (m, 4H). 191 1H NMR (300 MHz, CD3OD) δ 7.73 (s (br), Hz, 1H), 7.59 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 5.41(d, J = 7.9 Hz, 2H), 4.56-4.42 (m, 1H), 4.19-3.99 (m, 1H), 3.90 (d, J = 13.8 Hz, 1H), 3.85-3.3.73 (m, 1H), 3.30-3.15 (m, 2H), 3.13-3.0 (m, 1H), 2.66-2.52 (m, 1H), 2.52-2.36 (m, 1H), 2.08 (s (br), 3H), 2.05-1.68 (m, 6H), 1.33-0.98 (m, 2H). 192 1H NMR (300 MHz, cdcl3) δ 7.96 (d, J = 1.8 Hz, 2H), 7.25 (d, J = 4.5 Hz, 11H), 7.20-7.09 (m, 4H), 5.38 (d, J = 7.9 Hz, 1H), 4.94 (s, 1H), 4.58 (t, J = 6.0 Hz, 2H), 4.02 (s, 1H), 3.82-3.70 (m, 1H), 3.63 (s, 2H), 2.40-2.29 (m, 1H), 2.00-1.84 (m, 3H). 193 1H NMR (300 MHz, C6D6) δ 8.11 (d, J = 2.0 Hz, 1H), 8.04 (s, 1H), 7.64 (d, J = 6.4 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H), 6.93 (d, J = 8.0 Hz, 2H), 6.55 (d, J = 7.8 Hz, 1H), 6.11 (dd, J = 7.9, 6.4 Hz, 1H), 5.84-5.74 (m, 1H), 5.18 (d, J = 7.9 Hz, 1H), 4.20-3.99 (m, 2H), 3.92-3.75 (m, 1H), 3.64-3.46 (m, 1H), 1.89-1.68 (m, 1H), 1.48-1.28 (m, 3H). 194 1H NMR (300 MHz, DMSO-d6) δ 8.13-8.07 (m, 2H), 7.72 (d, J = 2.0 Hz, 1H), 7.69-7.62 (m, 2H), 7.51-7.44 (m, 1H), 7.41 (d, J = 8.1 Hz, 2H), 7.27-7.20 (m, 2H), 5.38 (d, J = 7.8 Hz, 2H), 4.43 (t, J = 5.5 Hz, 2H), 4.04-3.91 (m, 2H), 3.77-3.65 (m, 2H), 2.40-2.30 (m, 1H), 1.94-1.75 (m, 4H). 195 1H NMR (300 MHz, DMSO-d6) δ 12.19 (s, 1H), 8.07 (s, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 7.16 (s, 5H), 6.80-6.55 (m, 1H), 5.61 (d, J = 7.8 Hz, 1H), 5.44-5.19 (m, 2H), 4.32-4.05 (m, 1H), 4.05-3.78 (m, 1H), 3.50 (s, 2H), 2.44-2.27 (m, 1H), 2.12-1.70 (m, 3H). 196 1H NMR (300 MHz, DMSO-d6) δ 7.20 (s, 1H), 6.71 (d, J = 8.1 Hz, 2H), 6.53 (d, J = 8.1 Hz, 2H), 6.35 (d, J = 8.0 Hz, 2H), 6.24 (d, J = 7.9 Hz, 2H), 6.13 (s, 1H), 5.60 (s, 1H), 4.78 (d, J = 7.9 Hz, 1H), 4.55-4.35 (m, 2H), 3.43-3.27 (m, 1H), 3.21-3.03 (m, 1H), 1.74-1.52 (m, 1H), 1.26-1.02 (m, 3H). 197 1H NMR (300 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.64 (d, J = 8.9 Hz, 2H), 7.43-7.34 (m, 2H), 6.89 (s, 1H), 5.47-5.23 (m, 1H), 4.07-3.88 (m, 1H), 3.76-3.63 (m, 1H), 3.57-3.46 (m, 2H), 3.27-3.06 (m, 2H), 2.81 (s, 3H), 2.67-2.54 (m, 2H), 2.42-2.27 (m, 1H), 2.01-1.56 (m, 5H), 1.27-1.01 (m, 3H). 198 1H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 1.9 Hz, 1H), 7.55 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.41 (d, J = 7.9 Hz, 1H), 4.80 (s, 1H), 4.52 (dd, J = 6.1, 2.1 Hz, 2H), 4.38 (d, J = 6.0 Hz, 2H), 4.08-3.97 (m, 1H), 3.79-3.70 (m, 1H), 3.68 (dd, J = 13.7, 6.3 Hz, 1H), 3.58 (dd, J = 13.7, 5.9 Hz, 1H), 2.39-2.36 (m, 1H), 1.97-1.89 (m, 3H), 1.32 (s, 3H). 199 1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 1.8 Hz, 1H), 7.55 (d, J = 7.9 Hz, 2H), 7.29 (d, J = 9.3 Hz, 2H), 5.40 (d, J = 7.7 Hz, 1H), 4.92 (s, 1H), 4.03-4.01 (m, 1H), 3.89-3.72 (m, 3H), 3.52-.3.44 (m, 2H), 2.39-2.35 (m, 1H), 2.00-1.73 (m, 6H), 1.73-1.58 (m, 1H), 1.20 (d, J = 3.0 Hz, 3H). 200 1H NMR (300 MHz, CDCl3) δ 7.84 (t, J = 2.2 Hz, 1H), 7.55 (d, J = 7.9 Hz, 2H), 7.28 (d, J = 7.9 Hz, 2H), 5.38 (t, J = 7.5 Hz, 1H), 4.99 (s, 1H), 4.76 (s, 1H), 4.00 (s, 1H), 3.84-3.59 (m, 3H), 3.00-2.90 (m, 1H), 2.3-2.32 (m, 1H), 2.01-1.81 (m, 4H), 1.77-1.51 (m, 3H), 1.50-1.33 (m, 3H), 1.32-1.21 (m, 2H). 201 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 1.8 Hz, 1H), 7.55 (dd, J = 8.4, 2.2 Hz, 2H), 7.30 (dd, J = 8.5, 2.2 Hz, 2H), 5.41 (d, J = 7.2 Hz, 1H), 5.06 (s, 1H), 4.04 (s, 1H), 3.77 (td, J = 7.5, 3.2 Hz, 1H), 3.57 (dd, J = 6.1, 3.9 Hz, 1H), 3.01-2.80 (m, 2H), 2.37 (td, J = 9.6, 8.8, 4.5 Hz, 1H), 2.13-2.00 (m, 2H), 2.00-1.79 (m, 4H), 1.73-1.68 (m, 1H), 1.42 (s, 3H). 202 1H NMR (300 MHz, CDCl3) δ 7.91 (d, J = 1.9 Hz, 1H), 7.55 (d, J = 7.8 Hz, 2H), 7.28 (d, J = 8.8 Hz, 2H), 5.40 (d, J = 7.8 Hz, 1H), 4.77 (s, 1H), 4.57-4.42 (m, 1H), 4.21-4.09 (m, 2H), 4.02-4.01 (m, 1H), 3.85-3.50 (m, 3H), 3.26-3.13 (m, 2H), 2.38-2.35 (m, 1H), 2.20-2.05 (m, 2H), 1.97-1.89 (m, 3H). 203 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 1.9 Hz, 1H), 7.54 (d, J = 8.1 Hz, 2H), 7.29-7.26 (m, 2H), 7.20 (dd, J = 5.0, 1.3 Hz, 1H), 6.98 (d, J = 3.3 Hz, 1H), 6.94-6.92 (m, 1H), 5.40 (d, J = 8.0 Hz, 1H), 4.90-4.66 (m, 2H), 4.03-4.01 (m, 1H), 3.80-3.75 (m, 1H), 2.37-2.35 (m, 1H), 2.00-1.82 (m, 3H). 204 1H NMR (300 MHz, DMSO-d6) δ 7.84 (d, J = 1.7 Hz, 1H), 7.75-7.55 (m, 5H), 7.41 (s, 1H), 7.25-7.13 (m, 4H), 6.83 (s, 1H), 5.45 (s, 1H), 4.50 (d, J = 6.1 Hz, 2H), 4.29 (dd, J = 12.2, 2.3 Hz, 1H), 4.04-3.78 (m, 3H), 3.75-3.59 (m, 1H). 205 1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1H), 7.59 (d, J = 1.4 Hz, 4H), 5.53 (s, 1H), 4.81 (s, 1H), 4.34 (d, J = 12.0 Hz, 1H), 4.07-3.88 (m, 3H), 3.83-3.71 (m, 1H), 3.54-3.15 (m, 3H), 2.25 (d, J = 6.5 Hz, 2H), 1.91-1.80 (m, 5H), 1.09-0.99 (m, 4H). 206 1H NMR (300 MHz, CDCl3) δ 7.98 (d, J = 1.7 Hz, 1H), 7.62-7.55 (m, 4H), 5.52 (s, 1H), 5.40-5.21 (m, 2H), 4.80 (s, 1H), 4.33 (dd, J = 11.9, 2.4 Hz, 1H), 4.06-3.89 (m, 3H), 3.83-3.72 (m, 1H), 3.48-3.35 (m, 1H), 3.32 (t, J = 6.4 Hz, 2H), 2.10 (d, J = 6.8 Hz, 2H), 1.90-1.78 (m, 5H), 1.52-1.41 (m, 1H), 1.02 (q, J = 10.5, 10.1 Hz, 4H). 207 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 7.55 (d, J = 7.9 Hz, 2H), 7.27 (d, J = 8.9 Hz, 2H), 6.80 (dd, J = 20.3, 3.4 Hz, 2H), 5.42 (d, J = 7.8 Hz, 1H), 5.06 (s, 1H), 4.83-4.50 (m, 2H), 4.05 (m, 1H), 3.80 (s, 3H), 2.38 (q, J = 7.5 Hz, 1H), 2.01-1.87 (m, 3H). 208 1H NMR (300 MHz, CDCl3) δ 7.92 (d, J = 1.9 Hz, 1H), 7.55 (d, J = 7.9 Hz, 2H), 7.34-7.21 (m, 2H), 5.40 (d, J = 7.8 Hz, 1H), 4.61 (s, 1H), 4.07-3.90 (m, 3H), 3.85-3.69 (m, 1H), 3.43-3.22 (m, 4H), 2.46-2.30 (m, 1H), 2.03-1.71 (m, 4H), 1.71-1.47 (m, 2H), 1.41-1.17 (m, 3H). 209 1H NMR (300 MHz, CD3OD) δ 8.35 (s, 1H), 7.72-7.60 (m, 2H), 7.57 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.3 Hz, 2H), 7.24 (d, J = 8.0 Hz, 1H), 4.55 (s, 2H), 4.10-3.95 (m, 2H), 2.50 (s, 3H), 2.28-2.13 (m, 1H), 2.12-1.83 (m, 6H). 210 m/z 450 (M + H) 211 m/z 446 (M + H) 212 m/z 462 (M + H) 213 m/z 422 (M + H) 214 m/z 425 (M + H) 215 m/z 451 (M + H) 216 m/z 424 (M + H) 217 m/z 447 (M + H) 218 m/z 409 (M + H) 219 m/z 495 (M + H) 220 1H NMR (300 MHz, CDCl3) δ 7.85 (d, J = 1.8 Hz, 1H), 7.56 (d, J = 7.9 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 5.61 (s, 1H), 5.41 (d, J = 7.9 Hz, 1H), 5.05 (s, 1H), 4.09-3.70 (m, 5H), 3.64-3.54 (m, 3H), 2.46-2.30 (m, 1H), 2.05-1.86 (m, 5H). 221 1H NMR (400 MHz, CDCl3) δ 7.86 (d, J = 1.8 Hz, 1H), 7.55 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 7.9 Hz, 2H), 5.40 (d, J = 7.9 Hz, 1H), 5.07 (s, 1H), 4.03-4.00 (m, 1H), 3.82-3.72 (m, 6H), 3.65-3.57 (m, 3H), 3.50 (dd, J = 14.1, 6.8 Hz, 1H), 2.43-2.31 (m, 1H), 1.98-1.90 (m, 3H), 1.64 (t, J = 5.8 Hz, 2H), 1.59-1.42 (m, 4H). 222 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 1.8 Hz, 1H), 7.55 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.6 Hz, 3H), 5.39 (d, J = 8.1 Hz, 1H), 4.68 (s, 1H), 4.04-4.01 (m, 1H), 3.81-3.72 (m, 1H), 3.43-3.33 (m, 2H), 3.09-3.05 (m, 2H), 2.94 (t, J = 12.5 Hz, 2H), 2.39-2.34 (m, 1H), 2.15 (d, J = 10.4 Hz, 2H), 1.97-1.85 (m, 6H). 223 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 1.7 Hz, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.28 (s, 2H), 6.57 (s, 1H), 5.41 (d, J = 7.8 Hz, 1H), 4.95 (s, 1H), 4.05 (s, 1H), 3.79 (d, J = 7.9 Hz, 1H), 3.59-3.26 (m, 4H), 2.86 (d, J = 13.5 Hz, 2H), 2.39 (t, J = 7.2 Hz, 1H), 2.21-1.74 (m, 6H). 224 1H NMR (300 MHz, CDCl3) δ 7.92 (d, J = 1.9 Hz, 1H), 7.84 (d, J = 8.0 Hz, 2H), 7.55 (d, J = 7.8 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 5.46-5.33 (m, 1H), 4.94 (s, 1H), 4.80-4.62 (m, 3H), 4.05-4.01 (m, 1H), 3.80-3.78 (m, 1H), 2.41-2.36 (m, 1H), 2.23-2.21 (m, 1H), 1.99-1.91 (m, 3H), 0.70-0.54 (m, 4H). 225 1H NMR (300 MHz, CDCl3) δ 7.96 (s, 1H), 7.58 (d, J = 8.0 Hz, 2H), 5.47 (d, J = 7.9 Hz, 1H), 4.16-4.05 (m, 1H), 3.92-3.79 (m, 1H), 3.49-3.23 (m, 3H), 2.49-2.34 (m, 1H), 2.12-1.58 (m, 9H), 1.25 (s, 1H), 1.14-0.79 (m, 4H). 226 m/z 460 (M + H) 227 1H NMR (300 MHz, CDCl3) δ 7.87 (s, 1H), 7.51 (d, J = 8.1 Hz, 2H), 7.33-7.19 (m, 6H), 5.37 (d, J = 7.8 Hz, 1H), 4.59 (s, 2H), 4.55 (d, J = 6.0 Hz, 2H), 4.07-3.94 (m, 1H), 3.83-3.68 (m, 1H), 2.46-2.25 (m, 1H), 2.03-1.80 (m, 3H). 228 1H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 1.8 Hz, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 7.2 Hz, 2H), 5.44-5.24 (m, 2H), 4.89 (s, 1H), 4.46-4.31 (m, 4H), 4.10-3.96 (m, 1H), 3.86-3.66 (m, 5H), 2.46-2.28 (m, 1H), 2.04-1.85 (m, 3H). 229 1H NMR (300 MHz, CD3OD) δ 7.61 (s, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 4.53 (s, 2H), 4.10-3.96 (m, 2H), 3.48 (s, 2H), 2.26-2.10 (m, 1H), 2.09-1.82 (m, 6H). 230 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 1.7 Hz, 1H), 7.52 (d, J = 8.6 Hz, 2H), 7.35 (d, J = 7.8 Hz, 2H), 7.30-7.24 (m, 2H), 7.17 (d, J = 8.2 Hz, 2H), 5.53 (s, 1H), 5.32 (s, 2H), 5.03 (s, 1H), 4.67 (d, J = 5.7 Hz, 2H), 4.38-4.29 (m, 1H), 4.05-3.90 (m, 3H), 3.77 (td, J = 11.2, 2.8 Hz, 1H), 3.58 (s, 2H), 3.48-3.39 (m, 1H). 231 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 1.8 Hz, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 7.8 Hz, 2H), 7.24 (d, J = 7.4 Hz, 2H), 5.88-5.49 (m, 1H), 5.31 (s, 2H), 4.94 (s, 1H), 4.72-4.50 (m, 2H), 4.31 (q, J = 13.0 Hz, 1H), 4.19 (q, J = 12.6 Hz, 1H), 3.57 (s, 2H), 3.16-2.77 (m, 1H), 2.58-1.97 (m, 1H). 232 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 1.9 Hz, 1H), 7.34-7.28 (m, 4H), 7.25-7.17 (m, 3H), 5.60 (d, J = 8.2 Hz, 1H), 5.30 (s, 2H), 4.85 (s, 1H), 4.72-4.39 (m, 2H), 4.20-3.95 (m, 1H), 3.90-3.73 (m, 1H), 3.57 (s, 2H), 2.55-2.22 (m, 1H), 2.11-1.75 (m, 3H). 233 1H NMR (300 MHz, CD3OD) δ 7.86 (s, 1H), 7.65-7.56 (m, 4H), 5.45 (s, 1H), 4.60-4.46 (m, 1H), 4.30 (dd, J = 12.0, 2.8 Hz, 1H), 4.04-3.84 (m, 4H), 3.84-3.69 (m, 1H), 3.50-3.36 (m, 2H), 2.83 (s, 2H), 2.36 (t, J = 8.1 Hz, 1H), 2.13-2.06 (m, 3H), 1.96-1.69 (m, 3H), 1.33-0.98 (m, 2H). 234 1H NMR (300 MHz, CD3OD) δ 7.88 (s, 1H), 7.63 (d, J = 1.1 Hz, 4H), 5.53-5.47 (m, 1H), 4.34 (dd, J = 12.1, 2.5 Hz, 1H), 4.11 (q, J = 7.2 Hz, 1H), 4.06-3.88 (m, 3H), 3.85-3.70 (m, 1H), 3.52 (s, 2H), 3.50-3.36 (m, 2H), 2.97-2.86 (m, 2H), 2.15-2.02 (m, 4H). 235 1H NMR (300 MHz, CD3OD) δ 7.86 (s, 1H), 7.67-7.58 (m, 4H), 5.49-5.44 (m, 1H), 4.62 (d, J = 5.9 Hz, 2H), 4.36-4.26 (m, 3H), 4.05-3.87 (m, 3H), 3.84-3.71 (m, 1H), 3.61 (s, 2H), 3.50-3.38 (m, 1H), 1.33 (s, 3H). 236 1H NMR (300 MHz, CD3OD) δ 7.67-7.58 (m, 3H), 7.41 (s, 4H), 7.31 (d, J = 8.1 Hz, 2H), 5.34-5.23 (m, 1H), 4.51 (s, 2H), 4.12 (dd, J = 12.0, 2.6 Hz, 1H), 3.83-3.65 (m, 3H), 3.56 (td, J = 10.8, 2.8 Hz, 1H), 3.29-3.16 (m, 1H), 1.96-1.88 (m, 1H), 0.34-0.22 (m, 4H). 237 1H NMR (300 MHz, CD3OD) δ 7.86 (s, 1H), 7.66-7.59 (m, 4H), 5.47-5.42 (m, 1H), 4.30 (dd, J = 12.0, 2.9 Hz, 1H), 4.04-3.86 (m, 3H), 3.84-3.68 (m, 3H), 3.50-3.38 (m, 1H), 2.81 (s, 3H), 2.76-2.63 (m, 2H), 2.02 (d, J = 0.9 Hz, 1H), 1.92-1.67 (m, 3H), 1.38-1.19 (m, 3H). 238 m/z 443 (M + H) 239 m/z 485 (M + H) 240 m/z 517 (M + H) 241 m/z 492 (M + H) 242 m/z 492 (M + H) 243 m/z 513 (M + H) 244 m/z 504 (M + H) 245 1H NMR (300 MHz, CDCl3) δ 7.99 (d, J = 1.6 Hz, 1H), 7.52 (d, J = 8.3 Hz, 2H), 7.17 (d, J = 8.4 Hz, 2H), 5.50 (s, 1H), 5.41-5.18 (m, 2H), 4.81 (s, 1H), 4.33 (d, J = 11.8 Hz, 1H), 4.06-3.88 (m, 3H), 3.82-3.71 (m, 1H), 3.47-3.26 (m, 3H), 2.11 (d, J = 6.8 Hz, 2H), 1.91-1.73 (m, 5H), 1.03 (q, J = 10.3, 9.7 Hz, 4H). 246 1H NMR (300 MHz, CDCl3) δ 7.93 (d, J = 1.6 Hz, 1H), 7.58-7.46 (m, 2H), 7.27-7.10 (m, 6H), 5.56 (s, 1H), 5.36 (m, 1H), 4.59 (d, J = 5.7 Hz, 2H), 4.35 (dd, J = 12.0, 2.0 Hz, 1H), 4.24 (s, 2H), 4.08-3.89 (m, 3H), 3.77 (td, J = 11.2, 2.7 Hz, 1H), 3.49 (s, 1H), 3.43 (m, 1H). 247 1H NMR (300 MHz, CD3OD) δ 7.85 (s, 1H), 7.61 (s, 4H), 5.44 (t, J = 3.1 Hz, 1H), 4.29 (dd, J = 12.1, 2.9 Hz, 2H), 4.00-3.86 (m, 4H), 3.84-3.72 (m, 1H), 3.50-3.26 (m, 5H), 1.96-1.79 (m, 1H), 1.71-1.62 (m, 2H), 1.37-1.20 (m, 2H). 248 1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 1.8 Hz, 1H), 7.52 (d, J = 8.2 Hz, 2H), 7.36-7.27 (m, 4H), 7.23 (d, J = 8.1 Hz, 2H), 5.28-5.24 (m, 3H), 4.82 (m, 2H), 4.60 (dd, J = 10.3, 5.7 Hz, 2H), 4.08 (m, 1H), 3.57 (s, 2H), 3.45 (t, J = 10.3 Hz, 1H), 2.64-2.51 (m, 1H), 2.36 (m, 1H), 1.52-1.40 (m, 1H), 1.10 (d, J = 6.6 Hz, 3H). 249 1H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 1.6 Hz, 1H), 7.58 (s, 4H), 5.94 (s, 1H), 5.51 (d, J = 17.3 Hz, 2H), 5.39-5.17 (m, 1H), 4.39-4.28 (m, 1H), 4.07-3.85 (m, 4H), 3.85-3.69 (m, 1H), 3.66 (d, J = 6.0 Hz, 2H), 3.51-3.30 (m, 1H), 1.98-1.94 (m, 2H), 1.88-1.66 (m, 6H). 250 1H NMR (300 MHz, CDCl3) δ 7.93 (d, J = 1.6 Hz, 1H), 7.58 (s, 4H), 5.50 (s, 2H), 4.32 (dd, J = 12.1, 2.3 Hz, 1H), 4.09-3.86 (m, 3H), 3.82-3.68 (m, 1H), 3.63 (d, J = 5.8 Hz, 2H), 3.48-3.30 (m, 1H), 3.00 (s, 6H), 2.28-1.92 (m, 2H), 1.94-1.75 (m, 6H). 251 1H NMR (300 MHz, CDCl3) δ 7.97 (s, 1H), 7.58 (s, 4H), 5.65-5.39 (m, 2H), 4.63 (d, J = 8.1 Hz, 1H), 4.39-4.28 (m, 1H), 4.08-3.69 (m, 5H), 3.61-3.24 (m, 4H), 2.98 (d, J = 2.2 Hz, 3H), 2.33-1.80 (m, 3H), 1.83-1.58 (m, 3H). 252 1H NMR (300 MHz, CDCl3): δ 8.46 (s, 1H), 7.57 (d, J = 8.5 Hz, 2H), 7.28-7.18 (m, 6H), 6.97 (d, J = 3.7 Hz, 1H), 6.44 (d, J = 3.7 Hz, 1H), 6.05 (s, 1H), 5.44-5.35 (m, 3H), 4.55-451 (m, 2H), 4.13-08 (m, 2H), 3.86-3.72 (m, 1H), 3.60-155 (m, 3H). 253 1H NMR (300 MHz, CDCl3): δ 7.94 (d, J = 1.7 Hz, 1H), 7.59 (s, 4H), 5.78 (m, 1H), 5.55 (s, 1H), 4.35 (dd, J = 12.0, 2.2 Hz, 1H), 4.09-3.83 (m, 7H), 3.82-3.65 (m, 3H), 3.48-3.35 (m, 1H), 3.13 (s, 2H), 3.00 (s, 3H), 1.87-1.60 (m, 4H). 254 1H NMR (300 MHz, CDCl3) δ 7.96 (d, J = 1.7 Hz, 1H), 7.59 (s, 4H), 5.54 (s, 1H), 5.02 (m, 1H), 4.37-4.32 (m, 1H), 4.04-3.76 (m, 6H), 3.73-3.55 (m, 5H), 3.55-3.41 (m, 3H), 2.14-2.09 (m, 2H), 1.65-1.55 (m, 2H). 255 1H NMR (300 MHz, CDCl3): δ 7.95 (d, J = 1.8 Hz, 1H), 7.59 (s, 4H), 5.88 (s, 1H), 5.55 (s, 1H), 5.43 (s, 1H), 5.22 (q, J = 5.5 Hz, 1H), 4.37-4.33 (m, 1H), 4.04-4.63 (m, 10H), 3.46-3.37 (m, 1H), 2.06 (m, 2H), 1.75-1.66 (m, 2H). 256 1H NMR (300 MHz, DMSO-d6) δ 7.96-7.84 (m, 2H), 7.84-7.75 (m, 1H), 7.72 (d, J = 8.2 Hz, 2H), 7.59 (d, J = 8.2 Hz, 2H), 6.87 (s, 1H), 5.44 (s, 1H), 4.37-4.04 (m, 3H), 4.04-3.81 (m, 4H), 3.61 (dd, J = 42.7, 13.3 Hz, 5H), 3.40-3.21 (m, 4H), 2.82 (d, J = 6.2 Hz, 2H), 1.95 (d, J = 13.7 Hz, 2H), 1.48 (t, J = 11.0 Hz, 2H). 257 1H NMR (300 MHz, CDCl3): 7.97 (d, J = 1.7 Hz, 1H), 7.60 (s, 4H), 5.59 (s, 1H), 5.07 (s, 1H), 4.39-4.35 (m, 1H), 4.04-3.93 (m, 5H), 3.80-3.64 (m, 5H), 3.48-3.38 (m, 1H), 1.89-1.54 (m, 4H). 258 1H NMR (400 MHz, CDCl3): δ 8.00 (d, J = 1.6 Hz, 1H), 7.58 (t, J = 8.4 Hz, 1H), 7.33 (d, J = 7.9 Hz, 2H), 7.26 (s, 2H), 7.00-6.93 (m, 2H), 5.61 (s, 1H), 5.33 (s, 2H), 5.02 (s, 1H), 4.70-4.61 (m, 2H), 4.20-4.16 (m, 1H), 4.06-3.96 (m, 3H), 3.81-3.75 (m, 1H), 3.62-3.55 (m, 3H). 259 1H NMR (300 MHz, CDCl3): δ 7.89 (d, J = 1.8 Hz, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 5.60 (m, 1H), 4.73 (s, 1H), 4.32-4.16 (m, 2H), 3.99-3.94 (m, 2H), 3.40-3.30 (m, 4H), 2.94-2.87 (m, 1H), 2.41-2.35 (m, 1H), 1.82 (m, 1H), 1.66-1.62 (m, 2H), 1.40-1.26 (m, 2H). 260 1H NMR (300 MHz, CDCl3): δ 7.84 (d, J = 1.8 Hz, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 8.3 Hz, 2H), 5.66-5.58 (m, 2H), 4.31-4.15 (m, 2H), 4.06-3.86 (m, 4H), 3.70-3.66 (m, 2H), 3.09 (s, 2H), 2.98-2.86 (m, 4H), 2.40-2.34 (m, 1H), 1.80-1.54 (m, 4H), 1.11-0.95 (m, 1H). 261 1H NMR (400 MHz, CDCl3): δ 7.84 (d, J = 1.6 Hz, 1H), 7.58 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.1 Hz, 2H), 5.60 (m, 1H), 5.01 (m, 1H), 4.93 (t, J = 7.3 Hz, 1H), 4.44-4.32 (m, 4H), 4.29-4.15 (m, 2H), 3.86-3.80 (m, 2H), 3.71 (d, J = 7.1 Hz, 2H), 2.94-2.86 (m, 1H), 2.45-2.34 (m, 1H). 262 1H NMR (300 MHz, CD3OD) δ 7.86 (s, 1H), 7.70-7.55 (s, 4H), 5.47 (s, 1H), 4.38-4.25 (m, 2H), 4.05-3.86 (m, 3H), 3.86-3.55 (m, 4H), 3.53-3.30 (m, 3H), 2.10 (s, 3H), 1.96-1.48 (m, 4H). 263 1H NMR (300 MHz, CD3OD) δ 7.86 (s, 1H), 7.67-7.61 (m, 4H), 5.45 (s, 1H), 4.31 (dd, J = 12.0, 2.8 Hz, 2H), 4.05-3.88 (m, 5H), 3.85-3.72 (m, 1H), 3.51-3.35 (m, 2H), 3.16-3.01 (m, 2H), 1.95-1.81 (m, 3H), 1.38-1.20 (m, 2H). 264 1H NMR (300 MHz, CD3OD) δ 7.87 (t, J = 1.3 Hz, 1H), 7.67-7.61 (m, 4H), 5.47 (s, 1H), 4.06-3.89 (m, 3H), 3.86-3.63 (m, 7H), 3.49-3.38 (m, 1H), 1.92-1.69 (m, 4H). 265 1H NMR (400 MHz, CDCl3): δ 8.11 (s, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 7.9 Hz, 2H), 7.21 (d, J = 7.6 Hz, 2H), 5.39 (d, J = 8.0 Hz, 1H), 5.31 (s, 2H), 4.56-4.44 (m, 2H), 4.01 (t, J = 9.8 Hz, 1H), 3.79-3.77 (m, 1H), 3.56 (s, 2H), 3.28-3.10 (m, 3H), 2.91-2.63 (m, 1H), 2.35 (m, 1H), 1.96-1.90 (m, 3H). 266 1H NMR (300 MHz, CD3OD) δ 7.87 (s, 1H), 7.71-7.56 (m, 4H), 5.48 (s, 1H), 4.33 (d, J = 11.9 Hz, 2H), 4.06-3.85 (m, 3H), 3.85-3.53 (m, 5H), 3.52-3.30 (m, 2H), 2.85 (s, 3H), 2.05-1.63 (m, 4H). 267 1H NMR (400 MHz, CDCl3): δ 7.98 (d, J = 1.5 Hz, 1H), 7.51 (d, J = 8.8 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H), 5.51 (s, 1H), 4.79 (d, J = 2.9 Hz, 1H), 4.33 (dd, J = 1.7, 12.0 Hz, 1H), 4.18 (br d, J = 7.8 Hz, 1H), 4.05-3.90 (m, 3H), 3.76 (dt, J = 3.2, 11.4 Hz, 1H), 3.48-3.23 (m, 4H), 2.98 (s, 3H), 2.11 (d, J = 10.3 Hz, 2H), 1.89 (br d, J = 12.7 Hz, 2H), 1.59-1.49 (m, 1H), 1.33-1.19 (m, 3H), 1.12 (m, 2H). 268 m/z 485 (M + H) 273 m/z 484 (M + H) 274 m/z 450 (M + H) 276 m/z 423 (M + H) 279 m/z 406 (M + H) 280 1H NMR (400 MHz, CDCl3): δ 7.97 (s, 1H), 7.58 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.8 Hz, 4H), 7.26-7.21 (m, 2H), 5.99 (d, J = 9.3 Hz, 1H), 5.33 (br s, 2H), 4.99 (m, 1H), 4.69-4.56 (m, 2H), 4.38-4.20 (m, 2H), 3.57 (s, 2H), 3.22 (dd, J = 9.5, 18.3 Hz, 1H), 2.62-2.57 (m, 1H). 282 m/z 429 (M + H) 283 m/z 428 (M + H) 284 m/z 428 (M + H) 285 1H NMR (300 MHz, CDCl3) δ 7.98 (d, J = 1.7 Hz, 1H), 7.55-7.47 (m, 2H), 7.17 (dq, J = 8.9, 1.0 Hz, 2H), 5.51 (d, J = 2.8 Hz, 1H), 4.87 (s, 1H), 4.54 (d, J = 8.0 Hz, 1H), 4.33 (dd, J = 12.1, 2.1 Hz, 1H), 4.04-3.91 (m, 3H), 3.89-3.64 (m, 3H), 3.49-3.26 (m, 4H), 2.19-2.06 (m, 2H), 1.97-1.84 (m, 2H), 1.65-1.45 (m, 1H), 1.38-1.20 (m, 2H), 1.20-1.01 (m, 2H). 286 1H NMR (300 MHz, CD3OD) δ 7.86 (d, J = 1.6 Hz, 1H), 7.66-7.60 (m, 4H), 5.44 (t, J = 3.1 Hz, 1H), 4.31 (dd, J = 12.1, 2.9 Hz, 1H), 4.06-3.74 (m, 7H), 3.61 (d, J = 2.0 Hz, 2H), 3.53-3.39 (m, 3H), 2.67 (s, 3H), 2.14-1.99 (m, 2H), 1.72-1.54 (m, 2H). 287 1H NMR (300 MHz, DMSO-d6) δ 7.84 (d, J = 1.8 Hz, 1H), 7.71 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.12 (s, 1H), 5.44-5.39 (m, 1H), 4.27 (dd, J = 12.1, 2.5 Hz, 1H), 3.89 (m, 3H), 3.72-3.60 (m, 1H), 3.41-3.25 (m, 2H), 3.20-3.12 (m, 2H), 2.41 (d, J = 6.5 Hz, 2H), 1.80-1.67 (m, 4H), 1.60-1.43 (m, 2H), 1.07-0.80 (m, 4H). 288 1H NMR (300 MHz, DMSO-d6) δ 7.83 (d, J = 1.8 Hz, 1H), 7.70 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.15-7.06 (m, 1H), 5.41 (s, 1H), 4.27 (dd, J = 12.1, 2.5 Hz, 1H), 3.99-3.80 (m, 3H), 3.71-3.60 (m, 1H), 3.39-3.25 (m, 2H), 3.18-3.11 (m, 2H), 2.75 (d, J = 6.7 Hz, 2H), 1.75-1.57 (m, 5H), 1.57-1.41 (m, 1H), 1.03-0.79 (m, 4H). 290 1H NMR (400 MHz, DMSO-d6): δ 8.21 (s, 1H), 7.49 (d, J = 8.8 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 3.9 Hz, 1H), 6.54 (d, J = 2.9 Hz, 1H), 5.93 (s, 1H), 4.53 (d, J = 13.2 Hz, 1H), 4.42 (d, J = 11.7 Hz, 1H), 4.14-4.05 (m, 2H), 4.00-3.91 (m, 2H), 3.66 (dt, J = 2.7, 11.6 Hz, 1H), 3.57-3.43 (m, 3H), 2.81 (s, 3H), 2.69-2.55 (m, 2H), 1.97 (m, 1H), 1.54 (br d, J = 11.2 Hz, 2H), 1.32-1.19 (m, 2H). 291 1H NMR (400 MHz, CDCl3): δ 7.95 (s, 1H), 7.56 (s, 4H), 7.19 (d, J = 8.3 Hz, 2H), 7.11 (d, J = 8.3 Hz, 2H), 5.53 (s, 1H), 5.15-5.06 (m, 1H), 4.58 (d, J = 5.4 Hz, 2H), 4.32 (d, J = 12.2 Hz, 1H), 4.03-3.86 (m, 3H), 3.80-3.70 (m, 1H), 3.40 (t, J = 10.5 Hz, 1H), 2.60 (s, 1H). 292 1H NMR (300 MHz, CD3OD) δ 7.85 (d, J = 1.6 Hz, 1H), 7.67-7.62 (m, 4H), 7.32 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.2 Hz, 2H), 5.51-5.44 (m, 1H), 4.62 (s, 2H), 4.33 (dd, J = 12.1, 2.8 Hz, 1H), 4.07-3.89 (m, 3H), 3.85-3.75 (m, 1H), 3.66 (s, 2H), 3.53-3.37 (m, 1H). 293 1H NMR (400 MHz, CDCl3): δ 8.72 (s, 1H), 8.05 (d, J = 8.3 Hz, 1H), 8.00-7.92 (m, 2H), 7.60 (s, 4H), 5.60 (s, 1H), 5.22 (s, 1H), 4.81 (d, J = 5.9 Hz, 2H), 4.38 (dd, J = 2.0, 12.2 Hz, 1H), 4.09-3.99 (m, 2H), 3.95 (d, J = 11.2 Hz, 1H), 3.78 (dt, J = 2.7, 11.4 Hz, 1H), 3.44 (ddd, J = 3.4, 11.0, 13.9 Hz, 1H), 3.22 (s, 3H). 294 m/z 505 (M + H) 295 m/z 469 (M + H) 296 m/z 427 (M + H) 297 m/z 504 (M + H) 299 m/z 450 (M + H) 300 m/z 422 (M + H) 301 m/z 450 (M + H) 302 m/z 420 (M + H) 303 m/z 448 (M + H) 304 m/z 436 (M + H) 305 m/z 485 (M + H) 306 m/z 440 (M + H) 307 m/z 460 (M + H) 308 m/z 488 (M + H) 309 m/z 520 (M + H) 310 m/z 463 (M + H) 311 m/z 456 (M + H) 312 m/z 456 (M + H) 313 m/z 410 (M + H) 314 m/z 412 (M + H) 315 m/z 412 (M + H) 316 m/z 424 (M + H) 317 m/z 424 (M + H) 318 m/z 466 (M + H) 319 m/z 497 (M + H) 320 m/z 554 (M + H) 323 m/z 490 (M + H) 324 m/z 518 (M + H) 325 m/z 455 (M + H) 326 1H NMR (300 MHz, CDCl3): δ 8.92 (s, 1H), 8.40 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.69-7.60 (m, 1H), 7.25-7.17 (m, 4H), 6.95 (d, J = 3.7 Hz, 1H), 6.42 (d, J = 3.7 Hz, 1H), 6.21 (s, 1H), 5.40 (s, 2H), 5.33 (br s, 2H), 4.49 (d, J = 12.5 Hz, 1H), 4.39 (d, J = 12.8 Hz, 1H), 4.18-4.05 (m, 2H), 3.90-3.76 (m, 1H), 3.68-3.58 (m, 1H), 3.56 (s, 2H). 327 m/z 504 (M + H) 328 1H NMR (300 MHz, CDCl3): δ 8.91 (s, 1H), 8.38 (s, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.25-7.16 (m, 4H), 6.91 (d, J = 3.7 Hz, 1H), 6.35 (d, J = 3.7 Hz, 1H), 5.96 (s, 1H), 5.47-5.29 (m, 4H), 4.93 (d, J = 11.3 Hz, 1H), 4.70 (d, J = 12.4 Hz, 1H), 4.04 (dd, J = 3.7, 11.3 Hz, 2H), 3.88-3.62 (m, 2H), 3.55 (s, 2H). 329 m/z 534 (M + H) 330 m/z 534 (M + H) - Biological Evaluation
- The activity of the compounds was evaluated using a Fluorescence Polarization (FP) Assay and, in most cases, a Th17 Assay and/or RORγ Reporter assay (also referred to as Gal4 assay). The FP assay is an in vitro assay monitoring binding within the ligand binding pocket. The RORγ and the Th17 assays are both cell-based assays monitoring functional activity of the compound assayed.
- Fluorescence Polarization (FP) Assay
- A buffer containing 10 mM Hepes, 150 mM NaCl, 1 mM DTT, 0.05% Pluronic F-127 detergent (all from Sigma), and 100 nM human RORγt (Ligand Binding Domain obtained from Crelux (Planegg, Germany), batch no PC5032-1) was complemented with 1 μl test compounds diluted in 100% DMSO. The total volume was 25 μl, in a black Perkin Elmer OptiPlate. As negative control, 1 μl DMSO was used. Samples were incubated at room temperature for 30 min, followed by
addition 5 μl of probe diluted in assay buffer to a concentration of 125 nM (final concentration of probe is 25 nM). The probe is a fluorescently labeled (TAMRA) RORγt ligand identified by Nuevolution with a total molecular weight of 910 g/mole as shown in Graph A inFIG. 1 . Graph (B) inFIG. 2 shows the polarization signal rises with increasing concentration of human RORγt (LBD), using 50 nM TAMRA-labelled probe concentration. Graph (C) ofFIG. 2 shows the RORγt inhibitor SR2211 (1,1,1,3,3,3-hexafluoro-2-(2-fluoro-4′-((4-(pyridin-4-ylmethyl)piperazin-1-yl)methyl)-[1,1′-biphenyl]-4-yl)propan-2-ol; see Kumar et al, ACS Chem. Biol., 2012, 7 (4), pp 672-677) inhibits the probe from binding RORγt with an IC50 of 0.36 μM, which is close to the value reported in the literature. The plate was incubated for 10 min at room temperature and fluorescence polarization was read using an Envision 2102 plate reader (Perkin Elmer) with the TAMRA FP optical module installed. - Th17 Assay
- Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of healthy human volunteers using the Ficoll paque PLUS kit (GE Healthcare, cat no 17-1440-02), as instructed by the manufacturer. Naive CD4+ T cells were isolated with Naive CD4+ T cell kit, human (Milteny Biotec, cat no 130-094-131). The following modifications were made to the manufacturer's protocol: 1) Incubation with Biotin-Antibody Cocktail and Anti-Biotin MicroBeads was prolonged to 30 minutes, and 2) Cells were washed with 40 mL of Miltenyi buffer. Differentiation of Th17 cells in anti-CD3 (BD Pharmingen, 5 μg/ml) coated 96-well plates (400,000 cells/well, 160 μl RPMI 1640+10% Fetal Bovine Serum) containing 5 μg/ml anti-CD28 (BD Pharmingen), 10 ng/ml IL-2 (R&D Systems), 2.5 ng/ml TGFβ-1 (R&D Systems), 20 ng/ml IL-1β (R&D Systems), 20 ng/ml IL-6 (R&D Systems), 30 ng/ml IL-23 (R&D Systems), 2.5 μg/ml anti-IL-4 (R&D Systems) and 1 μg/ml anti-IFNγ (R&D Systems) and with test compound during the entire differentiation (or vehicle, 0.1% DMSO for control). Test compounds were tested in triplicates, diluted 1000-fold in medium (final DMSO concentration is 0.1%). Incubated for seven days at 37° C., 5% CO2, 95% humidity, and 2-fluoro-4′-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-α,α-bis(trifluoromethyl)-[1,1′-biphenyl]-4-methanol (SR2211 Calbiochem, Cat. No. 557353) was used as positive control. As negative control, cells were differentiated into Th0 using 5 μg/ml anti-CD28 (BD Pharmingen), 10 ng/ml IL-2 (R&D Systems), 2 μg/ml anti-IL4 (R&D Systems) and 2 μg/ml anti-IFNγ (R&D Systems) are negative control. IL-17 levels in supernatants were measured with ELISA (R&D Systems).
- RORγ Reporter Assay (Gal4)
- Cell-based RORγ functional assays were performed using a commercially available assay product (INDIGO Biosciences, State College, Pa., USA; product #IB04001). The RORγ reporter cells are HEK293t cells transfected with one vector that provides high level constitutive expression of a hybrid protein comprised of the yeast Gal4-DNA binding domain fused to the ligand binding domain of human RORγ, and a second vector comprising the firefly luciferase cDNA functionally linked to the upstream activation sequence (UAS) of yeast Gal4. A suspension of RORγ Reporter Cells was prepared using the protocol and culture medium provided in the kit product, and 100 μl of the Reporter Cell suspension was then dispensed into wells of a white, collagen-treated, 96-well assay plate. Concentrated stocks of test compounds were prepared in DMSO, then further diluted using media provided in the kit to generate ‘2×-concentration’ treatment media. 100 μl of medium for each respective treatment concentration dispensed into triplicate assay wells, thereby combining with the reporter cells. All media formulations contained 10% charcoal stripped Fetal Bovine Serum, but are otherwise proprietary to INDIGO Biosciences. Final treatment concentrations for each test compound were 1,000 nM and 100 nM, each with 0.1% residual DMSO. Separate control treatments were media supplemented with vehicle only (0.1% DMSO) to determine the constitutive level of RORγ activity in the reporter cells, and the reference inverse-agonist ursolic acid (f.c. 6,000 nM to 8.2 nM in 3-fold decrements) to establish a positive control inverse-agonist dose response. Assay plates were placed in a 37° C., 5% CO2, 85% humidity incubator for 24 hour. Treatment media were then discarded, 100 μl of luciferase detection reagent was added to each well, and relative light units (RLUs) were quantified from each assay well using a plate reading luminometer. Values of average RLU+/−standard deviation were computed for all treatment sets, followed by the calculations of fold-reduction: [Average RLUVehicle/Average RLUTest Cmpd]. Percent-reduction of RORγ activity in response to respective test compound treatments was calculated: [100*(1−[Ave RLUTest Cmpd/Ave RLUVehicle)] where the theoretical minimum reduction (0% reduction) derives from Vehicle treatment only, no treatment compound.
- In some aspects it may be of interest to provide compounds with selective modulation of RORγ for example compounds that are selective to RORγ over RORα, compounds that are selective for RORγ versus RORβ, and compounds that are selective for RORγ versus BOTH RORα and RORβ. It may also be of interest to provide compounds that are selective for RORγ versus further nuclear hormone receptors such as CAR1, FXR, GR, LXRα, LXRβ, PPARα, PXR, RARα, RXRα, TRα, VDR. It is apparent to those skilled in the art that these nuclear hormone receptors are merely examples, and that selectivity against other nuclear receptors may also be of interest. It may for example be of interest to provide compounds that modulate RORγ and one or more further nuclear hormone receptors, as well as compounds that modulate both RORγ and RORα, or RORγ and RORP. It may also be of interest to provide compounds that modulate RORγ and BOTH RORα and RORβ, as well as compounds that modulate both RORγ and one or more further nuclear hormone receptors such as CAR1, FXR, GR, LXRα, LXRβ, PPARα, PXR, RARα, RXRα, TRα, VDR. It is apparent to those skilled in the art that these nuclear hormone receptors are merely examples, and that modulation of even other nuclear receptors may also be of interest. By substituting the ligand binding domain of another nuclear hormone receptor for the ligand binding domain of RORγ, the reporter assay (Gal4) may be modified to provide activity data for compounds against said other nuclear hormone receptor. Those skilled in the art know how to accomplish such modification. By comparing activity against RORγ to activity against another nuclear hormone receptor in this assay, the selectivity of a compound towards RORγ versus said other nuclear hormone receptor can be established. A compound may be said to be selective for RORγ versus another nuclear hormone receptor if the activity of the compound against RORγ is greater than 5, 10, 20, or 100 fold higher for RORγ than for said other nuclear receptor. The compound(s) or pharmaceutical composition(s) described herein may modulate the activity of an RORγ receptor to a larger extent than it modulates the activity of RORα and/or RORβ receptors.
- The results of the Fluorescence Polarization (FP) Assay, Th17 Assay, and RORγ Reporter (Gal4) Assay are shown in Tables 2-5 below.
-
TABLE 2 Activity Data of Example Compounds obtained from the Fluorescence Polarization (FP) Assay. Example. FP activity range No. (nM) 4 <500 5 <500 6 <10000 9 <500 11 <500 13 <10000 14 <10000 15 <10000 17 <500 18 <500 19 <500 20 <2000 21 <10000 23 <500 24 <500 26 <500 29 <1000 30 <500 31 <10000 32 <500 33 <10000 34 <1000 35 <500 36 <2000 37 <1000 38 <2000 39 <10000 40 <1000 41 <2000 42 <2000 43 <1000 44 <10000 45 <10000 46 <1000 48 <2000 51 <1000 52 <2000 53 <1000 54 <1000 55 <10000 56 <2000 57 <10000 58 <10000 59 <10000 60 <2000 61 <10000 62 <500 63 <2000 64 <2000 65 <500 66 <2000 67 <2000 68 <2000 69 <1000 70 <2000 71 <10000 72 <1000 73 <2000 74 <2000 79 <500 81 <500 85 <500 88 <500 89 <500 90 <1000 91 <500 93 <500 94 <500 95 <1000 97 <1000 98 <1000 100 <2000 105 <10000 106 <10000 107 <10000 108 <10000 109 <2000 110 <10000 111 <500 113 <500 114 <1000 115 <500 116 <1000 117 <500 118 <10000 119 <1000 120 <10000 122 <10000 123 <10000 126 <2000 128 <500 129 <500 130 <10000 131 <2000 132 <10000 134 <10000 135 <10000 136 <2000 137 <10000 138 <500 139 <2000 140 <500 141 <2000 142 <2000 143 <2000 144 <10000 145 <10000 146 <2000 147 <2000 148 <1000 150 <10000 151 <10000 152 <500 154 <500 155 <10000 159 <2000 161 <500 164 <500 165 <500 166 <500 167 <500 168 <500 169 <500 170 <10000 175 <10000 178 <500 181 <10000 182 <500 183 <500 184 <500 185 <1000 186 <500 188 <500 189 <500 190 <500 191 <500 192 <500 193 <10000 194 <2000 195 <500 196 <500 197 <500 198 <500 199 <1000 200 <1000 201 <500 202 <10000 203 <2000 204 <500 205 <500 206 <1000 207 <500 208 <500 209 <1000 210 <1000 211 <1000 212 <10000 213 <10000 214 <10000 215 <10000 216 <10000 217 <10000 218 <10000 219 <10000 220 <500 221 <500 222 <2000 223 <500 224 <500 225 <500 226 <10000 227 <500 228 <500 229 <500 230 <500 231 <500 232 <500 233 <500 234 <1000 235 <2000 236 <500 237 <500 238 <10000 239 <500 240 <500 241 <1000 242 <2000 243 <500 244 <2000 245 <1000 246 <500 247 <10000 248 <1000 249 <10000 250 <10000 251 <10000 252 <500 253 <1000 254 <500 255 <2000 256 <10000 257 <500 258 <500 259 <500 260 <500 261 <1000 262 <1000 263 <500 264 <500 265 <500 266 <500 267 <500 268 <10000 273 <500 274 <2000 276 <2000 278 <500 280 <500 282 <10000 283 <1000 284 <500 285 <500 286 <2000 287 <500 288 <500 290 <500 291 <1000 292 <500 293 <1000 294 <10000 295 <500 296 <10000 297 <10000 299 <1000 300 <10000 301 <500 302 <500 303 <500 304 <500 305 <500 306 <500 307 <2000 308 <10000 309 <2000 310 <500 311 <500 312 <500 313 <500 314 <10000 315 <10000 316 <500 317 <10000 318 <500 319 <500 320 <500 323 <500 324 <500 325 <1000 326 <500 327 <1000 328 <500 329 <2000 330 <2000 -
TABLE 3 Activity Data of Example Compounds obtained from the Th17 Assay. Example. Th17 activity range @ 1 μM No. (% inhibition) 6 >20 13 >20 16 >0 18 >80 19 >80 29 >50 30 >50 33 >20 35 >50 36 >50 38 >50 40 >80 62 >80 67 >80 77 >50 78 >50 79 >50 80 >50 81 >80 83 >20 85 >80 88 >80 89 >20 91 >80 94 >80 -
TABLE 4 Activity Data of Example Compounds obtained from the RORγ Reporter Assay (Gal4) at 1 μM. Example. Gal4 activity range @ 1 μM No. (% inhibition) 14 >0 17 >80 20 >50 30 >80 31 >0 39 >20 42 >20 43 >80 51 >80 52 >80 53 >20 54 >50 56 >20 60 >20 62 >80 63 >20 64 >20 65 >20 66 >50 67 >80 68 >80 69 >50 72 >80 73 >20 74 >80 79 >50 81 >80 84 >20 85 >80 86 >20 87 >20 89 >80 90 >20 91 >80 93 >50 94 >80 95 >80 96 >20 97 >80 98 >80 99 >50 100 >20 104 >20 106 >20 107 >0 109 >20 110 >0 111 >80 112 >20 113 >80 114 >80 115 >80 116 >50 117 >80 118 >20 119 >80 121 >50 123 >20 124 >20 126 >50 190 >80 191 >80 197 >80 198 >80 199 >80 200 >80 201 >80 202 >50 203 >50 204 >80 205 >80 206 >80 207 >80 208 >80 209 >50 210 >80 211 >50 220 >80 221 >80 222 >80 223 >80 224 >80 225 >80 226 >50 227 >80 228 >80 229 >80 230 >80 231 >80 232 >80 233 >80 234 >50 235 >50 236 >80 237 >80 238 >50 239 >80 240 >80 245 >80 246 >80 247 >80 248 >80 252 >80 253 >80 254 >80 255 >50 257 >80 258 >80 259 >80 260 >80 261 >80 262 >50 263 >80 264 >80 265 >80 266 >80 267 >80 273 >80 274 >50 276 >20 279 >50 280 >20 282 >0 283 >20 284 >50 285 >20 286 >20 287 >80 288 >80 290 >80 291 >50 292 >20 295 >80 299 >80 300 >20 301 >80 302 >50 303 >80 304 >80 305 >80 306 >80 307 >50 308 >50 313 >80 316 >80 318 >20 319 >0 320 >80 323 >80 324 >80 326 >80 327 >80 328 >80 -
TABLE 5 Activity Data of Example Compounds obtained from the RORγ Reporter Assay (Gal4) at 0.1 μM. Example. Gal4 activity range @ 0.1 μM No. (% inhibition) 73 >0 89 >20 90 >0 91 >20 93 >0 94 >80 95 >20 96 >0 97 >20 98 >20 99 >20 104 >0 111 >50 112 >0 113 >50 114 >20 115 >50 116 >20 117 >50 118 >0 119 >20 121 >20 123 >0 126 >20 128 >50 129 >50 131 >20 140 >20 148 >50 152 >0 161 >20 164 >20 165 >50 167 >0 168 >50 169 >0 182 >50 183 >50 185 >50 186 >0 188 >0 189 >20 190 >80 191 >50 192 >50 195 >80 196 >80 197 >80 198 >20 199 >20 200 >20 201 >0 202 >0 203 >0 204 >50 205 >50 206 >20 207 >20 208 >50 209 >20 210 >50 211 >0 220 >20 221 >50 222 >20 223 >50 224 >80 225 >80 227 >80 228 >20 229 >50 230 >50 231 >50 232 >50 233 >20 234 >0 235 >0 236 >80 237 >80 238 >0 239 >20 240 >80 245 >20 246 >20 247 >20 248 >20 252 >80 253 >50 254 >50 255 >20 257 >50 258 >80 259 >50 260 >50 261 >20 262 >20 263 >50 264 >20 265 >80 266 >80 267 >80 273 >20 274 >20 276 >0 279 >20 280 >0 282 >0 283 >0 284 >20 285 >0 286 >20 287 >50 288 >80 290 >50 291 >0 292 >0 295 >20 299 >0 300 >20 301 >50 302 >20 303 >80 304 >20 305 >50 306 >50 307 >20 308 >20 313 >20 316 >20 318 >20 320 >80 323 >80 324 >50 326 >50 327 >20 328 >80 - As can be seen from the tables above, the compounds were found to show beneficial activity across the assays.
FIG. 3 graphically illustrates the assay results of example no. 89. - According to an embodiment, compounds having inhibition values of greater than 80% in both an RORγ Reporter Assay (Gal4) and a Th17 Assay are disclosed herein. According to an embodiment the compounds have inhibition values of greater than 80% in both a RORγ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 1000 nM, such as less than 500 nM.
- According to an embodiment the compounds are having inhibition values of greater than 80% in at least one of a RORγ Reporter Assay (Gal4) and a Th17 Assay. According to an embodiment the compounds have inhibition values of greater than 80% in at least one of a RORγ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 1000 nM, such as less than 500 nM.
- According to an embodiment the compounds are having inhibition values of greater than 50% in both an RORγ Reporter Assay (Gal4) and a Th17 Assay. According to an embodiment the compounds have inhibition values of greater than 50% in both a RORγ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 1000 nM, such as less than 500 nM.
- According to an embodiment the compounds are having inhibition values of greater than 50% in at least one of a RORγ Reporter Assay (Gal4) and a Th17 Assay. According to an embodiment the compounds have inhibition values of greater than 50% in at least one of a RORγ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 2000 nM, such as less than 1000 nM, such as less than 500 nM.
- According to an embodiment the compounds are having inhibition values of greater than 20% in both an RORγ Reporter Assay (Gal4) and a Th17 Assay. According to an embodiment the compounds have inhibition values of greater than 20% in both a RORγ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 2000 nM, such as less than 1000 nM, such as less than 500 nM.
- According to an embodiment the compounds are having inhibition values of greater than 50% in a RORγ Reporter Assay (Gal4) at 1 μM and inhibition values of greater than 20% in a RORγ Reporter Assay (Gal4) at 0.1 μM. According to an embodiment the compounds are having inhibition values of greater than 50% in a RORγ Reporter Assay (Gal4) at 1 μM and inhibition values of greater than 20% in a RORγ Reporter Assay (Gal4) at 0.1 μM, and a FP activity range less than 2000 nM, such as less than 1000 nM, such as less than 500 nM.
- According to an embodiment the compounds are having inhibition values of greater than 20% in at least one of a RORγ Reporter Assay (Gal4) and a Th17 Assay. According to an embodiment the compounds have inhibition values of greater than 20% in at least one of a RORγ Reporter Assay (Gal4) and a Th17 Assay, and a FP activity range less than 2000 nM, such as less than 1000 nM, such as less than 500 nM.
- Experimental Autoimmune Encephalomyelitis (EAE) Study
- EAE is an animal model for multiple sclerosis used to evaluate the efficacy of test compounds. EAE was induced at WuXi AppTec (Shanghai) in female C57BL/6 mice obtained from SLAC Laboratories, Shanghai by injection of 100 μl (100 μg MOG35-55 peptide in complete Freund's adjuvant containing 200 μg M. tuberculosis/mouse) emulsion (with a 25-G needle) subcutaneously in the shaved back of the mouse. Each mouse was also given 200 ng PTX in 200 μl of PBS by intraperitoneal injection at 0 and 48 hours after immunization. For treatment, compound or vehicle (2% DMSO, 10% HP-β-CD in MilliQ water) was given orally twice daily at various doses selected from 3, 10, and 30 mg/kg, beginning at the day of EAE induction. Treatment lasted for 25 days, and the animals were scored daily for EAE symptoms using the following scoring system: 0, Normal mouse; no overt signs of disease; 1, Limp tail or hind limb weakness but not both; 2 Limp tail and hind limb weakness; 3 Partial hind limb paralysis; 4 Complete hind limb paralysis; 5 Moribund state; death by EAE: sacrifice for humane reasons. The clinical score can be expressed as the mean score for each treatment group+/−S.E.M.
- Results: Example 204 was tested in the EAE study at 10 and 30 mg/kg. Example 204 was shown to delay onset and lower clinical score at both doses.
- Collagen-Induced Arthritis (CIA) Study
- Collagen-induced arthritis is an animal model of rheumatoid arthritis used to evaluate the efficacy of test compounds. CIA was induced at Washington Biotechnology Inc. (Baltimore) in male DBA/1J mice (Jackson Laboratories) by subcutaneous injection at the base of the tail with 50 μl of a bovine collagen/complete Freund's adjuvant emulsion. After 21 days, the mice were further boosted by a further subcutaneous injection of 50 μl of a collagen/incomplete Freund's adjuvant emulsion. For treatment, compound or vehicle (2% DMSO, 10% HP-β-CD in MilliQ water) was given orally twice daily at various doses selected from 3, 10, 30 mg/kg, beginning at the day of CIA induction (Prophylactic setting), or after disease initiation (at day 27, therapeutic setting). Treatment lasted until day 41, and the animals were scored three times weekly. Each paw was scored and the sum of all four scores was recorded as the Arthritic Index (AI). The maximum possible AI was 16. 0=no visible effects of arthritis; 1=edema and/or erythema of one digit; 2=edema and/or erythema of 2 joints; 3=edema and/or erythema of more than 2 joints; 4=severe arthritis of the entire paw and digits including limb deformation and ankylosis of the joint. The Arthritis Index for each treatment can be expressed as the mean score for each treatment group+/−S.E.M.
- Results: Example 204 was tested in the CIA study at 10 and 30 mg/kg in prophylactic setting and at 30 mg/kg in therapeutic setting. Example 204 was shown to significantly reduce disease severity at both prophylactic doses. Example 204 was shown to arrest disease development in the therapeutic setting.
- In summary, compounds disclosed herein have been found to at least modulate the activity of RORγ. Additionally it has been found that compounds disclosed herein have in vivo usefulness, and could consequently be useful in treating inflammatory, metabolic and autoimmune diseases.
Claims (69)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1450920-2 | 2014-08-04 | ||
SE1450920 | 2014-08-04 | ||
SE1450920 | 2014-08-04 | ||
SE1451406 | 2014-11-21 | ||
SE1451406 | 2014-11-21 | ||
SE1451406.1 | 2014-11-21 | ||
PCT/EP2015/067713 WO2016020295A1 (en) | 2014-08-04 | 2015-07-31 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
US20170327503A1 true US20170327503A1 (en) | 2017-11-16 |
US10689383B2 US10689383B2 (en) | 2020-06-23 |
Family
ID=53765209
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/501,226 Active US10683293B2 (en) | 2014-08-04 | 2015-07-31 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
US15/501,233 Active US10689383B2 (en) | 2014-08-04 | 2015-07-31 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
US16/871,719 Active US11254681B2 (en) | 2014-08-04 | 2020-05-11 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/501,226 Active US10683293B2 (en) | 2014-08-04 | 2015-07-31 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/871,719 Active US11254681B2 (en) | 2014-08-04 | 2020-05-11 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
Country Status (30)
Country | Link |
---|---|
US (3) | US10683293B2 (en) |
EP (2) | EP3177611B1 (en) |
JP (3) | JP6624594B2 (en) |
KR (2) | KR102538658B1 (en) |
CN (2) | CN106661002B (en) |
AU (3) | AU2015299149B2 (en) |
BR (1) | BR112017002214B1 (en) |
CA (2) | CA2957048C (en) |
CL (2) | CL2017000270A1 (en) |
CO (2) | CO2017002159A2 (en) |
CR (2) | CR20170076A (en) |
DK (1) | DK3177612T3 (en) |
ES (1) | ES2911707T3 (en) |
GT (1) | GT201700023A (en) |
HR (1) | HRP20220522T1 (en) |
IL (3) | IL250324B (en) |
LT (1) | LT3177612T (en) |
MA (1) | MA40552A (en) |
MX (2) | MX2017001553A (en) |
MY (2) | MY194204A (en) |
NZ (2) | NZ766530A (en) |
PE (2) | PE20170682A1 (en) |
PH (2) | PH12017500164A1 (en) |
PL (1) | PL3177612T3 (en) |
RS (1) | RS63190B1 (en) |
RU (2) | RU2719422C2 (en) |
SG (3) | SG11201700777VA (en) |
SI (1) | SI3177612T1 (en) |
WO (2) | WO2016020295A1 (en) |
ZA (2) | ZA201700671B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021236410A1 (en) * | 2020-05-19 | 2021-11-25 | Florida State University Research Foundation, Inc. | Antifibrotic compounds and related methods |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2719422C2 (en) | 2014-08-04 | 2020-04-17 | Нуэволюшон А/С | Optionally condensed heterocyclyl-substituted pyrimidine derivatives suitable for treating inflammatory, metabolic, oncological and autoimmune diseases |
JP6853819B2 (en) * | 2015-10-08 | 2021-03-31 | スーチョウ ユンシュアン イーヤオ カジ ヨウシェン ゴンス | WNT signaling pathway inhibitors and their therapeutic uses |
TN2018000188A1 (en) | 2015-12-15 | 2019-10-04 | Astrazeneca Ab | Isoindole compounds |
EP3638661A1 (en) | 2017-06-14 | 2020-04-22 | Astrazeneca AB | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
WO2019168874A1 (en) | 2018-02-27 | 2019-09-06 | The Research Foundation For The State University Of New York | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
WO2020035556A1 (en) | 2018-08-17 | 2020-02-20 | Leo Pharma A/S | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma |
WO2020035557A1 (en) | 2018-08-17 | 2020-02-20 | Leo Pharma A/S | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma |
CN113166130A (en) * | 2018-11-19 | 2021-07-23 | 11949098加拿大股份有限公司 | 4,5,6, 7-tetrahydro-L-benzothiophene modulators of retinoic acid receptor-associated (RAR) orphan nuclear receptors (ROR) |
WO2021124279A1 (en) | 2019-12-20 | 2021-06-24 | Nuevolution A/S | Compounds active towards nuclear receptors |
CA3160522A1 (en) | 2019-12-20 | 2021-06-24 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
MX2022012260A (en) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compounds active towards nuclear receptors. |
CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
IL310930A (en) * | 2021-08-30 | 2024-04-01 | Amgen Inc | Process for synthesizing naphthyridine derivatives and intermediates thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3236972A (en) * | 1963-12-31 | 1966-02-22 | Hudson Lamp Company | Noise level increaser for snap-action devices |
WO2011105572A1 (en) * | 2010-02-26 | 2011-09-01 | 持田製薬株式会社 | Novel heteroaryl derivative |
Family Cites Families (194)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4298602A (en) | 1978-10-13 | 1981-11-03 | The Dow Chemical Company | Heterocyclic substituted triazolyl phosphorous compounds and their use as insecticides |
DE3737748A1 (en) | 1987-11-03 | 1989-05-18 | Schering Ag | 3-arylsulphonylamino-1H-1,2,4-triazoles, processes for their preparation, and their use as herbicides and growth regulators |
DE3905714A1 (en) | 1989-02-24 | 1990-09-06 | Bayer Ag | SULFONYLIMINO-AZINYLHETEROAZOLES, METHODS AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THEIR USE AS HERBICIDES |
DE3928605A1 (en) | 1989-08-30 | 1991-03-07 | Bayer Ag | SUBSTITUTED SULFONYLAMINOAZOLES |
GB8929022D0 (en) | 1989-12-22 | 1990-02-28 | Ici Plc | Diazine derivatives |
JPH04348326A (en) | 1990-07-09 | 1992-12-03 | Sumitomo Electric Ind Ltd | Organic nonlinear optical material |
DE4124942A1 (en) | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING SUCH COMPOUNDS |
WO1993014082A1 (en) | 1992-01-13 | 1993-07-22 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
AU4288293A (en) | 1992-04-27 | 1993-11-29 | E.I. Du Pont De Nemours And Company | Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines |
JPH06220059A (en) | 1993-01-28 | 1994-08-09 | Tanabe Seiyaku Co Ltd | Condensed pyrimidine derivative and its production |
DE4427529A1 (en) | 1994-08-04 | 1996-02-08 | Bayer Ag | Process for the preparation of 1,2,4-triazine-3,5-diones |
EP0831829B1 (en) | 1995-06-07 | 2003-08-20 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
DE19536891A1 (en) | 1995-10-04 | 1997-04-10 | Basf Ag | New amino acid derivatives, their production and use |
ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
EP0946554A1 (en) | 1996-11-27 | 1999-10-06 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
JPH10251255A (en) | 1997-03-14 | 1998-09-22 | Nissan Chem Ind Ltd | Azine derivative |
JP2000086663A (en) | 1998-09-09 | 2000-03-28 | Taisho Pharmaceut Co Ltd | Aryltetrahydropyridine derivative |
EP1396489A1 (en) | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
US7122666B2 (en) | 1999-07-21 | 2006-10-17 | Sankyo Company, Limited | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses |
JP2003104971A (en) | 1999-08-12 | 2003-04-09 | Wakunaga Pharmaceut Co Ltd | New anilide derivative or salt thereof, and medicine containing the same |
WO2001030778A1 (en) | 1999-10-27 | 2001-05-03 | Novartis Ag | Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use |
AU2457201A (en) | 1999-12-28 | 2001-07-09 | Bristol-Myers Squibb Company | Cytokine, especially tnf-alpha, inhibitors |
EP1257551B1 (en) | 2000-02-01 | 2007-09-05 | Abbott GmbH & Co. KG | Heterocyclic compounds and their use as parp inhibitors |
WO2002022584A1 (en) | 2000-09-11 | 2002-03-21 | Merck & Co., Inc. | Thrombin inhibitors |
JP2002284779A (en) | 2001-01-18 | 2002-10-03 | Sankyo Co Ltd | Medicine containing heteroaryl-substituted pyrrole derivative |
DE10108480A1 (en) | 2001-02-22 | 2002-09-05 | Bayer Ag | Pyrazolylpyrimidine |
US6958340B2 (en) | 2001-08-01 | 2005-10-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US20030191121A1 (en) | 2001-08-09 | 2003-10-09 | Miller Ross A. | Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation |
GB0127929D0 (en) | 2001-11-21 | 2002-01-16 | Celltech R&D Ltd | Chemical compounds |
JP4607458B2 (en) | 2002-02-05 | 2011-01-05 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | Novel aryl and heteroaryl piperazines |
AU2003212634A1 (en) | 2002-03-11 | 2003-09-22 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
AU2003230367A1 (en) | 2002-05-10 | 2003-11-11 | Neurocrine Biosciences, Inc. | Substituted piperazine as melanocortin receptors ligands |
GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
SE0201980D0 (en) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
AU2003249539A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
MXPA05004607A (en) | 2002-10-30 | 2005-06-08 | Ciba Sc Holding Ag | Electroluminescent device. |
US20040097492A1 (en) | 2002-11-01 | 2004-05-20 | Pratt John K | Anti-infective agents |
US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
WO2004039785A1 (en) | 2002-11-01 | 2004-05-13 | Pfizer Products Inc. | Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination |
SE0203712D0 (en) | 2002-12-13 | 2002-12-13 | Astrazeneca Ab | Novel compounds |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7569591B2 (en) | 2003-01-31 | 2009-08-04 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
GB0306329D0 (en) | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Compounds |
WO2004110350A2 (en) | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Compouds and uses thereof in modulating amyloid beta |
DE10322469A1 (en) | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclic compounds |
WO2005033072A2 (en) | 2003-09-30 | 2005-04-14 | Scios Inc. | Heterocyclic amides and sulfonamides |
CA2540647C (en) | 2003-10-01 | 2012-07-10 | Bayer Healthcare Ag | Tetrahydro-naphthalene and urea derivatives |
US20050124623A1 (en) | 2003-11-26 | 2005-06-09 | Bender John A. | Diazaindole-dicarbonyl-piperazinyl antiviral agents |
WO2005068457A1 (en) | 2004-01-02 | 2005-07-28 | University Of Chicago | Cataltytic asymmetric hetero diels-alder reaction of a heteroaromatic c-nitroso dienophile: a novel method for synthesis of chiral non-racemic amino alcohols |
US20050239806A1 (en) | 2004-01-13 | 2005-10-27 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
CN1918128B (en) | 2004-02-13 | 2011-01-26 | 万有制药株式会社 | Fused ring 4-oxopyrimidine derivative |
US7435830B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
EP1747206A1 (en) | 2004-04-29 | 2007-01-31 | Abbott Laboratories | Amino-tetrazoles analogues and methods of use |
EP1745036A2 (en) | 2004-05-03 | 2007-01-24 | Boehringer Ingelheim Pharmaceuticals Inc. | Cytokine inhibitors |
FR2870541B1 (en) | 2004-05-18 | 2006-07-14 | Proskelia Sas | ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR |
SE0401342D0 (en) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
CA2568451A1 (en) * | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
TW200608966A (en) | 2004-06-28 | 2006-03-16 | Incyte Corp | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
NZ551673A (en) | 2004-06-28 | 2010-11-26 | Incyte Corp | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors |
EP1812429A4 (en) | 2004-09-29 | 2010-07-21 | Portola Pharm Inc | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
JP5118972B2 (en) | 2004-10-29 | 2013-01-16 | テイボテク・フアーマシユーチカルズ | HIV inhibitory bicyclic pyrimidine derivatives |
CA2590110C (en) | 2004-12-30 | 2014-06-03 | Exelixis, Inc. | Kinase modulators and method of use |
AU2006204724A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
CN101180275B (en) | 2005-02-25 | 2014-09-10 | 瑟瑞耐克斯有限公司 | Pyridine, and pyridazine derivatives |
US7470693B2 (en) | 2005-04-21 | 2008-12-30 | Bristol-Myers Squibb Company | Oxalamide derivatives as kinase inhibitors |
US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
DE102005023943A1 (en) | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Pentafluorosulfanyl-substituted compound and its use for the preparation of medicaments |
AU2006259525B2 (en) | 2005-06-14 | 2012-05-24 | Gpcr Therapeutics, Inc | Pyrimidine compounds |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
FR2889189A1 (en) | 2005-07-28 | 2007-02-02 | Cerep Sa | HYDANTOIN-DERIVED COMPOUNDS AND THEIR USE AS MCHR-1 ANTAGONISTS |
CA2620179C (en) | 2005-08-16 | 2013-10-29 | Icagen, Inc. | Inhibitors of voltage-gated sodium channels |
CA2621275A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
JP4531027B2 (en) | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
JP2007126551A (en) | 2005-11-02 | 2007-05-24 | Fujifilm Corp | Fine particle of fluorescent polymer, fluorescence detection kit and fluorescence detection method |
GB0525337D0 (en) | 2005-12-13 | 2006-01-18 | Novartis Ag | Organic compounds |
US7465795B2 (en) | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
NL2000323C2 (en) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine derivatives. |
MEP1008A (en) | 2005-12-21 | 2010-02-10 | Incyte Corp | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
EP1979325A1 (en) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
JP2007186580A (en) | 2006-01-12 | 2007-07-26 | Fujifilm Corp | Polymer particle, fluorescent polymer fine particle, method for producing polymer fine particle, method for producing the fluorescent polymer fine particle, fluorescence-detecting kit and method for detecting the fluorescence |
UY30117A1 (en) * | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | AMIS TRISUSTITUDED COMPOUND |
FR2897061B1 (en) | 2006-02-03 | 2010-09-03 | Sanofi Aventis | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE PATTERN, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
AU2007228784B2 (en) | 2006-03-22 | 2012-03-08 | Janssen Pharmaceutica N.V. | Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53 |
AR060403A1 (en) | 2006-04-12 | 2008-06-11 | Sanofi Aventis | AMINO COMPOUNDS- PYRIMIDINE 2.6- SUBSTITUTES -4- MONOSUSTITUTES AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEIVER |
US20080076924A1 (en) | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
WO2008005538A2 (en) | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
US20080021063A1 (en) | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
EP2057140B1 (en) | 2006-08-24 | 2012-08-08 | AstraZeneca AB | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
EP2057129A1 (en) | 2006-08-24 | 2009-05-13 | AstraZeneca AB | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
JP4776473B2 (en) | 2006-08-25 | 2011-09-21 | 株式会社ミツトヨ | Optical axis deflection laser interferometer, its calibration method, correction method, and measurement method |
JP2008074892A (en) | 2006-09-19 | 2008-04-03 | Fujifilm Corp | Fluorescent polymer fine particle set, complex set for detecting fluorescence, fluorescent polymer fine particle composition and method for detecting fluoroscence |
GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
WO2008115973A2 (en) | 2007-03-20 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
EP2014657A1 (en) | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidines as modulators for an EP2 receptor |
US20100261723A1 (en) | 2007-07-09 | 2010-10-14 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
US20100227858A1 (en) | 2007-07-09 | 2010-09-09 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
AR067478A1 (en) | 2007-07-09 | 2009-10-14 | Astrazeneca Ab | COMPOUNDS DERIVED FROM MORPHOLINE PYRIMIDINE |
BRPI0814688A2 (en) | 2007-07-09 | 2017-06-06 | Astrazeneca Ab | compound, use of a compound, methods for producing an antiproliferative effect on a warm-blooded animal, and for treating disease, and, pharmaceutical composition |
WO2009011627A1 (en) | 2007-07-13 | 2009-01-22 | Astrazeneca Ab | Pyridine compounds and their use as p2y12 antagonists |
ES2395081T3 (en) | 2007-07-26 | 2013-02-08 | Vitae Pharmaceuticals, Inc. | Synthesis of 11 beta-hydroxysteroid dehydrogenase inhibitors type 1 |
EP2217596B8 (en) | 2007-10-22 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 |
JP2011507910A (en) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | Methods for changing the lifetime of eukaryotes |
US8492379B2 (en) | 2007-12-21 | 2013-07-23 | The University Of Sydney | Translocator protein ligands |
FR2926556B1 (en) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
CN101938989B (en) | 2008-02-08 | 2012-07-11 | 株式会社资生堂 | Skin whitening agent and external preparation for the skin |
US8178658B2 (en) | 2008-02-12 | 2012-05-15 | Dow Agrosciences, Llc | Pesticidal compositions |
EP2262783A2 (en) | 2008-02-21 | 2010-12-22 | Sanofi-Aventis | Covalently binding imaging probes |
TW200946533A (en) | 2008-03-31 | 2009-11-16 | Zenyaku Kogyo Kk | Pyrimidine derivatives having effects on cell protection and the use thereof |
AU2009236824B2 (en) | 2008-04-18 | 2012-02-16 | Daewoong Pharmaceutical Co., Ltd. | A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof |
JP5451752B2 (en) | 2008-05-01 | 2014-03-26 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1 |
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
KR20130084328A (en) | 2008-06-27 | 2013-07-24 | 노파르티스 아게 | Organic compounds |
JP2010030970A (en) | 2008-07-31 | 2010-02-12 | Bayer Cropscience Ag | Insecticidal benzenedicarboxamide derivative |
US8715638B2 (en) | 2008-08-20 | 2014-05-06 | Merck Sharp & Dohme Corp. | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
WO2010022125A1 (en) | 2008-08-20 | 2010-02-25 | Schering Corporation | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
EP2326627A1 (en) | 2008-08-20 | 2011-06-01 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
BRPI0920237A2 (en) | 2008-10-21 | 2015-12-29 | Metabolex Inc | aril gpr120 receptor agonists and their respective uses |
GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
JP2012512252A (en) | 2008-12-17 | 2012-05-31 | ブイアイエイ・ファーマシューティカルズ・インコーポレーテッド | Inhibitors of diacylglycerol acyltransferase |
HUE027615T2 (en) | 2009-01-08 | 2016-10-28 | Curis Inc | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
WO2010099539A1 (en) | 2009-02-27 | 2010-09-02 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
CA2756808A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted indolo-piperidine compounds |
EP2414348B1 (en) | 2009-04-03 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
WO2010120994A2 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
ES2659725T3 (en) | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and disorder treatment procedure |
WO2010135470A1 (en) | 2009-05-19 | 2010-11-25 | Intermune, Inc. | Pifenidone derivatives for treating bronchial asthma |
WO2011017513A1 (en) | 2009-08-07 | 2011-02-10 | Dow Agrosciences Llc | Pesticidal compositions |
EP3205647B1 (en) | 2009-08-17 | 2020-05-13 | Memorial Sloan-Kettering Cancer Center | 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders |
US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
JP5699149B2 (en) | 2009-09-04 | 2015-04-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Bruton type tyrosine kinase inhibitor |
MX2012004577A (en) | 2009-10-19 | 2012-06-13 | Synta Pharmaceuticals Corp | Combination cancer therapy with hsp90 inhibitory compounds. |
KR20110049217A (en) | 2009-11-04 | 2011-05-12 | 다우어드밴스드디스플레이머티리얼 유한회사 | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
EA201200917A1 (en) | 2009-12-18 | 2012-12-28 | Эктивсайт Фармасьютикалз, Инк. | PROCARAXES OF PLASMA KALLIKREIN INHIBITORS |
WO2011078143A1 (en) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | Pyrimidine derivatives and pharmaceutical composition containing same |
JP5847733B2 (en) | 2010-01-28 | 2016-01-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Hanging drop array plate |
MX2012010035A (en) | 2010-03-16 | 2012-10-01 | Aventis Pharma Inc | Substituted pyrimidines as prostaglandin d2 receptor antagonists. |
MX2012013196A (en) | 2010-05-12 | 2013-03-22 | Abbvie Inc | Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases. |
AU2011253143A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
AU2011302124B2 (en) | 2010-09-14 | 2016-03-17 | Exelixis, Inc. | Inhibitors of PI3K-delta and methods of their use and manufacture |
AR083199A1 (en) | 2010-09-29 | 2013-02-06 | Intervet Internationale B V | N-HETEROARILO COMPOUNDS WITH CYCLE BRIDGE UNIT |
CN105294549B (en) | 2010-09-29 | 2017-12-26 | 英特维特国际股份有限公司 | N heteroaryl compounds |
AU2011313191A1 (en) | 2010-10-08 | 2013-05-02 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
DE102010050558A1 (en) | 2010-11-05 | 2012-05-10 | Merck Patent Gmbh | 1H-pyrrolo [2,3-b] pyridine |
AR084032A1 (en) | 2010-11-30 | 2013-04-17 | Takeda Pharmaceutical | BICYCLE COMPOUND |
JPWO2012074022A1 (en) | 2010-12-01 | 2014-05-19 | 旭硝子株式会社 | Iridium cation complex and luminescent composition |
JP2014510717A (en) | 2011-01-26 | 2014-05-01 | ユニバーシティー オブ ロチェスター | Small molecule RNase inhibitors and methods of use |
AR085908A1 (en) | 2011-03-16 | 2013-11-06 | Hoffmann La Roche | DERIVATIVES OF 3-BUTIN-2-OL AND CARBONITRILE WITH INHIBITING ACTIVITY OF THE NF-kB INDUCTING KINASE (NIK) |
US8691861B2 (en) | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
WO2012147890A1 (en) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | Novel azole derivative |
WO2012147516A1 (en) | 2011-04-28 | 2012-11-01 | 持田製薬株式会社 | Cyclic amide derivative |
SG194770A1 (en) | 2011-05-27 | 2013-12-30 | Probiodrug Ag | Radiolabelled glutaminyl cyclase inhibitors |
SG194681A1 (en) | 2011-05-27 | 2013-12-30 | Achillion Pharmaceuticals Inc | Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
WO2013019824A2 (en) | 2011-08-02 | 2013-02-07 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
EP2739143B1 (en) | 2011-08-05 | 2018-07-11 | Gary A. Flynn | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
KR20140072090A (en) | 2011-09-09 | 2014-06-12 | 뉴욕 유니버시티 | Amido compounds as rorγt modulators and uses thereof |
EP2763533B1 (en) | 2011-10-06 | 2021-12-29 | Merck Sharp & Dohme Corp. | Triazolyl pde10 inhibitors |
UA111640C2 (en) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | DERIVATIVES [1,2,3] TRIAZOLO [4,5-d] PYRIMIDINE AS A cannabinoid receptor agonist 2 |
AU2012353651B2 (en) | 2011-12-16 | 2017-09-14 | Northwestern University | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis |
CN103159738B (en) | 2011-12-19 | 2016-09-07 | 上海泓博智源医药股份有限公司 | The heteroaryl aroma compounds of alkynyl bridging and application thereof |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
WO2013117649A1 (en) | 2012-02-10 | 2013-08-15 | Galapagos Nv | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |
CA2866707A1 (en) | 2012-03-07 | 2013-09-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
EP2838898B1 (en) | 2012-04-20 | 2017-01-18 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
CN102786512A (en) | 2012-05-31 | 2012-11-21 | 中国人民解放军军事医学科学院毒物药物研究所 | N-aryl unsaturated fused ring tertiary amine compound, preparation method thereof and application thereof to tumor resistance |
JP2014078482A (en) | 2012-06-08 | 2014-05-01 | Fujifilm Corp | Nonaqueous electrolyte secondary battery and nonaqueous electrolytic solution |
AU2013282317A1 (en) | 2012-06-28 | 2015-01-22 | Abbvie Inc. | Cyanoguanidines and their use as antiviral agents |
US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
JP2015525775A (en) | 2012-07-23 | 2015-09-07 | メルク パテント ゲーエムベーハー | Ligand and production method thereof |
RU2665793C2 (en) | 2012-07-24 | 2018-09-04 | Ниссан Кемикал Индастриз, Лтд. | Composition of the culture medium and method of culturing of the cell or tissue using the specified composition |
WO2014015523A1 (en) * | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
CN104507923B (en) | 2012-08-02 | 2018-02-09 | 内尔维阿诺医学科学有限公司 | Substituted pyroles activating agent as kinase inhibitor |
JP6429280B2 (en) | 2013-05-14 | 2018-11-28 | 国立大学法人京都大学 | Efficient cardiomyocyte induction method |
EP3048169B1 (en) | 2013-09-04 | 2019-07-10 | Otsuka Pharmaceutical Factory, Inc. | Method for preparing pluripotent stem cells |
CN103588795A (en) | 2013-11-27 | 2014-02-19 | 中国科学院福建物质结构研究所 | Ionic cuprous luminous complexes and use thereof |
SG10202003061SA (en) | 2014-02-25 | 2020-05-28 | Corning Inc | Device for fabricating spheroid, and spheroid recovery method and manufacturing method |
TWI700283B (en) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | 2-(morpholin-4-yl)-1,7-naphthyridines |
RU2719422C2 (en) | 2014-08-04 | 2020-04-17 | Нуэволюшон А/С | Optionally condensed heterocyclyl-substituted pyrimidine derivatives suitable for treating inflammatory, metabolic, oncological and autoimmune diseases |
SG10201809428UA (en) | 2014-11-21 | 2018-11-29 | Merck Sharp & Dohme | Insulin receptor partial agonists |
WO2016081918A1 (en) | 2014-11-21 | 2016-05-26 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
US9695280B2 (en) | 2015-03-03 | 2017-07-04 | Ricoh Co., Ltd. | Methods for solid freeform fabrication |
-
2015
- 2015-07-31 RU RU2017104614A patent/RU2719422C2/en active
- 2015-07-31 KR KR1020177005925A patent/KR102538658B1/en active IP Right Grant
- 2015-07-31 MX MX2017001553A patent/MX2017001553A/en unknown
- 2015-07-31 CR CR20170076A patent/CR20170076A/en unknown
- 2015-07-31 AU AU2015299149A patent/AU2015299149B2/en active Active
- 2015-07-31 EP EP15744925.7A patent/EP3177611B1/en active Active
- 2015-07-31 ES ES15745475T patent/ES2911707T3/en active Active
- 2015-07-31 NZ NZ766530A patent/NZ766530A/en unknown
- 2015-07-31 CR CR20170077A patent/CR20170077A/en unknown
- 2015-07-31 MY MYPI2017700370A patent/MY194204A/en unknown
- 2015-07-31 CN CN201580041938.0A patent/CN106661002B/en active Active
- 2015-07-31 PL PL15745475.2T patent/PL3177612T3/en unknown
- 2015-07-31 RU RU2017104612A patent/RU2734261C2/en active
- 2015-07-31 EP EP15745475.2A patent/EP3177612B1/en active Active
- 2015-07-31 PE PE2017000167A patent/PE20170682A1/en not_active Application Discontinuation
- 2015-07-31 MX MX2017001554A patent/MX2017001554A/en unknown
- 2015-07-31 KR KR1020177005984A patent/KR102523430B1/en active IP Right Grant
- 2015-07-31 PE PE2017000166A patent/PE20170684A1/en unknown
- 2015-07-31 US US15/501,226 patent/US10683293B2/en active Active
- 2015-07-31 CA CA2957048A patent/CA2957048C/en active Active
- 2015-07-31 SG SG11201700777VA patent/SG11201700777VA/en unknown
- 2015-07-31 JP JP2017505167A patent/JP6624594B2/en active Active
- 2015-07-31 AU AU2015299142A patent/AU2015299142B2/en active Active
- 2015-07-31 MA MA040552A patent/MA40552A/en unknown
- 2015-07-31 SG SG10202006053UA patent/SG10202006053UA/en unknown
- 2015-07-31 BR BR112017002214-1A patent/BR112017002214B1/en active IP Right Grant
- 2015-07-31 MY MYPI2017700384A patent/MY195016A/en unknown
- 2015-07-31 US US15/501,233 patent/US10689383B2/en active Active
- 2015-07-31 RS RS20220427A patent/RS63190B1/en unknown
- 2015-07-31 CN CN201580041954.XA patent/CN106573899B/en active Active
- 2015-07-31 CA CA2957046A patent/CA2957046C/en active Active
- 2015-07-31 SG SG11201700779RA patent/SG11201700779RA/en unknown
- 2015-07-31 NZ NZ729137A patent/NZ729137A/en unknown
- 2015-07-31 HR HRP20220522TT patent/HRP20220522T1/en unknown
- 2015-07-31 JP JP2017505168A patent/JP6604664B2/en active Active
- 2015-07-31 SI SI201531831T patent/SI3177612T1/en unknown
- 2015-07-31 LT LTEPPCT/EP2015/067692T patent/LT3177612T/en unknown
- 2015-07-31 WO PCT/EP2015/067713 patent/WO2016020295A1/en active Application Filing
- 2015-07-31 DK DK15745475.2T patent/DK3177612T3/en active
- 2015-07-31 WO PCT/EP2015/067692 patent/WO2016020288A1/en active Application Filing
-
2017
- 2017-01-26 ZA ZA2017/00671A patent/ZA201700671B/en unknown
- 2017-01-26 ZA ZA2017/00672A patent/ZA201700672B/en unknown
- 2017-01-27 IL IL250324A patent/IL250324B/en active IP Right Grant
- 2017-01-27 PH PH12017500164A patent/PH12017500164A1/en unknown
- 2017-01-27 PH PH12017500163A patent/PH12017500163A1/en unknown
- 2017-01-29 IL IL250325A patent/IL250325B/en active IP Right Grant
- 2017-02-01 CL CL2017000270A patent/CL2017000270A1/en unknown
- 2017-02-01 CL CL2017000271A patent/CL2017000271A1/en unknown
- 2017-02-03 GT GT201700023A patent/GT201700023A/en unknown
- 2017-03-03 CO CONC2017/0002159A patent/CO2017002159A2/en unknown
- 2017-03-03 CO CONC2017/0002160A patent/CO2017002160A2/en unknown
-
2019
- 2019-10-10 JP JP2019187060A patent/JP7091596B2/en active Active
-
2020
- 2020-05-11 US US16/871,719 patent/US11254681B2/en active Active
- 2020-06-23 IL IL275624A patent/IL275624B/en active IP Right Grant
- 2020-08-03 AU AU2020213282A patent/AU2020213282B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3236972A (en) * | 1963-12-31 | 1966-02-22 | Hudson Lamp Company | Noise level increaser for snap-action devices |
WO2011105572A1 (en) * | 2010-02-26 | 2011-09-01 | 持田製薬株式会社 | Novel heteroaryl derivative |
Non-Patent Citations (1)
Title |
---|
Gergely et al. (Journal of Combinatorial Chemistry, 2004, 6(3), pp. 426-430). * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021236410A1 (en) * | 2020-05-19 | 2021-11-25 | Florida State University Research Foundation, Inc. | Antifibrotic compounds and related methods |
US11548874B2 (en) | 2020-05-19 | 2023-01-10 | Florida State University Research Foundation, Inc. | Antifibrotic compounds and related methods |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10689383B2 (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
US11332459B2 (en) | Benzimidazole derivatives and their uses | |
US11685727B2 (en) | Compounds active towards nuclear receptors | |
US11447479B2 (en) | Compounds active towards nuclear receptors | |
TW201910312A (en) | Cyclic amine derivative and pharmaceutical use thereof | |
US11613532B2 (en) | Compounds active towards nuclear receptors | |
US11780843B2 (en) | Compounds active towards nuclear receptors | |
BR112017002217B1 (en) | COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION, AND USES OF A COMPOUND |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NUEVOLUTION A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GLAD, SANNE SCHROEDER;JENSEN, KIM BIRKEBAEK;NOERAGER, NIELS GROEN;AND OTHERS;SIGNING DATES FROM 20170309 TO 20170317;REEL/FRAME:043207/0589 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |